fluorouracil has been researched along with Disease Exacerbation in 998 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Locally advanced breast cancer patients were randomly assigned onto a study comparing cyclophosphamide (C; 75 mg/m(2) orally days 1 to 14), epirubicin (E; 60 mg/m(2) intravenously [IV] days 1, 8), and fluorouracil (F; 500 mg/m(2) IV days 1, 8) six cycles every 28 days versus E (120 mg/m(2) IV day 1), C (830 mg/m(2) IV day 1), and granulocyte colony-stimulating factor (filgrastim; 5 micro g/kg/d subcutaneously days 2 to 13) six cycles every 14 days." | 10.20 | Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK mult ( Bonnefoi, H; Bruning, P; Cufer, T; Hamilton, A; Mauriac, L; Piccart, MJ; Pritchard, KI; Therasse, P; Tomiak, E; Welnicka-Jaskiewicz, M, 2003) |
| "BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer." | 9.34 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020) |
| "Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor." | 9.30 | Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. ( Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS, 2019) |
| " This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan." | 9.22 | Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016) |
| "This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens." | 9.20 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015) |
| "This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial." | 9.20 | Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015) |
| "We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea." | 9.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 9.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
| "We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial." | 9.17 | Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. ( Blum, JL; Glück, S; Hu, S; McKenna, EF; O'Shaughnessy, J; Odom, D; Russell, C, 2013) |
| "This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer." | 9.17 | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013) |
| "To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)." | 9.16 | Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 9.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy." | 9.16 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "We conducted this phase II study in an effort to evaluate the efficacy and safety of a gemcitabine single chemotherapy as a second-line treatment for biliary tract cancer (BTC) patients who evidenced disease progression after the administration of 5-fluorouracil (5-FU)-based palliative chemotherapy." | 9.15 | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. ( Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2011) |
| "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists." | 9.15 | A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011) |
| "The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer." | 9.15 | Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ( Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011) |
| "The aim of this prospective open-label study was to evaluate the efficacy and safety of oral vinorelbine in combination with capecitabine in patients with metastatic breast cancer (MBC)." | 9.15 | Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer. ( Adua, D; Basile, ML; De Sanctis, R; Del Signore, E; Di Seri, M; Gori, B; Grassi, P; Longo, F; Quadrini, S; Stumbo, L, 2011) |
| "This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and progression-free survival rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin chemoradiotherapy followed by carboplatin and 5-fluorouracil." | 9.15 | Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. ( Dechaphunkul, T; Pruegsanusak, K; Sangthawan, D; Sunpaweravong, P, 2011) |
| "This multicenter, open-label, single-arm, Phase II study assessed the efficacy of a neoadjuvant chemotherapy with docetaxel (75 mg/m(2) q3w) followed by 5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2) and cyclophosphamide 500 mg/m(2) q3w in patients with early-stage breast cancer." | 9.15 | Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. ( Akiyama, F; Iwata, H; Kuroi, K; Kurosumi, M; Masuda, N; Nakamura, S; Ohashi, Y; Sato, N; Toi, M; Tsuda, H; Yamamoto, N, 2011) |
| "We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 9.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 9.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 9.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "Using data from a recent randomized trial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metastatic breast cancer considered to be taxane-resistant and previously treated with or resistant to an anthracycline." | 9.14 | Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer." | 9.14 | Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. ( Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N, 2010) |
| "To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years." | 9.14 | Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010) |
| "The aim of this study was to explore the clinical value of gemcitabine combined with capecitabine (GC) in heavily pre-treated patients with metastatic breast cancer." | 9.14 | Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. ( Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R, 2010) |
| "On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two agents in advanced anthracycline-pretreated breast cancer patients." | 9.14 | Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). ( Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C, 2010) |
| "Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial." | 9.14 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010) |
| "Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities." | 9.14 | Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010) |
| "This phase II study prospectively evaluated the feasibility of vinorelbine in combination with capecitabine in Chinese patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 9.14 | Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P, 2010) |
| "To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer." | 9.14 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010) |
| "601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy." | 9.14 | Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010) |
| "To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy." | 9.13 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008) |
| "To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer." | 9.13 | Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008) |
| "The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC)." | 9.13 | Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. ( Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M, 2008) |
| "To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies." | 9.13 | Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008) |
| "Patients with advanced breast cancer were candidates to receive metronomic oral capecitabine (500 mg thrice daily) and cyclophosphamide (50 mg daily) plus bevacizumab (10 mg/kg every 2 weeks)." | 9.13 | Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. ( Bagnardi, V; Bertolini, F; Campagnoli, E; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Mancuso, P; Pietri, E; Rocca, A; Scarano, E; Shaked, Y; Torrisi, R, 2008) |
| " Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab." | 9.13 | FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. ( Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R, 2008) |
| "XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)." | 9.13 | Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 9.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 9.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "To evaluate the response rate of the combination of capecitabine (C) and vinorelbine (V) followed by Docetaxel (D) in the 1st line treatment of advanced and metastatic breast cancer patients." | 9.13 | Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial. ( Chahine, G; Farhat, F; Gasmi, J; Ghosn, M; Kattan, J; Moukadem, W; Nasr, F; Younes, F, 2008) |
| "This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas." | 9.13 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008) |
| " Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab." | 9.13 | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. ( Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P, 2008) |
| " This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 9.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
| "Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)." | 9.13 | A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. ( Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 9.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 9.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 9.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC)." | 9.12 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. ( Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A, 2006) |
| "In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined." | 9.12 | A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006) |
| "To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen." | 9.12 | Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006) |
| "To study the efficacy of subconjunctival 5-fluorouracil (5-FU) and triamcinolone injection in halting the progression of impending recurrent pterygium." | 9.12 | Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. ( Leelapatranura, K; Phonjan, T; Prabhasawat, P; Tesavibul, N, 2006) |
| "COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 9.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)." | 9.12 | Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006) |
| "This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)." | 9.12 | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006) |
| "The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer." | 9.12 | Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007) |
| "Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC)." | 9.12 | Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. ( Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007) |
| "Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy." | 9.12 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer. ( Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S, 2006) |
| "To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)." | 9.12 | Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 9.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients." | 9.12 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. ( Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S, 2007) |
| "The oral fluoropyrimidine carbamate, capecitabine, is a highly active and well-tolerated treatment for metastatic breast cancer." | 9.12 | Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. ( Bangemann, N; Fuchs, I; Gonsch, T; Hindenburg, HJ; Hinke, A; Klare, P; Kleine-Tebbe, A; Lakner, V; Schaller, G; Weber, J, 2007) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 9.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes." | 9.12 | Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B, 2007) |
| "Phase II/III trials have shown that capecitabine is an active, well-tolerated therapy for metastatic breast cancer (MBC)." | 9.12 | An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. ( Bell, R; Nortier, JW; Paridaens, R; Rodrigues, H; Rossner, D; Salzberg, M; Vaslamatzis, MM; Venturini, M, 2007) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 9.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 9.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin." | 9.11 | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 9.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC)." | 9.11 | Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. ( Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K, 2004) |
| "The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC)." | 9.11 | Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. ( Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 9.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 9.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 9.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "Thirty-six patients with advanced breast cancer were stratified for the presence of bone and non-bone involvement and treated at four dose levels from capecitabine 800 mg/m2 orally days 1-14 and vinorelbine 20 mg/m2 intravenously days 1 and 8, to capecitabine 1250 mg/m2 orally days 1-14 and vinorelbine 25 mg/m2 intravenously days 1 and 8, for a maximum of six cycles." | 9.11 | Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). ( Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B, 2004) |
| "Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)." | 9.11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005) |
| "To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer." | 9.11 | Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. ( Bajetta, E; Buzzoni, R; Catena, L; Celio, L; Della Torre, S; Gattinoni, L; Longarini, R; Mariani, L; Procopio, G; Ricotta, R; Zilembo, N, 2005) |
| "The objective of this study was to assess the efficacy and safety of two regimens of irinotecan, combined or alternated with bolus 5-fluorouracil (5-FU) and folinic acid (FA), and the Mayo Clinic regimen as first-line therapy for colorectal cancer (CRC)." | 9.11 | Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. ( Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J, 2005) |
| "The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)." | 9.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "The combination of 5-fluorouracil (5-FU) plus leucovorin (LV) with oxaliplatin has become one of the standard treatments for advanced colorectal cancer (CRC)." | 9.11 | Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Diaz-Rubio, E; Guallar, JL; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massutí, B; Navarro, M; Sastre, J, 2005) |
| "To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC)." | 9.11 | Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. ( Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A, 2005) |
| "Between July 2001 and September 2002, 49 eligible patients were enrolled in an open-label phase II study to assess the efficacy and safety of first-line treatment with capecitabine/irinotecan in metastatic colorectal cancer." | 9.11 | Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. ( Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ, 2005) |
| "Women with metastatic breast cancer, Karnofsky performance status > or = 70, and previous treatment with > or = 3 regimens containing anthracyclines, taxanes, and capecitabine were eligible." | 9.11 | Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. ( Blum, JL; Clark, RS; Liepa, AM; Melemed, AS; Mennel, RG; O'Shaughnessy, JA; Snyder, D; Yardley, DA; Ye, Z, 2005) |
| "Two hundred forty-nine patients with advanced carcinoid tumors were randomized to either doxorubicin with fluorouracil (FU/DOX) or streptozocin with fluorouracil (FU/STZ)." | 9.11 | Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. ( Catalano, P; Haller, DG; Lipsitz, S; Mailliard, JA; Sun, W, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 9.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "To compare the efficacy and safety of doxorubicin and docetaxel (AT) with fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line chemotherapy for metastatic breast cancer (MBC)." | 9.11 | Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of ( Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 9.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 9.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)." | 9.11 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU." | 9.10 | Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 9.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy." | 9.10 | Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. ( Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H, 2002) |
| "This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer." | 9.10 | A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003) |
| "The purpose of this study was to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 9.10 | Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. ( Bountouroglou, N; Farmakis, D; Kosmas, C; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M, 2003) |
| "To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer." | 9.10 | Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. ( Abrams, J; Aisner, J; Allen, SL; Berry, DA; Chuang, E; Cirrincione, C; Cooper, MR; Duggan, DB; Henderson, IC; Norton, L; Parnes, HL; Perry, MC; Szatrowski, TP, 2003) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 9.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "The purpose of this multicenter phase III trial was to assess the impact of a time-intensification of FEC (fluorouracil, epirubicin, cyclophosphamide) and MMM (mitoxantrone, methotrexate, mitomycin C) regimens, supported by lenograstim (G-CSF) on the objective response rate, time to progression and survival of patients with chemotherapy-naive metastatic breast cancer (mbc)." | 9.10 | Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma. ( Capotorto, AM; Da Prada, GA; Farris, A; Lelli, G; Martoni, A; Massidda, B; Pavesi, L; Pedrazzoli, P; Robustelli della Cuna, G; Zamagni, C, 2003) |
| "Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles." | 9.10 | Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM, 2003) |
| "Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer." | 9.10 | A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 9.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 9.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients." | 9.10 | Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003) |
| "The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients." | 9.10 | A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. ( Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM, 2003) |
| "Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States." | 9.10 | Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 9.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "Capecitabine, a tumor-selective, oral fluoropyrimidine, has demonstrated significant antitumor activity in patients with metastatic breast cancer." | 9.10 | Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study. ( Bokemeyer, C; Jakob, A; Kanz, L; Knop, S; Mayer, F; Schupp, M, 2002) |
| "To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase II studies." | 9.10 | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. ( Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002) |
| " This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m2/d given for 2 weeks followed by a 1-week rest period and repeated in 3-week cycles, in patients with paclitaxel-refractory metastatic breast cancer." | 9.09 | Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. ( Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C, 1999) |
| "To evaluate the substitution of methotrexate with doxorubicin (Dox) in CMF-(cyclophosphamide, methotrexate, 5-fluorouracil) containing regimen for advanced breast cancer, 415 postmenopausal patients below the age of 66 years, naïve to chemotherapy, were accrued from 1980 to 1984 and followed-up until 1995." | 9.09 | Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. ( Andersson, M; Dombernowsky, P; Madsen, EL; Mouridsen, HT; Overgaard, M; Rose, C, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure." | 9.09 | Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. ( Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 9.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs." | 9.09 | [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics]. ( Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S, 2000) |
| "This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer." | 9.09 | Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. ( Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N, 2001) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 9.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients." | 9.09 | Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G ( Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L, 2001) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 9.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | 9.09 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC)." | 9.09 | Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. ( Bensmaïne, MA; Bleiberg, H; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M, 2001) |
| "Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 9.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 9.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 9.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "To assess the activity of paclitaxel in combination with 5-fluorouracil (5-FU) and leucovorin in breast cancer, a phase II trial was conducted in women with metastatic disease." | 9.09 | Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ( Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y, 2000) |
| "To evaluate the effect of previous adjuvant chemotherapy with or without anthracyclines on overall survival (OS), progression-free survival (PFS), and objective response (OR) rates of metastatic breast cancer patients treated with cyclophosphamide, epidoxorubicin, and fluorouracil (CEF) as first-line chemotherapy." | 9.08 | Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. ( Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M, 1996) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil (5-FU)/folinic acid (FA) in intensively pretreated metastatic breast cancer patients prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this regimen in a phase I/ II outpatient study." | 9.08 | Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. ( Klaassen, U; Seeber, S; Wilke, H, 1996) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 9.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma." | 9.08 | A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997) |
| "To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer." | 9.08 | Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. ( Andreesen, R; Bade, J; Dörken, B; Harstick, A; Hecker, H; Hiddemann, W; Horster, A; Käufer, C; Klaasen, U; Köhne, CH; Ohl, U; Schmoll, HJ; Schöffski, P; Schott, G; Schubert, U; Westerhausen, M; Wilke, H, 1998) |
| "Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/leucovorin in intensively pretreated patients with metastatic breast cancer prompted addition of paclitaxel and cisplatin to this regimen for a phase II study of outpatient first-line treatment of metastatic breast cancer." | 9.08 | Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. ( Diergarten, K; Eberhardt, W; Hanske, M; Harstrick, A; Klaassen, U; Korn, M; Müller, C; Seeber, S; Weyhofen, R; Wilke, H, 1998) |
| "To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)." | 9.08 | Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 8.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| "Background Topical 5-fluorouracil (5-FU) is an antineoplastic antimetabolite used for the treatment of actinic keratosis." | 8.93 | 5-Fluorouracil-induced exacerbation of rosacea. ( Cohen, PR; Haddock, ES, 2016) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process." | 8.91 | The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 8.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| " Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine." | 8.86 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010) |
| "Literature searches from large publication databases (PubMed, ASCO, ASCO GI, ESMO) were performed to capture key data relevant to bevacizumab, irinotecan, and the treatment of colorectal cancer." | 8.86 | Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. ( Heinemann, V; Hoff, PM, 2010) |
| "To examine the clinical effectiveness and cost-effectiveness of oral capecitabine for locally advanced and metastatic breast cancer in relation to its licensed indications." | 8.82 | Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. ( Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 8.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 7.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance." | 7.91 | ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019) |
| "5-Fluorouracil (5-FU)-based chemotherapy has always been the first-line treatment of colorectal cancer (CRC)." | 7.91 | The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells. ( Chen, J; Hou, J; Liu, C; Qin, A; Ren, T; Ren, W; Shan, F; Xiong, X, 2019) |
| "Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment." | 7.88 | Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. ( Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC, 2018) |
| "To investigate expression of cell cycle-related and expression-elevated protein in tumor (CREPT) in colorectal cancer (CRC) and determine its prognostic value in response to 5-fluorouracil (5-FU)." | 7.88 | Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. ( Chang, ZJ; Ding, LD; Jia, BQ; Kuang, YS; Li, J; Liu, HY; Liu, SH; Wang, XN; Wang, Y; Wang, YY; Yang, L; Zhu, BT, 2018) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 7.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 7.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| "This study aimed to evaluate the progression and treatment of experimental periodontitis (EP) in rats treated with 5-fluorouracil (5-FU)." | 7.81 | Evaluation of the progression and treatment of experimental periodontitis in rats subjected to chemotherapy with 5-fluorouracil. ( Bomfim, SR; de Almeida, JM; Ervolino, E; Garcia, VG; Longo, M; Novaes, VC; Theodoro, LH, 2015) |
| "To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)." | 7.81 | Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015) |
| "Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 7.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
| " The present study evaluated the efficacy and tolerability of the combination of lapatinib and capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy with trastuzumab, a taxane and/or anthracycline." | 7.80 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). ( Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B, 2014) |
| "To evaluate the cost-effectiveness of the addition of bevacizumab to the irinotecan-fluorouracil (Douillard regimen-CPT-FUFA-) in first-line treatment of metastatic colorectal cancer in a single-institution population." | 7.80 | Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014) |
| "To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 7.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 7.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)." | 7.79 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013) |
| "The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy." | 7.78 | Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. ( Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY, 2012) |
| "To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts." | 7.78 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 7.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "Irinotecan (CPT11) at 180 mg/m(2) with LV5FU2 for metastatic colorectal cancer (MCRC) has response rates (RRs) of 56 and 4% as first- and second-line treatments, respectively [1-2], and higher doses of CPT11 result in higher RRs." | 7.77 | Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. ( Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 7.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 7.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)." | 7.77 | Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011) |
| "Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab." | 7.77 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011) |
| "To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.77 | Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011) |
| "We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC)." | 7.77 | Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. ( Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G, 2011) |
| "To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)." | 7.77 | 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011) |
| "For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen." | 7.77 | [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011) |
| "Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival." | 7.77 | Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer. ( Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N, 2011) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 7.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 7.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 7.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes." | 7.76 | Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010) |
| "Single agent capecitabine is effective and well tolerated in metastatic breast cancer (MBC)." | 7.76 | Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment? ( Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE, 2010) |
| "Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)." | 7.76 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "002], presence of visceral metastases at the beginning of capecitabine treatment (HR = 2." | 7.75 | Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. ( Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F, 2009) |
| "A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study." | 7.75 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009) |
| "The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer." | 7.75 | Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009) |
| "To predict the response to primary systemic chemotherapy (PSC) involving weekly paclitaxel (PTX) followed by FEC100, we analyzed the therapeutic effects of PSC on 58 cases of stage II - III advanced breast cancer, 2 cases of PD, 4 cases of suspension due to adverse events, and 52 successful cases (89." | 7.74 | [Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer]. ( Harano, M; Higaki, K; Kagemoto, M; Kin, R; Masumura, K; Matsuura, H; Ohtani, S; Takada, S; Urashima, M, 2008) |
| "To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer." | 7.74 | [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. ( Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X, 2008) |
| "Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes." | 7.74 | Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. ( Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C, 2007) |
| "Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC)." | 7.74 | Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. ( Adena, M; Damianovich, D; Tebbutt, NC, 2007) |
| "Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors." | 7.74 | Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007) |
| "Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)." | 7.74 | DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007) |
| "Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "Although 5-fluorouracil (5-FU)-based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients." | 7.73 | 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. ( Buroker, TR; Cha, SS; D'Andre, S; Goldberg, RM; Kugler, JW; O'Connell, MJ; Poon, MA; Sargent, DJ, 2005) |
| "The efficacy and tolerability of therapy with gemcitabine plus cisplatin were evaluated in 49 patients with disseminated breast cancer refractory to anthracyclines, docetaxel and capecitabine." | 7.73 | [Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine]. ( Filatova, LV; Gershanovich, ML; Semiglazova, TIu, 2005) |
| "Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable." | 7.73 | The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. ( Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A, 2005) |
| "The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients." | 7.73 | Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. ( Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B, 2005) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 7.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 7.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 7.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 7.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 7.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "Previous phase II studies of continuous infusion Fluorouracil (5-FU) (CI 5-FU) in refractory metastatic breast cancer have shown modest activity with low toxicity." | 7.69 | Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. ( Chu, L; Havlin, KA; Peterson, BL; Sutton, LM; Winer, EP, 1996) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 6.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| "Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed." | 6.90 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019) |
| "The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 6.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | 6.78 | Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| " The most frequently observed adverse events reported with AZD6244 were acneiform dermatitis, diarrhoea, asthenia and peripheral oedema, compared with hand-foot syndrome, diarrhoea, nausea and abdominal pain with capecitabine." | 6.76 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. ( Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M, 2011) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 6.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary." | 6.73 | Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| "Capecitabine is an orally administered precursor of 5'-deoxy-5-fluorouridine that was rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue." | 6.73 | Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. ( Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D, 2007) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 6.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy." | 6.71 | Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003) |
| "Topotecan has shown fewer side effects and higher efficacy when given as a continuous i." | 6.71 | Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004) |
| "Thirty-six patients died because of disease progression, and 3 are alive with progressive disease." | 6.71 | Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A, 2005) |
| "Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)." | 6.70 | Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002) |
| "Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy." | 6.69 | [Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]. ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "5-Fluorouracil is a key element to the treatment of colon cancer." | 6.66 | Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. ( Allison, JD; Birnbaum, G; Khalid, U; Tanavin, T; Yang, Y, 2020) |
| "Lapatinib is an oral receptor tyrosine kinase inhibitor that targets HER2 and the EGFR." | 6.44 | Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. ( Cameron, DA; Stein, S, 2008) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 6.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis." | 6.41 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001) |
| "Locally advanced breast cancer patients were randomly assigned onto a study comparing cyclophosphamide (C; 75 mg/m(2) orally days 1 to 14), epirubicin (E; 60 mg/m(2) intravenously [IV] days 1, 8), and fluorouracil (F; 500 mg/m(2) IV days 1, 8) six cycles every 28 days versus E (120 mg/m(2) IV day 1), C (830 mg/m(2) IV day 1), and granulocyte colony-stimulating factor (filgrastim; 5 micro g/kg/d subcutaneously days 2 to 13) six cycles every 14 days." | 6.20 | Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK mult ( Bonnefoi, H; Bruning, P; Cufer, T; Hamilton, A; Mauriac, L; Piccart, MJ; Pritchard, KI; Therasse, P; Tomiak, E; Welnicka-Jaskiewicz, M, 2003) |
| "Most patients had disease progression as the best response to treatment (75." | 5.51 | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| "A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated." | 5.40 | Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "Chemoresistance of breast cancer is a worldwide problem for breast cancer and the resistance to chemotherapeutic agents frequently led to the subsequent recurrence and metastasis." | 5.39 | 53BP1 sensitizes breast cancer cells to 5-fluorouracil. ( Kong, X; Li, X; Wang, Y; Yan, S; Yang, Q, 2013) |
| "Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials." | 5.39 | Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013) |
| "Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 5.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
| " Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event." | 5.35 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009) |
| "The median interval between breast cancer diagnosis and MBC was 52 months (range 0-479); 76% had received endocrine therapy for MBC, 58% had visceral involvement and 30% had 3 or more metastatic sites." | 5.35 | First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? ( Brouste, V; Debled, M; Donamaria, C; Durand, M; Floquet, A; Madranges, N; Mauriac, L; Trainaud, A, 2009) |
| "BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer." | 5.34 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020) |
| "Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 5.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "Median time to disease progression was 9." | 5.32 | Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003) |
| "These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer." | 5.32 | Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003) |
| "The prognosis of breast cancer patients with liver metastases is extremely poor." | 5.32 | Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. ( Jassem, J; Sosińska-Mielcarek, K; Zaucha, R, 2004) |
| "Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor." | 5.30 | Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. ( Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS, 2019) |
| "We investigated the expression patterns of Ki67 and p53 in metastatic pancreatic adenocarcinomas and analyzed their relationship with disease progression-free survival (PFS) and overall survival (OS) in the overall study population and in patients treated with a gemcitabine-containing chemotherapy versus FOLFIRINOX chemotherapy." | 5.30 | Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. ( Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A, 2019) |
| " The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer." | 5.30 | Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. ( Adenis, A; Artru, P; Bennouna, J; Bertaut, A; Borel, C; Borg, C; Bouché, O; Conroy, T; Denis, MG; Deplanque, G; des Guetz, G; François, E; Ghiringhelli, F; Hebbar, M; Hiret, S; Seitz, JF; Stanbury, T, 2019) |
| "Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs." | 5.27 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018) |
| "0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy." | 5.24 | Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. ( Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y, 2017) |
| "Panitumumab plus infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) significantly improved overall survival versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer (mCRC)." | 5.22 | Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. ( Barber, B; Dong, J; Douillard, JY; Hechmati, G; Maglinte, GA; Wang, J, 2016) |
| " This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan." | 5.22 | Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016) |
| "We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma." | 5.22 | An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. ( Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M, 2016) |
| "The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n=612) or placebo (n=614)." | 5.20 | Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. ( Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL, 2015) |
| "This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens." | 5.20 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015) |
| "This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial." | 5.20 | Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015) |
| "In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16)." | 5.20 | Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. ( Arnold, D; Fietkau, R; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hoffmanns, H; Hofheinz, RD; Hohenberger, W; Hothorn, T; Lang-Welzenbach, M; Liersch, T; Lindemann, F; Raab, HR; Rödel, C; Sauer, R; Schlenska-Lange, A; Staib, L; Ströbel, P; Wilhelm, M; Wittekind, C; Wolff, HA, 2015) |
| "The MTD of (90)Y delivered in conjunction with capecitabine in the setting of intrahepatic cholangiocarcinoma or metastatic disease confined to the liver exceeds 170 Gy." | 5.19 | Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. ( Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M, 2014) |
| "We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea." | 5.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 5.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
| "The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC)." | 5.17 | An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. ( Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N, 2013) |
| "We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial." | 5.17 | Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. ( Blum, JL; Glück, S; Hu, S; McKenna, EF; O'Shaughnessy, J; Odom, D; Russell, C, 2013) |
| "Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer." | 5.17 | Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. ( Bechstein, WO; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mauer, M; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Tanis, E; Van Cutsem, E; Walpole, ET, 2013) |
| "This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer." | 5.17 | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013) |
| "In this study we evaluated the clinical efficacy and tolerability of low dose, capecitabine (500mg twice daily) together with oral cyclophosphamide (CTX) (a dose of 50mg once daily) in patients with metastatic breast cancer." | 5.16 | Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. ( El Mahdy, MM; El-Arab, LR; Swellam, M, 2012) |
| "To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)." | 5.16 | Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 5.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy." | 5.16 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer." | 5.16 | Bevacizumab added to neoadjuvant chemotherapy for breast cancer. ( Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA, 2012) |
| "The addition of irinotecan to infusional 5 fluorouracil and leucovorin significantly improves the response rate and survival compared with 5 fluorouracil/leucovorin alone in metastatic colorectal cancer." | 5.16 | First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. ( Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| " Given preclinical evidence of synergy when a fluoropyrimidine is added to gemcitabine plus a taxane in a sequence-specific schedule, we conducted a phase I study to evaluate the combination of nab-paclitaxel, gemcitabine, and capecitabine administered biweekly in patients with metastatic pancreatic adenocarcinoma." | 5.16 | A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. ( Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG, 2012) |
| "We conducted this phase II study in an effort to evaluate the efficacy and safety of a gemcitabine single chemotherapy as a second-line treatment for biliary tract cancer (BTC) patients who evidenced disease progression after the administration of 5-fluorouracil (5-FU)-based palliative chemotherapy." | 5.15 | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. ( Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2011) |
| "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists." | 5.15 | A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011) |
| "The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer." | 5.15 | Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ( Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011) |
| "The aim of this prospective open-label study was to evaluate the efficacy and safety of oral vinorelbine in combination with capecitabine in patients with metastatic breast cancer (MBC)." | 5.15 | Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer. ( Adua, D; Basile, ML; De Sanctis, R; Del Signore, E; Di Seri, M; Gori, B; Grassi, P; Longo, F; Quadrini, S; Stumbo, L, 2011) |
| "This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and progression-free survival rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin chemoradiotherapy followed by carboplatin and 5-fluorouracil." | 5.15 | Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. ( Dechaphunkul, T; Pruegsanusak, K; Sangthawan, D; Sunpaweravong, P, 2011) |
| "This multicenter, open-label, single-arm, Phase II study assessed the efficacy of a neoadjuvant chemotherapy with docetaxel (75 mg/m(2) q3w) followed by 5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2) and cyclophosphamide 500 mg/m(2) q3w in patients with early-stage breast cancer." | 5.15 | Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. ( Akiyama, F; Iwata, H; Kuroi, K; Kurosumi, M; Masuda, N; Nakamura, S; Ohashi, Y; Sato, N; Toi, M; Tsuda, H; Yamamoto, N, 2011) |
| " We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), the ERBIRINOX regimen, as first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC)." | 5.15 | Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. ( Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M, 2011) |
| "We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 5.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
| "In this prospective pilot study, we assessed the efficacy and safety of the FOLFIRI regimen (irinotecan 180 mg/m², leucovorin 200 mg/m² d1 followed by bolus 400 mg/m² 5-fluorouracil (5-FU) and by a 46-h 2400 mg/m² 5-FU infusion, every 2 weeks) in patients with advanced esophageal or junctional adenocarcinoma." | 5.15 | FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study. ( Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP, 2011) |
| "Oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule does induce responses in advanced gastric and GEJ adenocarcinoma." | 5.14 | A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. ( Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I, 2009) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 5.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 5.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "Patients with HER-2-positive breast cancer that progresses during treatment with trastuzumab were randomly assigned to receive capecitabine (2,500 mg/m(2) body-surface area on days 1 through 14 [1,250 mg/m(2) semi-daily]) alone or with continuation of trastuzumab (6 mg/kg body weight) in 3-week cycles." | 5.14 | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. ( Andersson, M; Bauer, W; Baumann, KH; Clemens, MR; Cufer, T; de Jongh, FE; du Bois, A; Duerr, R; Kaufmann, M; Loibl, S; Maartense, E; Maass, N; Nekljudova, V; Schmidt, M; Stein, RC; Uleer, C; von Minckwitz, G; Zielinski, C, 2009) |
| "Using data from a recent randomized trial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metastatic breast cancer considered to be taxane-resistant and previously treated with or resistant to an anthracycline." | 5.14 | Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA, 2009) |
| "We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab." | 5.14 | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. ( Bodoky, G; Chang Chien, CR; D'Haens, G; Folprecht, G; Hitre, E; Köhne, CH; Lim, R; Makhson, A; Nippgen, J; Pintér, T; Roh, JK; Rougier, P; Ruff, P; Schlichting, M; Stroh, C; Tejpar, S; Van Cutsem, E; Zaluski, J, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Treatment-naive patients with stage III non-resectable pancreatic adenocarcinoma were treated with PEFG/PEXG (cisplatin, epirubicin, 5-fluorouracil (F)/capecitabine (X), gemcitabine) or PDXG (docetaxel substituting epirubicin) regimen for 6 months followed by radiotherapy (50-60 Gy) with concurrent F or X or G." | 5.14 | Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A, 2009) |
| "A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer." | 5.14 | Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. ( Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N, 2010) |
| "To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years." | 5.14 | Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010) |
| "The aim of this study was to explore the clinical value of gemcitabine combined with capecitabine (GC) in heavily pre-treated patients with metastatic breast cancer." | 5.14 | Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. ( Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R, 2010) |
| "On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two agents in advanced anthracycline-pretreated breast cancer patients." | 5.14 | Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). ( Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C, 2010) |
| "Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial." | 5.14 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010) |
| "Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency." | 5.14 | A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010) |
| "This phase II trial evaluated the efficacy and safety of cetuximab combined with FOLFOX6 (leucovorin [LV] 5-fluorouracil [5-FU]/oxaliplatin) in the first-line treatment of patients with advanced or metastatic colorectal cancer." | 5.14 | A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. ( Badarinath, S; Boccia, RV; Cosgriff, TM; Dakhil, SR; Headley, DL, 2010) |
| "Chemotherapy-naive patients with locally advanced or metastatic, histologically proven adenocarcinoma of the pancreas were treated with a 21-day regimen of gemcitabine [1000 mg/m² day (d) 1, d8], escalating doses of oxaliplatin (80-130 mg/m² d1) and capecitabine (650-800 mg/m² b." | 5.14 | Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. ( Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R, 2010) |
| "Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities." | 5.14 | Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010) |
| "This phase II study prospectively evaluated the feasibility of vinorelbine in combination with capecitabine in Chinese patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 5.14 | Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P, 2010) |
| "To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer." | 5.14 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010) |
| "Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma." | 5.14 | Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). ( Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M, 2010) |
| "601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy." | 5.14 | Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010) |
| "To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy." | 5.13 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008) |
| "To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer." | 5.13 | Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008) |
| "Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients." | 5.13 | Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. ( Abali, H; Budakoglu, B; Hayran, M; Oksuzoglu, B; Yildirim, N; Zengin, N, 2008) |
| "The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC)." | 5.13 | Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. ( Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M, 2008) |
| "To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies." | 5.13 | Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008) |
| "Patients with advanced breast cancer were candidates to receive metronomic oral capecitabine (500 mg thrice daily) and cyclophosphamide (50 mg daily) plus bevacizumab (10 mg/kg every 2 weeks)." | 5.13 | Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. ( Bagnardi, V; Bertolini, F; Campagnoli, E; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Mancuso, P; Pietri, E; Rocca, A; Scarano, E; Shaked, Y; Torrisi, R, 2008) |
| "PURPOSE To determine whether irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines." | 5.13 | Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. ( Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO, 2008) |
| " Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab." | 5.13 | FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. ( Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R, 2008) |
| "XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)." | 5.13 | Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 5.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 5.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "To evaluate the response rate of the combination of capecitabine (C) and vinorelbine (V) followed by Docetaxel (D) in the 1st line treatment of advanced and metastatic breast cancer patients." | 5.13 | Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial. ( Chahine, G; Farhat, F; Gasmi, J; Ghosn, M; Kattan, J; Moukadem, W; Nasr, F; Younes, F, 2008) |
| "This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas." | 5.13 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008) |
| " Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab." | 5.13 | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. ( Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P, 2008) |
| " This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 5.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
| "Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity." | 5.13 | U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. ( Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H, 2008) |
| "Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)." | 5.13 | A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. ( Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008) |
| "To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC)." | 5.12 | Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ( Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 5.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 5.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 5.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC)." | 5.12 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. ( Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A, 2006) |
| "In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined." | 5.12 | A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006) |
| "A randomized phase II study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been conducted." | 5.12 | Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. ( Boige, V; Bouché, O; Breau, JL; Bugat, R; Cvitkovic, E; Ducreux, M; Etienne, PL; Mitry, E; Morvan, F; Ould-Kaci, M; Rougier, P; Seitz, JF; Tigaud, JM, 2006) |
| "To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen." | 5.12 | Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006) |
| "To study the efficacy of subconjunctival 5-fluorouracil (5-FU) and triamcinolone injection in halting the progression of impending recurrent pterygium." | 5.12 | Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. ( Leelapatranura, K; Phonjan, T; Prabhasawat, P; Tesavibul, N, 2006) |
| "COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 5.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
| "The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-based first-line chemotherapy in advanced colorectal cancer patients." | 5.12 | The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. ( Aglietta, M; Alabiso, I; Alabiso, O; Berruti, A; Bitossi, R; Brizzi, MP; Dogliotti, L; Forti, L; Gorzegno, G; Harris, A; Magnino, A; Miraglia, S; Saini, A; Sculli, CM; Sperti, E; Tampellini, M, 2006) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)." | 5.12 | Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006) |
| "This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)." | 5.12 | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006) |
| "The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer." | 5.12 | Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007) |
| "Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC)." | 5.12 | Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. ( Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007) |
| "Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy." | 5.12 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer. ( Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S, 2006) |
| "To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)." | 5.12 | Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 5.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients." | 5.12 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. ( Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S, 2007) |
| "The oral fluoropyrimidine carbamate, capecitabine, is a highly active and well-tolerated treatment for metastatic breast cancer." | 5.12 | Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. ( Bangemann, N; Fuchs, I; Gonsch, T; Hindenburg, HJ; Hinke, A; Klare, P; Kleine-Tebbe, A; Lakner, V; Schaller, G; Weber, J, 2007) |
| "Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)." | 5.12 | First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. ( Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "In the OPTIMOX1 trial, previously untreated patients with advanced colorectal cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and oxaliplatin that were administered until progression in the control arm or in a stop-and-go fashion in the experimental arm." | 5.12 | Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. ( Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 5.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes." | 5.12 | Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B, 2007) |
| "Phase II/III trials have shown that capecitabine is an active, well-tolerated therapy for metastatic breast cancer (MBC)." | 5.12 | An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. ( Bell, R; Nortier, JW; Paridaens, R; Rodrigues, H; Rossner, D; Salzberg, M; Vaslamatzis, MM; Venturini, M, 2007) |
| "1) To confirm the efficacy of irinotecan plus folinic acid/continuous 5-fluorouracil as bimonthly FOLFIRI regimen in metastatic colorectal cancer patients." | 5.12 | FOLFIRI chemotherapy for metastatic colorectal cancer patients. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A, 2007) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 5.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 5.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin." | 5.11 | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies." | 5.11 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. ( Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E, 2004) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 5.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC)." | 5.11 | Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. ( Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K, 2004) |
| "The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC)." | 5.11 | Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. ( Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 5.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 5.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "A phase II trial was designed to determine whether mistletoe extract can induce objective tumor response in patients with metastatic colorectal cancer resistant to 5-fluorouracil and leucovorin (5FU/LCV)-based chemotherapy." | 5.11 | Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. ( Bar-Sela, G; Haim, N, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 5.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "Thirty-six patients with advanced breast cancer were stratified for the presence of bone and non-bone involvement and treated at four dose levels from capecitabine 800 mg/m2 orally days 1-14 and vinorelbine 20 mg/m2 intravenously days 1 and 8, to capecitabine 1250 mg/m2 orally days 1-14 and vinorelbine 25 mg/m2 intravenously days 1 and 8, for a maximum of six cycles." | 5.11 | Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). ( Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B, 2004) |
| "Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)." | 5.11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005) |
| "Previous small phase II trials have demonstrated that the combination of 5-fluorouracil (5FU) and cisplatin(CDDP) could have clinical activity in metastatic biliary tract cancer." | 5.11 | A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. ( Anak, O; Baron, B; Ducreux, M; Gress, TM; Jeziorski, K; Nordlinger, B; Rougier, P; Van Cutsem, E; Van Laethem, JL; Wagener, T, 2005) |
| "To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer." | 5.11 | Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. ( Bajetta, E; Buzzoni, R; Catena, L; Celio, L; Della Torre, S; Gattinoni, L; Longarini, R; Mariani, L; Procopio, G; Ricotta, R; Zilembo, N, 2005) |
| "The objective of this study was to assess the efficacy and safety of two regimens of irinotecan, combined or alternated with bolus 5-fluorouracil (5-FU) and folinic acid (FA), and the Mayo Clinic regimen as first-line therapy for colorectal cancer (CRC)." | 5.11 | Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. ( Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J, 2005) |
| "The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)." | 5.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "The combination of 5-fluorouracil (5-FU) plus leucovorin (LV) with oxaliplatin has become one of the standard treatments for advanced colorectal cancer (CRC)." | 5.11 | Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Diaz-Rubio, E; Guallar, JL; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massutí, B; Navarro, M; Sastre, J, 2005) |
| "To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC)." | 5.11 | Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. ( Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A, 2005) |
| "Between July 2001 and September 2002, 49 eligible patients were enrolled in an open-label phase II study to assess the efficacy and safety of first-line treatment with capecitabine/irinotecan in metastatic colorectal cancer." | 5.11 | Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. ( Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ, 2005) |
| "We conducted a phase II study to assess the efficacy and tolerability of irinotecan and cisplatin as salvage chemotherapy in patients with advanced gastric adenocarcinoma, progressing after both 5-fluorouracil (5-FU)- and taxane-containing regimen." | 5.11 | Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. ( Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB, 2005) |
| "We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer." | 5.11 | Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. ( Agostara, B; Borsellino, N; Brunetti, C; Carrozza, F; Cartenì, G; Caruso, M; Chiarenza, M; Colucci, G; Cordio, S; Cramarossa, A; Di Bisceglie, M; Di Seri, M; Durini, E; Filippelli, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Guida, T; Leonardi, V; Lopez, M; Lorusso, V; Maiello, E; Mancarella, S; Manzione, L; Misino, A; Montemurro, S; Nettis, G; Paoletti, G; Pezzella, G; Pisconti, S; Romito, S; Rosati, G; Valdesi, M; Valerio, MR, 2005) |
| "Women with metastatic breast cancer, Karnofsky performance status > or = 70, and previous treatment with > or = 3 regimens containing anthracyclines, taxanes, and capecitabine were eligible." | 5.11 | Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. ( Blum, JL; Clark, RS; Liepa, AM; Melemed, AS; Mennel, RG; O'Shaughnessy, JA; Snyder, D; Yardley, DA; Ye, Z, 2005) |
| "Two hundred forty-nine patients with advanced carcinoid tumors were randomized to either doxorubicin with fluorouracil (FU/DOX) or streptozocin with fluorouracil (FU/STZ)." | 5.11 | Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. ( Catalano, P; Haller, DG; Lipsitz, S; Mailliard, JA; Sun, W, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 5.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "To compare the efficacy and safety of doxorubicin and docetaxel (AT) with fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line chemotherapy for metastatic breast cancer (MBC)." | 5.11 | Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of ( Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 5.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 5.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)." | 5.11 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005) |
| "5-fluorouracil (5-FU), irinotecan, and oxaliplatin are the most active drugs in advanced colorectal cancer (CRC), and survival is improved with patient exposure to all of them." | 5.11 | FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. ( Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "We have investigated the efficacy, safety and quality of life profiles of three therapeutic combinations [irinotecan + leucovorin (LV)/5-fluorouracil (5-FU), oxaliplatin + LV/5-FU and irinotecan +oxaliplatin] in patients with metastatic colorectal cancer after failure of a 5-FU-based regimen, or whose disease had progressed within 6 months of the end of treatment." | 5.10 | Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. ( Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P, 2002) |
| "In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU." | 5.10 | Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 5.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy." | 5.10 | Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. ( Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H, 2002) |
| "This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer." | 5.10 | A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003) |
| "The purpose of this study was to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 5.10 | Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. ( Bountouroglou, N; Farmakis, D; Kosmas, C; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M, 2003) |
| "To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer." | 5.10 | Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. ( Abrams, J; Aisner, J; Allen, SL; Berry, DA; Chuang, E; Cirrincione, C; Cooper, MR; Duggan, DB; Henderson, IC; Norton, L; Parnes, HL; Perry, MC; Szatrowski, TP, 2003) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 5.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "The purpose of this multicenter phase III trial was to assess the impact of a time-intensification of FEC (fluorouracil, epirubicin, cyclophosphamide) and MMM (mitoxantrone, methotrexate, mitomycin C) regimens, supported by lenograstim (G-CSF) on the objective response rate, time to progression and survival of patients with chemotherapy-naive metastatic breast cancer (mbc)." | 5.10 | Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma. ( Capotorto, AM; Da Prada, GA; Farris, A; Lelli, G; Martoni, A; Massidda, B; Pavesi, L; Pedrazzoli, P; Robustelli della Cuna, G; Zamagni, C, 2003) |
| "The purpose of the study was to investigate whether baseline quality of life (QoL) and changes in QoL scores from baseline are prognostic for time to progression (TTP) and/or overall survival (OS) in patients with advanced breast cancer receiving docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF)." | 5.10 | Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. ( Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V, 2003) |
| "Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles." | 5.10 | Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM, 2003) |
| "Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer." | 5.10 | A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 5.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 5.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients." | 5.10 | Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003) |
| "The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients." | 5.10 | A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. ( Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM, 2003) |
| "Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States." | 5.10 | Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002) |
| "The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere 100 x mg x m(-2) docetaxel and FEC 75 cyclophosphamide 500 mg x m(-2), fluorouracil 500 x mg x m(-2) and epirubicin 75 mg x m(-2), in alternating and sequential schedules for the first-line treatment of metastatic breast cancer." | 5.10 | Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. ( Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 5.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "Capecitabine, a tumor-selective, oral fluoropyrimidine, has demonstrated significant antitumor activity in patients with metastatic breast cancer." | 5.10 | Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study. ( Bokemeyer, C; Jakob, A; Kanz, L; Knop, S; Mayer, F; Schupp, M, 2002) |
| "To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase II studies." | 5.10 | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. ( Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002) |
| " This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m2/d given for 2 weeks followed by a 1-week rest period and repeated in 3-week cycles, in patients with paclitaxel-refractory metastatic breast cancer." | 5.09 | Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. ( Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C, 1999) |
| "To evaluate the substitution of methotrexate with doxorubicin (Dox) in CMF-(cyclophosphamide, methotrexate, 5-fluorouracil) containing regimen for advanced breast cancer, 415 postmenopausal patients below the age of 66 years, naïve to chemotherapy, were accrued from 1980 to 1984 and followed-up until 1995." | 5.09 | Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. ( Andersson, M; Dombernowsky, P; Madsen, EL; Mouridsen, HT; Overgaard, M; Rose, C, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure." | 5.09 | Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. ( Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 5.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs." | 5.09 | [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics]. ( Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S, 2000) |
| "This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer." | 5.09 | Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. ( Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N, 2001) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 5.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients." | 5.09 | Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G ( Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L, 2001) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 5.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases." | 5.09 | Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | 5.09 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC)." | 5.09 | Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. ( Bensmaïne, MA; Bleiberg, H; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M, 2001) |
| "Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 5.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 5.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 5.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "To assess the activity of paclitaxel in combination with 5-fluorouracil (5-FU) and leucovorin in breast cancer, a phase II trial was conducted in women with metastatic disease." | 5.09 | Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ( Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y, 2000) |
| "To evaluate the effect of previous adjuvant chemotherapy with or without anthracyclines on overall survival (OS), progression-free survival (PFS), and objective response (OR) rates of metastatic breast cancer patients treated with cyclophosphamide, epidoxorubicin, and fluorouracil (CEF) as first-line chemotherapy." | 5.08 | Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. ( Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M, 1996) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil (5-FU)/folinic acid (FA) in intensively pretreated metastatic breast cancer patients prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this regimen in a phase I/ II outpatient study." | 5.08 | Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. ( Klaassen, U; Seeber, S; Wilke, H, 1996) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 5.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma." | 5.08 | A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997) |
| "To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer." | 5.08 | Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. ( Andreesen, R; Bade, J; Dörken, B; Harstick, A; Hecker, H; Hiddemann, W; Horster, A; Käufer, C; Klaasen, U; Köhne, CH; Ohl, U; Schmoll, HJ; Schöffski, P; Schott, G; Schubert, U; Westerhausen, M; Wilke, H, 1998) |
| "Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/leucovorin in intensively pretreated patients with metastatic breast cancer prompted addition of paclitaxel and cisplatin to this regimen for a phase II study of outpatient first-line treatment of metastatic breast cancer." | 5.08 | Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. ( Diergarten, K; Eberhardt, W; Hanske, M; Harstrick, A; Klaassen, U; Korn, M; Müller, C; Seeber, S; Weyhofen, R; Wilke, H, 1998) |
| "To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)." | 5.08 | Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998) |
| "Laser therapy appears the best option among nonsurgical approaches for actinic cheilitis, and PDT showed higher efficacy when sequentially combined with 5% imiquimod." | 5.05 | Treatments of actinic cheilitis: A systematic review of the literature. ( Cornacchia, L; Lai, M; Longo, C; Pampena, R; Pellacani, G; Peris, K, 2020) |
| "5-Fluorouracil- and leucovorin-based chemotherapy regimens are the backbone of colorectal cancer treatment." | 4.98 | Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? ( Bironzo, P; Di Maio, M; Scagliotti, GV; Tampellini, M, 2018) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 4.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| "Background Topical 5-fluorouracil (5-FU) is an antineoplastic antimetabolite used for the treatment of actinic keratosis." | 4.93 | 5-Fluorouracil-induced exacerbation of rosacea. ( Cohen, PR; Haddock, ES, 2016) |
| "This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety." | 4.93 | XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. ( Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T, 2016) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process." | 4.91 | The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015) |
| "The clinical benefit of first-line doublet chemotherapy (including oxaliplatin or irinotecan) compared to single-drug therapy (5FU) in elderly patients (>70 or >75 years old) with metastatic colorectal cancer (MCRC) is controversial." | 4.91 | Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. ( Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L, 2015) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 4.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| " Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine." | 4.86 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010) |
| "Literature searches from large publication databases (PubMed, ASCO, ASCO GI, ESMO) were performed to capture key data relevant to bevacizumab, irinotecan, and the treatment of colorectal cancer." | 4.86 | Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. ( Heinemann, V; Hoff, PM, 2010) |
| "To examine the clinical effectiveness and cost-effectiveness of oral capecitabine for locally advanced and metastatic breast cancer in relation to its licensed indications." | 4.82 | Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. ( Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 4.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "Fluorouracil (FU) has been the mainstay of treatment for metastatic colorectal cancer (mCRC) for many years." | 4.82 | Critical evaluation of current treatments in metastatic colorectal cancer. ( Venook, A, 2005) |
| " This metaregression analysis examines the relationship between several surrogate markers and survival in women with advanced breast cancer after receiving first-line combination anthracycline chemotherapy 5-fluorouracil, adriamycin and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin and cyclophosphamide (FEC)." | 4.82 | Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. ( Barrett-Lee, P; Hackshaw, A; Knight, A; Leonard, R, 2005) |
| "Oral capecitabine is a useful chemotherapy for metastatic breast cancer, both as monotherapy and in combination with other cytotoxic drugs." | 4.81 | Moving forward with capecitabine: a glimpse of the future. ( Biganzoli, L; Martin, M; Twelves, C, 2002) |
| "The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade." | 4.80 | The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. ( Papamichael, D, 2000) |
| "We investigated whether or not postoperative complications (POCs) themselves have a negative survival impact or indirectly worsen the survival due to insufficient adjuvant chemotherapy in a pooled analysis of two large phase III studies performed in Japan PATIENTS AND METHODS: The study examined the patients who enrolled in 1304, phase III study comparing the efficacy of 6 and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III study to confirm the tolerability of oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients." | 4.31 | The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Yoshikawa, T, 2023) |
| "MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker of patient recurrence and pathological response to 5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy in LARC." | 4.31 | Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells. ( Caramés, C; Cristóbal, I; García-Foncillas, J; Luque, M; Madoz-Gúrpide, J; Rojo, F; Santos, A; Sanz-Álvarez, M, 2023) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 3.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance." | 3.91 | ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019) |
| "5-Fluorouracil (5-FU)-based chemotherapy has always been the first-line treatment of colorectal cancer (CRC)." | 3.91 | The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells. ( Chen, J; Hou, J; Liu, C; Qin, A; Ren, T; Ren, W; Shan, F; Xiong, X, 2019) |
| "Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment." | 3.88 | Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. ( Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC, 2018) |
| "To investigate expression of cell cycle-related and expression-elevated protein in tumor (CREPT) in colorectal cancer (CRC) and determine its prognostic value in response to 5-fluorouracil (5-FU)." | 3.88 | Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. ( Chang, ZJ; Ding, LD; Jia, BQ; Kuang, YS; Li, J; Liu, HY; Liu, SH; Wang, XN; Wang, Y; Wang, YY; Yang, L; Zhu, BT, 2018) |
| " All patients were offered 3 months of induction chemotherapy (FOLFIRINOX or gemcitabine depending on performance status), followed by exploratory laparotomy for resection or IRE in patients with Response Evaluation Criteria in Solid Tumors (RECIST) 1." | 3.85 | Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. ( Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 3.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| " Additionally, functional studies indicated that over-expression of RAD51B promoted cell proliferation, aneuploidy, and drug resistance, while RAD51B knockdown led to G1 arrest and sensitized cells to 5-fluorouracil (5-FU)." | 3.83 | RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer. ( Chen, X; Cheng, Y; Xi, Y; Yang, B, 2016) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 3.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| " We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin])." | 3.81 | Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. ( Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR, 2015) |
| "This study aimed to evaluate the progression and treatment of experimental periodontitis (EP) in rats treated with 5-fluorouracil (5-FU)." | 3.81 | Evaluation of the progression and treatment of experimental periodontitis in rats subjected to chemotherapy with 5-fluorouracil. ( Bomfim, SR; de Almeida, JM; Ervolino, E; Garcia, VG; Longo, M; Novaes, VC; Theodoro, LH, 2015) |
| "Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m² i." | 3.81 | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. ( Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J, 2015) |
| "To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)." | 3.81 | Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015) |
| "Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 3.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
| " The present study evaluated the efficacy and tolerability of the combination of lapatinib and capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy with trastuzumab, a taxane and/or anthracycline." | 3.80 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). ( Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B, 2014) |
| "Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse." | 3.80 | AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014) |
| "To evaluate the cost-effectiveness of the addition of bevacizumab to the irinotecan-fluorouracil (Douillard regimen-CPT-FUFA-) in first-line treatment of metastatic colorectal cancer in a single-institution population." | 3.80 | Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014) |
| "To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 3.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
| "To explore genes of the killer-cell immunoglobulin-like receptor (KIR) and of the HLA ligand and their relationship with the outcome of metastatic colorectal cancer (mCRC) patients treated with first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI)." | 3.80 | Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. ( Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V, 2014) |
| "Capecitabine is a safe chemotherapeutic agent with moderate activity for first-line treatment of older metastatic colorectal cancer patients with limited performance status." | 3.80 | First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. ( Alacacioglu, A; Barutca, S; Degirmenci, M; Dirican, A; Karabulut, B; Oktay, E; Uslu, R; Varol, U; Yildiz, I, 2014) |
| "Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC)." | 3.80 | Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. ( Abrahamova, J; Benesova, V; Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kohoutek, M; Melichar, B; Obermannova, R; Pavlik, T; Usiakova, Z; Vyzula, R, 2014) |
| "To investigate the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) compared with bevacizumab plus mFOLFOX6 in first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)." | 3.80 | Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Barber, B; de Liège, F; Graham, CN; Hechmati, G; Hjelmgren, J; Knox, H; Lanier, J, 2014) |
| "The FFCD 2000-05 randomised trial included 410 patients with advanced colorectal cancer and compared a sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan) and a combination arm C that begins directly with FOLFOX followed by FOLFIRI." | 3.79 | Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. ( Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P, 2013) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 3.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)." | 3.79 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013) |
| "To evaluate efficacy, safety, and feasibility of maintenance therapy with capecitabine after fluoropyrimidines/oxaliplatin or fluoropyrimidines/irinotecan chemotherapy in patients with incurable colorectal cancer." | 3.79 | [Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer]. ( Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D, 2013) |
| "MTT assays revealed that tumor cells from ascites of primary and type II EOC were more sensitive to paclitaxel (PTX) and carboplatin (CBDCA) than relapse (p = 0." | 3.79 | In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. ( Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y, 2013) |
| "Preliminary results showed that there is a significant MCV increase in patients receiving capecitabine for metastatic colon and breast cancer after 12 weeks of treatment." | 3.79 | Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer. ( Gervasi, E; Giovanardi, F; Pezzuolo, D; Prati, G; Scaltriti, L; Scarabelli, L, 2013) |
| "Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second intention for patients who continue to progress despite TBT." | 3.79 | Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. ( Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G, 2013) |
| "Macrocytosis inversely related to risk of disease progression in patients treated with metronomic capecitabine plus cyclophosphamide and bevacizumab for metastatic breast cancer." | 3.78 | Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. ( Bagnardi, V; Balduzzi, A; Bertolini, F; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Luini, A; Mancuso, P; Montagna, E; Pastrello, D; Sandri, MT, 2012) |
| "The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy." | 3.78 | Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. ( Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY, 2012) |
| "To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts." | 3.78 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 3.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| " We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11)." | 3.77 | Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. ( Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R, 2011) |
| "Irinotecan (CPT11) at 180 mg/m(2) with LV5FU2 for metastatic colorectal cancer (MCRC) has response rates (RRs) of 56 and 4% as first- and second-line treatments, respectively [1-2], and higher doses of CPT11 result in higher RRs." | 3.77 | Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. ( Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 3.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 3.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011) |
| "Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab." | 3.77 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011) |
| "To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.77 | Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011) |
| "We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC)." | 3.77 | Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. ( Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G, 2011) |
| "The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer." | 3.77 | Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. ( Boc, M; Ocvirk, J; Rebersek, M, 2011) |
| "To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)." | 3.77 | 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011) |
| "For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen." | 3.77 | [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011) |
| "Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival." | 3.77 | Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer. ( Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N, 2011) |
| "It has been reported that thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and excision repair cross-complementing-1 (ERCC-1) were useful markers to predict the efficacy of anti cancer agents including 5-fluorouracil (5-FU) and oxaliplatin for unresectable advanced colorectal cancer." | 3.77 | [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]. ( Haga, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kumamoto, K; Kuwabara, K; Miura, I; Ohsawa, T; Okada, N, 2011) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 3.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 3.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 3.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes." | 3.76 | Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010) |
| "Single agent capecitabine is effective and well tolerated in metastatic breast cancer (MBC)." | 3.76 | Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment? ( Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE, 2010) |
| "The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity." | 3.76 | Trastuzumab beyond progression: a cost-utility analysis. ( Brauchli, P; Dedes, KJ; Matter-Walstra, KW; Pestalozzi, BC; Schwenkglenks, M; Szucs, TD, 2010) |
| "Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)." | 3.76 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "002], presence of visceral metastases at the beginning of capecitabine treatment (HR = 2." | 3.75 | Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. ( Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F, 2009) |
| "Patients with histologically proven, metastatic colorectal cancer receiving bevacizumab as first-line therapy in combination with irinotecan and 5-fluorouracil were eligible for our analysis." | 3.75 | Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. ( Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M, 2009) |
| "We investigated the efficacy and toxicity of metronomic capecitabine administered at a fixed dose of 1,000 mg daily in three elderly or poor performance status patients with advanced colorectal cancer (CRC) and gastric cancer." | 3.75 | To widen the setting of cancer patients who could benefit from metronomic capecitabine. ( Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA, 2009) |
| "A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study." | 3.75 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009) |
| "The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer." | 3.75 | Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009) |
| " demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer." | 3.75 | Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. ( Sobrero, A, 2009) |
| "Conflicting data exist regarding the relevance of high-frequency microsatellite instability (MSI-H) for predicting the prognosis and benefits of 5-fluorouracil (5-FU)-based chemotherapy." | 3.75 | Chemosensitivity and survival in gastric cancer patients with microsatellite instability. ( Ando, K; Kakeji, Y; Maehara, Y; Masuda, T; Morita, M; Ohgaki, K; Oki, E; Yoshida, R; Zhao, Y, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| "To predict the response to primary systemic chemotherapy (PSC) involving weekly paclitaxel (PTX) followed by FEC100, we analyzed the therapeutic effects of PSC on 58 cases of stage II - III advanced breast cancer, 2 cases of PD, 4 cases of suspension due to adverse events, and 52 successful cases (89." | 3.74 | [Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer]. ( Harano, M; Higaki, K; Kagemoto, M; Kin, R; Masumura, K; Matsuura, H; Ohtani, S; Takada, S; Urashima, M, 2008) |
| "To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer." | 3.74 | [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. ( Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X, 2008) |
| " We investigated the efficacy of the epirubicin+cisplatin+fluorouracil (ECF) as continuous infusion) regimen in association with a gonadotropin-releasing hormone (GnRH) analog in 36 premenopausal women with T2-T4a-d N0-2 M0 ER and/or PgR-positive breast cancer." | 3.74 | Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. ( Colleoni, M; Goldhirsch, A; Intra, M; Luini, A; Medici, M; Nolè, F; Peruzzotti, G; Renne, G; Rocca, A; Severi, G; Torrisi, R; Veronesi, P; Viale, G, 2007) |
| "Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes." | 3.74 | Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. ( Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C, 2007) |
| "Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC)." | 3.74 | Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. ( Adena, M; Damianovich, D; Tebbutt, NC, 2007) |
| "The aim of this study is to evaluate the safety and efficacy of hepatic artery infusion (HAI) of 5-fluorouracil (5FU) for patients with liver metastases from colorectal carcinoma after radiological placement of infusion catheters." | 3.74 | Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. ( Hirayama, I; Horikoshi, H; Motegi, K; Saito, T; Sameshima, S; Sawada, T; Tomozawa, S, 2007) |
| "Docetaxel, capecitabine and 5-fluorouracil have been shown to be active in the treatment of metastatic gastric adenocarcinoma." | 3.74 | Chemoimmunotherapy in the treatment of metastatic gastric cancer. ( Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G, 2007) |
| "Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors." | 3.74 | Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007) |
| "Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)." | 3.74 | DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007) |
| "Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
| "In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal cancer (mCRC)." | 3.74 | Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. ( Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S, 2008) |
| "The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue." | 3.74 | A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008) |
| "Although 5-fluorouracil (5-FU)-based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients." | 3.73 | 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. ( Buroker, TR; Cha, SS; D'Andre, S; Goldberg, RM; Kugler, JW; O'Connell, MJ; Poon, MA; Sargent, DJ, 2005) |
| "The efficacy and tolerability of therapy with gemcitabine plus cisplatin were evaluated in 49 patients with disseminated breast cancer refractory to anthracyclines, docetaxel and capecitabine." | 3.73 | [Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine]. ( Filatova, LV; Gershanovich, ML; Semiglazova, TIu, 2005) |
| "Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable." | 3.73 | The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. ( Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A, 2005) |
| "The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients." | 3.73 | Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. ( Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B, 2005) |
| "We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 3.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 3.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 3.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "Murine glioma 261 (Gl261) cells were transduced with an adenoviral vector (Adex-CAUPTK) encoding both uracil phosphoribosyltransferase and thymidine kinase genes which sensitise cells to 5-fluorouracil (5-FU) and ganciclovir (GC), respectively." | 3.72 | Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. ( Desaknai, S; Esik, O; Hamada, H; Lumniczky, K; Safrany, G, 2003) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 3.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "In this marker evaluation study, we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug metabolic pathways and DNA repair that predict clinical outcome to 5-fluorouracil (5-FU)/oxaliplatin chemotherapy in patients with advanced colorectal cancer could be identified." | 3.72 | A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Yang, D; Zahedy, S; Zhang, W, 2004) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 3.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| " High DPD mRNA levels in liver metastasis and advanced colorectal cancer may have clinical importance for 5-fluorouracil-based chemosensitivity." | 3.71 | Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. ( Ichikawa, W; Nihei, Z; Shirota, Y; Sugihara, K; Uetake, H; Yamada, H, 2002) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "An 83-year-old Caucasian man with cutaneous T-cell lymphoma developed an aggressive squamous cell carcinoma of the left forearm, which recurred and metastasized after Mohs micrographic surgery and systemic chemotherapy with cis-platin and 5-fluorouracil." | 3.70 | Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis. ( Beer, R; Elizeri, Y; Gmyrek, R; Grossman, ME; Oster, MW; Schneiderman, P; Silvers, DN, 1999) |
| "In a series of 71 patients with advanced colorectal cancer treated with biochemically modulated 5-fluorouracil (5-FU) and methotrexate (MTX), we investigated the relationship between the proliferating-cell nuclear antigen (PCNA) (PC10) and p53 (Pab1801) primary-tumor immunohistochemical expression with respect to clinical response and long-term prognosis." | 3.69 | p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. ( Cuevas, MA; De Lena, M; Lacava, J; Leone, B; Machiavelli, M; Paradiso, A; Perez, J; Rabinovich, M; Rodriquez, R; Romero, A; Sapia, MG; Simone, G; Vallejo, C, 1996) |
| "Sixty-nine patients with locally advanced breast cancer were given induction chemotherapy with doxorubicin and cyclophosphamide (day 1) followed by methotrexate and 5-Fu (day 8)." | 3.69 | Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer. ( Malmström, P; Sjövall, MP, 1997) |
| "Previous phase II studies of continuous infusion Fluorouracil (5-FU) (CI 5-FU) in refractory metastatic breast cancer have shown modest activity with low toxicity." | 3.69 | Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. ( Chu, L; Havlin, KA; Peterson, BL; Sutton, LM; Winer, EP, 1996) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 2.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| "Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed." | 2.90 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019) |
| " Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)." | 2.90 | Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019) |
| "Even clearly resectable pancreatic cancer still has an unfavorable prognosis." | 2.87 | Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. ( Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U, 2018) |
| "Data of 179 patients with N3 HNSCC from two GORTEC randomized trials (96-01 and 99-02) were pooled." | 2.84 | Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. ( Alfonsi, M; Aupérin, A; Bardet, E; Bourhis, J; Calais, G; Deprez, P; Geoffrois, L; Gery, B; Graff, P; Grégoire, V; Lapeyre, M; Maingon, P; Martin, L; Pignon, T; Rives, M; Sire, C; Tao, Y; Verrelle, P, 2017) |
| "In this cohort of rectal cancer patients dominated by T4 and advanced T3 cases given sequential oxaliplatin-containing preoperative therapy with acceptable toxicity, high tumour response rates and overall survival were obtained, consistent with both local and systemic effects." | 2.82 | Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. ( Boye, K; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Larsen, SG; Ree, AH; Saelen, MG; Seierstad, T; Wiig, JN, 2016) |
| " All patients experienced at least one grade 3 or higher adverse event: neutropenia (five patients, 83%), proteinuria (two patients; 33%) and anemia, thrombocytopenia and hypertension (one patient each, 17%)." | 2.80 | Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. ( Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N, 2015) |
| "Patients with locally advanced rectal cancer who achieve a pathological complete response to neoadjuvant chemoradiation have an improved prognosis." | 2.80 | Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. ( Avila, K; Cataldo, PA; Chow, OS; Coutsoftides, T; Dietz, DW; Fichera, A; Garcia-Aguilar, J; Herzig, DO; Hunt, SR; Kumar, AS; Marcet, JE; Oommen, S; Patil, S; Polite, BN; Smith, DD; Stamos, MJ; Ternent, CA; Varma, MG, 2015) |
| " Preclinical evidence suggests that the scheduling of bevacizumab may be crucial to optimize its combination with chemo-radiotherapy." | 2.80 | Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. ( Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F, 2015) |
| "Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle." | 2.80 | A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. ( Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015) |
| "The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 2.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "Capecitabine monotherapy was continued for patients without disease progression." | 2.79 | The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma. ( Bai, C; Bai, Y; Cheng, Y; Fan, Q; Gong, J; Hu, B; Hu, G; Jiao, S; Liang, J; Liu, Y; Shen, L; Shi, Y; Wang, J; Xu, N; Xu, R; Zhang, F; Zhang, J; Zhang, X; Zheng, L, 2014) |
| "Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin." | 2.79 | Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). ( Bethe, U; Brümmendorf, TH; Clement, PM; Delord, JP; Erfán, J; Gauler, TC; Hicking, C; Iglesias, L; Keilholz, U; Krauss, J; Mesía, R; Peyrade, F; Remenar, E; Schafhausen, P; Vermorken, JB, 2014) |
| "The aim of this study was the evaluation of pharmacokinetic parameters, biomarkers, clinical outcome, and imaging parameters in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus sunitinib." | 2.79 | FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. ( Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D, 2014) |
| " Predicted Cp [median and 90% prediction interval] was simulated using the population pharmacokinetic model established for other cancers (PPK model) and compared to observed Cp." | 2.79 | Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ( Allison, DE; Han, K; Jin, J; Lowe, J; Maia, M; Sersch, MA, 2014) |
| "Resistant HNSCC cell lines were generated by exposure to an EGFR TKI, gefitinib, in vitro." | 2.78 | A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. ( Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A, 2013) |
| " A multicenter phase II study was conducted to evaluate the efficacy and toxicity of capecitabine combined with nedaplatin for these patients." | 2.78 | Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy. ( Chen, ZB; Liao, H; Lin, Z; Ou, XQ; Peng, PJ; Peng, YL; Wang, SY; Zhang, HY, 2013) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Penis cancer is rare and clinical trial evidence on which to base treatment decisions is limited." | 2.78 | Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). ( Bahl, A; Barber, J; Burnett, S; Carrington, B; Chester, JD; Cruickshank, C; Elliott, T; Hall, E; Harland, SJ; Nicholson, S; Pickering, L; Thomson, A; Waters, R, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | 2.78 | Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| "The main reason for early disease progression was the appearance of new lesions or progression of non-target lesions." | 2.78 | Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. ( Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM, 2013) |
| "Patients with locally advanced or low rectal cancer were treated with capecitabine 825 mg/m(2) twice daily on days 1-14 and 22-35, oxaliplatin 50mg/m(2) on days 1, 8, 22 and 29, bevacizumab 5mg/kg on days 14, 1, 15 and 29, and radiation 50." | 2.77 | Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. ( Berry, S; Easaw, J; Hay, J; Kennecke, H; Post, J; Rao, S; Tankel, K; Wong, R; Zhou, C, 2012) |
| "Gemcitabine was given for 3 cycles after CRT." | 2.77 | Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. ( Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB, 2012) |
| "IGF-1 was associated with the number of metastases (p = 0." | 2.77 | Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. ( Camphausen, K; Graves, CA; Kim, HJ; Kim, SH; Kwon, HC; Lee, JH; Lee, S; Oh, SY, 2012) |
| " The most frequently observed adverse events reported with AZD6244 were acneiform dermatitis, diarrhoea, asthenia and peripheral oedema, compared with hand-foot syndrome, diarrhoea, nausea and abdominal pain with capecitabine." | 2.76 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. ( Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M, 2011) |
| "Patients with clinical T3, T4, or N1-2 rectal cancer were subjected to a preoperative CCRT protocol with FOLFOX and bevacizumab (5 mg/kg) biweekly for 6 cycles followed by a standardized laparoscopic TME procedure, as detailed in the attached video." | 2.76 | Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. ( Cheng, KW; Lai, HS; Liang, JT, 2011) |
| "Eligible patients had newly diagnosed HNSCC." | 2.76 | A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. ( Blair, EA; Cohen, EE; Haraf, DJ; Kunnavakkam, R; Salama, JK; Seiwert, T; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2011) |
| "Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26." | 2.76 | Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. ( Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J, 2011) |
| "Capecitabine and lapatinib were given orally at escalating doses, starting at capecitabine 1500 mg/m(2)/day on days 1-14 and lapatinib 1000 mg daily on days 1-21." | 2.76 | A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. ( Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K, 2011) |
| "Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev." | 2.75 | Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. ( Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M, 2010) |
| " After two cycles, a 4-week outpatient treatment of gemcitabine (1000 mg/m(2)) on days 1 and 15 combined with 5-FU (500 mg/m(2)) and CDDP (7 mg/m(2)) on days 1 and 15 was commenced." | 2.75 | Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. ( Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y, 2010) |
| "Capecitabine was administered at 850 mg/m twice daily every day with 5 days per week radiotherapy (1." | 2.75 | Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. ( Choi, DW; Choi, SH; Heo, JS; Jun, HJ; Kang, WK; Kim, HS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS; Yi, SY, 2010) |
| "We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2/VEGFR-3), platelet-derived growth factor receptor beta, and c-Kit in combination with capecitabine and irinotecan." | 2.75 | Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. ( Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO, 2010) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | 2.75 | Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. ( Chen, XQ; Li, FH; Li, YH; Luo, HY; Qiu, MZ; Wang, F; Xu, RH; Zhou, ZW, 2010) |
| "Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50." | 2.75 | A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. ( Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE, 2010) |
| "To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer." | 2.75 | [Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer]. ( Chen, SC; Lu, ZH; Wu, F; Xiong, JP, 2010) |
| "Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules." | 2.75 | Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. ( Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J, 2010) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| "We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK parameters of S-1 and the relationship between toxicity and the individual maximum concentrations (Cmax) or the area under the concentration-time curve (AUC) of 5-fluorouracil (5-FU) in Japanese patients with advanced cancer." | 2.75 | Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. ( Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K, 2010) |
| "The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada." | 2.75 | Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. ( Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN, 2010) |
| "Standard adjuvant chemoradiotherapy of rectal cancer still consists of 5-fluorouracil (5-FU) only." | 2.75 | Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α. ( Baumann, W; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Staib, L; Wiegel, T, 2010) |
| "All the patients with metastatic colorectal cancer treated with at least one line of chemotherapy for metastatic disease and progressed after I line chemotherapy were considered eligible and enrolled into the trial." | 2.74 | [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer]. ( Carloni, F; Nicoletti, S; Ravaioli, A; Tamburini, E; Tassinari, D, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| "Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy." | 2.74 | Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. ( Goldberg, RM; Green, EM; McLeod, HL; Sanoff, HK; Sargent, DJ, 2009) |
| "To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer." | 2.74 | [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009) |
| " Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia." | 2.74 | Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. ( Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP, 2009) |
| "This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC)." | 2.73 | Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, YF; Chao, TY; Chen, PM; Chiou, TJ; Chiu, CF; Chung, CY; Hwang, WS; Lin, SF, 2008) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| "Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0." | 2.73 | Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. ( Hermans, JJ; Hop, WC; Incrocci, L; Jeekel, J; Kazemier, G; Morak, MJ; van Dekken, H; van der Gaast, A; van Eijck, CH, 2008) |
| "Celecoxib was given daily during CRT at one of five doses (200 mg bd to 600 mg bd)." | 2.73 | A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. ( Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR, 2007) |
| "Metastatic breast cancer patients who experienced disease progression after at least one (taxane or anthracycline based) chemotherapy regimen and an expected survival of at least 3 months and ECOG performance status 0-2 were eligible." | 2.73 | A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. ( Creaven, P; Levine, E; O'connor, T; Rustum, Y, 2008) |
| "Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | 2.73 | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 2.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| " The relation between adverse events on IROX to selected characteristics was analyzed." | 2.73 | Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. ( Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2007) |
| "Metastatic renal carcinoma patients without prior fluoropyrimidine therapy and normal organ function were treated with oral capecitabine 880 mg/m(2) twice daily along with continuous infusion GTI-2040 starting at 148 mg/m(2)/day for 21 days, for each 28-day cycle." | 2.73 | A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. ( Bukowski, R; Desai, AA; Kardinal, CG; Lewis, N; Makalinao, A; Murray, P; Poiesz, B; Quinn, DI; Stadler, WM; Torti, FM, 2008) |
| "Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy." | 2.73 | Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. ( Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A, 2007) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| " This approach to treatment of locally advanced pancreatic cancer is safe and promising, with good local control for a substantial proportion of patients, and merits testing in a randomised trial." | 2.73 | Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. ( Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E, 2007) |
| "Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary." | 2.73 | Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| "All patients had histologically proven squamous cell carcinoma of the esophagus." | 2.73 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. ( Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM, 2008) |
| " But given the low efficacy of 5-FU in the dosage we applied in the study, it cannot be recommended as a single treatment for further studies." | 2.73 | Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study. ( Babić, DR; Jelić, SB; Jezdić, SD; Krivokapić, ZV; Micev, MT; Pesko, PM; Popov, IP, 2008) |
| " Treatment of patients diagnosed with pancreatic cancer with radiotherapy and 5-fluorouracil was a safer approach than treatment with radiotherapy and gemcitabine, which induced more severe toxic adverse effects." | 2.73 | The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. ( Brasiūniene, B; Juozaityte, E, 2007) |
| "Capecitabine was given at a dose of 900 mg m(-2) for 5 days per week combined with 45 Gy of radiotherapy in 25 doses." | 2.73 | Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. ( Byrne, P; Cooper, R; Craven, I; Crellin, A; Melcher, A; Sebag-Montefiore, D, 2007) |
| "on day 1 every 3 weeks until disease progression or unacceptable toxicities." | 2.73 | A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH, 2008) |
| "Capecitabine is an orally administered precursor of 5'-deoxy-5-fluorouridine that was rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue." | 2.73 | Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. ( Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D, 2007) |
| "The median time to disease progression was 9." | 2.73 | [A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy]. ( Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M, 2008) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 2.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "4), use of antiglaucoma medication, dosage of topical steroid postoperatively, and being operated on by a trainee surgeon (odds ratio, 2." | 2.72 | Effect of trabeculectomy on lens opacities in an East Asian population. ( Aung, T; Chew, PT; Devereux, JG; Foster, PJ; Gazzard, G; Husain, R; Khaw, PT; Oen, FT; Seah, SK, 2006) |
| "Capecitabine is an effective salvage regimen in patients with recurrent and metastatic NPC." | 2.71 | A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. ( Au, GK; Chua, DT; Sham, JS, 2003) |
| "A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy." | 2.71 | Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003) |
| "Thirteen patients had limited extrahepatic cancer." | 2.71 | A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. ( Blind, PJ; Gustavsson, B; Hafström, L; Lindnér, P; Naredi, P; Oman, M, 2003) |
| "The median dysphagia free time was 9." | 2.71 | A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. ( Glynne-Jones, R; Goodchild, K; Harney, J; Hoskin, PJ; Phillips, H; Saunders, MI, 2003) |
| "The time to disease progression and the median survival time were 5." | 2.71 | A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Beretta, GD; Cascinu, S; Catalano, V; Graziano, F; Labianca, R; Lai, V; Mosconi, S; Santini, D; Testa, E; Tonini, G, 2003) |
| "Treatment was given until disease progression or unacceptable toxicity." | 2.71 | A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. ( Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH, 2003) |
| "5-Fluorouracil was given at 750 mg m(-2) day(-1) on days 1-5 every 4 weeks." | 2.71 | Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. ( Bui, BN; Cany, L; Debled, M; Ferrière, JM; Gaston, R; Mathoulin-Pélissier, S; Palussière, J; Ravaud, A; Trufflandier, N, 2003) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| "Topotecan has shown fewer side effects and higher efficacy when given as a continuous i." | 2.71 | Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004) |
| "The median time to disease progression was 8 weeks, and the median overall survival was 15 weeks." | 2.71 | Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E, 2004) |
| "Gemcitabine was dose escalated, 50-300 mg/m(2) on day 1." | 2.71 | Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. ( Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME, 2004) |
| "Thirty-six patients died because of disease progression, and 3 are alive with progressive disease." | 2.71 | Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A, 2005) |
| "The median time to disease progression was 6." | 2.70 | A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. ( Ryan, CW; Stadler, WM; Vogelzang, NJ, 2002) |
| "Febrile neutropenia was observed in 10% of patients and 2." | 2.70 | Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. ( Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P, 2002) |
| "In four patients with disease progression per bidimensional and unidimensional criteria, the response was stable disease per volumetric criteria." | 2.70 | CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. ( Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE, 2002) |
| " The current study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma." | 2.70 | Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. ( Ishikawa, O; Matsuno, S; Okada, S; Okusaka, T; Saisho, H; Sato, K; Sato, T; Tokuuye, K; Wakasugi, H, 2001) |
| "Twenty-one patients with metastatic renal cell carcinoma (RCC) and a Cancer and Leukemia Group B performance status of 0 to 2 were enrolled." | 2.70 | A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. ( Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ, 2002) |
| "Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002) |
| "We report the results of the Subcutaneous Administration Propeukin Program (SCAPP) II trial of an outpatient treatment in renal cell carcinoma using interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) administered subcutaneously in combination with fluorouracil (5-FU)." | 2.69 | Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Pr ( Abourachid, H; Andrieu, JM; Azagury, M; Benhammouda, A; Berdah, JF; Brewer, Y; Chastang, C; Chretien, Y; Di Palma, M; Guillet, P; Hauteville, D; Krakowski, I; Larregain-Fournier, D; Lucas, V; Malaurie, E; Mayeur, D; Mejean, A; Monnier, A; Paule, B; Pavlovitch, JM; Pfister, C; Salze, P; Tadrist, Z; Tourani, JM; Untereiner, M, 1998) |
| " However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin." | 2.69 | Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv ( Apolone, G; Couvreur, ML; Curran, D; De Waele, B; Doci, R; Labianca, R; Lasser, P; Marsoni, S; Nakajima, T; Nitti, D; Pector, JC; Rauschecker, H; Rougier, P; Sahmoud, T; Wils, J, 1998) |
| "Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years." | 2.69 | Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. ( Bjarnason, GA; Cripps, C; Fields, AL; Goel, R; Hrincu, A; Jensen, JL; Kerr, IA; Khoo, KE; Warner, E, 1999) |
| "A total of 99 patients with advanced colorectal cancer were treated with carboplatin (80 mg/m2, day 1-7), 5-FU (750 mg/m2, day 1-5), leucovorin (100 mg/m2, day 1-5) every 4 weeks." | 2.69 | The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category? ( Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D, 1999) |
| "Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy." | 2.69 | [Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]. ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy." | 2.69 | Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. ( Dolan, ME; Haraf, DJ; Hsieh, YC; Humerickhouse, R; Kies, MS; List, M; Mittal, BB; Pelzer, H; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RR; Witt, ME, 2000) |
| "Febrile neutropenia was recorded in 15% of courses." | 2.69 | Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. ( Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E, 2000) |
| "This paclitaxel-based treatment regimen for locoregionally advanced esophageal cancer produced increased toxicity with no improvement in results when compared with our previous 5-FU experience." | 2.69 | Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. ( Adelstein, DJ; Ciezki, J; DeCamp, M; Dumot, JA; Larto, MA; Rice, TW; Rybicki, LA; Saxton, J; Vargo, JJ; Zuccaro, G, 2000) |
| "5-Fluorouracil has been reported to have modest antitumor activity in androgen independent prostate cancer." | 2.68 | The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. ( Daliani, DD; Eisenberg, PD; Fueger, R; Logothetis, CJ; Lord, R; Weems, J, 1995) |
| "Sixty-three patients developed distant metastases or local relapse, 30 in the CT + RT group and 33 in the RT group." | 2.68 | Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. ( Bertelsen, K; Högberg, T; Koern, J; Onsrud, M; Simonsen, E; Sundfør, K; Tropé, CG; Westberg, R, 1996) |
| "From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy." | 2.68 | Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. ( Aman, E; Barugel, M; Blajman, C; Carraro, S; Fiorini, A; Giglio, R; Gonzalez, G; Jarentchuk, A; Kneitschel, R; Milano, C; Nadal, J; Navigante, A; Pennella, E; Roca, E; Santarelli, MT; Sardi, M, 1996) |
| "After a median follow-up of 9 years, disease progression was reported in 40% of patients in the control group, 40% in the HEP group and 29% in the HEP/5-FU group." | 2.68 | Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Can ( Couvreur, ML; Curran, D; dos Santos, JG; Lise, M; Nitti, D; Rauschecker, H; Roelofsen, F; Sahmoud, T; Stremmel, W; Wils, J, 1997) |
| " Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)." | 2.67 | A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994) |
| "5-Fluorouracil is a key element to the treatment of colon cancer." | 2.66 | Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. ( Allison, JD; Birnbaum, G; Khalid, U; Tanavin, T; Yang, Y, 2020) |
| "AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC." | 2.66 | Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020) |
| "Currently, cancer and its progression to metastasis result in a large number of deaths." | 2.61 | Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues. ( de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL, 2019) |
| "The management of metastatic colorectal cancer remains a significant clinical challenge to oncologists worldwide." | 2.50 | Sequencing of treatment in metastatic colorectal cancer: where to fit the target. ( Mukherji, D; Shamseddine, A; Temraz, S, 2014) |
| "We conducted a meta-analysis to compare oral S-1 and infusional 5-fluorouracil (5-FU) to determine which agent was more efficacious and less toxic in combination with PTX." | 2.50 | The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. ( Chen, X; Gao, P; Liu, H; Lu, X; Song, Y; Sun, J; Wang, Z; Xu, H; Zhang, N, 2014) |
| "Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied." | 2.49 | Locally advanced pancreatic cancer. ( Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN, 2013) |
| "In head and neck squamous cell carcinoma (HNSCC), the inhibition of epidermal growth factor receptor (EGFR) signaling as a central step in carcinogenesis, progression, and metastasis is the predominant approach." | 2.49 | Molecular targeting agents in the context of primary chemoradiation strategies. ( Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ, 2013) |
| "For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear." | 2.48 | Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012) |
| "Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease." | 2.46 | Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. ( Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM, 2010) |
| "Advanced pancreatic cancer is usually treated with first-line gemcitabine (GEM) (alone or in combination)." | 2.46 | What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. ( Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F, 2010) |
| "In advanced pancreatic cancer, level one evidence has established a significant survival advantage with chemotherapy, compared to best supportive care." | 2.44 | Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. ( Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C, 2008) |
| "Lapatinib is an oral receptor tyrosine kinase inhibitor that targets HER2 and the EGFR." | 2.44 | Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. ( Cameron, DA; Stein, S, 2008) |
| "The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies." | 2.44 | Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group. ( Antonini, N; Koopman, M; Mol, L; Punt, C; Simkens, L; Tol, J; van Krieken, H, 2008) |
| "In advanced pancreatic cancer, oxaliplatin has been found to be clinically effective in phase II trials in which it was combined with either 5-fluorouracil (5-FU) or gemcitabine, the current standard chemotherapy for this disease." | 2.42 | The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. ( Scheithauer, W; Van Cutsem, E, 2003) |
| "Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures." | 2.42 | Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003) |
| "Gemcitabine has thus become the de facto standard of care for advanced pancreatic cancer, and current efforts are directed toward finding strategies that can capitalize on and extend these clinical benefits." | 2.42 | Chemotherapy for advanced pancreatic cancer. ( Haller, DG, 2003) |
| "No case of epidermoid (squamous cell) cancer of the colon has been previously described in a pregnant woman." | 2.42 | [Colon cancer in pregnancy]. ( Fermeaux, V; Mathonnet, M, 2003) |
| "Renal cell cancer is still a challenge not only concerning operative techniques (nephron-sparing techniques, established minimally-invasive techniques, such as laparoscopy, and experimental minimally-invasive techniques, such as cryoablation, radiofrequency ablation and others), but also with regard to the impact of systemic (immuno)therapy." | 2.42 | [Immunotherapy of renal cell carcinoma: results from current phase-III-trials]. ( Doehn, C; Jocham, D, 2004) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 2.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Survival, disease progression, quality of life, and toxicity." | 2.41 | Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. ( Simmonds, PC, 2000) |
| "Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis." | 2.41 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001) |
| " The activity (first- and second-line) of Xeloda (capecitabine) with limited side effects and the development of oral vinorelbine and anthracyclines should improve access to chemotherapy and also concentrate further interest on treatment with long-term administration of cytotoxic agents." | 2.40 | Optimizing chemotherapy for patients with advanced breast cancer. ( Cottu, PH; Cuvier, C; Espie, M; Lerebours, F; Marty, M, 1999) |
| "Hazard ratios for overall survival and disease progression were 0." | 1.72 | A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. ( Cheng, S; Gu, J; Jiang, D; Lau, WY; Liu, C; Mao, F; Shen, L; Shi, J; Sun, J; Wang, N; Zhou, L, 2022) |
| "Colorectal cancer is one of the most common cancers in the world." | 1.62 | Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. ( Akkuş, E; Gürbüz, M; Utkan, G, 2021) |
| "The incidence of pancreatic cancer is increasing in developed countries." | 1.62 | Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting. ( Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A, 2021) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "Although the continuation of cetuximab in combination with paclitaxel after EXTREME provides moderate benefit, it could be an interesting option for selected patients." | 1.62 | Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. ( Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C, 2021) |
| "Using drug-resistant TP53-null colon cancer cells as a model we demonstrated that p65BTK silencing or chemical inhibition overcame the 5-fluorouracil resistance of CRC cell lines and patient-derived organoids and significantly reduced the growth of xenografted tumours." | 1.56 | BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. ( Agostini, M; Bonomo, S; Canzonieri, V; Cerrito, MG; Cialdella, A; D'Amato, F; Ferri, GL; Giovannoni, R; Grassilli, E; Helin, K; Ianzano, L; Lavitrano, M; Leone, BE; McLean, CM; Missaglia, C; Noli, B; Pisano, F; Pucciarelli, S; Romano, G; Voest, EE, 2020) |
| "Over 50% of colorectal cancer patients develop resistance after a transient response to therapy." | 1.56 | Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. ( Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J, 2020) |
| "At the time of disease progression, sTGF-β was increased compared with that of diagnosis (mean, 26." | 1.56 | The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. ( Bang, JH; Bang, YJ; Jin, MH; Nam, AR; Oh, DY; Park, H; Park, JE, 2020) |
| " Physiological information of treatment response derived via diffuse reflectance spectroscopy (DRS) from murine primary CRC tumors provide a better understanding for the development of new drugs and dosing strategies in CRC." | 1.56 | Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response. ( Bullard, EA; Fahr, MJ; Greening, GJ; Hale, LN; Muldoon, TJ; Mundo, AI; Rajaram, N, 2020) |
| "At the time of disease progression, FOLFIRI cetuximab regimen was reintroduced resulting in stabilization of disease and he continued with capecitabine cetuximab therapy until disease progression in October 2016." | 1.56 | Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. ( Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE, 2020) |
| "She was diagnosed with esophageal cancer (cT3N2M0, stage III)." | 1.56 | A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020) |
| " Within multivariable logistic regression analysis, patients with an ECOG score of 0 have a lower probability of serious adverse events (OR 0." | 1.51 | ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. ( Abdel-Rahman, O, 2019) |
| "Most patients had disease progression as the best response to treatment (75." | 1.51 | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| " No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups." | 1.51 | Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. ( Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019) |
| "Data were analyzed from a prospective pancreatic cancer database." | 1.48 | Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. ( Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA, 2018) |
| "LINP1 knockdown mitigated breast cancer cell growth by inducing G1-phase cell cycle arrest and apoptosis." | 1.48 | Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. ( Chen, B; Guo, R; Li, Y; Liang, Y; Liu, Y; Sang, Y; Song, X; Wang, L; Yang, Q; Yu, Z; Zhang, H; Zhang, N; Zhao, W, 2018) |
| "Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival." | 1.48 | Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? ( Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L, 2018) |
| "For patients with disease progression with FOLFIRINOX who have a good performance status, NG might be a reasonable second-line option." | 1.48 | Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. ( Kellett, C; Kim, CA; Lambert, P; Zhang, H, 2018) |
| "A total of 80 cases of colorectal cancer tissues were examined by immunohistochemistry for MTA3 protein expression." | 1.46 | MTA3 regulates malignant progression of colorectal cancer through Wnt signaling pathway. ( Feng, M; Gao, T; Jiao, T; Li, Y; Liu, M; Sun, M; Zhang, Y; Zhou, H, 2017) |
| "Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression." | 1.46 | A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017) |
| "For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment." | 1.43 | Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin. ( Ohi, H; Ozaki, T; Seki, H; Yabusaki, H, 2016) |
| "The patient was diagnosed with thrombotic thrombocytopenic purpura and treated with a plasma exchange." | 1.43 | [A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course]. ( Hatano, Y; Ishibashi, M; Kato, K; Konda, R; Michishita, Y; Nozawa, T; Oyama, K; Sasaki, A, 2016) |
| "DDA1 overexpression in colon cancer lines promoted cell proliferation, facilitated cell cycle progression, inhibited 5-FU-induced apoptosis, enhanced invasion, and induced the epithelial-mesenchymal transition." | 1.43 | DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling. ( Chen, J; Cui, F; Fan, J; Jiang, W; Liu, C; Liu, X; Mi, Y; Peng, Z; Qin, X; Sun, H; Tang, H; Wang, J; Wang, X; Wen, Y; Xue, Y; Yan, D; Yu, F; Yu, Y; Yue, B; Zhang, D; Zhang, M; Zhao, S; Zhou, Z, 2016) |
| "Fifty patients with rectal cancer undergoing neoadjuvant (chemo)radiotherapy and surgery were included in the study." | 1.43 | NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival. ( Dvorak, J; Fanta, J; Kubecova, M; Rychterova, V; Voboril, R; Voborilova, J, 2016) |
| "We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC." | 1.43 | Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. ( Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG, 2016) |
| "Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide." | 1.43 | Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer. ( Esmaeilpour, K; Haghighi, S; Kasbkar, H; Yasaei, M, 2016) |
| " The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients." | 1.42 | Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. ( Kanazawa, S; Katsui, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Onishi, H; Sakaguchi, K; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N; Yamamoto, K; Yasunaka, T, 2015) |
| "Stable disease and further disease progression were achieved in 36 and 14 patients, respectively." | 1.42 | Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. ( Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ, 2015) |
| "After disease progression, a second line based on FOLFIRI-aflibercept was started achieving an initial partial response followed by a long-lasting disease stability with a good tolerability." | 1.42 | [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]. ( Aroldi, F; Zaniboni, A, 2015) |
| "Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the majority of whom present with unresectable disease." | 1.40 | A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. ( Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W, 2014) |
| "A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated." | 1.40 | Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship." | 1.40 | Colon cancer, version 3.2014. ( Bekaii-Saab, T; Benson, AB; Chan, E; Chen, YJ; Cooper, HS; Engstrom, PF; Enzinger, PC; Fenton, MJ; Freedman-Cass, DA; Fuchs, CS; Gregory, KM; Grem, JL; Hunt, S; Kamel, A; Leong, LA; Lin, E; Messersmith, W; Mulcahy, MF; Murphy, JD; Nurkin, S; Rohren, E; Ryan, DP; Saltz, L; Sharma, S; Shibata, D; Skibber, JM; Sofocleous, CT; Stoffel, EM; Stotsky-Himelfarb, E; Venook, AP; Willett, CG, 2014) |
| "Irinotecan (CPT-11) was used as a chemotherapeutic agent in 24 patients, gemcitabine (GEM) in 24 and doxorubicin in 59." | 1.40 | Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY, 2014) |
| "Gastric samples from patients with gastric cancer were further analyzed for levels of a specifically downregulated lncRNA (termed as LEIGC)." | 1.40 | LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. ( Chen, J; Chen, Z; Gao, S; Han, Y; Huang, J; Wu, D; Wu, P; Ye, J, 2014) |
| "Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy." | 1.40 | Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014) |
| "The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection." | 1.40 | Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. ( Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014) |
| "All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy." | 1.40 | Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer. ( Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S, 2014) |
| "Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy." | 1.39 | Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013) |
| "Head and neck carcinomas are among the most frequent tumor diseases and, because of different multimodal therapy options, cause enormous costs." | 1.39 | Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. ( Guntinas-Lichius, O; Hartmann, M; Himmel, M, 2013) |
| "Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port." | 1.39 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013) |
| "Silencing of PI3K p85α in colorectal cancer cells increased disruption of mitochondrial membrane potential and enhanced 5-FU-induced apoptosis." | 1.39 | The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis. ( Sun, Y; Tian, H; Wang, L; Yang, H, 2013) |
| "Chemoresistance of breast cancer is a worldwide problem for breast cancer and the resistance to chemotherapeutic agents frequently led to the subsequent recurrence and metastasis." | 1.39 | 53BP1 sensitizes breast cancer cells to 5-fluorouracil. ( Kong, X; Li, X; Wang, Y; Yan, S; Yang, Q, 2013) |
| "Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials." | 1.39 | Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013) |
| "Gastric cancer is one of the most common human cancers and ranks the second in the global cancer-related mortality." | 1.39 | High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. ( Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L, 2013) |
| "The role of second-line therapy in gastric cancer patients mostly stemmed from clinical trials with monochemotherapy carried out in Asian countries." | 1.39 | FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. ( Amodio, A; Barba, M; Belli, F; Boggia, S; Di Lauro, L; Fattoruso, S; Giannarelli, D; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P, 2013) |
| "She underwent curative resection for sigmoid colon cancer( T4a, N2, M0, Stage IIIC)." | 1.39 | [Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer]. ( Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kikuchi, A; Kobayashi, H; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H, 2013) |
| "The prognosis of unresectable biliary tract cancer has improved recently." | 1.39 | Improvement of prognosis for unresectable biliary tract cancer. ( Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N, 2013) |
| "To evaluate the efficacy and treatment-related toxicity of accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer (LRIRC)." | 1.38 | Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. ( Dai, Y; Li, L; Shao, ZY; Sun, DS; Yu, JM; Zhang, JD, 2012) |
| "A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008." | 1.38 | Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer. ( Chen, PC; Chen, SK; Chen, YC; Chuang, EY; Hsiao, CK; Lai, LC; Lee, JM; Lee, YC; Tsai, MH; Yang, PW, 2012) |
| "Ten patients had disease progression." | 1.38 | Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer. ( Bi, CP; Chang, TH; Chen, MK; Lai, GM; Lin, JT; Liu, MT; Wang, JW, 2012) |
| "Moreover, circulating tumor cells were demonstrated by flow cytometry." | 1.38 | [Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012]. ( Horger, M; Jaschonek, K; Kanz, L; Kopp, HG; Kurth, R; Mayer, F; Orgel, M, 2012) |
| "Unresectable pancreatic cancer (UPC) has low survival." | 1.38 | Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. ( Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ, 2012) |
| "In patients with cervical oesophageal cancer 35 of 55 (64%) underwent oesophageal resection or pharyngo-laryngectomy." | 1.38 | [The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus]. ( Bellyei, S; Cseke, L; Farkas, R; Horváth, OP; Márton, S; Papp, A; Pavlovics, G; Potó, L; Varga, G, 2012) |
| "In early-stage breast cancer, radiotherapy delivered after conservative surgery leads to a reduction in the risk of local recurrences by approximately two thirds." | 1.38 | [A case of cutaneous mammary re-irradiation]. ( Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY, 2012) |
| "Obesity is a risk factor for the development of esophageal malignancy." | 1.37 | Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity. ( Mathew, J; Odell, JA; Stauffer, JA, 2011) |
| "Head and neck squamous cell carcinoma (HNSCC) is one prevalent human cancer worldwide." | 1.37 | Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. ( Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH, 2011) |
| "Treatment with temozolomide alone or in combination with capecitabine and bevacizumab resulted in objective response or stabilization in 71% of PDEC patients who failed on first-line chemotherapy." | 1.37 | Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. ( Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S, 2011) |
| "Here, we report on 2 patients with colorectal cancer and severe liver dysfunction secondary to hepatic metastases." | 1.37 | Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. ( Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C, 2011) |
| "For patients with HER2-overexpressing gastric cancer, there is an improved prognosis with additional trastuzumab to chemotherapy with a platinum compound and a fluoropyrimidin in first-line therapy." | 1.37 | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). ( Dumke, K; Krüger, M; Reymond, M; Weissinger, F, 2011) |
| "At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders." | 1.37 | miRNA signature associated with outcome of gastric cancer patients following chemotherapy. ( Aprelikova, O; Choi, IJ; Green, JE; Kim, CH; Kim, HK; Kim, J; Lee, ET; Munroe, DJ; Rettig, RL, 2011) |
| "Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 1.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
| "XELOX for unresectable advanced colorectal cancer has been approved in Japan." | 1.37 | [Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer]. ( Amano, R; Fuyuhiro, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Tanaka, H; Yamada, N; Yashiro, M, 2011) |
| "A total of 107 patients with advanced gastric cancer treated in our hospital from December 2005 to November 2008 were included in this retrospective analysis." | 1.37 | [HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis]. ( Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH, 2011) |
| "The risk of venous thromboembolism has been reported to increase when receiving bevacizumab." | 1.36 | Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. ( Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T, 2010) |
| "Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | 1.36 | Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. ( Jiang, T; Li, QF; Liang, J; Liu, KW; Lv, HY; Yao, RY, 2010) |
| "However, the role of CSCs in colorectal cancer metastasis is unclear." | 1.36 | A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. ( Cheung, LW; Chow, AK; Chu, AC; Lam, CS; Lan, HY; Lan, XR; Law, WL; Ng, L; Pang, R; Poon, JT; Poon, RT; Tan, VP; Wong, BC; Yau, TC, 2010) |
| "Patients with locally advanced pancreatic cancer (LAPC) are most commonly managed with chemotherapy or concurrent chemoradiotherapy (CRT), which may or may not include non-involved regional lymph nodes in the clinical target volume." | 1.36 | Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. ( Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA, 2010) |
| "To compare the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of FOLFOX6 and TLF regimens for advanced gastric cancer." | 1.36 | [Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer]. ( Deng, YM; Li, LL; Xian, HB; Yu, HB, 2010) |
| "Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | 1.36 | [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. ( Jiang, J; Jiang, T; Li, QF; Liang, J; Lü, HY; Song, SA; Sun, YY; Yao, RY, 2010) |
| "CRP was associated with disease progression and factors reflecting nutritional depletion such as serum albumin, lymphocyte count and body weight loss ratio." | 1.35 | Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. ( Inoue, Y; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Tanaka, K; Toiyama, Y; Yokoe, T, 2008) |
| "Patients with locally advanced pancreatic cancer were treated with concurrent radiation therapy (1." | 1.35 | Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer. ( Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| " Since all these measures are accompanied by relatively low risks of chronic bleeding a choice of palliative or radical dosage of radiation is possible." | 1.35 | [Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck]. ( Korytova, LI; Sokurenko, VP; Suvorova, IuV; Tarazov, PG, 2008) |
| " In addition, relative dose intensity (RDI), therapeutic efficacy, and adverse events in the patients who were given the regimen, we compared between the groups." | 1.35 | [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kuwabara, K; Matsuki, M; Miyazaki, T; Okada, N; Sano, M; Yokoyama, M, 2008) |
| "The increased MMP-7 levels at disease progression support the hypothesis that this protease could play a role in acquired resistance by degrading IGFBP-3." | 1.35 | Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. ( Augé, JM; Carcereny, E; Codony-Servat, J; Gallego, R; García-Albéniz, X; Gascón, P; Longarón, R; Maurel, J; Oliveras, A; Tosca, M, 2009) |
| " Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event." | 1.35 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009) |
| "Juvenile-onset Open Angle Glaucoma (JOAG) has been proposed to be a small subset of Primary Open Angle Glaucoma (POAG) and on a continual spectrum of Primary Open Angle Glaucoma." | 1.35 | Bilateral ocular hypertension with rapidly progressive optic neuropathy in a teen. ( Byrne, E; Hua, LV; Yudcovitch, L, 2009) |
| "The median interval between breast cancer diagnosis and MBC was 52 months (range 0-479); 76% had received endocrine therapy for MBC, 58% had visceral involvement and 30% had 3 or more metastatic sites." | 1.35 | First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? ( Brouste, V; Debled, M; Donamaria, C; Durand, M; Floquet, A; Madranges, N; Mauriac, L; Trainaud, A, 2009) |
| "Patients with potentially resectable gastric cancer treated with preoperative CRT are found to be ineligible for surgery principally because of peritoneal progression." | 1.35 | Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. ( Ajani, JA; Badgwell, BD; Crane, CH; Das, P; Delclos, ME; Janjan, NA; Kim, MM; Krishnan, S; Mansfield, PF; Maru, D; Phan, AT, 2008) |
| "Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU)." | 1.35 | A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. ( Alba, E; Carabantes, F; Dueñas, R; González, E; López-Siles, J; Márquez, A; Ribelles, N; Sánchez, A; Sánchez, MJ; Sánchez-Rovira, P; Sevilla, I, 2008) |
| "About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases." | 1.34 | Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? ( Amisano, M; Bouzari, H; Capussotti, L; Massucco, P; Muratore, A; Sperti, E; Zorzi, D, 2007) |
| "After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases)." | 1.34 | Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. ( Chung, HC; Jeung, HC; Kim, BS; Moon, YW; Noh, SH; Rha, SY; Roh, JK; Yoo, NC, 2007) |
| "All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH." | 1.34 | Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007) |
| "In advanced colorectal cancer (ACC), FOLFOX4 has been accepted as a standard chemotherapeutic regimen." | 1.34 | UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. ( Brugnatelli, S; Corazza, GR; Gattoni, E; Luchena, G; Riccardi, A; Sagrada, P; Scalamogna, R; Tinelli, C; Tronconi, MC, 2007) |
| "Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 1.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "In our cohort of patients with advanced pancreatic cancer treated with second-line chemotherapy, TTP1 <6 months is a strong negative prognostic factor for TTP2 and residual survival." | 1.34 | Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. ( Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W, 2007) |
| "Median time to disease progression was 9." | 1.32 | Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003) |
| "5-Fluorouracil (5-FU) is an anticancer agent clinically used against various cancers including renal cell carcinoma (RCC)." | 1.32 | Significance of thymidylate synthase activity in renal cell carcinoma. ( Fukushima, M; Miki, T; Mizutani, Y; Nakao, M; Nonomura, M; Wada, H; Yoshida, O, 2003) |
| "The local recurrence rate of colorectal cancer has been significantly reduced due to the use of combined radiochemotherapy." | 1.32 | Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer--preliminary results. ( Abdel-Rahman, S; D hmke, E; Ertl-Wagner, B; Issels, RD; Krych, M; Pachmann, S; Schaffer, M; Schaffer, PM, 2003) |
| "These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer." | 1.32 | Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003) |
| "We compared expression profiles from gastric cancer endoscopic biopsy specimens obtained at a chemosensitive state (partial remission after 5-FU/cisplatin) with those obtained at a refractory state (disease progression), using Affymetrix oligonucleotide microarray technology (U133A)." | 1.32 | DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. ( Bae, JM; Choi, IJ; Chun, JH; Kang, HC; Kim, E; Kim, HK; Kim, HS; Kim, IH; Kim, IJ; Kim, JH; Lee, JS; Park, IS; Park, JG; Park, JH, 2004) |
| "With this knowledge breast cancer patients can be better informed about what they can expect." | 1.32 | Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. ( Abu-Saad, HH; Candel, MJ; Courtens, AM; de Jong, N; Schouten, HC, 2004) |
| "The prognosis of breast cancer patients with liver metastases is extremely poor." | 1.32 | Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. ( Jassem, J; Sosińska-Mielcarek, K; Zaucha, R, 2004) |
| "5-Fluorouracil (5-FU) was given as a bolus (500-1000 mg/m2/day) during the first and last weeks of RT in 22 patients, whereas continuous 5-FU (225 mg/m2/day) was given to 3 patients." | 1.31 | Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. ( Latona, C; Paulino, AC, 2000) |
| "The outcome of patients with mucinous appendiceal neoplasms with peritoneal surface dissemination has changed as a result of a better understanding of the clinical and pathologic features of this disease." | 1.31 | Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. ( Esquivel, J; Sugarbaker, PH, 2001) |
| "In this cohort of breast cancer patients treated with chemotherapy, summed EDR scores were significantly associated with time to tumor progression and overall survival." | 1.31 | Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. ( Bornstein, R; Fruehauf, JP; Li, KT; McLaren, CE; Mehta, RS; Nguyen, KP; Parker, RJ; Yu, IR, 2001) |
| "The first site of disease progression was local in 72% of cases." | 1.31 | Limitations of conventional doses of chemoradiation for unresectable biliary cancer. ( Brown, T; Charnsangavej, C; Crane, CH; Curley, S; Delclos, M; Janjan, NA; Macdonald, KO; Vauthey, JN; Wong, A; Yehuda, P, 2002) |
| "About one-third of patients with gastric cancer are unresectable at the time of diagnosis." | 1.30 | Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. ( Cho, JY; Chung, HC; Kim, BS; Kim, CB; Kim, JH; Min, JS; Noh, SH; Park, JO; Rha, SY; Roh, JK; You, NC, 1997) |
| "Measuring a bone resorption marker, ICTP, allows clinicians to monitor patients' responses to CAF therapy and may prevent prolonged ineffective therapy or unnecessary changes in therapy as a result of the flare phenomenon." | 1.30 | Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. ( Koizumi, M; Matsumoto, S; Ogata, E; Takahashi, S; Yamashita, T, 1999) |
| "Metaplastic breast cancer is a rare disease with little information available to guide therapy." | 1.30 | Metaplastic breast cancer: prognosis and response to systemic therapy. ( Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE, 1999) |
| "These guidelines for management of Bowen's disease have been prepared for dermatologists on behalf of the British Association of Dermatologists." | 1.30 | Guidelines for management of Bowen's disease. British Association of Dermatologists. ( Cox, NH; Eedy, DJ; Morton, CA, 1999) |
| "Primary tumours were carcinoids in nine, gastrinomas in five, non-functioning pancreatic tumours in six and calcitonin-secreting tumours in two patients." | 1.29 | Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. ( Bernades, P; Menu, Y; Ruszniewski, P; Skinazi, F; Zins, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 65 (6.51) | 18.2507 |
| 2000's | 470 (47.09) | 29.6817 |
| 2010's | 411 (41.18) | 24.3611 |
| 2020's | 52 (5.21) | 2.80 |
| Authors | Studies |
|---|---|
| Prashanth, T | 1 |
| Thirusangu, P | 1 |
| Vijay Avin, BR | 1 |
| Lakshmi Ranganatha, V | 1 |
| Prabhakar, BT | 1 |
| Khanum, SA | 1 |
| de Siqueira, LRP | 1 |
| de Moraes Gomes, PAT | 1 |
| de Lima Ferreira, LP | 1 |
| de Melo Rêgo, MJB | 1 |
| Leite, ACL | 1 |
| Hou, XY | 1 |
| Zhang, P | 2 |
| Du, HZ | 1 |
| Gao, YQ | 1 |
| Sun, RQ | 1 |
| Qin, SY | 1 |
| Tian, Y | 2 |
| Li, J | 11 |
| Zhang, YX | 1 |
| Chu, WH | 1 |
| Zhang, ZJ | 1 |
| Xu, FG | 1 |
| Phelip, JM | 2 |
| Desrame, J | 3 |
| Edeline, J | 2 |
| Barbier, E | 2 |
| Terrebonne, E | 2 |
| Michel, P | 2 |
| Perrier, H | 1 |
| Dahan, L | 4 |
| Bourgeois, V | 2 |
| Akouz, FK | 1 |
| Soularue, E | 1 |
| Ly, VL | 1 |
| Molin, Y | 1 |
| Lecomte, T | 3 |
| Ghiringhelli, F | 4 |
| Coriat, R | 3 |
| Louafi, S | 3 |
| Neuzillet, C | 2 |
| Manfredi, S | 3 |
| Malka, D | 3 |
| van der Sijde, F | 1 |
| Homs, MYV | 1 |
| van Bekkum, ML | 1 |
| van den Bosch, TPP | 1 |
| Bosscha, K | 1 |
| Besselink, MG | 2 |
| Bonsing, BA | 1 |
| de Groot, JWB | 1 |
| Karsten, TM | 1 |
| Groot Koerkamp, B | 1 |
| Haberkorn, BCM | 1 |
| Luelmo, SAC | 1 |
| Mekenkamp, LJM | 1 |
| Mustafa, DAM | 1 |
| Wilmink, JW | 2 |
| van Eijck, CHJ | 1 |
| Vietsch, EE | 1 |
| Yamamoto, S | 1 |
| Nagashima, K | 2 |
| Kawakami, T | 1 |
| Mitani, S | 1 |
| Komoda, M | 1 |
| Tsuji, Y | 1 |
| Izawa, N | 1 |
| Kawakami, K | 1 |
| Yamamoto, Y | 5 |
| Makiyama, A | 1 |
| Yamazaki, K | 4 |
| Masuishi, T | 1 |
| Esaki, T | 2 |
| Nakajima, TE | 1 |
| Okuda, H | 1 |
| Moriwaki, T | 1 |
| Boku, N | 2 |
| Raghavan, R | 1 |
| Koyande, N | 1 |
| Beher, R | 1 |
| Chetlangia, N | 1 |
| Ramadwar, M | 1 |
| Pawade, S | 1 |
| Thorat, R | 1 |
| van Hengel, J | 1 |
| Sklyarova, T | 1 |
| van Roy, F | 1 |
| Dalal, SN | 1 |
| Chaukar, D | 1 |
| Prabash, K | 1 |
| Rane, P | 1 |
| Patil, VM | 1 |
| Thiagarajan, S | 1 |
| Ghosh-Laskar, S | 1 |
| Sharma, S | 2 |
| Pai, PS | 1 |
| Chaturvedi, P | 1 |
| Pantvaidya, G | 1 |
| Deshmukh, A | 1 |
| Nair, D | 1 |
| Nair, S | 2 |
| Vaish, R | 1 |
| Noronha, V | 1 |
| Patil, A | 1 |
| Arya, S | 1 |
| D'Cruz, A | 1 |
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| Jiang, Z | 1 |
| Hou, Z | 1 |
| Liu, W | 1 |
| Yu, Z | 2 |
| Liang, Z | 1 |
| Chen, S | 2 |
| Rossini, D | 2 |
| Germani, MM | 2 |
| Lonardi, S | 4 |
| Pietrantonio, F | 2 |
| Dell'Aquila, E | 1 |
| Borelli, B | 1 |
| Allegrini, G | 2 |
| Maddalena, G | 1 |
| Randon, G | 1 |
| Marmorino, F | 1 |
| Zaniboni, A | 7 |
| Buonadonna, A | 3 |
| Boccaccino, A | 1 |
| Conca, V | 1 |
| Antoniotti, C | 5 |
| Passardi, A | 3 |
| Masi, G | 5 |
| Cremolini, C | 4 |
| Aparicio, J | 6 |
| Virgili Manrique, AC | 1 |
| Capdevila, J | 1 |
| Muñoz Boza, F | 1 |
| Galván, P | 1 |
| Richart, P | 1 |
| Oliveres, H | 1 |
| Páez, D | 1 |
| Hernando, J | 1 |
| Serrano, S | 1 |
| Vera, R | 3 |
| Hernandez-Yagüe, X | 1 |
| Gallego, RÁ | 1 |
| Riesco-Martinez, MC | 2 |
| García de Albeniz, X | 1 |
| Maurel, J | 2 |
| Sun, J | 4 |
| Liu, C | 5 |
| Shi, J | 2 |
| Wang, N | 2 |
| Jiang, D | 1 |
| Mao, F | 1 |
| Gu, J | 1 |
| Zhou, L | 2 |
| Shen, L | 5 |
| Lau, WY | 1 |
| Cheng, S | 2 |
| Wang, MQ | 2 |
| Chen, YR | 2 |
| Xu, HW | 2 |
| Zhan, JR | 2 |
| Suo, DQ | 2 |
| Wang, JJ | 2 |
| Ma, YZ | 2 |
| Guan, XY | 2 |
| Li, Y | 10 |
| Zhu, SL | 2 |
| Fong, ZV | 1 |
| Verdugo, FL | 1 |
| Fernandez-Del Castillo, C | 1 |
| Ferrone, CR | 1 |
| Allen, JN | 1 |
| Blaszkowsky, LS | 1 |
| Clark, JW | 4 |
| Parikh, AR | 1 |
| Ryan, DP | 4 |
| Weekes, CD | 1 |
| Hong, TS | 2 |
| Wo, JY | 1 |
| Lillemoe, KD | 1 |
| Qadan, M | 1 |
| Aoyama, T | 1 |
| Oba, K | 4 |
| Honda, M | 2 |
| Muto, M | 1 |
| Mayanagi, S | 1 |
| Maeda, H | 1 |
| Kanda, M | 1 |
| Kashiwabara, K | 1 |
| Sakamoto, J | 6 |
| Yoshikawa, T | 2 |
| Santos, A | 1 |
| Cristóbal, I | 1 |
| Caramés, C | 1 |
| Luque, M | 1 |
| Sanz-Álvarez, M | 1 |
| Madoz-Gúrpide, J | 1 |
| Rojo, F | 1 |
| García-Foncillas, J | 4 |
| Lai, M | 1 |
| Pampena, R | 1 |
| Cornacchia, L | 1 |
| Pellacani, G | 2 |
| Peris, K | 2 |
| Longo, C | 1 |
| Mohammad, O | 1 |
| Faisal, SM | 1 |
| Ahmad, N | 1 |
| Rauf, MA | 1 |
| Umar, MS | 1 |
| Mujeeb, AA | 1 |
| Pachauri, P | 1 |
| Ahmed, A | 1 |
| Kashif, M | 1 |
| Ajmal, M | 1 |
| Zubair, S | 1 |
| Lavitrano, M | 1 |
| Ianzano, L | 1 |
| Bonomo, S | 1 |
| Cialdella, A | 1 |
| Cerrito, MG | 1 |
| Pisano, F | 1 |
| Missaglia, C | 1 |
| Giovannoni, R | 1 |
| Romano, G | 2 |
| McLean, CM | 1 |
| Voest, EE | 2 |
| D'Amato, F | 1 |
| Noli, B | 1 |
| Ferri, GL | 1 |
| Agostini, M | 1 |
| Pucciarelli, S | 1 |
| Helin, K | 1 |
| Leone, BE | 1 |
| Canzonieri, V | 2 |
| Grassilli, E | 1 |
| Zhou, J | 3 |
| Liu, Y | 7 |
| Zhang, Y | 6 |
| Li, Q | 5 |
| Cao, Y | 2 |
| Park, H | 2 |
| Bang, JH | 2 |
| Nam, AR | 2 |
| Park, JE | 1 |
| Jin, MH | 1 |
| Bang, YJ | 5 |
| Oh, DY | 4 |
| Abdel-Rahman, O | 1 |
| Wattanavises, S | 1 |
| Silsirivanit, A | 1 |
| Sawanyawisuth, K | 1 |
| Cha'on, U | 1 |
| Waraasawapati, S | 1 |
| Saentaweesuk, W | 1 |
| Luang, S | 1 |
| Chalermwat, C | 1 |
| Wongkham, C | 1 |
| Wongkham, S | 1 |
| Ma, CJ | 1 |
| Chang, TK | 1 |
| Tsai, HL | 1 |
| Su, WC | 1 |
| Huang, CW | 1 |
| Yeh, YS | 1 |
| Chang, YT | 1 |
| Wang, JY | 2 |
| Brown, J | 1 |
| Liepa, AM | 2 |
| Bapat, B | 1 |
| Madhwani, S | 1 |
| Lorenzen, S | 4 |
| Candrilli, SD | 1 |
| Kaye, JA | 1 |
| Ron, DA | 1 |
| Labandeira, CM | 1 |
| Manrique, MCA | 1 |
| Núñez, MÁ | 1 |
| Cid, NG | 1 |
| Mata, JG | 1 |
| Montes, AF | 1 |
| Wang, G | 4 |
| Sheng, W | 1 |
| Tang, J | 1 |
| Li, X | 4 |
| Dong, M | 1 |
| Randrian, V | 1 |
| Adenis, A | 7 |
| Di Fiore, F | 2 |
| Lièvre, A | 2 |
| Laurent-Puig, P | 1 |
| Mineur, L | 6 |
| Breysacher, G | 1 |
| Roquin, G | 1 |
| Lopez, A | 1 |
| Louvet, C | 6 |
| Borg, C | 4 |
| Metges, JP | 1 |
| Faroux, R | 2 |
| Gaba, L | 1 |
| Tougeron, D | 2 |
| Allison, JD | 1 |
| Tanavin, T | 1 |
| Yang, Y | 4 |
| Birnbaum, G | 1 |
| Khalid, U | 1 |
| Dianzani, C | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Corneli, P | 1 |
| di Meo, N | 1 |
| Farinazzo, E | 1 |
| Moret, A | 1 |
| Magaton Rizzi, G | 1 |
| Zalaudek, I | 1 |
| Iveson, T | 1 |
| Carter, AM | 1 |
| Shiu, KK | 1 |
| Spooner, C | 1 |
| Stevens, D | 1 |
| Mullamitha, S | 1 |
| Wei, L | 1 |
| Chen, J | 9 |
| Wen, J | 1 |
| Wu, D | 2 |
| Ma, X | 1 |
| Chen, Z | 3 |
| Huang, J | 2 |
| Pothuraju, R | 1 |
| Rachagani, S | 1 |
| Krishn, SR | 1 |
| Chaudhary, S | 1 |
| Nimmakayala, RK | 1 |
| Siddiqui, JA | 1 |
| Ganguly, K | 1 |
| Lakshmanan, I | 1 |
| Cox, JL | 1 |
| Mallya, K | 1 |
| Kaur, S | 1 |
| Batra, SK | 1 |
| Ang, BCH | 1 |
| Seen, S | 1 |
| Kumaran, A | 1 |
| De Leon, JMS | 1 |
| Seah, SKL | 1 |
| Foster, PJ | 3 |
| Gazzard, G | 3 |
| Htoon, HM | 2 |
| Khaw, PT | 4 |
| Aung, T | 3 |
| Husain, R | 3 |
| Mundo, AI | 1 |
| Greening, GJ | 1 |
| Fahr, MJ | 1 |
| Hale, LN | 1 |
| Bullard, EA | 1 |
| Rajaram, N | 1 |
| Muldoon, TJ | 1 |
| Das, S | 1 |
| Allen, A | 1 |
| Berlin, J | 1 |
| Thiis-Evensen, E | 1 |
| Poole, AC | 1 |
| Nguyen, HT | 1 |
| Sponheim, J | 1 |
| Kurreck, A | 1 |
| Geissler, M | 2 |
| Martens, UM | 1 |
| Riera-Knorrenschild, J | 1 |
| Greeve, J | 1 |
| Florschütz, A | 1 |
| Wessendorf, S | 1 |
| Ettrich, T | 1 |
| Kanzler, S | 1 |
| Nörenberg, D | 1 |
| Seidensticker, M | 1 |
| Held, S | 1 |
| Buechner-Steudel, P | 2 |
| Atzpodien, J | 3 |
| Heinemann, V | 6 |
| Stintzing, S | 1 |
| Seufferlein, T | 3 |
| Tannapfel, A | 4 |
| Reinacher-Schick, AC | 1 |
| Modest, DP | 1 |
| Owen, D | 1 |
| Lukovic, J | 1 |
| Hosni, A | 1 |
| Crane, CH | 7 |
| Dawson, LA | 1 |
| Velec, M | 1 |
| Lawrence, TS | 1 |
| Rinaldi, Y | 1 |
| Pointet, AL | 1 |
| Khemissa Akouz, F | 1 |
| Le Malicot, K | 1 |
| Wahiba, B | 1 |
| Gratet, A | 1 |
| Miglianico, L | 1 |
| Laharie, H | 1 |
| Bouhier Leporrier, K | 1 |
| Thirot Bidault, A | 1 |
| Texereau, P | 2 |
| Gouttebel, MC | 1 |
| Bachet, JB | 3 |
| Lepage, C | 1 |
| Taieb, J | 3 |
| Gürbüz, M | 1 |
| Akkuş, E | 1 |
| Utkan, G | 1 |
| Sinclair, R | 1 |
| Baker, C | 1 |
| Spelman, L | 1 |
| Supranowicz, M | 1 |
| MacMahon, B | 1 |
| Franco, F | 1 |
| Camara, JC | 1 |
| Martín-Valadés, JI | 1 |
| López-Alfonso, A | 1 |
| Marrupe, D | 1 |
| Gutiérrez-Abad, D | 1 |
| Martínez-Amores, B | 1 |
| León, A | 1 |
| Juez, I | 1 |
| Pérez, M | 1 |
| Royuela, A | 1 |
| Ruiz-Casado, A | 1 |
| Lastraioli, E | 1 |
| Lavacchi, D | 1 |
| Palmieri, VE | 1 |
| Castiglione, F | 2 |
| Messerini, L | 1 |
| Di Costanzo, F | 4 |
| Antonuzzo, L | 3 |
| Gilchrest, BA | 1 |
| Cui, J | 1 |
| Zhang, X | 3 |
| Qu, S | 1 |
| Wang, L | 6 |
| Santini, D | 8 |
| Tomasello, G | 3 |
| Ermacora, P | 1 |
| Bergamo, F | 2 |
| Ricci, V | 1 |
| Caponnetto, S | 1 |
| Moretto, R | 1 |
| Ritorto, G | 1 |
| Latiano, TP | 1 |
| Rapisardi, S | 1 |
| Falcone, A | 5 |
| Castro, MP | 1 |
| Afshar, M | 1 |
| Williams, C | 1 |
| Turcat, T | 1 |
| Parker, D | 1 |
| Gordon, E | 1 |
| Zambelli, J | 1 |
| McDonald, A | 2 |
| Suh, C | 1 |
| Baylon, S | 1 |
| Biskup, S | 1 |
| Hecht, JR | 2 |
| Bendell, J | 2 |
| Sim, HW | 1 |
| Macarulla, T | 2 |
| Lopez, CD | 1 |
| Van Cutsem, E | 11 |
| Muñoz Martin, AJ | 1 |
| Park, JO | 8 |
| Greil, R | 2 |
| Wang, H | 3 |
| Hozak, RR | 1 |
| Gueorguieva, I | 1 |
| Lin, Y | 1 |
| Rao, S | 3 |
| Ryoo, BY | 2 |
| Zhu, J | 1 |
| Wen, B | 1 |
| Lu, Y | 1 |
| Xu, W | 1 |
| Auclin, E | 1 |
| Marthey, L | 1 |
| Abdallah, R | 1 |
| Mas, L | 1 |
| Francois, E | 5 |
| Saint, A | 1 |
| Cunha, AS | 1 |
| Vienot, A | 1 |
| Hautefeuille, V | 1 |
| de La Fouchardière, C | 2 |
| Sarabi, M | 1 |
| Ksontini, F | 1 |
| Forestier, J | 1 |
| Fabiano, E | 1 |
| Leroy, F | 1 |
| Williet, N | 1 |
| Gutierrez-Sainz, L | 1 |
| Viñal, D | 1 |
| Villamayor, J | 1 |
| Martinez-Perez, D | 1 |
| Garcia-Cuesta, JA | 1 |
| Ghanem, I | 1 |
| Custodio, A | 1 |
| Feliu, J | 5 |
| Abrams, SL | 1 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 1 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 1 |
| Ratti, S | 1 |
| Cocco, L | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Ruvolo, P | 1 |
| Libra, M | 1 |
| Falzone, L | 1 |
| Candido, S | 1 |
| McCubrey, JA | 1 |
| Chevalier, T | 1 |
| Daste, A | 1 |
| Saada-Bouzid, E | 1 |
| Loundou, A | 1 |
| Peyraud, F | 1 |
| Lambert, T | 1 |
| Le Tourneau, C | 1 |
| Peyrade, F | 3 |
| Dupuis, C | 1 |
| Alfonsi, M | 3 |
| Fayette, J | 1 |
| Reure, J | 1 |
| Huguet, F | 1 |
| Fakhry, N | 1 |
| Toullec, C | 1 |
| Salas, S | 1 |
| Szturz, P | 1 |
| Vinches, M | 1 |
| Remenár, É | 4 |
| van Herpen, CML | 1 |
| Abdeddaim, C | 1 |
| Stewart, JS | 2 |
| Fortpied, C | 2 |
| Vermorken, JB | 5 |
| Haddock, ES | 1 |
| Cohen, PR | 1 |
| Pelzer, U | 3 |
| Blanc, JF | 2 |
| Melisi, D | 3 |
| Cubillo, A | 2 |
| Von Hoff, DD | 4 |
| Wang-Gillam, A | 3 |
| Chen, LT | 4 |
| Siveke, JT | 2 |
| Wan, Y | 1 |
| Solem, CT | 1 |
| Botteman, MF | 1 |
| de Jong, FA | 2 |
| Hubner, RA | 2 |
| Jiao, T | 1 |
| Gao, T | 1 |
| Feng, M | 2 |
| Liu, M | 1 |
| Zhou, H | 1 |
| Sun, M | 1 |
| Pernot, S | 1 |
| Badoual, C | 1 |
| Terme, M | 1 |
| Castan, F | 1 |
| Cazes, A | 1 |
| Bouche, O | 5 |
| Bennouna, J | 5 |
| Samalin, E | 2 |
| Ducreux, M | 8 |
| Marcheteau, E | 1 |
| Stanbury, T | 3 |
| Gourgou, S | 1 |
| Dore-Savard, L | 1 |
| Winnard, PT | 1 |
| Krishnamachary, B | 1 |
| Raman, V | 1 |
| Black, ME | 1 |
| Bhujwalla, ZM | 1 |
| Vogel, JA | 1 |
| Rombouts, SJ | 1 |
| de Rooij, T | 1 |
| van Delden, OM | 1 |
| Dijkgraaf, MG | 1 |
| van Gulik, TM | 1 |
| van Hooft, JE | 1 |
| van Laarhoven, HW | 1 |
| Martin, RC | 1 |
| Schoorlemmer, A | 1 |
| van Lienden, KP | 1 |
| Busch, OR | 1 |
| Martínez-Pérez, J | 1 |
| Lopez-Calderero, I | 1 |
| Saez, C | 1 |
| Benavent, M | 1 |
| Limon, ML | 1 |
| Gonzalez-Exposito, R | 1 |
| Soldevilla, B | 1 |
| Salamanca, J | 1 |
| Carnero, A | 1 |
| Garcia-Carbonero, R | 1 |
| Tao, Y | 1 |
| Aupérin, A | 1 |
| Graff, P | 1 |
| Lapeyre, M | 1 |
| Grégoire, V | 3 |
| Maingon, P | 4 |
| Geoffrois, L | 2 |
| Verrelle, P | 2 |
| Calais, G | 3 |
| Gery, B | 2 |
| Martin, L | 1 |
| Deprez, P | 1 |
| Bardet, E | 4 |
| Pignon, T | 1 |
| Rives, M | 1 |
| Sire, C | 2 |
| Bourhis, J | 2 |
| Miyauchi, Y | 1 |
| Yasuchika, K | 1 |
| Fukumitsu, K | 1 |
| Ishii, T | 1 |
| Ogiso, S | 1 |
| Minami, T | 1 |
| Kojima, H | 3 |
| Yamaoka, R | 1 |
| Katayama, H | 1 |
| Kawai, T | 1 |
| Yoshitoshi-Uebayashi, EY | 1 |
| Kita, S | 1 |
| Yasuda, K | 2 |
| Sasaki, N | 1 |
| Uemoto, S | 1 |
| Okamura, A | 1 |
| Watanabe, M | 4 |
| Mine, S | 1 |
| Kurogochi, T | 1 |
| Yamashita, K | 3 |
| Hayami, M | 1 |
| Imamura, Y | 1 |
| Ogura, M | 2 |
| Ichimura, T | 2 |
| Takahari, D | 2 |
| Chin, K | 4 |
| Fernandes, GDS | 1 |
| Braghiroli, MI | 1 |
| Artioli, M | 1 |
| Paterlini, ACCR | 1 |
| Teixeira, MC | 2 |
| Gumz, BP | 1 |
| Girardi, DDM | 1 |
| Braghiroli, OFM | 1 |
| Costa, FP | 2 |
| Hoff, PM | 5 |
| Kluger, MD | 1 |
| Rashid, MF | 1 |
| Rosario, VL | 1 |
| Schrope, BA | 1 |
| Steinman, JA | 1 |
| Hecht, EM | 1 |
| Chabot, JA | 1 |
| Wang, C | 2 |
| Song, DJ | 1 |
| Xu, ZL | 1 |
| Xie, SP | 1 |
| Hu, JH | 1 |
| Tang, YC | 1 |
| Zhi, Q | 1 |
| Wu, MY | 1 |
| Gong, FR | 1 |
| Shen, M | 1 |
| Liu, L | 3 |
| Tao, M | 1 |
| Shen, B | 1 |
| Gu, DM | 1 |
| Yu, J | 1 |
| Xu, MD | 1 |
| Gao, Y | 2 |
| Li, W | 2 |
| Liang, Y | 1 |
| Song, X | 1 |
| Zhang, N | 2 |
| Sang, Y | 1 |
| Zhang, H | 5 |
| Chen, B | 1 |
| Zhao, W | 1 |
| Guo, R | 1 |
| Yang, Q | 2 |
| Hagino, S | 1 |
| Miyata, T | 1 |
| Sakamoto, K | 1 |
| Kuang, YS | 1 |
| Wang, Y | 7 |
| Ding, LD | 1 |
| Yang, L | 4 |
| Liu, SH | 1 |
| Zhu, BT | 1 |
| Wang, XN | 1 |
| Liu, HY | 1 |
| Chang, ZJ | 1 |
| Wang, YY | 1 |
| Jia, BQ | 1 |
| Lee, BM | 1 |
| Chung, SY | 1 |
| Chang, JS | 1 |
| Lee, KJ | 1 |
| Seong, J | 1 |
| Zhao, Y | 4 |
| Xu, K | 1 |
| Liu, P | 1 |
| Vigano, L | 2 |
| Darwish, SS | 1 |
| Rimassa, L | 2 |
| Cimino, M | 1 |
| Carnaghi, C | 1 |
| Donadon, M | 1 |
| Procopio, F | 1 |
| Personeni, N | 1 |
| Del Fabbro, D | 1 |
| Santoro, A | 1 |
| Torzilli, G | 1 |
| Pastorino, A | 1 |
| Di Bartolomeo, M | 3 |
| Maiello, E | 4 |
| Iaffaioli, V | 1 |
| Ciuffreda, L | 1 |
| Fasola, G | 2 |
| Frassineti, GL | 2 |
| Marchetti, P | 1 |
| Leone, F | 2 |
| Aprile, G | 3 |
| Zilocchi, C | 1 |
| Sobrero, A | 6 |
| Bordonaro, R | 4 |
| Kellett, C | 1 |
| Lambert, P | 1 |
| Kim, CA | 1 |
| Hanna, DL | 1 |
| Loupakis, F | 4 |
| Yang, D | 4 |
| Schirripa, M | 1 |
| Li, M | 2 |
| Matsusaka, S | 3 |
| Berger, MD | 1 |
| Miyamoto, Y | 1 |
| Zhang, W | 3 |
| Ning, Y | 1 |
| Salvatore, L | 2 |
| Moran, M | 1 |
| Zeger, G | 1 |
| Astrow, SH | 1 |
| Lenz, HJ | 4 |
| Tampellini, M | 3 |
| Bironzo, P | 1 |
| Di Maio, M | 2 |
| Scagliotti, GV | 1 |
| Takahashi, K | 1 |
| Fukushima, K | 1 |
| Onishi, Y | 1 |
| Minami, K | 1 |
| Otagaki, S | 1 |
| Ishimoto, K | 1 |
| Fukushima, N | 1 |
| Honoki, K | 1 |
| Tsujiuchi, T | 1 |
| Fernández, LP | 1 |
| Sánchez-Martínez, R | 1 |
| Vargas, T | 1 |
| Herranz, J | 1 |
| Martín-Hernández, R | 1 |
| Mendiola, M | 2 |
| Hardisson, D | 1 |
| Reglero, G | 1 |
| Redondo, A | 1 |
| Ramírez de Molina, A | 1 |
| Gharaibeh, M | 1 |
| McBride, A | 1 |
| Alberts, DS | 2 |
| Erstad, B | 1 |
| Slack, M | 1 |
| Alsaid, N | 1 |
| Bootman, JL | 1 |
| Abraham, I | 1 |
| Fan, B | 1 |
| Shen, C | 1 |
| Wu, M | 1 |
| Zhao, J | 3 |
| Guo, Q | 2 |
| Luo, Y | 1 |
| Girardi, DM | 1 |
| Faria, LDBB | 1 |
| Hoff, PMG | 1 |
| Fernandes, GS | 1 |
| Temraz, S | 2 |
| Shamseddine, A | 2 |
| Mukherji, D | 2 |
| Charafeddine, M | 1 |
| Tfayli, A | 1 |
| Assi, H | 1 |
| Hammoud, MS | 1 |
| Makki, I | 1 |
| Nassif, S | 1 |
| Buzdar, AU | 3 |
| Suman, VJ | 2 |
| Meric-Bernstam, F | 1 |
| Leitch, AM | 1 |
| Ellis, MJ | 1 |
| Boughey, JC | 1 |
| Unzeitig, GW | 1 |
| Royce, ME | 1 |
| Hunt, KK | 1 |
| Hiret, S | 1 |
| Bertaut, A | 1 |
| Deplanque, G | 1 |
| Borel, C | 1 |
| Conroy, T | 4 |
| des Guetz, G | 2 |
| Seitz, JF | 6 |
| Artru, P | 5 |
| Hebbar, M | 2 |
| Denis, MG | 1 |
| Wang, F | 3 |
| Zhao, L | 2 |
| Zhang, J | 7 |
| Meng, Z | 1 |
| Zhou, C | 2 |
| Xi, J | 1 |
| Niu, W | 1 |
| Becker, C | 1 |
| Mamlouk, K | 1 |
| Belanger, B | 1 |
| Fanotto, V | 1 |
| Fornaro, L | 1 |
| Rosati, G | 3 |
| Di Donato, S | 2 |
| Silvestris, N | 1 |
| Stragliotto, S | 1 |
| Scartozzi, M | 4 |
| Giampieri, R | 2 |
| Nichetti, F | 1 |
| Cinieri, S | 1 |
| Avallone, A | 3 |
| Pellegrino, A | 1 |
| Vasile, E | 1 |
| Gerratana, L | 1 |
| Ettrich, TJ | 1 |
| Berger, AW | 1 |
| Perkhofer, L | 1 |
| Daum, S | 1 |
| König, A | 1 |
| Dickhut, A | 1 |
| Wittel, U | 1 |
| Wille, K | 1 |
| Algül, H | 1 |
| Gallmeier, E | 1 |
| Kornmann, M | 2 |
| Muche, R | 1 |
| Prasnikar, N | 1 |
| Reinacher-Schick, A | 3 |
| Uhl, W | 1 |
| Wu, W | 1 |
| He, K | 1 |
| Zhang, M | 2 |
| Huang, K | 1 |
| Wu, L | 1 |
| Deng, Y | 1 |
| Luo, X | 3 |
| Yu, H | 2 |
| Ding, Q | 1 |
| Xiang, G | 1 |
| Lin, C | 1 |
| Verma, V | 1 |
| Ly, QP | 1 |
| Lazenby, A | 1 |
| Sasson, A | 1 |
| Schwarz, JK | 1 |
| Meza, JL | 1 |
| Are, C | 1 |
| Li, S | 1 |
| Wang, S | 2 |
| Hahn, SM | 1 |
| Grem, JL | 2 |
| Ou, J | 1 |
| Peng, Y | 1 |
| Yang, W | 3 |
| Hao, J | 1 |
| Li, F | 1 |
| Chen, Y | 4 |
| Xie, X | 1 |
| Wu, S | 1 |
| Zha, L | 1 |
| Xie, G | 1 |
| Sun, W | 2 |
| Zhou, Q | 1 |
| Liang, H | 2 |
| Yamamoto, KN | 1 |
| Nakamura, A | 1 |
| Liu, LL | 1 |
| Stein, S | 5 |
| Tramontano, AC | 1 |
| Kartoun, U | 1 |
| Shimizu, T | 1 |
| Inoue, Y | 2 |
| Asakuma, M | 1 |
| Haeno, H | 1 |
| Kong, CY | 1 |
| Uchiyama, K | 1 |
| Gonen, M | 1 |
| Hur, C | 1 |
| Michor, F | 1 |
| Chai, Z | 1 |
| Moon, JR | 1 |
| Oh, SJ | 1 |
| Lee, CK | 1 |
| Chi, SG | 1 |
| Kim, HJ | 10 |
| Kircik, LH | 1 |
| Byun, Y | 1 |
| Han, Y | 3 |
| Kang, JS | 1 |
| Choi, YJ | 3 |
| Kim, H | 3 |
| Kwon, W | 1 |
| Kim, SW | 1 |
| Lee, SH | 7 |
| Ryu, JK | 3 |
| Kim, YT | 3 |
| Jang, JY | 2 |
| Riechelmann, RP | 1 |
| Srimuninnimit, V | 1 |
| Kavan, P | 1 |
| Cicin, I | 1 |
| García-Alfonso, P | 3 |
| Chau, I | 5 |
| Fedyanin, MY | 1 |
| Martos, CF | 1 |
| Ter-Ovanesov, M | 1 |
| Peeters, M | 2 |
| Ko, YJ | 1 |
| Yalcin, S | 2 |
| Karthaus, M | 1 |
| Picard, P | 1 |
| Bury, D | 1 |
| Drea, E | 1 |
| Ren, T | 1 |
| Hou, J | 1 |
| Shan, F | 1 |
| Xiong, X | 1 |
| Qin, A | 1 |
| Ren, W | 1 |
| Huelster, HL | 1 |
| Hogan, MMS | 1 |
| Resnick, MJ | 1 |
| Jafek, JL | 1 |
| Shakya, A | 1 |
| Tai, PY | 1 |
| Ibarra, A | 1 |
| Maddox, J | 1 |
| Chumley, J | 1 |
| Spangrude, GJ | 1 |
| Miles, RR | 1 |
| Kelley, TW | 1 |
| Tantin, D | 1 |
| Yasuda, T | 1 |
| Tanaka, O | 1 |
| Hayashi, S | 1 |
| Nakahata, Y | 1 |
| Yasuda, Y | 1 |
| Omatsu, T | 1 |
| Obora, A | 1 |
| Kojima, T | 2 |
| Matsuo, M | 1 |
| Yagi, N | 1 |
| Hayakawa, Y | 1 |
| Kobayashi, K | 2 |
| Sakamoto, N | 2 |
| Matsuoka, M | 2 |
| Nozaka, T | 1 |
| Misumi, Y | 1 |
| Matsumoto, T | 2 |
| Miura, N | 1 |
| Furumoto, Y | 1 |
| Asano, T | 1 |
| Horiuchi, T | 1 |
| Fujiki, K | 1 |
| Eun Park, J | 1 |
| Hua Jin, M | 1 |
| Lin, JA | 1 |
| Fang, SU | 1 |
| Su, CL | 1 |
| Hsiao, CJ | 1 |
| Chang, CC | 1 |
| Lin, YF | 1 |
| Cheng, CW | 1 |
| Schwartzberg, LS | 1 |
| Tauer, KW | 1 |
| Hermann, RC | 1 |
| Makari-Judson, G | 1 |
| Isaacs, C | 1 |
| Beck, JT | 1 |
| Kaklamani, V | 1 |
| Stepanski, EJ | 1 |
| Rugo, HS | 1 |
| Wang, W | 1 |
| Bell-McGuinn, K | 1 |
| Kirshner, JJ | 1 |
| Eisenberg, P | 1 |
| Emanuelson, R | 1 |
| Keaton, M | 1 |
| Levine, E | 2 |
| Medgyesy, DC | 1 |
| Qamar, R | 1 |
| Starr, A | 1 |
| Ro, SK | 1 |
| Lokker, NA | 1 |
| Hudis, CA | 1 |
| Oikonomopoulos, GM | 1 |
| Huber, KE | 1 |
| Syrigos, KN | 1 |
| Saif, MW | 3 |
| Pénichoux, J | 1 |
| Michiels, S | 2 |
| Etienne, PL | 4 |
| Auby, D | 1 |
| Rougier, P | 17 |
| Pignon, JP | 3 |
| Clarke, S | 1 |
| Burge, M | 1 |
| Cordwell, C | 1 |
| Gibbs, P | 1 |
| Reece, W | 2 |
| Tebbutt, N | 1 |
| Alici, S | 1 |
| Buyukberber, S | 4 |
| Alkis, N | 1 |
| Benekli, M | 4 |
| Ozkan, M | 2 |
| Bilici, A | 1 |
| Demirci, U | 2 |
| Karaca, H | 2 |
| Arpaci, E | 1 |
| Gumus, M | 1 |
| Altunbas, M | 1 |
| Dane, F | 2 |
| Turk, HM | 1 |
| Scheithauer, W | 7 |
| Schaller, G | 2 |
| Box, C | 1 |
| Gowan, S | 1 |
| Box, GM | 1 |
| Valenti, M | 1 |
| Brandon, Ade H | 1 |
| Al-Lazikani, B | 1 |
| Rogers, SJ | 1 |
| Wilkins, A | 1 |
| Harrington, KJ | 2 |
| Eccles, SA | 1 |
| El-Arab, LR | 1 |
| Swellam, M | 1 |
| El Mahdy, MM | 1 |
| Chen, XL | 1 |
| Chen, XZ | 1 |
| Yang, C | 2 |
| Liao, YB | 1 |
| Li, H | 2 |
| Yang, K | 1 |
| Li, K | 1 |
| Hu, JK | 1 |
| Zhang, B | 1 |
| Chen, ZX | 1 |
| Chen, JP | 1 |
| Zhou, ZG | 1 |
| Innominato, PF | 1 |
| Giacchetti, S | 1 |
| Moreau, T | 1 |
| Bjarnason, GA | 3 |
| Smaaland, R | 1 |
| Focan, C | 2 |
| Garufi, C | 2 |
| Iacobelli, S | 1 |
| Tumolo, S | 1 |
| Carvalho, C | 1 |
| Karaboué, A | 1 |
| Poncet, A | 1 |
| Spiegel, D | 1 |
| Lévi, F | 2 |
| Himmel, M | 1 |
| Hartmann, M | 1 |
| Guntinas-Lichius, O | 1 |
| Musio, D | 1 |
| De Felice, F | 1 |
| Bulzonetti, N | 1 |
| Guarnaccia, R | 1 |
| Caiazzo, R | 1 |
| Bangrazi, C | 1 |
| Raffetto, N | 1 |
| Tombolini, V | 1 |
| Peng, PJ | 1 |
| Ou, XQ | 1 |
| Chen, ZB | 1 |
| Liao, H | 1 |
| Peng, YL | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Lin, Z | 1 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Ajani, JA | 3 |
| Buyse, M | 6 |
| Lichinitser, M | 1 |
| Gorbunova, V | 2 |
| Bodoky, G | 3 |
| Douillard, JY | 6 |
| Cascinu, S | 5 |
| Zaucha, R | 2 |
| Carrato, A | 3 |
| Ferry, D | 1 |
| Moiseyenko, V | 2 |
| He, SL | 1 |
| Shen, J | 1 |
| Sun, XJ | 1 |
| Zhu, XJ | 1 |
| Liu, LM | 1 |
| Dong, JC | 1 |
| Song, DS | 2 |
| Bae, SH | 4 |
| Song, MJ | 2 |
| Lee, SW | 1 |
| Kim, HY | 2 |
| Lee, YJ | 2 |
| Oh, JS | 1 |
| Chun, HJ | 1 |
| Lee, HG | 1 |
| Choi, JY | 2 |
| Yoon, SK | 2 |
| Sinn, M | 2 |
| Nicolaou, A | 1 |
| Ricke, J | 1 |
| Podrabsky, P | 1 |
| Seehofer, D | 2 |
| Gebauer, B | 1 |
| Pech, M | 1 |
| Neuhaus, P | 3 |
| Dörken, B | 5 |
| Riess, H | 5 |
| Hildebrandt, B | 2 |
| Sun, Y | 2 |
| Tian, H | 1 |
| Yang, H | 1 |
| Kim, HS | 6 |
| Shin, SJ | 4 |
| Kim, JH | 9 |
| Choi, HJ | 4 |
| Xu, J | 2 |
| He, X | 1 |
| Cheng, K | 1 |
| Guo, W | 1 |
| Bian, X | 1 |
| Jiang, X | 1 |
| Zhang, L | 6 |
| Huang, S | 2 |
| Thalheimer, A | 1 |
| Korb, D | 1 |
| Bönicke, L | 1 |
| Wiegering, A | 1 |
| Mühling, B | 1 |
| Schneider, M | 1 |
| Koch, S | 1 |
| Riedel, SS | 1 |
| Germer, CT | 1 |
| Beilhack, A | 1 |
| Brändlein, S | 1 |
| Otto, C | 1 |
| Peserico, A | 1 |
| Neri, L | 1 |
| Calzavara Pinton, P | 1 |
| Catricalà, C | 1 |
| Pimpinelli, N | 1 |
| Nasyrov, AR | 1 |
| Pirtskhalava, TL | 1 |
| Korovina, IaV | 1 |
| Kong, X | 2 |
| Yan, S | 1 |
| Yoon, EL | 1 |
| Yeon, JE | 1 |
| Lee, HJ | 2 |
| Suh, SJ | 1 |
| Lee, SJ | 3 |
| Kang, SH | 1 |
| Kang, K | 1 |
| Yoo, YJ | 1 |
| Yim, HJ | 2 |
| Byun, KS | 1 |
| Aitchison, M | 1 |
| Bray, CA | 1 |
| Van Poppel, H | 1 |
| Sylvester, R | 1 |
| Graham, J | 1 |
| Innes, C | 1 |
| McMahon, L | 1 |
| Vasey, PA | 1 |
| Hashash, JG | 1 |
| Proksell, S | 1 |
| Regueiro, MD | 1 |
| Glück, S | 1 |
| Russell, C | 2 |
| O'Shaughnessy, J | 3 |
| McKenna, EF | 1 |
| Hu, S | 1 |
| Odom, D | 1 |
| Blum, JL | 3 |
| Berretta, M | 2 |
| Nasti, G | 1 |
| Urbani, M | 1 |
| Bearz, A | 3 |
| Lutrino, S | 1 |
| Foltran, L | 1 |
| Ferrari, L | 4 |
| Talamini, R | 3 |
| Fiorica, F | 1 |
| Lleshi, A | 2 |
| Lestuzzi, C | 1 |
| Borsatti, E | 1 |
| Fisichella, R | 1 |
| Tirelli, U | 2 |
| Cetin, B | 1 |
| Turker, I | 1 |
| Koral, L | 1 |
| Ulas, A | 1 |
| Oksuzoglu, B | 2 |
| Kaplan, MA | 1 |
| Koca, D | 1 |
| Boruban, C | 1 |
| Yilmaz, B | 1 |
| Sevinc, A | 1 |
| Berk, V | 2 |
| Uncu, D | 2 |
| Harputluoglu, H | 1 |
| Coskun, U | 3 |
| Nordlinger, B | 3 |
| Sorbye, H | 3 |
| Glimelius, B | 5 |
| Poston, GJ | 1 |
| Schlag, PM | 1 |
| Bechstein, WO | 2 |
| Primrose, JN | 1 |
| Walpole, ET | 1 |
| Finch-Jones, M | 1 |
| Jaeck, D | 1 |
| Mirza, D | 1 |
| Parks, RW | 1 |
| Mauer, M | 1 |
| Tanis, E | 1 |
| Gruenberger, T | 2 |
| Fuchs, CS | 7 |
| Fakih, M | 2 |
| Schwartzberg, L | 1 |
| Cohn, AL | 1 |
| Yee, L | 1 |
| Dreisbach, L | 1 |
| Kozloff, MF | 2 |
| Hei, YJ | 1 |
| Galimi, F | 1 |
| Pan, Y | 2 |
| Haddad, V | 1 |
| Hsu, CP | 1 |
| Sabin, A | 1 |
| Saltz, L | 2 |
| Huang, H | 3 |
| Gao, J | 1 |
| Feng, J | 1 |
| Zhu, L | 1 |
| Qu, L | 1 |
| Shou, C | 1 |
| Nicholson, S | 1 |
| Hall, E | 1 |
| Harland, SJ | 2 |
| Chester, JD | 1 |
| Pickering, L | 1 |
| Barber, J | 1 |
| Elliott, T | 1 |
| Thomson, A | 1 |
| Burnett, S | 1 |
| Cruickshank, C | 1 |
| Carrington, B | 1 |
| Waters, R | 1 |
| Bahl, A | 1 |
| Dunne, PD | 1 |
| McArt, DG | 1 |
| Blayney, JK | 1 |
| Kalimutho, M | 1 |
| Greer, S | 1 |
| Wang, T | 3 |
| Srivastava, S | 1 |
| Ong, CW | 1 |
| Arthur, K | 1 |
| Loughrey, M | 1 |
| Redmond, K | 1 |
| Longley, DB | 1 |
| Salto-Tellez, M | 1 |
| Johnston, PG | 1 |
| Van Schaeybroeck, S | 1 |
| Ruiz-Millo, O | 1 |
| Albert-Mari, A | 1 |
| Sendra-Garcia, A | 1 |
| Jimenez-Torres, NV | 1 |
| Tzeng, CW | 1 |
| Tran Cao, HS | 1 |
| Lee, JE | 3 |
| Pisters, PW | 2 |
| Varadhachary, GR | 1 |
| Wolff, RA | 4 |
| Abbruzzese, JL | 4 |
| Evans, DB | 2 |
| Abbott, DE | 1 |
| Vauthey, JN | 3 |
| Aloia, TA | 1 |
| Fleming, JB | 1 |
| Katz, MH | 1 |
| Budach, V | 1 |
| Becker, ET | 1 |
| Boehmer, D | 1 |
| Badakhshi, H | 1 |
| Jahn, U | 1 |
| Wernecke, KD | 1 |
| Stromberger, C | 1 |
| Maugeri-Saccà, M | 1 |
| Pizzuti, L | 1 |
| Sergi, D | 1 |
| Barba, M | 1 |
| Belli, F | 1 |
| Fattoruso, S | 1 |
| Giannarelli, D | 1 |
| Amodio, A | 1 |
| Boggia, S | 1 |
| Vici, P | 1 |
| Di Lauro, L | 1 |
| Tan, C | 1 |
| Peng, L | 1 |
| Zeng, X | 1 |
| Wan, X | 1 |
| Chen, G | 1 |
| Yi, L | 1 |
| Zhao, Z | 1 |
| He, MM | 1 |
| Wu, WJ | 1 |
| Wang, ZQ | 3 |
| Zhang, DS | 2 |
| Luo, HY | 2 |
| Qiu, MZ | 2 |
| Wang, FH | 4 |
| Ren, C | 1 |
| Zeng, ZL | 1 |
| Xu, RH | 4 |
| Liu, J | 3 |
| Jiang, W | 2 |
| Ma, D | 1 |
| Kobayashi, H | 1 |
| Uetake, H | 2 |
| Iida, S | 1 |
| Ishikawa, T | 3 |
| Ishiguro, M | 1 |
| Okazaki, S | 1 |
| Kikuchi, A | 1 |
| Baba, H | 1 |
| Takahashi, H | 1 |
| Iwata, N | 1 |
| Sugihara, K | 2 |
| You, YK | 1 |
| Lee, MA | 2 |
| Hompes, D | 1 |
| Aalbers, A | 1 |
| Boot, H | 1 |
| van Velthuysen, ML | 1 |
| Vogel, W | 1 |
| Prevoo, W | 1 |
| van Tinteren, H | 2 |
| Verwaal, V | 1 |
| Bosset, JF | 3 |
| Stojanovic-Rundic, S | 1 |
| Bensadoun, RJ | 2 |
| Beny, A | 1 |
| Ollier, JC | 1 |
| Bolla, M | 1 |
| Marchal, D | 1 |
| Van Laethem, JL | 3 |
| Klein, V | 1 |
| Giralt, J | 1 |
| Clavère, P | 2 |
| Glanzmann, C | 1 |
| Cellier, P | 1 |
| Collette, L | 2 |
| Gong, J | 1 |
| Hu, B | 1 |
| Zhang, F | 2 |
| Xu, N | 2 |
| Fan, Q | 1 |
| Bai, Y | 3 |
| Jiao, S | 1 |
| Wang, J | 5 |
| Bai, C | 1 |
| Zheng, L | 1 |
| Shi, Y | 2 |
| Liang, J | 4 |
| Hu, G | 1 |
| Cheng, Y | 3 |
| Xu, R | 1 |
| De Re, V | 1 |
| Caggiari, L | 1 |
| De Zorzi, M | 1 |
| Racanelli, V | 1 |
| D' Andrea, M | 1 |
| Zagonel, V | 1 |
| Cecchin, E | 1 |
| Innocenti, F | 1 |
| Toffoli, G | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Bozkurt, O | 1 |
| Ozaslan, E | 1 |
| Şendur, MA | 1 |
| Zengin, N | 2 |
| Krauss, J | 1 |
| Mesía, R | 3 |
| Gauler, TC | 1 |
| Keilholz, U | 3 |
| Delord, JP | 1 |
| Schafhausen, P | 2 |
| Erfán, J | 2 |
| Brümmendorf, TH | 1 |
| Iglesias, L | 1 |
| Bethe, U | 1 |
| Hicking, C | 1 |
| Clement, PM | 1 |
| Xu, X | 4 |
| Dai, H | 1 |
| Qian, Z | 1 |
| Chen, X | 3 |
| Hickey, R | 1 |
| Mulcahy, MF | 2 |
| Lewandowski, RJ | 1 |
| Gates, VL | 1 |
| Vouche, M | 1 |
| Habib, A | 1 |
| Kircher, S | 1 |
| Newman, S | 1 |
| Nimeiri, H | 1 |
| Benson, AB | 6 |
| Salem, R | 1 |
| Yang, CZ | 1 |
| Ma, J | 2 |
| Zhu, DW | 1 |
| Montgomery, B | 1 |
| Wang, LZ | 1 |
| Zhang, ZY | 1 |
| Zhang, CP | 1 |
| Zhong, LP | 1 |
| Kasliwal, MK | 1 |
| Tan, LA | 1 |
| O'Toole, JE | 1 |
| Muñoz, A | 1 |
| Pericay, C | 1 |
| García-Girón, C | 1 |
| Alonso, V | 2 |
| Dueñas, R | 2 |
| Cirera, L | 1 |
| Rivera, F | 4 |
| Falcó, E | 1 |
| Bustos, IA | 1 |
| Salud, A | 3 |
| Mross, K | 1 |
| Scheulen, M | 1 |
| Strumberg, D | 1 |
| Kuhlmann, J | 1 |
| Kanefendt, F | 1 |
| Sörgel, F | 1 |
| Jaehde, U | 1 |
| Burkholder, I | 1 |
| Moritz, B | 1 |
| Büchert, M | 1 |
| Hayashi, H | 1 |
| Arao, T | 1 |
| Matsumoto, K | 1 |
| Kimura, H | 1 |
| Togashi, Y | 1 |
| Hirashima, Y | 1 |
| Horita, Y | 1 |
| Iwasa, S | 1 |
| Okita, NT | 2 |
| Honma, Y | 1 |
| Takashima, A | 1 |
| Kato, K | 3 |
| Hamaguchi, T | 1 |
| Shimada, Y | 1 |
| Nakagawa, K | 2 |
| Nishio, K | 1 |
| Yamada, Y | 2 |
| Varol, U | 2 |
| Dirican, A | 1 |
| Yildiz, I | 1 |
| Oktay, E | 1 |
| Degirmenci, M | 1 |
| Alacacioglu, A | 1 |
| Barutca, S | 1 |
| Karabulut, B | 2 |
| Uslu, R | 2 |
| Scarabelli, L | 1 |
| Giovanardi, F | 1 |
| Gervasi, E | 1 |
| Prati, G | 1 |
| Pezzuolo, D | 1 |
| Scaltriti, L | 1 |
| Nitz, U | 1 |
| Gluz, O | 1 |
| Huober, J | 1 |
| Kreipe, HH | 1 |
| Kates, RE | 1 |
| Hartmann, A | 1 |
| Erber, R | 1 |
| Moustafa, Z | 1 |
| Scholz, M | 1 |
| Lisboa, B | 1 |
| Mohrmann, S | 1 |
| Möbus, V | 1 |
| Augustin, D | 1 |
| Hoffmann, G | 1 |
| Weiss, E | 1 |
| Böhmer, S | 1 |
| Kreienberg, R | 1 |
| Du Bois, A | 2 |
| Sattler, D | 1 |
| Thomssen, C | 1 |
| Kiechle, M | 1 |
| Jänicke, F | 1 |
| Wallwiener, D | 1 |
| Harbeck, N | 1 |
| Kuhn, W | 1 |
| Buchler, T | 1 |
| Pavlik, T | 1 |
| Melichar, B | 1 |
| Bortlicek, Z | 1 |
| Usiakova, Z | 1 |
| Dusek, L | 1 |
| Kiss, I | 2 |
| Kohoutek, M | 1 |
| Benesova, V | 1 |
| Vyzula, R | 1 |
| Abrahamova, J | 1 |
| Obermannova, R | 1 |
| Han, K | 1 |
| Jin, J | 1 |
| Maia, M | 1 |
| Lowe, J | 1 |
| Sersch, MA | 1 |
| Allison, DE | 1 |
| Grey, A | 1 |
| Cooper, A | 1 |
| McNeil, C | 1 |
| O'Toole, S | 1 |
| Thompson, J | 3 |
| Grimison, P | 1 |
| Oettle, H | 3 |
| Stieler, JM | 1 |
| Heil, G | 1 |
| Schwaner, I | 2 |
| Seraphin, J | 2 |
| Görner, M | 1 |
| Mölle, M | 1 |
| Greten, TF | 1 |
| Lakner, V | 2 |
| Bischoff, S | 1 |
| Venook, AP | 2 |
| Bekaii-Saab, T | 1 |
| Chan, E | 4 |
| Chen, YJ | 1 |
| Cooper, HS | 1 |
| Engstrom, PF | 1 |
| Enzinger, PC | 4 |
| Fenton, MJ | 1 |
| Hunt, S | 1 |
| Kamel, A | 1 |
| Leong, LA | 1 |
| Lin, E | 2 |
| Messersmith, W | 1 |
| Murphy, JD | 1 |
| Nurkin, S | 1 |
| Rohren, E | 1 |
| Shibata, D | 2 |
| Skibber, JM | 1 |
| Sofocleous, CT | 1 |
| Stoffel, EM | 1 |
| Stotsky-Himelfarb, E | 1 |
| Willett, CG | 1 |
| Gregory, KM | 1 |
| Freedman-Cass, DA | 1 |
| Siegel, EM | 1 |
| Eschrich, S | 1 |
| Winter, K | 1 |
| Riggs, B | 1 |
| Berglund, A | 3 |
| Ajidahun, A | 1 |
| Simko, J | 1 |
| Moughan, J | 1 |
| Ajani, J | 2 |
| Magliocco, A | 1 |
| Elahi, A | 1 |
| Hoffe, S | 1 |
| Chung, WJ | 1 |
| Kim, YS | 2 |
| Park, JY | 3 |
| Cho, SB | 1 |
| Park, SY | 2 |
| Yang, JM | 1 |
| Park, JS | 2 |
| Jeung, HC | 5 |
| Rha, SY | 7 |
| Ahn, JB | 5 |
| Kang, B | 1 |
| Chon, HJ | 1 |
| Hong, MH | 2 |
| Lim, S | 1 |
| Yang, WI | 1 |
| Nam, CM | 1 |
| Chung, HC | 8 |
| Chen, WT | 1 |
| Yang, TS | 3 |
| Chen, HC | 2 |
| Chen, HH | 1 |
| Chiang, HC | 1 |
| Lin, TC | 1 |
| Yeh, CH | 1 |
| Ke, TW | 1 |
| Chen, JS | 5 |
| Hsiao, KH | 1 |
| Kuo, ML | 1 |
| Wu, J | 1 |
| Song, L | 1 |
| Zhao, DY | 1 |
| Guo, B | 1 |
| Bellamkonda, K | 1 |
| Sime, W | 1 |
| Sjölander, A | 1 |
| Aoe, K | 1 |
| Takigawa, N | 1 |
| Hotta, K | 1 |
| Maeda, T | 1 |
| Kishino, D | 1 |
| Nogami, N | 1 |
| Tabata, M | 1 |
| Harita, S | 1 |
| Okada, T | 1 |
| Kubo, T | 1 |
| Hosokawa, S | 1 |
| Fujiwara, K | 1 |
| Gemba, K | 1 |
| Yasugi, M | 1 |
| Kozuki, T | 1 |
| Kato, Y | 1 |
| Katsui, K | 2 |
| Kanazawa, S | 2 |
| Ueoka, H | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 1 |
| Graham, CN | 1 |
| Hechmati, G | 2 |
| Hjelmgren, J | 1 |
| de Liège, F | 1 |
| Lanier, J | 1 |
| Knox, H | 1 |
| Barber, B | 2 |
| Donini, M | 1 |
| Buti, S | 1 |
| Lazzarelli, S | 1 |
| Bozzetti, R | 1 |
| Rivoltini, L | 1 |
| Camisaschi, C | 1 |
| Castelli, C | 1 |
| Simonelli, C | 1 |
| Lo Re, G | 1 |
| Mattioli, R | 2 |
| Caminiti, C | 1 |
| Passalacqua, R | 1 |
| Sharma, MR | 1 |
| Gray, E | 1 |
| Goldberg, RM | 12 |
| Sargent, DJ | 11 |
| Karrison, TG | 1 |
| Liu, H | 2 |
| Gao, P | 1 |
| Song, Y | 1 |
| Lu, X | 2 |
| Xu, H | 1 |
| Wang, Z | 2 |
| Lam, SW | 1 |
| de Groot, SM | 1 |
| Honkoop, AH | 1 |
| Jager, A | 1 |
| ten Tije, AJ | 2 |
| Bos, MM | 1 |
| Linn, SC | 1 |
| van den Bosch, J | 1 |
| Kroep, JR | 1 |
| Braun, JJ | 1 |
| Boven, E | 1 |
| Ruff, P | 2 |
| Ferry, DR | 1 |
| Lakomỳ, R | 1 |
| Prausová, J | 1 |
| Van Hazel, GA | 1 |
| Cunningham, D | 13 |
| Arnold, D | 5 |
| Schmoll, HJ | 3 |
| Moiseyenko, VM | 2 |
| McKendrick, JJ | 1 |
| Vishwanath, RL | 1 |
| Bhargava, P | 1 |
| Chevalier, S | 1 |
| Ye, J | 1 |
| Wu, P | 1 |
| Gao, S | 2 |
| Garcia, VG | 1 |
| Novaes, VC | 1 |
| de Almeida, JM | 1 |
| Longo, M | 1 |
| Ervolino, E | 1 |
| Bomfim, SR | 1 |
| Theodoro, LH | 1 |
| Derouet, MF | 1 |
| Liu, G | 1 |
| Darling, GE | 1 |
| Briani, C | 1 |
| Argyriou, AA | 1 |
| Izquierdo, C | 1 |
| Velasco, R | 1 |
| Campagnolo, M | 1 |
| Alberti, P | 1 |
| Frigeni, B | 1 |
| Cacciavillani, M | 1 |
| Cortinovis, D | 1 |
| Cazzaniga, M | 1 |
| Bruna, J | 1 |
| Cavaletti, G | 1 |
| Kalofonos, HP | 3 |
| Wade, R | 1 |
| Duarte, A | 1 |
| Simmonds, M | 1 |
| Rodriguez-Lopez, R | 1 |
| Duffy, S | 1 |
| Woolacott, N | 1 |
| Spackman, E | 1 |
| Kwak, EL | 1 |
| Hwang, J | 2 |
| Heiskala, M | 1 |
| de La Bourdonnaye, G | 1 |
| Mita, M | 1 |
| Choi, DR | 1 |
| Yoon, SN | 1 |
| Kim, KY | 1 |
| Kim, BC | 1 |
| Choi, YK | 1 |
| Kim, JB | 1 |
| Han, B | 1 |
| Song, HH | 1 |
| Zang, DY | 2 |
| Qu, K | 1 |
| Yan, Z | 1 |
| Wu, Y | 1 |
| Qu, P | 1 |
| Yuan, P | 2 |
| Huang, X | 1 |
| Xing, J | 1 |
| Kozak, MM | 1 |
| von Eyben, R | 1 |
| Pai, J | 1 |
| Vossler, SR | 1 |
| Limaye, M | 1 |
| Jayachandran, P | 1 |
| Anderson, EM | 1 |
| Shaffer, JL | 1 |
| Longacre, T | 1 |
| Pai, RK | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Riera Knorrenschild, J | 1 |
| Haag, GM | 1 |
| Pohl, M | 1 |
| Thuss-Patience, P | 1 |
| Bassermann, F | 1 |
| Helbig, U | 1 |
| Weißinger, F | 1 |
| Schnoy, E | 1 |
| Becker, K | 1 |
| Stocker, G | 1 |
| Rüschoff, J | 1 |
| Eisenmenger, A | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Lordick, F | 3 |
| Giuliani, J | 1 |
| Martelli, S | 1 |
| Piacentini, P | 2 |
| Bonetti, A | 3 |
| Cortesi, E | 1 |
| Spadi, R | 1 |
| Tonini, G | 6 |
| Barone, C | 2 |
| Vitello, S | 1 |
| Longarini, R | 2 |
| D'Amico, M | 1 |
| Granetto, C | 1 |
| Boni, L | 1 |
| Yamashita, M | 1 |
| Takenaka, HY | 1 |
| Guion-Dusserre, JF | 1 |
| Lorgis, V | 1 |
| Vincent, J | 1 |
| Bengrine, L | 1 |
| Nanni, O | 1 |
| Tassinari, D | 2 |
| Turci, D | 1 |
| Cavanna, L | 1 |
| Fontana, A | 2 |
| Ruscelli, S | 1 |
| Mucciarini, C | 1 |
| Lorusso, V | 3 |
| Ragazzini, A | 1 |
| Amadori, D | 1 |
| Delbaldo, C | 2 |
| Ychou, M | 8 |
| Zawadi, A | 1 |
| André, T | 4 |
| Guerin-Meyer, V | 1 |
| Dupuis, O | 1 |
| Jouhaud, A | 1 |
| Quinaux, E | 2 |
| Piedbois, P | 2 |
| Onishi, H | 1 |
| Nouso, K | 1 |
| Nakamura, S | 2 |
| Wada, N | 1 |
| Morimoto, Y | 1 |
| Miyahara, K | 1 |
| Takeuchi, Y | 1 |
| Kuwaki, K | 1 |
| Yasunaka, T | 1 |
| Miyake, Y | 1 |
| Shiraha, H | 1 |
| Takaki, A | 1 |
| Kobayashi, Y | 1 |
| Sakaguchi, K | 1 |
| Yamamoto, K | 1 |
| Yoshioka, M | 1 |
| Shibata, S | 1 |
| Uchinami, H | 1 |
| Watanabe, G | 1 |
| Miyazawa, H | 1 |
| Iida, M | 1 |
| Yoshida, M | 2 |
| Yoshioka, T | 1 |
| Nanjo, H | 1 |
| Li, JH | 1 |
| Xie, XY | 1 |
| Le, F | 1 |
| Ge, NL | 1 |
| Li, LX | 1 |
| Gan, YH | 1 |
| Zhang, JB | 1 |
| Xue, TC | 1 |
| Chen, RX | 1 |
| Xia, JL | 1 |
| Zhang, BH | 1 |
| Ye, SL | 1 |
| Wang, YH | 2 |
| Ren, ZG | 1 |
| Irving, GR | 1 |
| Iwuji, CO | 1 |
| Morgan, B | 1 |
| Berry, DP | 1 |
| Steward, WP | 2 |
| Thomas, A | 1 |
| Brown, K | 1 |
| Howells, LM | 1 |
| Yang, J | 2 |
| Luo, F | 1 |
| Zhao, N | 1 |
| Zhang, D | 3 |
| Qian, J | 1 |
| Yu, Y | 4 |
| Zheng, X | 1 |
| Feng, Y | 2 |
| Liu, T | 2 |
| Chu, Y | 1 |
| Amankwatia, EB | 1 |
| Chakravarty, P | 1 |
| Carey, FA | 1 |
| Weidlich, S | 1 |
| Steele, RJ | 1 |
| Munro, AJ | 1 |
| Wolf, CR | 1 |
| Smith, G | 1 |
| Gérard, JP | 1 |
| Chamorey, E | 2 |
| Gourgou-Bourgade, S | 2 |
| Benezery, K | 1 |
| de Laroche, G | 1 |
| Mahé, MA | 1 |
| Boige, V | 2 |
| Juzyna, B | 1 |
| Saeki, I | 1 |
| Yamasaki, T | 1 |
| Tanabe, N | 1 |
| Iwamoto, T | 1 |
| Urata, Y | 1 |
| Hidaka, I | 1 |
| Takami, T | 1 |
| Yamamoto, N | 3 |
| Uchida, K | 1 |
| Terai, S | 1 |
| Sakaida, I | 1 |
| Wu, X | 2 |
| Jin, Z | 2 |
| Li, G | 2 |
| Zhao, H | 2 |
| Landre, T | 1 |
| Uzzan, B | 1 |
| Nicolas, P | 1 |
| Aparicio, T | 3 |
| Zelek, L | 1 |
| Mary, F | 1 |
| Taleb, C | 1 |
| Giommoni, E | 1 |
| Pastorelli, D | 1 |
| Latiano, T | 1 |
| Pavese, I | 1 |
| Azzarello, D | 1 |
| Aieta, M | 1 |
| Pastina, I | 1 |
| Di Fabio, F | 2 |
| Bertolini, A | 1 |
| Corsi, DC | 1 |
| Mogavero, S | 1 |
| Angelini, V | 1 |
| Pazzagli, M | 1 |
| Chi, JY | 1 |
| Hsiao, YW | 1 |
| Li, CF | 1 |
| Lo, YC | 1 |
| Lin, ZY | 1 |
| Hong, JY | 1 |
| Liu, YM | 1 |
| Han, X | 1 |
| Wang, SM | 1 |
| Chen, BK | 1 |
| Tsai, KK | 1 |
| Wang, JM | 1 |
| Yoshino, T | 4 |
| Gotoh, M | 1 |
| Nasroulah, F | 2 |
| Gao, L | 2 |
| Yoshizuka, N | 1 |
| Ohtsu, A | 3 |
| Dong, Y | 1 |
| Liu, JW | 2 |
| Gao, YJ | 1 |
| Zhou, T | 1 |
| Chen, YM | 3 |
| Paik, WH | 1 |
| Park, JM | 1 |
| Song, BJ | 1 |
| Badiyan, SN | 1 |
| Olsen, JR | 1 |
| Lee, AY | 1 |
| Yano, M | 1 |
| Menias, CO | 1 |
| Khwaja, S | 1 |
| Strasberg, SM | 2 |
| Hawkins, WG | 2 |
| Linehan, DC | 2 |
| Myerson, RJ | 1 |
| Parikh, PJ | 1 |
| Wu, Z | 1 |
| Ma, S | 1 |
| Jing, S | 1 |
| Deng, Q | 1 |
| Zheng, Z | 1 |
| Wu, K | 1 |
| Tang, R | 1 |
| Tsutsumi, S | 2 |
| Fujii, T | 2 |
| Yamaguchi, S | 1 |
| Suto, T | 1 |
| Yajima, R | 1 |
| Morita, H | 1 |
| Kato, T | 3 |
| Asao, T | 2 |
| Kuwano, H | 2 |
| Umemura, A | 1 |
| Nitta, H | 1 |
| Sasaki, A | 2 |
| Takahara, T | 2 |
| Hasegawa, Y | 1 |
| Wakabayashi, G | 1 |
| Piotrowski, MJ | 1 |
| Gunn, H | 1 |
| Kirby, J | 1 |
| Ali, L | 1 |
| Helm, K | 1 |
| Garcia-Aguilar, J | 1 |
| Chow, OS | 1 |
| Smith, DD | 1 |
| Marcet, JE | 1 |
| Cataldo, PA | 1 |
| Varma, MG | 1 |
| Kumar, AS | 1 |
| Oommen, S | 1 |
| Coutsoftides, T | 1 |
| Hunt, SR | 1 |
| Stamos, MJ | 1 |
| Ternent, CA | 1 |
| Herzig, DO | 1 |
| Fichera, A | 1 |
| Polite, BN | 1 |
| Dietz, DW | 1 |
| Patil, S | 1 |
| Avila, K | 1 |
| Abdullah, A | 1 |
| Sane, S | 1 |
| Branick, KA | 1 |
| Freeling, JL | 1 |
| Rezvani, K | 1 |
| Rödel, C | 3 |
| Graeven, U | 7 |
| Fietkau, R | 2 |
| Hohenberger, W | 3 |
| Hothorn, T | 1 |
| Hofheinz, RD | 4 |
| Ghadimi, M | 2 |
| Wolff, HA | 3 |
| Lang-Welzenbach, M | 1 |
| Raab, HR | 1 |
| Wittekind, C | 1 |
| Ströbel, P | 1 |
| Staib, L | 2 |
| Wilhelm, M | 1 |
| Grabenbauer, GG | 2 |
| Hoffmanns, H | 1 |
| Lindemann, F | 1 |
| Schlenska-Lange, A | 1 |
| Folprecht, G | 4 |
| Sauer, R | 3 |
| Liersch, T | 3 |
| Kwon, HJ | 1 |
| Park, MI | 2 |
| Park, SJ | 2 |
| Moon, W | 1 |
| Kim, SE | 1 |
| Lee, HW | 1 |
| Chung, KH | 1 |
| Lee, BS | 1 |
| Jang, DK | 1 |
| Yoshida, Y | 2 |
| Ogura, K | 1 |
| Hiratsuka, A | 1 |
| Aisu, N | 1 |
| Yamada, T | 1 |
| Kojima, D | 1 |
| Tanimura, S | 1 |
| Ogata, K | 1 |
| Hara, S | 1 |
| Mogi, A | 1 |
| Takamatsu, Y | 1 |
| Tamura, K | 1 |
| Mishima, H | 3 |
| Yamashita, Y | 2 |
| Pan, J | 1 |
| Zhang, YF | 1 |
| Yang, HY | 1 |
| Xu, HF | 1 |
| Sang, XT | 1 |
| Zhong, SX | 1 |
| Mao, YL | 1 |
| Pecori, B | 1 |
| Bianco, F | 1 |
| Aloj, L | 1 |
| Tatangelo, F | 1 |
| Romano, C | 2 |
| Granata, V | 1 |
| Marone, P | 1 |
| Leone, A | 1 |
| Botti, G | 2 |
| Petrillo, A | 1 |
| Caracò, C | 1 |
| Iaffaioli, VR | 1 |
| Muto, P | 1 |
| Comella, P | 5 |
| Budillon, A | 1 |
| Delrio, P | 1 |
| Seki, H | 2 |
| Ohi, H | 1 |
| Ozaki, T | 2 |
| Yabusaki, H | 1 |
| Hegewisch-Becker, S | 2 |
| Lerchenmüller, CA | 1 |
| Killing, B | 1 |
| Depenbusch, R | 1 |
| Steffens, CC | 1 |
| Al-Batran, SE | 2 |
| Lange, T | 1 |
| Dietrich, G | 1 |
| Stoehlmacher, J | 2 |
| Quidde, J | 1 |
| Trarbach, T | 1 |
| Hinke, A | 2 |
| McRee, AJ | 1 |
| Sanoff, HK | 4 |
| Carlson, C | 1 |
| Ivanova, A | 2 |
| O'Neil, BH | 2 |
| Liu, LT | 1 |
| Tang, LQ | 1 |
| Chen, QY | 1 |
| Guo, SS | 1 |
| Guo, L | 1 |
| Mo, HY | 1 |
| Zhao, C | 1 |
| Guo, X | 1 |
| Cao, KJ | 1 |
| Qian, CN | 1 |
| Zeng, MS | 1 |
| Bei, JX | 1 |
| Shao, JY | 1 |
| Mai, HQ | 1 |
| Leon, O | 1 |
| Guren, MG | 1 |
| Radu, C | 1 |
| Gunnlaugsson, A | 1 |
| Johnsson, A | 2 |
| Dodagoudar, C | 1 |
| Doval, DC | 1 |
| Mahanta, A | 1 |
| Goel, V | 1 |
| Upadhyay, A | 1 |
| Goyal, P | 1 |
| Talwar, V | 1 |
| Singh, S | 1 |
| John, MC | 1 |
| Tiwari, S | 1 |
| Patnaik, N | 1 |
| Dong, J | 2 |
| Maglinte, GA | 1 |
| Weng, CC | 1 |
| Kuo, KK | 1 |
| Su, HT | 1 |
| Hsiao, PJ | 1 |
| Chen, YW | 1 |
| Wu, DC | 1 |
| Hung, WC | 1 |
| Cheng, KH | 1 |
| Driessen, CM | 1 |
| de Boer, JP | 1 |
| Gelderblom, H | 1 |
| Rasch, CR | 1 |
| de Jong, MA | 1 |
| Verbist, BM | 1 |
| Melchers, WJ | 1 |
| Tesselaar, ME | 1 |
| van der Graaf, WT | 1 |
| Kaanders, JH | 1 |
| van Herpen, CM | 2 |
| Jeannin, G | 1 |
| Merle, P | 1 |
| Janicot, H | 1 |
| Thibonnier, L | 1 |
| Kwiatkowski, F | 1 |
| Naame, A | 1 |
| Chadeyras, JB | 1 |
| Galvaing, G | 1 |
| Belliere, A | 1 |
| Filaire, M | 1 |
| Aroldi, F | 1 |
| Michishita, Y | 1 |
| Oyama, K | 1 |
| Hatano, Y | 1 |
| Nozawa, T | 1 |
| Ishibashi, M | 1 |
| Konda, R | 1 |
| Veloz-Martínez, MG | 1 |
| Quintana-Romero, V | 1 |
| Contreras-Morales, Mdel R | 1 |
| Jiménez-Vieyra, CR | 1 |
| Feng, Q | 1 |
| Wei, Y | 2 |
| Ren, L | 1 |
| Zheng, P | 1 |
| Ye, Q | 1 |
| Ding, J | 1 |
| Chang, W | 1 |
| Zhong, Y | 1 |
| Zhu, D | 1 |
| Lin, Q | 1 |
| Qin, X | 2 |
| Guo, Y | 1 |
| Xiong, BH | 1 |
| Zhang, T | 1 |
| Ma, L | 1 |
| Katada, N | 1 |
| Moriya, H | 1 |
| Hosoda, K | 1 |
| Mieno, H | 1 |
| Katada, C | 1 |
| Koizumi, W | 3 |
| Hoshi, K | 1 |
| Dueland, S | 1 |
| Ree, AH | 1 |
| Grøholt, KK | 1 |
| Saelen, MG | 1 |
| Folkvord, S | 1 |
| Hole, KH | 1 |
| Seierstad, T | 1 |
| Larsen, SG | 1 |
| Giercksky, KE | 1 |
| Wiig, JN | 1 |
| Boye, K | 1 |
| Flatmark, K | 1 |
| Yoshimatsu, K | 2 |
| Osawa, G | 1 |
| Yokomizo, H | 2 |
| Yano, Y | 1 |
| Nakayama, M | 1 |
| Okayama, S | 1 |
| Matsumoto, A | 1 |
| Fujimoto, T | 2 |
| Morita, S | 2 |
| Naritaka, Y | 1 |
| Zhao, S | 1 |
| Tang, H | 1 |
| Yan, D | 1 |
| Fan, J | 1 |
| Sun, H | 1 |
| Wen, Y | 1 |
| Yu, F | 2 |
| Cui, F | 1 |
| Xue, Y | 2 |
| Yue, B | 1 |
| Wang, X | 2 |
| Liu, X | 1 |
| Mi, Y | 1 |
| Zhou, Z | 1 |
| Peng, Z | 1 |
| Voboril, R | 1 |
| Rychterova, V | 1 |
| Voborilova, J | 1 |
| Kubecova, M | 1 |
| Fanta, J | 1 |
| Dvorak, J | 1 |
| Yan, X | 1 |
| Shan, Z | 1 |
| Yan, L | 1 |
| Zhu, Q | 1 |
| Xu, B | 5 |
| Liu, S | 1 |
| Ock, CY | 1 |
| Keam, B | 1 |
| Kim, TM | 2 |
| Han, DH | 1 |
| Won, TB | 1 |
| Hah, JH | 2 |
| Kwon, TK | 1 |
| Kim, DW | 3 |
| Kim, DY | 3 |
| Rhee, CS | 2 |
| Wu, HG | 1 |
| Sung, MW | 2 |
| Heo, DS | 3 |
| Bai, X | 1 |
| Su, R | 1 |
| Ma, T | 2 |
| Shen, S | 1 |
| Lou, J | 1 |
| Que, R | 1 |
| Yuan, Y | 1 |
| Yu, R | 1 |
| Wei, Q | 1 |
| Liang, T | 1 |
| Xie, N | 1 |
| Nice, EC | 1 |
| Huang, C | 1 |
| Lei, Y | 1 |
| Shigeta, K | 1 |
| Hasegawa, H | 1 |
| Okabayashi, K | 1 |
| Tsuruta, M | 1 |
| Ishii, Y | 1 |
| Endo, T | 1 |
| Ochiai, H | 1 |
| Kondo, T | 1 |
| Kitagawa, Y | 1 |
| Körber, MI | 1 |
| Staribacher, A | 1 |
| Ratzenböck, I | 1 |
| Steger, G | 1 |
| Mader, RM | 2 |
| Smid, D | 1 |
| Kulda, V | 1 |
| Srbecka, K | 1 |
| Kubackova, D | 1 |
| Dolezal, J | 1 |
| Daum, O | 1 |
| Kucera, R | 1 |
| Topolcan, O | 1 |
| Treska, V | 1 |
| Skalicky, T | 1 |
| Pesta, M | 1 |
| Nozawa, H | 1 |
| Ishihara, S | 1 |
| Kawai, K | 2 |
| Murono, K | 1 |
| Otani, K | 1 |
| Nishikawa, T | 1 |
| Tanaka, T | 1 |
| Kiyomatsu, T | 1 |
| Hata, K | 1 |
| Watanabe, T | 1 |
| Burtness, BA | 1 |
| Niedzwiecki, D | 3 |
| Ye, X | 1 |
| Douglas, K | 1 |
| Ilson, DH | 2 |
| Villaflor, VM | 1 |
| Cohen, SJ | 1 |
| Mayer, RJ | 4 |
| Venook, A | 2 |
| Bridgewater, J | 2 |
| Eskens, FA | 2 |
| Sasse, C | 1 |
| Vossen, S | 1 |
| Van Sant, C | 1 |
| Ball, HA | 1 |
| Keating, A | 1 |
| Krivoshik, A | 1 |
| Henriques De Figueiredo, B | 1 |
| Menis, J | 1 |
| Lefebvre, JL | 1 |
| Barzan, L | 1 |
| de Raucourt, D | 3 |
| Giurgea, L | 1 |
| Hupperets, P | 1 |
| Leemans, CR | 1 |
| Licitra, L | 2 |
| Rolland, F | 1 |
| Tesselaar, M | 1 |
| Siegel, JA | 1 |
| Korgavkar, K | 1 |
| Weinstock, MA | 1 |
| Zhou, Y | 2 |
| Liao, Z | 2 |
| Huang, Q | 1 |
| Feng, S | 1 |
| Konishi, H | 1 |
| Fujiya, M | 1 |
| Tanaka, H | 2 |
| Ueno, N | 1 |
| Moriichi, K | 1 |
| Sasajima, J | 1 |
| Ikuta, K | 1 |
| Akutsu, H | 1 |
| Tanabe, H | 1 |
| Kohgo, Y | 1 |
| Haghighi, S | 1 |
| Kasbkar, H | 1 |
| Esmaeilpour, K | 1 |
| Yasaei, M | 1 |
| Liang, L | 1 |
| Zhuang, R | 1 |
| Cui, Y | 1 |
| Yang, B | 1 |
| Xi, Y | 1 |
| Díez de Corcuera, I | 1 |
| Manzano, JL | 3 |
| Valladares-Ayerbes, M | 2 |
| Alcaide, J | 1 |
| García García, T | 1 |
| Sastre, J | 2 |
| Moore, M | 2 |
| Gill, S | 1 |
| Asmis, T | 1 |
| Berry, S | 2 |
| Burkes, R | 1 |
| Zbuk, K | 1 |
| Alcindor, T | 1 |
| Jeyakumar, A | 1 |
| Chan, T | 1 |
| Spratlin, J | 1 |
| Tang, PA | 1 |
| Rothenstein, J | 1 |
| Kudrik, F | 1 |
| Kauh, J | 1 |
| Tang, S | 1 |
| Kambhampati, SR | 1 |
| Ramdas, N | 1 |
| Binder, P | 1 |
| Strevel, E | 1 |
| Péron, J | 1 |
| Roy, P | 1 |
| Desseigne, F | 2 |
| Roche, L | 1 |
| Ozenne, B | 1 |
| Li, CY | 1 |
| Huang, PM | 1 |
| Chu, PY | 2 |
| Chen, PM | 2 |
| Lin, MW | 1 |
| Kuo, SW | 1 |
| Lee, JM | 2 |
| He, Y | 1 |
| Zhu, Y | 1 |
| Chen, M | 1 |
| Weng, M | 1 |
| Ning, N | 1 |
| Zhao, R | 1 |
| Jin, Y | 2 |
| Redpath, RJ | 1 |
| Jin, X | 1 |
| Zhong, Z | 1 |
| Shen, G | 1 |
| Wang, D | 1 |
| Parikh, A | 1 |
| Atreya, C | 1 |
| Korn, WM | 1 |
| Hall, PS | 1 |
| Lord, SR | 1 |
| Collinson, M | 1 |
| Marshall, H | 1 |
| Jones, M | 1 |
| Lowe, C | 1 |
| Howard, H | 1 |
| Swinson, D | 1 |
| Velikova, G | 1 |
| Anthoney, A | 1 |
| Roy, R | 1 |
| Dent, J | 1 |
| Cheeseman, S | 1 |
| Last, K | 1 |
| Seymour, MT | 4 |
| Ohman, KA | 1 |
| Tan, MC | 1 |
| Tan, BR | 2 |
| Fields, RC | 1 |
| Viaud, J | 1 |
| Brac, C | 1 |
| Le Pabic, E | 1 |
| Leconte, B | 2 |
| Bodère, A | 1 |
| Pracht, M | 1 |
| Le Sourd, S | 1 |
| Hwang, WS | 1 |
| Chao, TY | 2 |
| Lin, SF | 1 |
| Chung, CY | 1 |
| Chiu, CF | 1 |
| Chang, YF | 1 |
| Chiou, TJ | 1 |
| Brenner, WS | 1 |
| Picus, J | 1 |
| Marsh, S | 1 |
| Gao, F | 1 |
| Fournier, C | 1 |
| Fracasso, PM | 1 |
| James, J | 1 |
| Yen-Revollo, JL | 1 |
| McLeod, HL | 2 |
| Rothenberg, ML | 5 |
| Cox, JV | 2 |
| Butts, C | 1 |
| Navarro, M | 2 |
| Goel, R | 2 |
| Gollins, S | 2 |
| Siu, LL | 3 |
| Laguerre, S | 1 |
| Sultana, A | 1 |
| Tudur Smith, C | 1 |
| Starling, N | 2 |
| Neoptolemos, JP | 2 |
| Ghaneh, P | 2 |
| Cameron, DA | 1 |
| Mizushima, T | 2 |
| Mizuno, H | 1 |
| Sugiura, T | 1 |
| Ito, T | 1 |
| Udatsu, Y | 1 |
| Okazawa, M | 1 |
| Sugimura, K | 1 |
| Tomokuni, A | 1 |
| Kusumoto, H | 1 |
| Nakagawa, T | 1 |
| Kishimoto, T | 1 |
| Iwase, K | 1 |
| Izukura, M | 1 |
| Chu, E | 2 |
| Koeberle, D | 1 |
| Saletti, P | 1 |
| Borner, M | 2 |
| Gerber, D | 1 |
| Dietrich, D | 1 |
| Caspar, CB | 1 |
| Mingrone, W | 1 |
| Beretta, K | 1 |
| Strasser, F | 1 |
| Ruhstaller, T | 1 |
| Mora, O | 1 |
| Herrmann, R | 3 |
| Brell, JM | 1 |
| Krishnamurthi, SS | 1 |
| Javle, M | 1 |
| Saltzman, J | 1 |
| Wollner, I | 1 |
| Pelley, R | 1 |
| Dowlati, A | 1 |
| Kantharaj, BN | 1 |
| Schluchter, MD | 1 |
| Rath, L | 1 |
| Ivy, SP | 1 |
| Remick, SC | 1 |
| Frustaci, S | 1 |
| Lombardi, D | 2 |
| Fratino, L | 1 |
| Bonanno, S | 1 |
| Spartà, D | 1 |
| Palmucci, S | 1 |
| Berretta, S | 1 |
| Massidda, B | 5 |
| Filippelli, G | 3 |
| Farris, A | 2 |
| Natale, D | 2 |
| Barberis, G | 2 |
| Maiorino, L | 1 |
| Palmeri, S | 4 |
| Cannone, M | 1 |
| Condemi, G | 2 |
| Abali, H | 1 |
| Hayran, M | 1 |
| Yildirim, N | 1 |
| Budakoglu, B | 1 |
| Sherrill, B | 1 |
| Amonkar, MM | 1 |
| Walker, M | 2 |
| Geyer, C | 1 |
| Cameron, D | 3 |
| Granci, V | 1 |
| Bibeau, F | 2 |
| Kramar, A | 2 |
| Boissière-Michot, F | 1 |
| Thézénas, S | 2 |
| Thirion, A | 1 |
| Gongora, C | 1 |
| Martineau, P | 1 |
| Del Rio, M | 1 |
| Xu, JM | 2 |
| Zhang, XD | 3 |
| Chu, YP | 1 |
| Liu, DQ | 1 |
| Jin, ML | 1 |
| Andreetta, C | 2 |
| Puppin, C | 1 |
| Minisini, A | 1 |
| Valent, F | 1 |
| Pegolo, E | 1 |
| Damante, G | 2 |
| Di Loreto, C | 2 |
| Pizzolitto, S | 1 |
| Pandolfi, M | 1 |
| Piga, A | 1 |
| Puglisi, F | 2 |
| Kabbinavar, FF | 1 |
| Wallace, JF | 1 |
| Holmgren, E | 1 |
| Yi, J | 1 |
| Cella, D | 1 |
| Yost, KJ | 1 |
| Hurwitz, HI | 2 |
| Kawecki, A | 1 |
| Rottey, S | 1 |
| Zabolotnyy, D | 1 |
| Kienzer, HR | 1 |
| Cupissol, D | 1 |
| Benasso, M | 1 |
| Vynnychenko, I | 1 |
| Bokemeyer, C | 4 |
| Schueler, A | 1 |
| Amellal, N | 1 |
| Hitt, R | 3 |
| Dellapasqua, S | 2 |
| Bertolini, F | 2 |
| Bagnardi, V | 2 |
| Campagnoli, E | 1 |
| Scarano, E | 1 |
| Torrisi, R | 2 |
| Shaked, Y | 1 |
| Mancuso, P | 2 |
| Goldhirsch, A | 5 |
| Rocca, A | 2 |
| Pietri, E | 1 |
| Colleoni, M | 4 |
| Higaki, K | 1 |
| Ohtani, S | 1 |
| Kin, R | 1 |
| Masumura, K | 1 |
| Harano, M | 1 |
| Urashima, M | 1 |
| Kagemoto, M | 1 |
| Takada, S | 1 |
| Matsuura, H | 1 |
| Metro, G | 1 |
| Mottolese, M | 1 |
| Fabi, A | 1 |
| Haller, DG | 7 |
| Wong, AO | 2 |
| Koralewski, PM | 1 |
| Miller, WH | 1 |
| Habboubi, N | 1 |
| Garay, C | 1 |
| Olivatto, LO | 1 |
| Galizia, E | 2 |
| Chiorrini, S | 1 |
| Berardi, R | 3 |
| Pierantoni, C | 1 |
| Ryan, Q | 1 |
| Ibrahim, A | 2 |
| Cohen, MH | 2 |
| Johnson, J | 1 |
| Ko, CW | 1 |
| Sridhara, R | 1 |
| Justice, R | 1 |
| Pazdur, R | 5 |
| Sirohi, B | 1 |
| Pluzanska, A | 3 |
| Utracka-Hutka, B | 1 |
| Zaluski, J | 2 |
| Glynne-Jones, R | 4 |
| Koralewski, P | 1 |
| Mainwaring, P | 1 |
| Wasan, H | 2 |
| Szczylik, C | 2 |
| Clingan, P | 1 |
| Chan, RT | 1 |
| Tabah-Fisch, I | 2 |
| Cassidy, J | 3 |
| Janot, F | 1 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Hamoir, M | 1 |
| Julieron, M | 1 |
| Castaing, M | 1 |
| Koike, Y | 1 |
| Miki, C | 1 |
| Okugawa, Y | 1 |
| Yokoe, T | 1 |
| Toiyama, Y | 1 |
| Tanaka, K | 2 |
| Kusunoki, M | 1 |
| Catalano, V | 5 |
| Graziano, F | 4 |
| D'Emidio, S | 1 |
| Baldelli, AM | 2 |
| Rossi, D | 2 |
| Vincenzi, B | 4 |
| Giordani, P | 2 |
| Alessandroni, P | 2 |
| Testa, E | 2 |
| Catalano, G | 6 |
| Veerasarn, V | 1 |
| Boonnuch, W | 1 |
| Chinswangwatanakul, V | 1 |
| Lohsiriwat, D | 1 |
| Mahamadsolaeh, P | 1 |
| Campbell, ME | 2 |
| Morton, RF | 3 |
| Ramanathan, RK | 6 |
| Williamson, SK | 3 |
| Findlay, BP | 3 |
| Pitot, HC | 3 |
| Taira, K | 1 |
| Fukutomi, A | 1 |
| Onozawa, Y | 1 |
| Hironaka, S | 1 |
| Yasui, H | 1 |
| Taku, K | 1 |
| Hashimoto, T | 1 |
| Nishimura, T | 1 |
| Vakhabova, JV | 1 |
| Semenov, NN | 1 |
| Dobrova, NV | 1 |
| Lichinitser, MR | 1 |
| Cartwright, T | 2 |
| Kuefler, P | 1 |
| Cohn, A | 1 |
| Hyman, W | 1 |
| Berger, M | 2 |
| Richards, D | 1 |
| Vukelja, S | 1 |
| Nugent, JE | 1 |
| Ruxer, RL | 1 |
| Boehm, KA | 2 |
| Asmar, L | 4 |
| Christante, D | 1 |
| Pommier, S | 1 |
| Givi, B | 1 |
| Pommier, R | 1 |
| Sokurenko, VP | 1 |
| Korytova, LI | 1 |
| Tarazov, PG | 1 |
| Suvorova, IuV | 1 |
| Morak, MJ | 1 |
| van der Gaast, A | 2 |
| Incrocci, L | 1 |
| van Dekken, H | 1 |
| Hermans, JJ | 1 |
| Jeekel, J | 1 |
| Hop, WC | 1 |
| Kazemier, G | 1 |
| van Eijck, CH | 1 |
| Tanvetyanon, T | 1 |
| Ishiguro, T | 2 |
| Ishibashi, K | 4 |
| Okada, N | 2 |
| Kuwabara, K | 2 |
| Miyazaki, T | 1 |
| Yokoyama, M | 1 |
| Matsuki, M | 1 |
| Sano, M | 1 |
| Inoue, N | 1 |
| Ishida, H | 4 |
| Gallego, R | 1 |
| Codony-Servat, J | 1 |
| García-Albéniz, X | 1 |
| Carcereny, E | 1 |
| Longarón, R | 1 |
| Oliveras, A | 1 |
| Tosca, M | 1 |
| Augé, JM | 1 |
| Gascón, P | 1 |
| Haurani, MJ | 1 |
| Foreman, K | 1 |
| Yang, JJ | 1 |
| Siddiqui, A | 1 |
| Aguilar, G | 1 |
| Palencia, S | 1 |
| Newton, E | 1 |
| Abo, A | 1 |
| Park, IJ | 2 |
| Choi, GS | 2 |
| Lim, KH | 2 |
| Kang, BM | 2 |
| Jun, SH | 2 |
| Suenaga, M | 2 |
| Mizunuma, N | 3 |
| Shinozaki, E | 2 |
| Oya, M | 1 |
| Ueno, M | 1 |
| Yamaguchi, T | 1 |
| Muto, T | 1 |
| Konishi, F | 2 |
| Hatake, K | 2 |
| Niki, T | 1 |
| Soejima, T | 1 |
| Fujii, O | 1 |
| Ohta, Y | 1 |
| Tsuda, M | 1 |
| Horita, K | 1 |
| Tsujino, K | 1 |
| Hirohata, S | 1 |
| Fujino, Y | 1 |
| Nishisaki, H | 1 |
| Nannini, M | 1 |
| Nobili, E | 1 |
| Di Cicilia, R | 1 |
| Brandi, G | 1 |
| Maleddu, A | 1 |
| Pantaleo, MA | 1 |
| Biasco, G | 1 |
| Li, SF | 1 |
| He, LH | 1 |
| Shi, YH | 1 |
| Hao, CF | 1 |
| Dong, GL | 1 |
| Tong, ZS | 1 |
| Cao, W | 1 |
| Lou, G | 1 |
| Jiang, J | 2 |
| Geng, M | 1 |
| Xi, W | 1 |
| Wong, TT | 1 |
| Oen, FT | 2 |
| Devereux, JG | 2 |
| Minassian, D | 1 |
| Tan, SB | 1 |
| Chew, PT | 2 |
| Seah, SK | 2 |
| Ross, PJ | 3 |
| Teoh, EM | 1 |
| A'hern, RP | 1 |
| Rhys-Evans, PH | 1 |
| Nutting, CM | 1 |
| Gore, ME | 2 |
| Yilmaz, G | 1 |
| Oztürk, B | 2 |
| Akyürek, N | 1 |
| Yildiz, R | 2 |
| Tonyali, O | 1 |
| Kim, JG | 3 |
| Chae, YS | 2 |
| Sohn, SK | 3 |
| Moon, JH | 1 |
| Ryoo, HM | 1 |
| Kum, Y | 1 |
| Jeon, SW | 1 |
| Ku, GY | 1 |
| O'Reilly, EM | 1 |
| Saltz, LB | 2 |
| Schrag, D | 1 |
| Maki, RG | 1 |
| Kelsen, DP | 2 |
| Yata, Y | 1 |
| Nakayama, Y | 1 |
| Hirano, K | 2 |
| Tokimitsu, Y | 1 |
| Kudo, H | 1 |
| Kajiura, S | 1 |
| Yasumura, S | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Zhao, JG | 1 |
| Qiu, F | 1 |
| Xiong, JP | 2 |
| Xiang, XJ | 2 |
| Yan, J | 1 |
| Zhan, ZY | 1 |
| von Minckwitz, G | 3 |
| Schmidt, M | 1 |
| Maass, N | 2 |
| Cufer, T | 2 |
| de Jongh, FE | 1 |
| Maartense, E | 1 |
| Zielinski, C | 1 |
| Kaufmann, M | 3 |
| Bauer, W | 2 |
| Baumann, KH | 1 |
| Clemens, MR | 1 |
| Duerr, R | 1 |
| Uleer, C | 1 |
| Andersson, M | 2 |
| Stein, RC | 1 |
| Nekljudova, V | 1 |
| Loibl, S | 3 |
| Shiina, M | 1 |
| Katamura, Y | 2 |
| Aikata, H | 3 |
| Takaki, S | 3 |
| Azakami, T | 1 |
| Kawaoka, T | 3 |
| Waki, K | 2 |
| Hiramatsu, A | 2 |
| Kawakami, Y | 2 |
| Takahashi, S | 4 |
| Kenjo, M | 1 |
| Toyota, N | 2 |
| Ito, K | 2 |
| Chayama, K | 3 |
| Lee, JJ | 3 |
| Im, SA | 2 |
| Kim, SY | 1 |
| Kim, KH | 1 |
| Reed, SD | 1 |
| Anstrom, KJ | 1 |
| Schulman, KA | 1 |
| Köhne, CH | 7 |
| Hitre, E | 1 |
| Chang Chien, CR | 1 |
| Makhson, A | 1 |
| D'Haens, G | 1 |
| Pintér, T | 1 |
| Lim, R | 2 |
| Roh, JK | 6 |
| Stroh, C | 1 |
| Tejpar, S | 1 |
| Schlichting, M | 1 |
| Nippgen, J | 2 |
| Chen, ML | 1 |
| Fang, CH | 1 |
| Liang, LS | 1 |
| Dai, LH | 1 |
| Wang, XK | 1 |
| Tamburini, E | 1 |
| Carloni, F | 1 |
| Nicoletti, S | 1 |
| Ravaioli, A | 1 |
| Raoul, JL | 3 |
| Brezault, C | 1 |
| Husseini, F | 1 |
| Cals, L | 1 |
| Loos, AH | 1 |
| Reni, M | 1 |
| Cereda, S | 1 |
| Balzano, G | 1 |
| Passoni, P | 1 |
| Rognone, A | 1 |
| Zerbi, A | 1 |
| Nicoletti, R | 1 |
| Mazza, E | 1 |
| Arcidiacono, PG | 1 |
| Di Carlo, V | 1 |
| Villa, E | 1 |
| Teitelbaum, UR | 1 |
| Kovács, AF | 1 |
| Eberlein, K | 2 |
| Hülsmann, T | 1 |
| Okines, A | 1 |
| Allum, W | 1 |
| Wotherspoon, A | 1 |
| Benson, M | 1 |
| Thomas, J | 1 |
| Brown, G | 1 |
| Riddell, A | 1 |
| Stavridi, F | 1 |
| Ashley, S | 3 |
| Oates, J | 1 |
| Chao, Y | 2 |
| Chou, WC | 1 |
| Lee, KD | 1 |
| Lin, YC | 2 |
| Matsushita, H | 1 |
| Tsuboi, K | 2 |
| Honda, I | 1 |
| Kato, N | 1 |
| Okochi, O | 1 |
| Kobayashi, D | 1 |
| Hattori, M | 1 |
| Kleibl, Z | 1 |
| Fidlerova, J | 1 |
| Kleiblova, P | 1 |
| Kormunda, S | 1 |
| Bilek, M | 1 |
| Bouskova, K | 1 |
| Sevcik, J | 1 |
| Novotny, J | 1 |
| Kotecha, A | 1 |
| Spratt, A | 1 |
| Bunce, C | 2 |
| Garway-Heath, DF | 1 |
| Viswanathan, A | 1 |
| Sun, WL | 1 |
| Hutarew, G | 1 |
| Gradl, J | 1 |
| Gratzl, M | 1 |
| Denz, H | 1 |
| Fiegl, M | 1 |
| Seo, BG | 2 |
| Kwon, HC | 6 |
| Oh, SY | 7 |
| Lee, S | 4 |
| Kim, SG | 1 |
| Kim, SH | 5 |
| Han, H | 1 |
| Valentini, V | 1 |
| Massaccesi, M | 1 |
| Balducci, M | 1 |
| Mantini, G | 1 |
| Micciché, F | 1 |
| Mattiucci, GC | 1 |
| Dinapoli, N | 1 |
| Meduri, B | 1 |
| D'Agostino, GR | 1 |
| Salvi, G | 1 |
| Nardone, L | 1 |
| Neumann, UP | 1 |
| Thelen, A | 1 |
| Röcken, C | 1 |
| Bahra, M | 1 |
| Jonas, S | 1 |
| Schmeding, M | 1 |
| Pratschke, J | 1 |
| Bova, R | 1 |
| Oki, E | 1 |
| Kakeji, Y | 1 |
| Yoshida, R | 1 |
| Ando, K | 1 |
| Masuda, T | 1 |
| Ohgaki, K | 1 |
| Morita, M | 1 |
| Maehara, Y | 4 |
| Taha, FM | 1 |
| Zeeneldin, AA | 1 |
| Helal, AM | 1 |
| Gaber, AA | 1 |
| Sallam, YA | 1 |
| Ramadan, H | 1 |
| Moneer, MM | 1 |
| Dong, NN | 1 |
| Wang, MY | 1 |
| Zhang, Q | 2 |
| Liu, ZF | 1 |
| Segal, NH | 1 |
| Mol, L | 2 |
| Koopman, M | 2 |
| Ottevanger, PB | 1 |
| Punt, CJA | 1 |
| Viale, G | 2 |
| Giobbie-Hurder, A | 1 |
| Gusterson, BA | 1 |
| Maiorano, E | 1 |
| Mastropasqua, MG | 1 |
| Sonzogni, A | 1 |
| Mallon, E | 1 |
| Castiglione-Gertsch, M | 2 |
| Regan, MM | 1 |
| Price, KN | 1 |
| Brown, RW | 1 |
| Golouh, R | 1 |
| Crivellari, D | 2 |
| Karlsson, P | 1 |
| Öhlschlegel, C | 1 |
| Gelber, RD | 1 |
| Coates, AS | 1 |
| Kusama, M | 1 |
| Nomizu, T | 1 |
| Aogi, K | 1 |
| Yoshimoto, M | 1 |
| Horikoshi, N | 1 |
| Tabei, T | 1 |
| Noguchi, S | 1 |
| Miura, S | 1 |
| Yoshimura, N | 1 |
| Kimura, M | 1 |
| Toyama, K | 1 |
| Shin, E | 1 |
| Green, EM | 1 |
| Hua, LV | 1 |
| Byrne, E | 1 |
| Yudcovitch, L | 1 |
| Stec, R | 1 |
| Bodnar, L | 1 |
| Kuboki, Y | 1 |
| Ozaka, M | 1 |
| Fujiwara, Y | 2 |
| Matsueda, K | 1 |
| Ho, JC | 1 |
| Lam, DC | 1 |
| Wong, MK | 1 |
| Lam, B | 1 |
| Ip, MS | 1 |
| Lam, WK | 1 |
| Cordio, S | 2 |
| Caputo, G | 1 |
| Novello, G | 1 |
| Reggiardo, G | 1 |
| Manzione, L | 2 |
| Bonnetain, F | 6 |
| Gamelin, E | 2 |
| Cadiot, G | 1 |
| Mitry, E | 4 |
| Smith, D | 2 |
| Cvitkovic, F | 1 |
| Coudert, B | 1 |
| Ricard, F | 1 |
| Bedenne, L | 4 |
| Li, YH | 4 |
| Feng, F | 2 |
| Jiang, WQ | 2 |
| He, YJ | 2 |
| An, X | 1 |
| Parthan, A | 1 |
| Posner, MR | 2 |
| Brammer, C | 1 |
| Beltran, P | 1 |
| Jansen, JP | 1 |
| Fraunholz, I | 1 |
| Weiss, C | 1 |
| Haberl, A | 1 |
| Nagy, Z | 1 |
| Turcsik, V | 1 |
| Blaskó, G | 1 |
| Taketomi, A | 1 |
| Itoh, S | 1 |
| Harimoto, N | 1 |
| Tsujita, E | 1 |
| Sugimachi, K | 2 |
| Gion, T | 1 |
| Yim, KL | 1 |
| Lu, M | 1 |
| Yi, SY | 1 |
| Jun, HJ | 1 |
| Lee, J | 6 |
| Park, SH | 3 |
| Lee, JK | 1 |
| Lee, KT | 2 |
| Lee, KH | 4 |
| Choi, DW | 1 |
| Choi, SH | 3 |
| Heo, JS | 2 |
| Park, YS | 5 |
| Lim, HY | 3 |
| Kang, WK | 8 |
| Park, HC | 1 |
| Lim, DH | 2 |
| Malmström, A | 1 |
| Hansen, J | 1 |
| Malmberg, L | 1 |
| Carlsson, L | 2 |
| Svensson, JH | 1 |
| Ahlgren, J | 2 |
| Ahlin, C | 1 |
| Jansson, T | 1 |
| Westberg, R | 2 |
| Ciruelos, EM | 1 |
| Cortés, J | 1 |
| Cortés-Funes, H | 1 |
| Mayordomo, JI | 2 |
| Bermejo, B | 1 |
| Ojeda, B | 1 |
| García, E | 1 |
| Rodríguez, CA | 1 |
| Muñoz, M | 1 |
| Gómez, P | 1 |
| Manso, L | 1 |
| Andrés, R | 2 |
| Lluch, A | 1 |
| Saura, C | 1 |
| Mendiola, C | 1 |
| Baselga, J | 1 |
| Debled, M | 2 |
| Madranges, N | 1 |
| Trainaud, A | 1 |
| Floquet, A | 1 |
| Donamaria, C | 1 |
| Brouste, V | 1 |
| Durand, M | 1 |
| Mauriac, L | 3 |
| Luber, B | 1 |
| Wöll, E | 1 |
| Decker, T | 1 |
| Endlicher, E | 2 |
| Röthling, N | 1 |
| Schuster, T | 2 |
| Keller, G | 1 |
| Fend, F | 1 |
| Peschel, C | 2 |
| Kimura, Y | 1 |
| Ishikawa, M | 1 |
| Hieda, M | 1 |
| Kakizawa, H | 1 |
| Gaedcke, J | 1 |
| Jung, K | 2 |
| Hermann, RM | 1 |
| Rothe, H | 1 |
| Schirmer, M | 1 |
| Herrmann, MKA | 1 |
| Hennies, S | 2 |
| Rave-Fränk, M | 1 |
| Hess, CF | 2 |
| Christiansen, H | 2 |
| Seo, YR | 1 |
| Kim, CK | 1 |
| Park, SK | 1 |
| Koh, ES | 1 |
| Hong, DS | 1 |
| Lang, I | 1 |
| Boer, K | 1 |
| Escudero, P | 5 |
| Kim, TY | 3 |
| Pover, GM | 1 |
| Morris, CD | 1 |
| Bayraktar, S | 1 |
| Bayraktar, UD | 1 |
| Rocha-Lima, CM | 1 |
| Yasue, H | 1 |
| Hanyu, N | 1 |
| Usuba, T | 1 |
| Abe, M | 1 |
| Hsu, CH | 4 |
| Hsu, C | 3 |
| Toh, HC | 1 |
| Epstein, RJ | 1 |
| Hsiao, LT | 1 |
| Chen, PJ | 1 |
| Lin, ZZ | 1 |
| Cheng, AL | 5 |
| Chang, PY | 1 |
| Cheng, MF | 1 |
| Lee, HS | 2 |
| Hsieh, CB | 1 |
| Yao, NS | 1 |
| Vrdoljak, E | 1 |
| Mise, BP | 1 |
| Lukić, B | 1 |
| Curić, Z | 1 |
| Bosković, L | 1 |
| Tica, I | 1 |
| Petrelli, F | 1 |
| Borgonovo, K | 1 |
| Ghilardi, M | 1 |
| Cabiddu, M | 1 |
| Barni, S | 2 |
| Yuuki, S | 1 |
| Komatsu, Y | 2 |
| Fuse, N | 2 |
| Miyagishima, T | 1 |
| Kudo, M | 1 |
| Tateyama, M | 1 |
| Kunieda, Y | 1 |
| Wakahama, O | 1 |
| Sakata, Y | 1 |
| Asaka, M | 2 |
| Langenberg, MH | 1 |
| Witteveen, PO | 1 |
| Roodhart, JM | 1 |
| Verheul, HM | 1 |
| Mergui-Roelvink, M | 1 |
| van der Sar, J | 1 |
| Brendel, E | 1 |
| Laferriere, N | 1 |
| Schellens, JH | 2 |
| Ishihara, Y | 1 |
| Matsunaga, K | 1 |
| Iijima, H | 1 |
| Hasegawa, G | 1 |
| Suzuki, T | 1 |
| Sato, A | 1 |
| Kobayashi, T | 2 |
| Yang, M | 1 |
| Hoffman, RM | 1 |
| Tamás, N | 1 |
| László, L | 1 |
| Edina, M | 1 |
| Li, FH | 1 |
| Zhou, ZW | 1 |
| Chen, XQ | 1 |
| Jeong, CY | 1 |
| Hong, SC | 1 |
| Kim, TH | 1 |
| Ha, CY | 1 |
| Lee, GW | 1 |
| Hwang, IG | 2 |
| Jang, JS | 1 |
| Kang, JH | 4 |
| Pillai, M | 1 |
| Gollard, R | 1 |
| Heim, W | 1 |
| Swan, F | 1 |
| Patel, R | 1 |
| Dreiling, L | 1 |
| Mo, M | 1 |
| Malik, I | 1 |
| Boccia, RV | 1 |
| Cosgriff, TM | 1 |
| Headley, DL | 1 |
| Badarinath, S | 1 |
| Dakhil, SR | 3 |
| Raftery, L | 1 |
| Calvo, BF | 1 |
| Chakravarthy, AB | 1 |
| Myers, MO | 1 |
| Wise, PE | 1 |
| Caskey, LS | 1 |
| Bernard, SA | 2 |
| Tepper, JE | 1 |
| Correale, P | 4 |
| Rotundo, MS | 1 |
| Del Vecchio, MT | 2 |
| Remondo, C | 1 |
| Migali, C | 1 |
| Ginanneschi, C | 1 |
| Tsang, KY | 2 |
| Licchetta, A | 2 |
| Mannucci, S | 1 |
| Loiacono, L | 1 |
| Tassone, P | 1 |
| Francini, G | 6 |
| Tagliaferri, P | 1 |
| Kotsori, AA | 1 |
| Noble, JL | 1 |
| Johnston, S | 1 |
| Smith, IE | 1 |
| Sperone, P | 1 |
| Ferrero, A | 1 |
| Daffara, F | 1 |
| Priola, A | 1 |
| Zaggia, B | 1 |
| Volante, M | 1 |
| Badalamenti, G | 1 |
| Intrivici, C | 2 |
| Del Buono, S | 1 |
| De Francia, S | 1 |
| Kalomirakis, E | 1 |
| Ratti, R | 1 |
| Angeli, A | 1 |
| Dogliotti, L | 2 |
| Papotti, M | 1 |
| Terzolo, M | 1 |
| Berruti, A | 3 |
| Block, S | 1 |
| Durando, X | 1 |
| Farges, MC | 1 |
| Buc, E | 1 |
| Abrial, C | 1 |
| Petorin-Lesens, C | 1 |
| Gillet, B | 1 |
| Vasson, MP | 1 |
| Pezet, D | 1 |
| Chollet, P | 2 |
| Thivat, E | 1 |
| Bosch, J | 1 |
| Overbeck, T | 1 |
| Matthias, C | 1 |
| Roedel, RM | 1 |
| Hess, V | 1 |
| Pratsch, S | 1 |
| Potthast, S | 1 |
| Lee, L | 1 |
| Winterhalder, R | 1 |
| Widmer, L | 1 |
| Cescato, C | 1 |
| Lohri, A | 1 |
| Jost, L | 1 |
| Stillhart, P | 1 |
| Pestalozzi, B | 1 |
| Matter-Walstra, KW | 1 |
| Dedes, KJ | 1 |
| Schwenkglenks, M | 1 |
| Brauchli, P | 1 |
| Szucs, TD | 1 |
| Pestalozzi, BC | 1 |
| Wu, F | 1 |
| Chen, SC | 1 |
| Lu, ZH | 1 |
| Martinez-Trufero, J | 1 |
| Isla, D | 2 |
| Adansa, JC | 1 |
| Irigoyen, A | 1 |
| Gil-Arnaiz, I | 1 |
| Lambea, J | 2 |
| Lecumberri, MJ | 1 |
| Cruz, JJ | 1 |
| Walter, B | 1 |
| Rogenhofer, S | 1 |
| Vogelhuber, M | 1 |
| Berand, A | 1 |
| Wieland, WF | 1 |
| Andreesen, R | 2 |
| Reichle, A | 1 |
| Fan, Y | 2 |
| Mochizuki, S | 1 |
| Ikematsu, H | 1 |
| Minashi, K | 1 |
| Yano, T | 1 |
| Tahara, M | 1 |
| Kaneko, K | 1 |
| Doi, T | 2 |
| Koike, K | 2 |
| Li, QF | 2 |
| Yao, RY | 2 |
| Liu, KW | 1 |
| Lv, HY | 1 |
| Jiang, T | 2 |
| Zhuang, L | 1 |
| Bai, J | 1 |
| Tang, C | 1 |
| Zhou, B | 1 |
| Gong, Y | 1 |
| Duanmu, Z | 1 |
| Liang, JT | 1 |
| Lai, HS | 1 |
| Cheng, KW | 1 |
| Miura, A | 1 |
| Izumi, Y | 1 |
| Ryotokuji, T | 1 |
| Monma, K | 1 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Nemoto, T | 1 |
| Shimura, T | 1 |
| Kataoka, H | 1 |
| Hirata, Y | 1 |
| Murakami, K | 1 |
| Mabuchi, M | 1 |
| Mizoshita, T | 1 |
| Kubota, E | 1 |
| Tanida, S | 1 |
| Kamiya, T | 1 |
| Joh, T | 1 |
| Pang, R | 1 |
| Law, WL | 1 |
| Chu, AC | 1 |
| Poon, JT | 1 |
| Lam, CS | 1 |
| Chow, AK | 1 |
| Ng, L | 1 |
| Cheung, LW | 1 |
| Lan, XR | 1 |
| Lan, HY | 1 |
| Tan, VP | 1 |
| Yau, TC | 1 |
| Poon, RT | 1 |
| Wong, BC | 1 |
| Boni, V | 1 |
| Zarate, R | 1 |
| Villa, JC | 1 |
| Bandrés, E | 1 |
| Gomez, MA | 1 |
| Aranda, E | 3 |
| Hirose, T | 1 |
| Fujita, K | 1 |
| Nishimura, K | 1 |
| Sunakawa, Y | 1 |
| Mizuno, K | 1 |
| Miwa, K | 1 |
| Nagashima, F | 1 |
| Tanigawara, Y | 1 |
| Adachi, M | 1 |
| Sasaki, Y | 1 |
| Hashiguchi, K | 1 |
| Kitajima, Y | 1 |
| Kai, K | 1 |
| Hiraki, M | 1 |
| Nakamura, J | 1 |
| Tokunaga, O | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Lorvidhaya, V | 3 |
| Chitapanarux, I | 3 |
| Phromratanapongse, P | 1 |
| Kamnerdsupaphon, P | 3 |
| Tharavichitkul, E | 2 |
| Lertsanguansinchai, P | 1 |
| Hsieh, CY | 1 |
| Sukthomya, V | 3 |
| Jackson, AS | 1 |
| Jain, P | 1 |
| Watkins, GR | 1 |
| Whitfield, GA | 1 |
| Green, MM | 1 |
| Valle, J | 1 |
| Taylor, MB | 1 |
| Dickinson, C | 1 |
| Price, PM | 1 |
| Saleem, A | 1 |
| Lassen, U | 1 |
| Jensen, LH | 1 |
| Sorensen, M | 1 |
| Rohrberg, KS | 1 |
| Ujmajuridze, Z | 1 |
| Jakobsen, A | 3 |
| Ma, F | 1 |
| Cai, R | 1 |
| Chua, TC | 1 |
| Al-Zahrani, A | 1 |
| Saxena, A | 1 |
| Liauw, W | 1 |
| Morris, DL | 1 |
| Costa, SD | 2 |
| Schneeweiss, A | 1 |
| Sütterlin, MW | 1 |
| Schrader, I | 1 |
| Gerber, B | 1 |
| Wiest, W | 1 |
| Tomé, O | 1 |
| Distelrath, A | 1 |
| Hagen, V | 1 |
| Kleine-Tebbe, A | 2 |
| Ruckhaeberle, E | 1 |
| Mehta, K | 1 |
| Satoh, T | 1 |
| Muro, K | 3 |
| Oriuchi, N | 1 |
| Labianca, R | 6 |
| Ferraù, F | 1 |
| Pucci, F | 1 |
| Silva, RR | 1 |
| Luppi, G | 1 |
| Beretta, GD | 3 |
| Stocken, DD | 1 |
| Bassi, C | 1 |
| Goldstein, D | 2 |
| Padbury, R | 1 |
| Moore, MJ | 4 |
| Gallinger, S | 1 |
| Mariette, C | 3 |
| Wente, MN | 1 |
| Izbicki, JR | 1 |
| Friess, H | 1 |
| Lerch, MM | 1 |
| Dervenis, C | 1 |
| Oláh, A | 1 |
| Butturini, G | 1 |
| Doi, R | 1 |
| Lind, PA | 3 |
| Valle, JW | 1 |
| Palmer, DH | 1 |
| Buckels, JA | 1 |
| McKay, CJ | 1 |
| Rawcliffe, CL | 1 |
| Büchler, MW | 1 |
| Chen, WK | 1 |
| Guo, ZM | 1 |
| Gu, MF | 1 |
| Huang, HQ | 1 |
| Yang, AK | 1 |
| Mauer, ME | 1 |
| Degardin, M | 1 |
| Jelic, S | 3 |
| Coens, C | 1 |
| Betka, J | 1 |
| Bernier, J | 1 |
| Preiss, JH | 1 |
| van den Weyngaert, D | 1 |
| Bottomley, A | 1 |
| Liu, Z | 1 |
| Fusi, A | 1 |
| Schmittel, A | 1 |
| Tinhofer, I | 1 |
| Schneider, A | 1 |
| Spigel, DR | 1 |
| Greco, FA | 1 |
| Waterhouse, D | 1 |
| Shipley, D | 1 |
| Lane, CM | 1 |
| Vazquez, ER | 1 |
| Clark, BL | 1 |
| Infante, JR | 1 |
| Bendell, JC | 1 |
| Burris, HA | 2 |
| Hainsworth, JD | 2 |
| Wiegel, T | 1 |
| Kreuser, ED | 1 |
| Kron, M | 1 |
| Baumann, W | 1 |
| Henne-Bruns, D | 1 |
| Link, KH | 1 |
| Egerton, N | 1 |
| López, R | 2 |
| Salgado, M | 1 |
| Reboredo, M | 1 |
| Grande, C | 1 |
| Méndez, JC | 1 |
| Jorge, M | 1 |
| Romero, C | 1 |
| Quintero, G | 1 |
| de la Cámara, J | 1 |
| Candamio, S | 1 |
| Gasmi, M | 1 |
| Cattan, S | 1 |
| Hammel, P | 3 |
| Chauffert, B | 2 |
| Legoux, JL | 1 |
| Yu, HB | 1 |
| Xian, HB | 1 |
| Deng, YM | 1 |
| Li, LL | 1 |
| Muñoz-Martin, AJ | 1 |
| Alvarez-Suarez, S | 1 |
| Jerez-Gilarranz, Y | 1 |
| Riesco-Martinez, M | 1 |
| Khosravi, P | 1 |
| Martin, M | 2 |
| Lü, HY | 1 |
| Sun, YY | 1 |
| Song, SA | 1 |
| Yasumatsu, R | 1 |
| Nakashima, T | 1 |
| Yamauchi, M | 1 |
| Wakasaki, T | 1 |
| Masuda, M | 1 |
| Komune, S | 1 |
| Byström, P | 2 |
| Nygren, P | 2 |
| Wernroth, L | 1 |
| Johansson, B | 1 |
| Larsson, A | 1 |
| Einarsson, R | 1 |
| Castillo-Fernández, O | 1 |
| Santibáñez, M | 1 |
| Bauza, A | 1 |
| Calderillo, G | 1 |
| Castro, C | 1 |
| Herrera, R | 1 |
| Serrano, A | 1 |
| Arrieta, O | 2 |
| Herrera, LA | 1 |
| Claringbold, PG | 1 |
| Brayshaw, PA | 1 |
| Price, RA | 1 |
| Turner, JH | 1 |
| Choi, CH | 1 |
| Lee, YY | 1 |
| Kim, MK | 1 |
| Kim, TJ | 1 |
| Lee, JW | 1 |
| Nam, HR | 1 |
| Huh, SJ | 1 |
| Lee, JH | 4 |
| Bae, DS | 1 |
| Kim, BG | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Kohno, N | 1 |
| Sabatier, R | 1 |
| Kirscher, S | 1 |
| Plat, F | 1 |
| Goubely, Y | 1 |
| Molinari, N | 1 |
| Madajewicz, S | 2 |
| Waterhouse, DM | 1 |
| Ritch, PS | 1 |
| Khan, MQ | 1 |
| Higby, DJ | 1 |
| Leichman, CG | 1 |
| Malik, SK | 1 |
| Hentschel, P | 1 |
| Gill, JF | 1 |
| Nicol, SJ | 1 |
| Moehler, M | 3 |
| Ababneh, Y | 1 |
| Verpoort, K | 1 |
| Schmidt, B | 1 |
| Musch, R | 1 |
| Soeling, U | 1 |
| Maintz, C | 1 |
| Siebler, J | 2 |
| Schimanski, CC | 1 |
| Galle, PR | 2 |
| Fahlke, J | 1 |
| Becker, H | 1 |
| Hess, C | 1 |
| Hofheinz, R | 2 |
| Post, S | 2 |
| Raab, R | 1 |
| Wenz, F | 1 |
| Ho, YF | 1 |
| Lu, WC | 1 |
| Chen, RR | 1 |
| Yeh, KH | 3 |
| Wickham, L | 1 |
| Ho-Yen, GO | 1 |
| Wong, D | 1 |
| Charteris, DG | 1 |
| Stauffer, JA | 1 |
| Mathew, J | 1 |
| Odell, JA | 1 |
| Shitara, K | 1 |
| Yuki, S | 1 |
| Utsunomiya, S | 1 |
| Yokota, T | 1 |
| Sato, Y | 1 |
| Inaba, Y | 1 |
| Tajika, M | 1 |
| Kawai, H | 1 |
| Yamaura, H | 1 |
| Kato, M | 2 |
| Gallerani, E | 1 |
| Bauer, J | 1 |
| Hess, D | 3 |
| Boehm, S | 1 |
| Droege, C | 1 |
| Jeckelmann, S | 1 |
| Miani, M | 1 |
| Marsoni, S | 2 |
| Sperka, S | 1 |
| Sessa, C | 1 |
| Park, KS | 1 |
| Hong, YS | 4 |
| Kim, TW | 5 |
| Kim, HR | 1 |
| Kim, DH | 3 |
| Kim, C | 1 |
| Tai, SK | 1 |
| Yang, MH | 1 |
| Chang, SY | 1 |
| Chang, YC | 1 |
| Li, WY | 1 |
| Tsai, TL | 1 |
| Wang, YF | 1 |
| Hsieh, SL | 1 |
| Barhoumi, M | 1 |
| Mornex, F | 2 |
| Azzedine, A | 1 |
| Butel, J | 1 |
| Stremsdoerfer, N | 1 |
| Nuzzo, F | 1 |
| Morabito, A | 1 |
| Gravina, A | 1 |
| Di Rella, F | 1 |
| Landi, G | 1 |
| Pacilio, C | 1 |
| Labonia, V | 1 |
| Rossi, E | 1 |
| De Maio, E | 1 |
| Piccirillo, MC | 1 |
| D'Aiuto, G | 1 |
| Thomas, R | 1 |
| Rinaldo, M | 1 |
| Di Bonito, M | 1 |
| Gallo, C | 1 |
| Perrone, F | 1 |
| de Matteis, A | 1 |
| Salama, JK | 1 |
| Haraf, DJ | 5 |
| Stenson, KM | 2 |
| Blair, EA | 1 |
| Witt, ME | 5 |
| Williams, R | 1 |
| Kunnavakkam, R | 1 |
| Cohen, EE | 1 |
| Seiwert, T | 1 |
| Vokes, EE | 7 |
| Brodell, EE | 1 |
| Smith, E | 1 |
| Brodell, RT | 1 |
| Sun, DS | 1 |
| Zhang, JD | 1 |
| Li, L | 1 |
| Dai, Y | 1 |
| Yu, JM | 1 |
| Shao, ZY | 1 |
| Backshall, A | 1 |
| Sharma, R | 2 |
| Clarke, SJ | 2 |
| Keun, HC | 1 |
| Ch'ang, HJ | 1 |
| Lin, YL | 1 |
| Wang, HP | 1 |
| Chiu, YF | 1 |
| Chang, MC | 1 |
| Tien, YW | 1 |
| Hsieh, RK | 1 |
| Lin, PW | 1 |
| Shan, YS | 1 |
| Chang, JY | 1 |
| Whang-Peng, J | 1 |
| Hwang, TL | 1 |
| Yeh, CT | 1 |
| Sung, CM | 1 |
| Hsu, CL | 1 |
| Lin, CC | 1 |
| Pan, KT | 1 |
| Tseng, JH | 1 |
| Hung, CF | 1 |
| Welin, S | 1 |
| Sebjornsen, S | 1 |
| Knappskog, S | 1 |
| Busch, C | 1 |
| Oberg, K | 2 |
| Yin, H | 1 |
| Xie, F | 1 |
| Deng, B | 1 |
| Wang, Q | 1 |
| Qu, X | 1 |
| Mao, H | 1 |
| Rodriguez, NA | 1 |
| Ascaso, FJ | 1 |
| Deenen, MJ | 1 |
| Tol, J | 2 |
| Burylo, AM | 1 |
| Doodeman, VD | 1 |
| de Boer, A | 1 |
| Vincent, A | 1 |
| Guchelaar, HJ | 1 |
| Smits, PH | 1 |
| Beijnen, JH | 1 |
| Punt, CJ | 3 |
| Cats, A | 1 |
| Chuma, M | 1 |
| Taguchi, H | 1 |
| Shimizu, S | 1 |
| Nakanishi, M | 1 |
| Ogawa, K | 2 |
| Sho, T | 1 |
| Horimoto, H | 1 |
| Nakai, M | 1 |
| Terashita, K | 1 |
| Sakuhara, Y | 1 |
| Abo, D | 1 |
| Tsukuda, Y | 1 |
| Tsunematsu, S | 1 |
| Hige, S | 1 |
| Shirato, H | 1 |
| Xu, BH | 1 |
| Jiang, ZF | 2 |
| Chua, D | 1 |
| Shao, ZM | 1 |
| Luo, RC | 1 |
| Wang, XJ | 1 |
| Liu, DG | 1 |
| Yeo, W | 2 |
| Yu, SY | 1 |
| Newstat, B | 2 |
| Preston, A | 1 |
| Martin, AM | 1 |
| Chi, HD | 1 |
| Stieler, J | 2 |
| Adler, M | 1 |
| Di Seri, M | 4 |
| De Sanctis, R | 1 |
| Quadrini, S | 1 |
| Adua, D | 1 |
| Stumbo, L | 1 |
| Del Signore, E | 1 |
| Gori, B | 1 |
| Grassi, P | 1 |
| Basile, ML | 1 |
| Longo, F | 1 |
| Chen, PC | 1 |
| Chen, YC | 1 |
| Lai, LC | 1 |
| Tsai, MH | 1 |
| Chen, SK | 1 |
| Yang, PW | 1 |
| Lee, YC | 2 |
| Hsiao, CK | 1 |
| Chuang, EY | 1 |
| Roderburg, C | 1 |
| do O, N | 1 |
| Fuchs, R | 2 |
| Bubenzer, J | 1 |
| Spannbauer, M | 1 |
| Luedde, T | 1 |
| Trautwein, C | 1 |
| Tischendorf, JJ | 1 |
| Baraniskin, A | 1 |
| Munding, J | 1 |
| Schulmann, K | 1 |
| Meier, D | 1 |
| Porschen, R | 1 |
| Arkenau, HT | 1 |
| Schmiegel, W | 3 |
| Putzu, C | 2 |
| Sandomenico, C | 2 |
| Vessia, G | 1 |
| Ionta, MT | 1 |
| Tafuto, S | 1 |
| Barbato, E | 1 |
| Dennie, TW | 1 |
| Fleming, RA | 1 |
| Bowen, CJ | 1 |
| Dar, MM | 1 |
| Alberti, D | 1 |
| Oliver, K | 1 |
| Loconte, N | 1 |
| Mulkerin, D | 1 |
| Holen, KD | 1 |
| Ocvirk, J | 1 |
| Rebersek, M | 1 |
| Boc, M | 1 |
| Dechaphunkul, T | 1 |
| Pruegsanusak, K | 1 |
| Sangthawan, D | 1 |
| Sunpaweravong, P | 1 |
| Adams, RA | 1 |
| Meade, AM | 1 |
| Wilson, RH | 1 |
| Madi, A | 1 |
| Fisher, D | 1 |
| Kenny, SL | 1 |
| Kay, E | 1 |
| Hodgkinson, E | 1 |
| Pope, M | 1 |
| Rogers, P | 1 |
| Falk, S | 2 |
| Hickish, T | 2 |
| Bessell, EM | 1 |
| Propper, D | 1 |
| Kennedy, MJ | 2 |
| Kaplan, R | 1 |
| Maughan, TS | 3 |
| Kennecke, H | 1 |
| Wong, R | 2 |
| Tankel, K | 1 |
| Easaw, J | 1 |
| Post, J | 1 |
| Hay, J | 1 |
| Iwata, H | 1 |
| Sato, N | 1 |
| Masuda, N | 1 |
| Kuroi, K | 1 |
| Kurosumi, M | 1 |
| Tsuda, H | 1 |
| Akiyama, F | 1 |
| Ohashi, Y | 1 |
| Toi, M | 1 |
| Kawaguchi, K | 1 |
| Sato, K | 2 |
| Yamada, H | 2 |
| Horie, A | 1 |
| Nomura, T | 2 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Suzuki, S | 2 |
| Nakatani, Y | 1 |
| Hamada, Y | 1 |
| Assaf, E | 1 |
| Verlinde-Carvalho, M | 1 |
| Grenier, J | 1 |
| Sellam, Z | 1 |
| Pouessel, D | 1 |
| Bouaita, L | 1 |
| Baumgaertner, I | 1 |
| Sobhani, I | 1 |
| Tayar, C | 1 |
| Paul, M | 1 |
| Culine, S | 2 |
| Hasegawa, J | 1 |
| Nishimura, J | 1 |
| Hirota, M | 1 |
| Kim, Y | 1 |
| Nezu, R | 1 |
| Durante, E | 1 |
| Trolese, A | 1 |
| Mercanti, A | 1 |
| Shien, T | 1 |
| Doihara, H | 2 |
| Nishiyama, K | 1 |
| Masuda, H | 1 |
| Nogami, T | 1 |
| Ikeda, H | 3 |
| Taira, N | 1 |
| Chen, SF | 1 |
| Gong, C | 1 |
| Luo, M | 1 |
| Yao, HR | 1 |
| Zeng, YJ | 1 |
| Su, FX | 1 |
| Li, JL | 1 |
| Ji, JF | 1 |
| Cai, Y | 1 |
| Li, XF | 1 |
| Wu, H | 1 |
| Dou, FY | 1 |
| Li, ZY | 1 |
| Bu, ZD | 1 |
| Wu, AW | 1 |
| Tham, IW | 1 |
| Oberic, L | 1 |
| Viret, F | 3 |
| Baey, C | 1 |
| Peiffert, D | 1 |
| Celier, P | 1 |
| Berille, J | 1 |
| Chibaudel, B | 1 |
| Shi, Q | 1 |
| Tournigand, C | 3 |
| Allegra, CJ | 1 |
| de Gramont, A | 6 |
| Weissinger, F | 1 |
| Reymond, M | 1 |
| Dumke, K | 1 |
| Krüger, M | 1 |
| Assenat, E | 1 |
| Portales, F | 1 |
| Crapez-Lopez, E | 1 |
| Bleuse, JP | 1 |
| Ahn, SH | 1 |
| Kim, SU | 1 |
| Choi, SB | 1 |
| Park, MS | 1 |
| Lee, DY | 1 |
| Han, KH | 1 |
| Kim, KS | 1 |
| Nie, J | 1 |
| Zheng, W | 1 |
| Chen, L | 1 |
| Xu, Y | 1 |
| Du, X | 1 |
| Han, W | 1 |
| Kim, CH | 1 |
| Kim, HK | 3 |
| Rettig, RL | 1 |
| Kim, J | 1 |
| Lee, ET | 1 |
| Aprelikova, O | 1 |
| Choi, IJ | 3 |
| Munroe, DJ | 1 |
| Green, JE | 1 |
| Baba, E | 1 |
| Sakai, D | 1 |
| Tokunaga, S | 1 |
| Takiuchi, H | 1 |
| Lin, JT | 1 |
| Lai, GM | 1 |
| Chang, TH | 1 |
| Liu, MT | 1 |
| Bi, CP | 1 |
| Wang, JW | 1 |
| Chen, MK | 1 |
| Hyodo, I | 3 |
| Abbas, A | 1 |
| Nehme, E | 1 |
| Kashiwagi, S | 1 |
| Maeda, K | 1 |
| Fuyuhiro, Y | 1 |
| Nagahara, H | 1 |
| Kimura, K | 1 |
| Amano, R | 1 |
| Noda, E | 1 |
| Kubo, N | 1 |
| Muguruma, K | 1 |
| Yashiro, M | 1 |
| Yamada, N | 1 |
| Nakata, B | 2 |
| Ohira, M | 1 |
| Hirakawa, K | 2 |
| Kumamoto, K | 1 |
| Ohsawa, T | 1 |
| Haga, N | 1 |
| Miura, I | 1 |
| Ferte, C | 1 |
| Romano, O | 1 |
| Peugniez, C | 1 |
| Lindet, C | 1 |
| Ladrat, L | 1 |
| Triboulet, JP | 1 |
| Petrioli, R | 4 |
| Roviello, G | 1 |
| Pascucci, A | 2 |
| Francini, E | 2 |
| Bargagli, G | 1 |
| Conca, R | 1 |
| Miano, ST | 1 |
| Marzocca, G | 1 |
| Kim, GM | 1 |
| Jung, I | 1 |
| Nam, BH | 1 |
| Laban, S | 1 |
| Wang, CJ | 1 |
| Münscher, A | 1 |
| Tribius, S | 1 |
| Knecht, R | 1 |
| Zhang, JQ | 1 |
| Hooker, CM | 1 |
| Brock, MV | 1 |
| Shin, J | 1 |
| How, R | 1 |
| Franco, N | 1 |
| Prevas, H | 1 |
| Hulbert, A | 1 |
| Yang, SC | 1 |
| Bear, HD | 1 |
| Tang, G | 1 |
| Rastogi, P | 1 |
| Geyer, CE | 4 |
| Robidoux, A | 1 |
| Atkins, JN | 1 |
| Baez-Diaz, L | 1 |
| Brufsky, AM | 1 |
| Mehta, RS | 2 |
| Fehrenbacher, L | 1 |
| Young, JA | 1 |
| Senecal, FM | 1 |
| Gaur, R | 1 |
| Margolese, RG | 1 |
| Adams, PT | 1 |
| Gross, HM | 1 |
| Costantino, JP | 1 |
| Swain, SM | 1 |
| Mamounas, EP | 1 |
| Wolmark, N | 1 |
| Huang, HY | 1 |
| Zhang, SH | 1 |
| Bian, L | 1 |
| Wu, SK | 1 |
| Song, ST | 1 |
| Liu, JZ | 1 |
| Lin, L | 1 |
| Ge, FJ | 1 |
| Li, SS | 1 |
| Liu, LJ | 1 |
| Zhao, CH | 1 |
| Sandri, MT | 1 |
| Pastrello, D | 1 |
| Cancello, G | 1 |
| Montagna, E | 1 |
| Balduzzi, A | 1 |
| Luini, A | 2 |
| Assy, N | 1 |
| Basher, W | 1 |
| Chetver, L | 1 |
| Shnaider, J | 1 |
| Zidan, J | 1 |
| Ferrand, FR | 1 |
| Gontier, E | 1 |
| Guymar, S | 1 |
| Fagot, T | 1 |
| Ceccaldi, B | 1 |
| Malfuson, JV | 1 |
| de Revel, T | 1 |
| Park, LC | 1 |
| Shin, SH | 1 |
| Baek, JH | 3 |
| Kang, MJ | 1 |
| Zhao, HY | 1 |
| Hu, ZH | 1 |
| Huang, Y | 1 |
| Lin, SX | 1 |
| Lin, TY | 1 |
| Capussotti, L | 2 |
| Barroso, E | 1 |
| Nuzzo, G | 1 |
| Laurent, C | 1 |
| Ijzermans, JN | 1 |
| Gigot, JF | 2 |
| Figueras, J | 1 |
| Mirza, DF | 1 |
| Elias, D | 2 |
| Poston, G | 1 |
| Letoublon, C | 1 |
| Isoniemi, H | 1 |
| Herrera, J | 1 |
| Sousa, FC | 1 |
| Pardo, F | 1 |
| Lucidi, V | 1 |
| Popescu, I | 1 |
| Adam, R | 1 |
| Karaca, B | 1 |
| Cakar, B | 1 |
| Sezgin, C | 2 |
| Karachaliou, N | 1 |
| Ziras, N | 4 |
| Syrigos, K | 3 |
| Tryfonidis, K | 1 |
| Papadimitraki, E | 1 |
| Kontopodis, E | 1 |
| Bozionelou, V | 1 |
| Kalykaki, A | 2 |
| Georgoulias, V | 5 |
| Mavroudis, D | 3 |
| Guo, ST | 1 |
| Jiang, CC | 1 |
| Wang, GP | 1 |
| Li, YP | 1 |
| Wang, CY | 1 |
| Guo, XY | 1 |
| Yang, RH | 1 |
| Tseng, HY | 1 |
| Thorne, RF | 1 |
| Jin, L | 1 |
| Roy, A | 1 |
| Hawkins, R | 1 |
| Barcelo, JR | 1 |
| Lopez-Vivanco, G | 1 |
| Adler, G | 1 |
| Canon, JL | 2 |
| Lofts, F | 1 |
| Castanon, C | 1 |
| Fonseca, E | 1 |
| Rixe, O | 1 |
| Cassinello, J | 2 |
| Nicolson, M | 1 |
| Mousseau, M | 2 |
| Schalhorn, A | 1 |
| D'Hondt, L | 1 |
| Kerger, J | 1 |
| Hossfeld, DK | 1 |
| Garcia Giron, C | 1 |
| Rodriguez, R | 1 |
| Schoffski, P | 3 |
| Misset, JL | 4 |
| Kim, JS | 3 |
| Lim, JH | 1 |
| Chie, EK | 1 |
| Hwang, JH | 2 |
| Ha, SW | 1 |
| Yoon, YB | 1 |
| de las Heras, M | 1 |
| Arias, F | 1 |
| del Moral-Avila, R | 1 |
| Gómez-Millán, J | 1 |
| Jiménez, E | 1 |
| Wals, A | 1 |
| Tisaire, JL | 1 |
| Alcantara, MP | 1 |
| Nakayama, G | 1 |
| Uehara, K | 1 |
| Ishigure, K | 1 |
| Yokoyama, H | 1 |
| Ishiyama, A | 1 |
| Eguchi, T | 1 |
| Ohashi, N | 1 |
| Sugimoto, H | 1 |
| Koike, M | 1 |
| Fujiwara, M | 1 |
| Ando, Y | 1 |
| Kodera, Y | 1 |
| Uchida, N | 1 |
| Ojima, H | 1 |
| Hosouchi, Y | 1 |
| Yashuda, N | 1 |
| Kigure, W | 1 |
| Yamauchi, S | 1 |
| Shivapurkar, N | 1 |
| Mikhail, S | 1 |
| Navarro, R | 1 |
| Bai, W | 1 |
| Marshall, J | 2 |
| Pishvaian, M | 1 |
| Wellstein, A | 1 |
| He, AR | 1 |
| Orgel, M | 1 |
| Horger, M | 2 |
| Kurth, R | 1 |
| Kanz, L | 4 |
| Jaschonek, K | 1 |
| Mayer, F | 2 |
| Kopp, HG | 2 |
| Lee, I | 1 |
| Park, C | 1 |
| Fajardo, AD | 1 |
| Tan, B | 1 |
| Reddy, R | 1 |
| Fleshman, J | 1 |
| Wu, XL | 1 |
| Zhang, LW | 1 |
| Hentic, O | 1 |
| Rousseau, B | 1 |
| Rebours, V | 1 |
| Bengrine-Lefèvre, L | 1 |
| Lévy, P | 1 |
| Raymond, E | 1 |
| Ruszniewski, P | 2 |
| Benjamin, L | 1 |
| Buthion, V | 1 |
| Iskedjian, M | 1 |
| Farah, B | 1 |
| Rioufol, C | 1 |
| Vidal-Trécan, G | 1 |
| Golden, DW | 1 |
| Novak, CJ | 1 |
| Minsky, BD | 3 |
| Liauw, SL | 1 |
| Uguen, T | 1 |
| Desgrippes, R | 1 |
| Tchoundeu, B | 1 |
| Bretagne, JF | 1 |
| Aguilar-Ponce, JL | 1 |
| Granados-García, M | 1 |
| Cruz López, JC | 1 |
| Maldonado-Magos, F | 1 |
| Alvarez-Avitia, MA | 1 |
| González-Ramírez, I | 1 |
| Lara-Cruz, G | 1 |
| Martinez-Juárez, I | 1 |
| Medina-Santillan, R | 1 |
| Castillo-Hernández, C | 1 |
| De la Garza-Salazar, J | 1 |
| Yoshikawa, R | 1 |
| Tsujimura, T | 1 |
| Tao, L | 1 |
| Kamikonya, N | 1 |
| Ko, AH | 1 |
| Truong, TG | 1 |
| Kantoff, E | 1 |
| Jones, KA | 1 |
| Dito, E | 1 |
| Ong, A | 1 |
| Tempero, MA | 1 |
| Papp, A | 1 |
| Cseke, L | 1 |
| Varga, G | 1 |
| Pavlovics, G | 1 |
| Potó, L | 1 |
| Márton, S | 1 |
| Farkas, R | 1 |
| Bellyei, S | 1 |
| Horváth, OP | 1 |
| Jacob, J | 2 |
| Pierga, JY | 1 |
| Fourchotte, V | 1 |
| Kirova, YM | 1 |
| Bollet, MA | 1 |
| Kreutz, F | 1 |
| Graas, MP | 1 |
| Longrée, L | 1 |
| Focan-Henrard, D | 1 |
| Demolin, G | 1 |
| Moeneclaey, N | 1 |
| Lee, CH | 1 |
| Kim, G | 1 |
| Jung, EJ | 1 |
| Ryu, CG | 1 |
| Hwang, DY | 1 |
| Graves, CA | 1 |
| Camphausen, K | 1 |
| Suzuki, C | 1 |
| Blomqvist, L | 1 |
| Hatschek, T | 1 |
| Einbeigi, Z | 1 |
| Linderholm, B | 1 |
| Lindh, B | 1 |
| Loman, N | 1 |
| Malmberg, M | 1 |
| Rotstein, S | 1 |
| Söderberg, M | 2 |
| Sundqvist, M | 1 |
| Walz, TM | 1 |
| Aström, G | 1 |
| Fujii, H | 1 |
| Jacobsson, H | 1 |
| Sasaki, T | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Takahara, N | 1 |
| Sasahira, N | 1 |
| Kogure, H | 1 |
| Mizuno, S | 1 |
| Yagioka, H | 1 |
| Ito, Y | 1 |
| Toda, N | 1 |
| Tada, M | 1 |
| Omata, M | 1 |
| Lv, H | 1 |
| Qiu, W | 1 |
| Xiang, J | 1 |
| Wei, H | 1 |
| Sui, A | 1 |
| Cirillo, M | 1 |
| Musola, M | 1 |
| Cassandrini, PA | 1 |
| Lunardi, G | 1 |
| Venturini, M | 4 |
| Wong, ZW | 1 |
| Tan, EH | 1 |
| Yap, SP | 1 |
| Tan, T | 1 |
| Leong, SS | 1 |
| Fong, KW | 1 |
| Wee, J | 1 |
| Hartung, G | 2 |
| Samel, S | 2 |
| Hochhaus, A | 4 |
| Pichlmeier, U | 1 |
| Hehlmann, R | 3 |
| Queisser, W | 2 |
| Meyer, L | 1 |
| Puls, R | 1 |
| Bartels, B | 1 |
| Stroszczynski, C | 1 |
| Ryan, CW | 1 |
| Vogelzang, NJ | 2 |
| Stadler, WM | 3 |
| Messinese, S | 2 |
| Pozzessere, D | 2 |
| Marsili, S | 4 |
| Sabatino, M | 2 |
| Fiaschi, AI | 1 |
| Lepille, D | 1 |
| Marre, A | 1 |
| Mignot, L | 1 |
| Hua, A | 1 |
| Méry-Mignard, D | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Guadagni, S | 1 |
| Zamagni, D | 1 |
| Aitini, E | 1 |
| Constenla, M | 2 |
| Garcia-Arroyo, R | 1 |
| Lorenzo, I | 1 |
| Carrete, N | 1 |
| Campos, B | 1 |
| Palacios, P | 1 |
| Carlomagno, C | 3 |
| Lauria, R | 1 |
| De Laurentiis, M | 1 |
| Arpino, G | 1 |
| Massarelli, E | 1 |
| Ferrara, C | 1 |
| Milano, A | 1 |
| Vernaglia Lombardi, A | 1 |
| Costanzo, R | 1 |
| Bianco, AR | 1 |
| De Placido, S | 3 |
| Prasad, SR | 1 |
| Jhaveri, KS | 1 |
| Saini, S | 1 |
| Hahn, PF | 1 |
| Halpern, EF | 1 |
| Sumner, JE | 1 |
| Tsavaris, N | 2 |
| Kosmas, C | 3 |
| Gennatas, K | 1 |
| Vadiaka, M | 2 |
| Skopelitis, E | 1 |
| Xila, V | 1 |
| Rokana, S | 2 |
| Margaris, E | 1 |
| Zografos, G | 1 |
| Papastratis, G | 2 |
| Kouraklis, G | 1 |
| Boxberger, F | 1 |
| Happich, K | 1 |
| Schirner, I | 1 |
| Brueckl, WM | 2 |
| Hahn, EG | 1 |
| Wein, A | 2 |
| Emig, M | 1 |
| Pilz, L | 1 |
| Willeke, F | 1 |
| Bonneterre, J | 3 |
| Roché, H | 2 |
| Monnier, A | 3 |
| Guastalla, JP | 2 |
| Namer, M | 5 |
| Fargeot, P | 2 |
| Assadourian, S | 2 |
| Rose, MG | 1 |
| Farrell, MP | 1 |
| Schmitz, JC | 1 |
| Twelves, C | 4 |
| Aapro, M | 1 |
| Seidman, AD | 1 |
| Biganzoli, L | 1 |
| Stenson, K | 3 |
| Rosen, FR | 2 |
| Kies, MS | 3 |
| Rademaker, AW | 1 |
| Brockstein, BE | 2 |
| List, MA | 2 |
| Fung, BB | 1 |
| Portugal, L | 2 |
| Mittal, BB | 4 |
| Pelzer, H | 4 |
| Weichselbaum, RR | 3 |
| Grandi, C | 1 |
| Guzzo, M | 1 |
| Mariani, L | 2 |
| Lo Vullo, S | 1 |
| Valvo, F | 1 |
| Quattrone, P | 1 |
| Valagussa, P | 3 |
| Bonadonna, G | 3 |
| Molinari, R | 1 |
| Cantù, G | 1 |
| Papagikos, M | 1 |
| Skibber, J | 3 |
| Janjan, NA | 5 |
| Feig, B | 2 |
| Rodriguez-Bigas, MA | 2 |
| Hung, A | 1 |
| Delclos, M | 3 |
| Cleary, K | 2 |
| James, RD | 1 |
| Kerr, DJ | 2 |
| Ledermann, JA | 1 |
| Topham, C | 1 |
| McArdle, C | 1 |
| Cain, D | 1 |
| Stephens, RJ | 1 |
| Loesch, DM | 1 |
| Canfield, VA | 1 |
| Parker, GA | 1 |
| Hynes, HE | 1 |
| Ellis, PG | 1 |
| Ferri, WA | 1 |
| Robert, NJ | 1 |
| Therasse, P | 1 |
| Welnicka-Jaskiewicz, M | 1 |
| Bruning, P | 1 |
| Bonnefoi, H | 1 |
| Tomiak, E | 1 |
| Pritchard, KI | 1 |
| Hamilton, A | 1 |
| Piccart, MJ | 1 |
| Yuste, AL | 2 |
| Segura, A | 1 |
| López-Tendero, P | 1 |
| Gironés, R | 1 |
| Pérez-Fidalgo, JA | 1 |
| Díaz, R | 2 |
| Calderero, V | 1 |
| Pectasides, D | 1 |
| Pectasides, M | 1 |
| Farmakis, D | 1 |
| Bountouroglou, N | 1 |
| Nikolaou, M | 1 |
| Koumpou, M | 1 |
| Mylonakis, N | 1 |
| Magnin, V | 1 |
| Moutardier, V | 1 |
| Giovannini, MH | 1 |
| Lelong, B | 1 |
| Giovannini, M | 1 |
| Monges, G | 1 |
| Bardou, VJ | 1 |
| Alzieu, C | 1 |
| Delpero, JR | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Mizutani, Y | 1 |
| Wada, H | 3 |
| Yoshida, O | 1 |
| Fukushima, M | 1 |
| Nonomura, M | 1 |
| Nakao, M | 1 |
| Miki, T | 1 |
| Parnes, HL | 1 |
| Cirrincione, C | 2 |
| Aisner, J | 1 |
| Berry, DA | 2 |
| Allen, SL | 1 |
| Abrams, J | 1 |
| Chuang, E | 1 |
| Cooper, MR | 1 |
| Perry, MC | 1 |
| Duggan, DB | 2 |
| Szatrowski, TP | 1 |
| Henderson, IC | 3 |
| Norton, L | 3 |
| Weiss, RB | 1 |
| Woolf, SH | 1 |
| Demakos, E | 1 |
| Holland, JF | 1 |
| Falkson, G | 1 |
| Cirrincione, CT | 1 |
| Robbins, A | 1 |
| Bothun, S | 1 |
| Desaknai, S | 1 |
| Lumniczky, K | 1 |
| Esik, O | 1 |
| Hamada, H | 1 |
| Safrany, G | 1 |
| Schaffer, M | 1 |
| Krych, M | 1 |
| Pachmann, S | 1 |
| Abdel-Rahman, S | 1 |
| Schaffer, PM | 1 |
| Ertl-Wagner, B | 1 |
| D hmke, E | 1 |
| Issels, RD | 1 |
| Weisser, A | 1 |
| Willer, A | 1 |
| Roth, AD | 1 |
| Usuki, H | 2 |
| Ishimura, K | 1 |
| Yachida, S | 1 |
| Hagiike, M | 1 |
| Okano, K | 1 |
| Izuishi, K | 1 |
| Karasawa, Y | 1 |
| Goda, F | 1 |
| Maeta, H | 1 |
| Shirao, K | 1 |
| Arai, Y | 1 |
| Denda, T | 1 |
| Ambo, T | 1 |
| Fallik, D | 1 |
| Colin, P | 1 |
| Baulieux, J | 1 |
| Couzigou, P | 1 |
| Mahjoubi, R | 1 |
| Mahjoubi, M | 2 |
| Capotorto, AM | 1 |
| Pavesi, L | 1 |
| Pedrazzoli, P | 1 |
| Da Prada, GA | 1 |
| Zamagni, C | 1 |
| Martoni, A | 2 |
| Lelli, G | 2 |
| Robustelli della Cuna, G | 1 |
| Naredi, P | 1 |
| Oman, M | 1 |
| Blind, PJ | 1 |
| Lindnér, P | 1 |
| Gustavsson, B | 2 |
| Hafström, L | 1 |
| Harney, J | 1 |
| Goodchild, K | 1 |
| Phillips, H | 1 |
| Hoskin, PJ | 1 |
| Saunders, MI | 1 |
| Luoma, ML | 1 |
| Hakamies-Blomqvist, L | 1 |
| Sjöström, J | 3 |
| Ottoson, S | 1 |
| Mouridsen, H | 2 |
| Bengtsson, NO | 3 |
| Bergh, J | 2 |
| Malmström, P | 3 |
| Valvere, V | 3 |
| Tennvall, L | 1 |
| Blomqvist, C | 4 |
| Chang, HM | 4 |
| Kang, HJ | 2 |
| Lee, JR | 1 |
| Ryu, MH | 3 |
| Ahn, JH | 1 |
| Lee, JS | 5 |
| Kang, YK | 4 |
| Vicent, JM | 3 |
| Maestu, I | 2 |
| Garcerá, S | 1 |
| Busquier, I | 2 |
| Bosch, C | 1 |
| Llorca, C | 2 |
| Fernández-Martos, C | 2 |
| Galán, A | 2 |
| Bouzid, K | 1 |
| Khalfallah, S | 1 |
| Tujakowski, J | 1 |
| Piko, B | 1 |
| Purkalne, G | 1 |
| Plate, S | 1 |
| Padrik, P | 1 |
| Serafy, M | 1 |
| Pshevloutsky, EM | 1 |
| Boussard, B | 2 |
| Ceciarini, F | 1 |
| Cerretani, D | 1 |
| Pellegrini, M | 1 |
| Di Palma, T | 1 |
| Neri, A | 1 |
| Calvanese, A | 1 |
| Pinto, E | 1 |
| Giorgi, G | 2 |
| Kemeny, NE | 2 |
| Gococo, KO | 1 |
| Mitchell, EP | 3 |
| Kardinal, CG | 2 |
| Gonzalez, MA | 1 |
| Biswas, S | 1 |
| Clifton, L | 1 |
| Corrie, PG | 1 |
| Kato, H | 1 |
| Hashimoto, M | 1 |
| Umehara, A | 1 |
| Yoshida, K | 1 |
| Iwasaki, K | 1 |
| Yeoh, C | 1 |
| Norman, AR | 2 |
| Hill, M | 2 |
| Marcos, F | 1 |
| Pujol, E | 1 |
| Pérez-Carrión, R | 1 |
| Colmenarejo, A | 1 |
| González del Val, R | 1 |
| Valero, J | 1 |
| Oruezábal, MJ | 1 |
| Guillem, V | 1 |
| García, I | 1 |
| Arcediano, A | 1 |
| Marfà, X | 1 |
| Alimonti, A | 1 |
| Ferretti, G | 1 |
| Di Cosimo, S | 2 |
| Cognetti, F | 2 |
| Vecchione, A | 1 |
| Mathonnet, M | 1 |
| Fermeaux, V | 1 |
| Giannakakis, T | 1 |
| Gouveris, P | 1 |
| Dimitrakopoulos, A | 1 |
| Karadima, D | 1 |
| Papalambros, E | 1 |
| Margaris, H | 1 |
| Tsipras, H | 1 |
| Polyzos, A | 2 |
| Braun, MS | 1 |
| Adab, F | 1 |
| Bradley, C | 1 |
| McAdam, K | 1 |
| Thomas, G | 1 |
| Wadd, NJ | 1 |
| Rea, D | 1 |
| Philips, R | 1 |
| Bozzino, J | 1 |
| MacMillan, C | 1 |
| Saunders, MP | 1 |
| Counsell, R | 1 |
| Anderson, H | 2 |
| Stewart, J | 1 |
| Robinson, A | 1 |
| Davies, S | 1 |
| Richards, FJ | 1 |
| Long, HJ | 1 |
| Kulke, MH | 2 |
| Earle, CC | 2 |
| Stuart, K | 2 |
| Catarius, KJ | 1 |
| Winkelmann, J | 1 |
| Mosconi, S | 1 |
| Lai, V | 1 |
| Belloc, J | 1 |
| Etienney, I | 1 |
| Montembault, S | 1 |
| Vayre, L | 1 |
| Locher, C | 1 |
| Ezenfis, J | 1 |
| Mabro, M | 4 |
| Dominguez, S | 1 |
| Shimoyama, S | 1 |
| Kondo, K | 3 |
| Kataoka, M | 1 |
| Bria, E | 2 |
| Vanni, B | 1 |
| Zappalà, AM | 1 |
| Sperduti, I | 1 |
| Terzoli, E | 2 |
| Denis, F | 1 |
| Garaud, P | 1 |
| Germain, T | 1 |
| Bergerot, P | 1 |
| Rhein, B | 1 |
| Tortochaux, J | 1 |
| Alberts, SR | 5 |
| Sobrero, AF | 1 |
| Feldman, AL | 1 |
| Libutti, SK | 1 |
| Pingpank, JF | 1 |
| Bartlett, DL | 1 |
| Beresnev, TH | 1 |
| Mavroukakis, SM | 1 |
| Steinberg, SM | 1 |
| Liewehr, DJ | 1 |
| Kleiner, DE | 1 |
| Alexander, HR | 1 |
| Han, JY | 1 |
| Lee, DH | 1 |
| Kim, EA | 1 |
| Ju, SY | 1 |
| Shin, EH | 1 |
| Argiris, A | 3 |
| Ravaud, A | 1 |
| Trufflandier, N | 1 |
| Ferrière, JM | 1 |
| Palussière, J | 1 |
| Cany, L | 1 |
| Gaston, R | 1 |
| Mathoulin-Pélissier, S | 1 |
| Bui, BN | 1 |
| Sørbye, H | 1 |
| Fokstuen, T | 1 |
| Tveit, KM | 1 |
| Braendengen, M | 1 |
| Øgreid, D | 1 |
| Dahl, O | 1 |
| Skarlos, D | 3 |
| Bafaloukos, D | 1 |
| Papakostas, P | 1 |
| Bamias, A | 1 |
| Janinis, J | 2 |
| Timotheadou, E | 1 |
| Kouvatseas, G | 1 |
| Stavropoulos, M | 1 |
| Economopulos, T | 1 |
| Fountzilas, G | 2 |
| Hirschfeld, S | 1 |
| Griebel, DJ | 1 |
| Williams, GA | 1 |
| Stathopoulos, GP | 1 |
| Rigatos, SK | 1 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Androulakis, N | 3 |
| Aravantinos, G | 1 |
| Athanasiadis, A | 1 |
| Papakotoulas, P | 1 |
| Jones, L | 1 |
| Hawkins, N | 1 |
| Westwood, M | 1 |
| Wright, K | 2 |
| Richardson, G | 1 |
| Riemsma, R | 1 |
| Harper, P | 2 |
| Bukowski, RM | 1 |
| Dufour, P | 1 |
| Lokich, J | 3 |
| Maroun, JA | 1 |
| Marshall, JL | 1 |
| Perez-Manga, G | 4 |
| Schoelmerich, J | 1 |
| Schilsky, RL | 5 |
| Kim, E | 1 |
| Park, IS | 1 |
| Chun, JH | 1 |
| Kim, IH | 1 |
| Kim, IJ | 1 |
| Kang, HC | 1 |
| Park, JH | 1 |
| Bae, JM | 1 |
| Park, JG | 1 |
| Tsamandas, AC | 1 |
| Kardamakis, D | 1 |
| Ravazoula, P | 1 |
| Zolota, V | 1 |
| Salakou, S | 1 |
| Tepetes, K | 1 |
| Kalogeropoulou, C | 1 |
| Tsota, I | 1 |
| Kourelis, T | 1 |
| Makatsoris, T | 1 |
| Karavias, D | 1 |
| Scopa, CD | 1 |
| Bonikos, DS | 1 |
| Petsas, T | 1 |
| Kondo, Y | 1 |
| Takemiya, S | 1 |
| Nishisho, I | 1 |
| Knox, JJ | 2 |
| Hedley, D | 2 |
| Oza, A | 2 |
| Pond, GR | 2 |
| Hütter, G | 1 |
| Szélenyi, H | 1 |
| Deckert, PM | 1 |
| Thiel, E | 1 |
| Pandya, KJ | 2 |
| Lefkopoulou, M | 1 |
| Petrelli, NJ | 1 |
| Vaughn, DJ | 2 |
| Smith, TJ | 1 |
| Harris, JE | 1 |
| Doehn, C | 1 |
| Jocham, D | 1 |
| Shen, YC | 1 |
| Yang, CH | 1 |
| Lu, YS | 2 |
| Liu, HT | 1 |
| Li, CC | 1 |
| Wu, CY | 1 |
| Batista, N | 1 |
| Ruiz, A | 1 |
| Carabantes, F | 3 |
| Castellanos, J | 1 |
| Gonzalez Barón, M | 1 |
| Villman, K | 2 |
| Casinello, J | 1 |
| Regueiro, P | 1 |
| Murias, A | 1 |
| de Jong, N | 1 |
| Candel, MJ | 1 |
| Schouten, HC | 1 |
| Abu-Saad, HH | 1 |
| Courtens, AM | 1 |
| Eng, C | 2 |
| Kindler, HL | 1 |
| Nattam, S | 1 |
| Ansari, RH | 2 |
| Kasza, K | 1 |
| Wade-Oliver, K | 1 |
| Chen, VM | 1 |
| Thrift, KM | 1 |
| Morel-Kopp, MC | 1 |
| Jackson, D | 1 |
| Ward, CM | 1 |
| Flower, RL | 1 |
| Gradishar, WJ | 1 |
| Meza, LA | 1 |
| Amin, B | 1 |
| Samid, D | 1 |
| Hill, T | 1 |
| Lower, EE | 1 |
| Marcom, PK | 1 |
| Park, DJ | 1 |
| Groshen, S | 1 |
| Zahedy, S | 1 |
| Blackwell, K | 1 |
| Hurwitz, H | 1 |
| Liebérman, G | 1 |
| Novotny, W | 1 |
| Snyder, S | 1 |
| Dewhirst, M | 1 |
| Greenberg, C | 1 |
| Milella, M | 1 |
| Gelibter, A | 1 |
| Ruggeri, EM | 1 |
| Carlini, P | 2 |
| Malaguti, P | 1 |
| Pellicciotta, M | 1 |
| Teufel, A | 1 |
| Steinmann, S | 1 |
| Zanke, C | 1 |
| Hohl, H | 1 |
| Adami, B | 1 |
| Schroeder, M | 1 |
| Klein, O | 1 |
| Höhler, T | 1 |
| Heike, M | 1 |
| Schwedler, K | 1 |
| Schmidt, KA | 1 |
| Höper, D | 1 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 1 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 2 |
| De Becker, D | 1 |
| Bleiberg, H | 4 |
| Maindrault-Goebel, F | 3 |
| Carola, E | 3 |
| Kurihara, M | 1 |
| Hasegawa, K | 1 |
| Chonan, A | 1 |
| Kubo, Y | 1 |
| Maekawa, R | 1 |
| Iwasaki, R | 1 |
| Sasai, T | 1 |
| Fukuyama, Y | 1 |
| Ishikawa, K | 1 |
| Miyoshi, K | 1 |
| Yasutake, K | 1 |
| Hayakawa, M | 1 |
| Sundar, S | 1 |
| Symonds, RP | 1 |
| Decatris, MP | 1 |
| Kumar, DM | 1 |
| Osman, A | 1 |
| Vasanthan, S | 1 |
| O'byrne, KJ | 1 |
| Milano, MT | 1 |
| Sosińska-Mielcarek, K | 1 |
| Jassem, J | 3 |
| Lassere, Y | 1 |
| Hoff, P | 3 |
| Yu, SJ | 1 |
| Joh, YH | 1 |
| Kwon, JH | 1 |
| Kim, NK | 1 |
| El-Deiry, WS | 1 |
| Sakon, M | 2 |
| Nagano, H | 2 |
| Monden, M | 2 |
| Marcuello, E | 3 |
| Altés, A | 1 |
| del Rio, E | 1 |
| César, A | 1 |
| Menoyo, A | 1 |
| Baiget, M | 1 |
| Liu, N | 1 |
| Bi, F | 1 |
| Sun, L | 1 |
| Yao, X | 1 |
| Zheng, Y | 1 |
| Fan, D | 1 |
| Forastiere, A | 1 |
| Altundag, K | 1 |
| Aksoy, S | 1 |
| Gullu, I | 1 |
| Altundag, O | 1 |
| Ozyar, E | 1 |
| Cengiz, M | 1 |
| Akyol, F | 1 |
| Bar-Sela, G | 1 |
| Haim, N | 1 |
| Benavides, M | 1 |
| Cobo, M | 1 |
| Muñoz-Martín, A | 1 |
| Gil-Calle, S | 1 |
| Villar, E | 1 |
| Graupera, J | 1 |
| Balcells, M | 2 |
| Van Hazel, G | 3 |
| Blackwell, A | 1 |
| Anderson, J | 1 |
| Price, D | 1 |
| Moroz, P | 1 |
| Bower, G | 1 |
| Cardaci, G | 1 |
| Gray, B | 1 |
| Thürlimann, B | 2 |
| Pagani, O | 2 |
| Aebi, S | 1 |
| Rauch, D | 2 |
| Ballabeni, P | 2 |
| Rufener, B | 1 |
| Rodriguez-Pinilla, M | 1 |
| Rodriguez-Peralto, JL | 1 |
| Sanchez, JJ | 1 |
| Ballestin, C | 1 |
| Diez, A | 1 |
| Sanchez-Verde, L | 1 |
| Alameda, F | 1 |
| Sanchez-Cespedes, M | 1 |
| Thuss-Patience, PC | 1 |
| Kretzschmar, A | 1 |
| Repp, M | 1 |
| Kingreen, D | 1 |
| Hennesser, D | 1 |
| Micheel, S | 1 |
| Pink, D | 1 |
| Scholz, C | 1 |
| Reichardt, P | 2 |
| D'Andre, S | 1 |
| Cha, SS | 1 |
| Buroker, TR | 1 |
| Kugler, JW | 2 |
| O'Connell, MJ | 1 |
| Poon, MA | 1 |
| Gress, TM | 1 |
| Jeziorski, K | 1 |
| Wagener, T | 1 |
| Anak, O | 2 |
| Baron, B | 1 |
| Bajetta, E | 4 |
| Procopio, G | 3 |
| Celio, L | 2 |
| Gattinoni, L | 1 |
| Della Torre, S | 1 |
| Catena, L | 3 |
| Ricotta, R | 1 |
| Zilembo, N | 1 |
| Buzzoni, R | 2 |
| Nielsen, JN | 2 |
| Gyldenkerne, N | 1 |
| Lindeberg, J | 1 |
| Ridwelski, K | 1 |
| Artandi, M | 1 |
| Espana, P | 1 |
| Schölmerich, J | 1 |
| Rosales, AM | 1 |
| Carlsson, G | 1 |
| Park, BB | 2 |
| Ji, SH | 1 |
| Park, KW | 2 |
| Kim, K | 3 |
| Kim, WS | 2 |
| Jung, CW | 2 |
| Im, YH | 3 |
| Park, K | 3 |
| Feld, R | 1 |
| Chen, E | 1 |
| Nematollahi, M | 1 |
| Abad, A | 2 |
| Cervantes, A | 2 |
| Antón, A | 2 |
| Martinez-Villacampa, M | 2 |
| Massutí, B | 3 |
| Guallar, JL | 1 |
| Diaz-Rubio, E | 2 |
| Corry, J | 1 |
| Rischin, D | 1 |
| Mukesh, BN | 1 |
| Porceddu, S | 1 |
| Peters, LJ | 1 |
| Llosa, F | 1 |
| Bolaños, M | 2 |
| Yubero, A | 2 |
| Sanz-Lacalle, JJ | 1 |
| Lopez-Gómez, L | 2 |
| Casado, E | 2 |
| Gómez-Reina, MJ | 1 |
| González-Baron, M | 2 |
| Kim, ST | 1 |
| de Bree, E | 1 |
| Volalakis, E | 1 |
| Tsetis, D | 2 |
| Varthalitis, Y | 1 |
| Panagiotidis, J | 1 |
| Romanos, J | 1 |
| Tsiftsis, DD | 1 |
| Semiglazova, TIu | 1 |
| Filatova, LV | 1 |
| Gershanovich, ML | 1 |
| Bazan, V | 1 |
| Agnese, V | 1 |
| Corsale, S | 1 |
| Calò, V | 1 |
| Valerio, MR | 2 |
| Latteri, MA | 1 |
| Vieni, S | 1 |
| Grassi, N | 1 |
| Cicero, G | 1 |
| Dardanoni, G | 1 |
| Tomasino, RM | 1 |
| Colucci, G | 3 |
| Gebbia, N | 3 |
| Russo, A | 1 |
| Lopez, T | 1 |
| Vukelja, SJ | 1 |
| Encarnacion, C | 1 |
| Larsson, R | 1 |
| Choi, EY | 1 |
| Bang, SM | 1 |
| Cho, EK | 2 |
| Shin, DB | 2 |
| Ki Lee, W | 1 |
| Chung, M | 2 |
| Gebbia, V | 2 |
| Paoletti, G | 1 |
| Giuliani, F | 1 |
| Caruso, M | 1 |
| Cartenì, G | 1 |
| Agostara, B | 1 |
| Pezzella, G | 2 |
| Borsellino, N | 1 |
| Misino, A | 1 |
| Romito, S | 1 |
| Durini, E | 1 |
| Lopez, M | 1 |
| Montemurro, S | 1 |
| Cramarossa, A | 1 |
| Di Bisceglie, M | 1 |
| Chiarenza, M | 1 |
| Guida, T | 1 |
| Leonardi, V | 1 |
| Pisconti, S | 1 |
| Carrozza, F | 1 |
| Nettis, G | 1 |
| Valdesi, M | 1 |
| Fortunato, S | 2 |
| Mancarella, S | 1 |
| Brunetti, C | 1 |
| Wils, J | 3 |
| El-Serafi, M | 1 |
| Lutz, MP | 2 |
| Lorenz, M | 3 |
| Rückle-Lanz, H | 1 |
| Frickhofen, N | 1 |
| Mergenthaler, HG | 1 |
| Langenbuch, T | 1 |
| Vanhoefer, U | 1 |
| Voigtmann, R | 1 |
| Müller, L | 1 |
| Genicot, B | 1 |
| Doni, L | 1 |
| Iop, A | 1 |
| Barletta, E | 2 |
| Moscetti, L | 1 |
| Recchia, F | 2 |
| Tralongo, P | 1 |
| Gasperoni, S | 1 |
| O'Shaughnessy, JA | 1 |
| Clark, RS | 1 |
| Mennel, RG | 1 |
| Snyder, D | 1 |
| Ye, Z | 1 |
| Melemed, AS | 1 |
| Yardley, DA | 1 |
| Lara, R | 1 |
| Lastra, R | 1 |
| Ortega, E | 1 |
| Polo, E | 1 |
| Saenz-Cusi, A | 1 |
| Tres, A | 1 |
| Moerike, K | 1 |
| Hartmann, JT | 3 |
| Sung, WJ | 1 |
| Kim, TB | 1 |
| Jung, HY | 1 |
| Yu, W | 1 |
| Lee, KB | 2 |
| Herbst, RS | 1 |
| Arquette, M | 1 |
| Shin, DM | 1 |
| Dicke, K | 1 |
| Azarnia, N | 1 |
| Hong, WK | 2 |
| Gasparini, G | 1 |
| Lipsitz, S | 1 |
| Catalano, P | 1 |
| Mailliard, JA | 3 |
| Cusi, MG | 1 |
| Placa, ML | 1 |
| Aquino, A | 1 |
| Micheli, L | 1 |
| Nencini, C | 1 |
| Ferrari, F | 1 |
| Bonmassar, E | 1 |
| Ahn, JS | 1 |
| Kim, SR | 1 |
| Gubanski, M | 1 |
| Naucler, G | 1 |
| Almerud, A | 1 |
| Lideståhl, A | 1 |
| La Cesa, A | 1 |
| Caricato, M | 2 |
| Schiavon, G | 3 |
| Spalletta, B | 2 |
| Coppola, R | 2 |
| Rocci, L | 1 |
| Lin, JF | 1 |
| Kuo, SH | 1 |
| Li, SJ | 1 |
| Ota, H | 1 |
| Eguchi, H | 1 |
| Kondo, M | 1 |
| Yamamoto, T | 1 |
| Nakamura, M | 1 |
| Damdinsuren, B | 1 |
| Marubashi, S | 1 |
| Miyamoto, A | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Nakamori, S | 1 |
| Wakasa, K | 1 |
| Fodor, MB | 1 |
| Tjulandin, SA | 1 |
| Cabral Filho, S | 1 |
| Majlis, A | 1 |
| Ho, WM | 1 |
| Ma, B | 1 |
| Mok, T | 1 |
| Lai, P | 1 |
| Koh, J | 1 |
| Wong, YY | 1 |
| King, A | 1 |
| Leow, CK | 1 |
| Chan, AT | 1 |
| Hong, SK | 1 |
| Kwak, C | 1 |
| Lee, SE | 1 |
| Fiore, F | 2 |
| Daniele, B | 1 |
| Ottaiano, A | 1 |
| D'Angelo, R | 1 |
| Ferrari, E | 1 |
| Formato, R | 1 |
| Tortoriello, A | 1 |
| Turitto, G | 1 |
| Bruni, GS | 1 |
| Pignata, S | 1 |
| Iaffaioli, RV | 1 |
| Chang, DZ | 1 |
| Bontenbal, M | 1 |
| Creemers, GJ | 1 |
| Braun, HJ | 1 |
| de Boer, AC | 1 |
| Janssen, JT | 1 |
| Leys, RB | 1 |
| Ruit, JB | 1 |
| Goey, SH | 1 |
| van der Velden, PC | 1 |
| Kerkhofs, LG | 1 |
| Schothorst, KL | 1 |
| Schmitz, PI | 1 |
| Bokma, HJ | 1 |
| Verweij, J | 1 |
| Seynaeve, C | 1 |
| Horvath, WL | 1 |
| Sternfeld, WC | 1 |
| Mahoney, MR | 1 |
| Levitt, R | 1 |
| Rowland, K | 1 |
| Donohue, JH | 1 |
| Jeon, SB | 1 |
| Sohn, JH | 2 |
| Kim, JC | 1 |
| Park, IK | 1 |
| Farrell, PJ | 1 |
| Hackshaw, A | 1 |
| Knight, A | 1 |
| Barrett-Lee, P | 1 |
| Leonard, R | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Pasinetti, N | 1 |
| Marini, G | 1 |
| Byun, JH | 1 |
| Shim, BY | 1 |
| Woo, IS | 1 |
| Lee, KS | 2 |
| Choi, MG | 1 |
| Chang, SK | 1 |
| Oh, ST | 3 |
| Choi, SI | 1 |
| Lee, DS | 1 |
| Nolting, A | 1 |
| Pollert, P | 1 |
| Souglakos, J | 2 |
| Pallis, A | 1 |
| Kakolyris, S | 1 |
| Kouroussis, C | 1 |
| Agelaki, S | 2 |
| Xenidis, N | 1 |
| Milaki, G | 1 |
| Donadio, M | 1 |
| Ardine, M | 1 |
| Beano, A | 1 |
| Bottini, A | 1 |
| Mistrangelo, M | 1 |
| Bonardi, S | 1 |
| Generali, D | 1 |
| Polimeni, MA | 1 |
| Bretti, S | 1 |
| Alabiso, O | 2 |
| Bertetto, O | 1 |
| Kim, GP | 1 |
| Grothey, A | 4 |
| Vincent, JM | 1 |
| Campos, JM | 1 |
| Perez-Enguix, D | 1 |
| Cupini, S | 1 |
| Marcucci, L | 1 |
| Cerri, E | 1 |
| Brunetti, IM | 1 |
| Pfanner, E | 1 |
| Viti, M | 1 |
| Goletti, O | 1 |
| Filipponi, F | 1 |
| Terashima, M | 1 |
| Yamamura, Y | 1 |
| Tsujinaka, T | 1 |
| McCollum, AD | 1 |
| Wu, B | 1 |
| Michelini, A | 1 |
| Jensen, SA | 1 |
| Lønborg, JT | 1 |
| Sørensen, JB | 1 |
| Quek, R | 1 |
| Lim, ST | 1 |
| Ong, S | 2 |
| Cho, BC | 3 |
| Kim, CB | 2 |
| Giordano, KF | 1 |
| Jatoi, A | 1 |
| Stella, PJ | 1 |
| Foster, N | 1 |
| Tschetter, LK | 1 |
| Flynn, PJ | 1 |
| Nikcevich, DA | 1 |
| Hollis, DR | 1 |
| Warren, RS | 1 |
| Naughton, MJ | 1 |
| Weeks, JC | 1 |
| Sigurdson, ER | 1 |
| Herndon, JE | 1 |
| Zhang, C | 1 |
| Sugarbaker, PH | 2 |
| Alderman, R | 1 |
| Edwards, G | 1 |
| Marquardt, CE | 1 |
| Gushchin, V | 1 |
| Esquivel, J | 2 |
| Chang, D | 1 |
| Rivory, L | 1 |
| Beale, P | 1 |
| Horvath, L | 1 |
| Losa, F | 1 |
| De Castro, J | 1 |
| de Mon, MA | 1 |
| Okita, A | 1 |
| Tsukuda, K | 1 |
| Murakami, M | 1 |
| Ota, T | 1 |
| Suda, M | 1 |
| Nakano, T | 1 |
| Matsuoka, K | 1 |
| Suzuki, E | 1 |
| Naito, M | 1 |
| Andou, A | 1 |
| Shimizu, N | 1 |
| Kurzawinski, T | 1 |
| Harrison, P | 1 |
| Middleton, G | 1 |
| Daniels, F | 1 |
| Prendeville, J | 1 |
| Theis, B | 1 |
| Hull, R | 1 |
| Shankley, N | 1 |
| Kalindjian, B | 1 |
| Murray, G | 1 |
| Gillbanks, A | 1 |
| Black, J | 1 |
| Flesch, M | 2 |
| Landi, B | 1 |
| Lledo, G | 2 |
| Plantade, A | 1 |
| Brunner, TB | 1 |
| Tinkl, D | 1 |
| Meyer, T | 1 |
| Ould-Kaci, M | 1 |
| Bugat, R | 3 |
| Breau, JL | 1 |
| Tigaud, JM | 1 |
| Morvan, F | 1 |
| Cvitkovic, E | 3 |
| Potamianou, A | 1 |
| Varthalitis, I | 1 |
| Tsousis, S | 1 |
| Boukovinas, I | 1 |
| Tselepatiotis, E | 1 |
| Christofillakis, C | 1 |
| Forshaw, MJ | 1 |
| Gossage, JA | 1 |
| Chrystal, K | 1 |
| Cheong, K | 1 |
| Harper, PG | 1 |
| Mason, RC | 1 |
| Lamberti, C | 1 |
| Lundin, S | 1 |
| Bogdanow, M | 1 |
| Pagenstecher, C | 1 |
| Friedrichs, N | 1 |
| Büttner, R | 1 |
| Sauerbruch, T | 1 |
| Prabhasawat, P | 1 |
| Tesavibul, N | 1 |
| Leelapatranura, K | 1 |
| Phonjan, T | 1 |
| Lin, EH | 1 |
| Curley, SA | 1 |
| Crane, CC | 1 |
| Delcos, M | 1 |
| Vadhan, SR | 1 |
| Morris, J | 1 |
| Ayers, GD | 1 |
| Ross, A | 1 |
| Brown, T | 2 |
| Janjan, N | 1 |
| Saini, A | 1 |
| Alabiso, I | 1 |
| Bitossi, R | 1 |
| Brizzi, MP | 1 |
| Sculli, CM | 1 |
| Gorzegno, G | 1 |
| Magnino, A | 1 |
| Sperti, E | 2 |
| Miraglia, S | 1 |
| Forti, L | 1 |
| Aglietta, M | 1 |
| Harris, A | 1 |
| Escudier, B | 1 |
| Haddad, R | 1 |
| Tishler, R | 1 |
| Wirth, L | 1 |
| Norris, CM | 1 |
| Goguen, L | 1 |
| Sullivan, C | 1 |
| O'Donnell, L | 1 |
| Posner, M | 1 |
| Ferrero, JM | 1 |
| Oudard, S | 1 |
| Dides, S | 1 |
| Lesbats, G | 1 |
| Cavaglione, G | 1 |
| Nouyrigat, P | 1 |
| Foa, C | 1 |
| Kaphan, R | 1 |
| Wilkowski, R | 1 |
| Thoma, M | 1 |
| Bruns, C | 1 |
| Wagner, A | 1 |
| Orditura, M | 3 |
| Martinelli, E | 2 |
| Galizia, G | 2 |
| Aurilio, G | 1 |
| Vecchione, L | 1 |
| Lieto, E | 2 |
| Ciardiello, F | 1 |
| De Vita, F | 3 |
| Veronesi, P | 1 |
| Peruzzotti, G | 1 |
| Severi, G | 1 |
| Medici, M | 1 |
| Renne, G | 1 |
| Intra, M | 1 |
| Nolè, F | 1 |
| Kirchner, H | 1 |
| Rebmann, U | 1 |
| Soder, M | 1 |
| Gertenbach, U | 1 |
| Siebels, M | 1 |
| Roigas, J | 1 |
| Raschke, R | 1 |
| Salm, S | 1 |
| Schwindl, B | 1 |
| Müller, SC | 1 |
| Hauser, S | 1 |
| Leiber, C | 1 |
| Huland, E | 1 |
| Heinzer, H | 1 |
| Siemer, S | 1 |
| Metzner, B | 1 |
| Heynemann, H | 1 |
| Fornara, P | 1 |
| Reitz, M | 1 |
| Beresford, MJ | 1 |
| Burcombe, R | 1 |
| Ah-See, ML | 1 |
| Stott, D | 1 |
| Makris, A | 1 |
| De Dosso, S | 1 |
| Bichisao, E | 1 |
| Martinetti, A | 2 |
| Platania, M | 1 |
| Verzoni, E | 1 |
| Formisano, B | 1 |
| Bajetta, R | 1 |
| De Rosa, V | 1 |
| Izzo, F | 1 |
| Casaretti, R | 2 |
| Virzí, V | 1 |
| Kwon, JM | 1 |
| Lee, HR | 2 |
| Han, MJ | 1 |
| Wang, SL | 1 |
| Swisher, S | 1 |
| Cox, JD | 1 |
| Komaki, R | 1 |
| Végran, F | 1 |
| Boidot, R | 1 |
| Oudin, C | 1 |
| Riedinger, JM | 1 |
| Lizard-Nacol, S | 1 |
| Gibson, TB | 1 |
| Wagner, AD | 1 |
| Schmalenberg, H | 1 |
| Lindig, U | 1 |
| Behrens, R | 1 |
| Kleber, G | 1 |
| Kuss, O | 1 |
| Fleig, WE | 1 |
| Shiiki, S | 1 |
| Sonoo, H | 1 |
| Seki, M | 1 |
| Hironou, M | 1 |
| Ookubo, S | 1 |
| Udagawa, K | 1 |
| Nakashima, K | 1 |
| Ikeda, M | 1 |
| Kurebayashi, J | 1 |
| Dawson, SJ | 1 |
| Michael, M | 2 |
| Biagi, J | 1 |
| Foo, KF | 1 |
| Jefford, M | 1 |
| Ngan, SY | 1 |
| Leong, T | 1 |
| Hui, A | 1 |
| Milner, AD | 1 |
| Thomas, RJ | 1 |
| Zalcberg, JR | 1 |
| Vamvakas, L | 1 |
| Kalbakis, K | 1 |
| Vardakis, N | 1 |
| Tzardi, M | 1 |
| Kotsakis, AP | 1 |
| Gioulbasanis, J | 1 |
| Sfakiotaki, G | 1 |
| Chatzidaki, D | 1 |
| Karakuzu, A | 1 |
| Koc, M | 1 |
| Ozdemir, S | 1 |
| Martoni, AA | 1 |
| Pinto, C | 2 |
| Rojas Llimpe, FL | 1 |
| Gentile, AL | 2 |
| Mutri, V | 1 |
| Ballardini, P | 1 |
| Giaquinta, S | 1 |
| Piana, E | 2 |
| Muratore, A | 1 |
| Zorzi, D | 1 |
| Bouzari, H | 1 |
| Amisano, M | 1 |
| Massucco, P | 1 |
| Lee, SC | 1 |
| Landriscina, M | 1 |
| Quirino, M | 1 |
| Basso, M | 1 |
| Pozzo, C | 1 |
| Schinzari, G | 1 |
| Di Leonardo, G | 1 |
| D'Argento, E | 1 |
| Trigila, N | 1 |
| Cassano, A | 1 |
| Popov, IP | 2 |
| Milicevic, M | 1 |
| Kecmanovic, D | 1 |
| Tomasevic, Z | 1 |
| Radosevic-Jelic, Lj | 1 |
| Borojevic, N | 1 |
| Micev, MT | 2 |
| Kezic, I | 1 |
| Forster, J | 1 |
| Lindquist, D | 2 |
| Chan, S | 2 |
| Romieu, CG | 2 |
| Pienkowski, T | 3 |
| Jagiello-Gruszfeld, A | 2 |
| Crown, J | 2 |
| Chan, A | 2 |
| Kaufman, B | 2 |
| Campone, M | 3 |
| Davidson, N | 2 |
| Oliva, C | 2 |
| Rubin, SD | 1 |
| Muss, HB | 1 |
| Cox, NH | 2 |
| Eedy, DJ | 2 |
| Morton, CA | 2 |
| Salgado, J | 1 |
| Zabalegui, N | 1 |
| Gil, C | 1 |
| Monreal, I | 1 |
| Rodríguez, J | 1 |
| Tokar, M | 1 |
| Bobilev, D | 1 |
| Ariad, S | 1 |
| Geffen, DB | 1 |
| Nagai, H | 1 |
| Kanayama, M | 1 |
| Higami, K | 1 |
| Momiyama, K | 1 |
| Ikoma, A | 1 |
| Okano, N | 1 |
| Matsumaru, K | 1 |
| Ishii, K | 1 |
| Sumino, Y | 1 |
| Miki, K | 1 |
| Meadows, HM | 1 |
| Sebag-Montefiore, D | 2 |
| Kurt, E | 1 |
| Evrensel, T | 1 |
| Ozdemir, N | 1 |
| Manavoglu, O | 1 |
| Goker, E | 1 |
| Damianovich, D | 1 |
| Adena, M | 1 |
| Tebbutt, NC | 1 |
| Sameshima, S | 1 |
| Horikoshi, H | 1 |
| Motegi, K | 1 |
| Tomozawa, S | 1 |
| Hirayama, I | 1 |
| Saito, T | 1 |
| Sawada, T | 1 |
| Zhang, CX | 1 |
| Fang, JW | 1 |
| Shen, P | 1 |
| Bao, YH | 1 |
| Mou, BH | 1 |
| Shi, MG | 1 |
| Zhong, XL | 1 |
| Xiong, PJ | 1 |
| Saggio, G | 1 |
| Candeloro, G | 1 |
| Cesta, A | 1 |
| Amiconi, G | 1 |
| Blasio, AD | 1 |
| Necozione, S | 1 |
| Rea, S | 1 |
| Yoo, NC | 2 |
| O'connor, T | 1 |
| Rustum, Y | 1 |
| Creaven, P | 1 |
| El-Rayes, BF | 1 |
| Zalupski, MM | 1 |
| Manza, SG | 1 |
| Rusin, B | 1 |
| Ferris, AM | 1 |
| Vaishampayan, U | 1 |
| Heilbrun, LK | 1 |
| Venkatramanamoorthy, R | 1 |
| Shields, AF | 1 |
| Philip, PA | 2 |
| van Meerten, E | 1 |
| van Gameren, EC | 1 |
| Doorn, L | 1 |
| Giantonio, BJ | 1 |
| Catalano, PJ | 1 |
| Meropol, NJ | 3 |
| O'Dwyer, PJ | 1 |
| Schwartz, MA | 1 |
| Dupont, J | 1 |
| Jensen, HA | 1 |
| Jensen, BV | 1 |
| Pfeiffer, P | 1 |
| Larsen, S | 1 |
| Serup-Hansen, E | 1 |
| Andersen, LJ | 1 |
| Lindeløv, B | 1 |
| McCulloch, T | 1 |
| Adimi, P | 1 |
| Bastholt, L | 1 |
| Pintoffl, JP | 1 |
| Quietzsch, D | 1 |
| Meisinger, I | 1 |
| Nehls, O | 2 |
| Königsrainer, A | 1 |
| Jäger, E | 1 |
| Isacoff, WH | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Macdonald, JS | 2 |
| Kerbrat, P | 1 |
| Veyret, C | 1 |
| Lortholary, A | 1 |
| Fumoleau, P | 1 |
| Goudier, MJ | 1 |
| Audhuy, B | 1 |
| Simon, H | 1 |
| Montcuquet, P | 1 |
| Eymard, JC | 2 |
| Walter, S | 1 |
| Lee, JL | 1 |
| Yook, JH | 2 |
| Kim, BS | 5 |
| Kim, M | 1 |
| Chun, YJ | 1 |
| Nabhan, C | 1 |
| Ragam, A | 1 |
| Samuels, B | 1 |
| Milton, DT | 1 |
| Prasad, L | 1 |
| Hooberman, A | 1 |
| Hartsell, W | 1 |
| Anthony, A | 1 |
| Weisman, R | 1 |
| Bitran, JD | 1 |
| Hwang, IT | 1 |
| Chung, YM | 1 |
| Kim, JJ | 1 |
| Chung, JS | 1 |
| Yoo, YD | 1 |
| Prall, F | 1 |
| Ostwald, C | 1 |
| Schiffmann, L | 1 |
| Barten, M | 1 |
| Sowa, M | 1 |
| Tsuji, A | 1 |
| Kamano, T | 1 |
| Sasaki, K | 1 |
| Fukunaga, Y | 1 |
| Takahashi, M | 1 |
| Tsujitani, S | 1 |
| Mikami, Y | 1 |
| Mitachi, Y | 1 |
| Nishimura, S | 1 |
| Araki, H | 1 |
| Yamamitsu, S | 1 |
| Tominaga, S | 1 |
| Shirasaka, T | 1 |
| Inokuchi, K | 1 |
| Ashley, AC | 1 |
| Desai, AA | 1 |
| Quinn, DI | 1 |
| Bukowski, R | 1 |
| Poiesz, B | 1 |
| Lewis, N | 1 |
| Makalinao, A | 1 |
| Murray, P | 1 |
| Torti, FM | 1 |
| Ogasawara, S | 1 |
| Yano, H | 1 |
| Momosaki, S | 1 |
| Akiba, J | 1 |
| Nishida, N | 1 |
| Kojiro, S | 1 |
| Moriya, F | 1 |
| Ishizaki, H | 1 |
| Kuratomi, K | 1 |
| Kojiro, M | 1 |
| Fuchs, I | 1 |
| Gonsch, T | 1 |
| Weber, J | 1 |
| Klare, P | 1 |
| Hindenburg, HJ | 1 |
| Bangemann, N | 1 |
| Paolelli, L | 1 |
| Sciandivasci, A | 1 |
| de Rubertis, G | 1 |
| Barbanti, G | 1 |
| Manganelli, A | 1 |
| Salvestrini, F | 1 |
| Laber, DA | 1 |
| Khan, MI | 1 |
| Kloecker, GH | 1 |
| Schonard, C | 1 |
| Taft, BS | 1 |
| Salvador, C | 1 |
| Crehange, G | 1 |
| Peignaux, K | 1 |
| Bosset, M | 1 |
| Servagi-Vernat, S | 1 |
| Zampino, MG | 1 |
| Magni, E | 1 |
| Massacesi, C | 1 |
| Martignetti, A | 1 |
| Zorzino, L | 1 |
| Lorizzo, K | 1 |
| Santoro, L | 1 |
| Boselli, S | 1 |
| de Braud, F | 1 |
| Ruutiainen, AT | 1 |
| Soulen, MC | 1 |
| Tuite, CM | 1 |
| Clark, TW | 1 |
| Mondschein, JI | 1 |
| Stavropoulos, SW | 1 |
| Trerotola, SO | 1 |
| Vallböhmer, D | 1 |
| Yang, DY | 1 |
| Kuramochi, H | 1 |
| Shimizu, D | 1 |
| Danenberg, KD | 1 |
| Lindebjerg, J | 1 |
| Danenberg, PV | 1 |
| Moon, YW | 1 |
| Noh, SH | 2 |
| Zhang, HG | 1 |
| Qin, SK | 1 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 1 |
| Walpole, E | 1 |
| Underhill, C | 1 |
| Kotasek, D | 2 |
| Shapiro, J | 1 |
| Davies, T | 1 |
| Harvey, J | 1 |
| Spry, N | 1 |
| Carstens, H | 1 |
| Albertsson, M | 1 |
| Hentrich, M | 1 |
| Haberl, C | 1 |
| Seroneit, T | 1 |
| Roethling, N | 1 |
| Abrahantes, JC | 1 |
| Burzykowski, T | 2 |
| Figer, A | 2 |
| Chirivella, I | 1 |
| Perez-Staub, N | 1 |
| Liljefors, M | 1 |
| Nilsson, B | 1 |
| Mellstedt, H | 1 |
| Frödin, JE | 1 |
| Bartsch, R | 1 |
| Wenzel, C | 1 |
| Altorjai, G | 1 |
| Pluschnig, U | 1 |
| Rudas, M | 1 |
| Gnant, M | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Hubert, C | 1 |
| Sempoux, C | 1 |
| Horsmans, Y | 1 |
| Rahier, J | 1 |
| Humblet, Y | 1 |
| Machiels, JP | 1 |
| Ceratti, A | 1 |
| Ghosn, M | 1 |
| Kattan, J | 1 |
| Farhat, F | 1 |
| Younes, F | 1 |
| Nasr, F | 1 |
| Moukadem, W | 1 |
| Gasmi, J | 1 |
| Chahine, G | 1 |
| Cho, EY | 1 |
| Kim, MJ | 1 |
| Shim, YM | 1 |
| Lee, MS | 1 |
| Ho, HC | 1 |
| Hsiao, SH | 1 |
| Lee, CC | 1 |
| Hung, SK | 1 |
| Ninomiya, M | 1 |
| Matsuo, K | 1 |
| Hirabayashi, N | 1 |
| Kobayashi, M | 2 |
| Kawamura, S | 1 |
| Ando, T | 1 |
| Musha, N | 1 |
| Konno, H | 1 |
| Nagata, N | 1 |
| Miyashita, Y | 1 |
| Isaksson, B | 1 |
| Almström, M | 1 |
| Albiin, N | 1 |
| Permert, J | 1 |
| Sarbia, M | 1 |
| Ott, N | 1 |
| Pühringer-Oppermann, F | 1 |
| Brücher, BL | 1 |
| Uka, K | 1 |
| Miki, D | 1 |
| Jeong, SC | 1 |
| Vega, ME | 1 |
| Tabernero, J | 1 |
| Thomas, ES | 2 |
| Gomez, HL | 1 |
| Li, RK | 1 |
| Fein, LE | 1 |
| Chan, VF | 1 |
| Pivot, XB | 1 |
| Klimovsky, JV | 1 |
| de Mendoza, FH | 1 |
| Lerzo, GL | 1 |
| Peck, RA | 1 |
| Mukhopadhyay, P | 1 |
| Vahdat, LT | 2 |
| Roché, HH | 1 |
| Jelić, SB | 1 |
| Krivokapić, ZV | 1 |
| Jezdić, SD | 1 |
| Pesko, PM | 1 |
| Babić, DR | 1 |
| Brasiūniene, B | 1 |
| Juozaityte, E | 1 |
| Craven, I | 1 |
| Crellin, A | 1 |
| Cooper, R | 1 |
| Melcher, A | 1 |
| Byrne, P | 1 |
| Paridaens, R | 1 |
| Rossner, D | 1 |
| Vaslamatzis, MM | 1 |
| Nortier, JW | 1 |
| Salzberg, M | 1 |
| Rodrigues, H | 1 |
| Bell, R | 1 |
| Carroll, K | 1 |
| Miller, LL | 2 |
| Elfring, GL | 2 |
| Tonusin, A | 1 |
| Akmansu, M | 1 |
| Yamac, D | 1 |
| Uner, A | 1 |
| Yaman, E | 1 |
| Kaya, AO | 1 |
| Bora, H | 1 |
| Unsal, D | 1 |
| Pak, Y | 1 |
| Nam, E | 1 |
| Park, J | 1 |
| Lee, WK | 1 |
| Lee, SI | 2 |
| Di Lorenzo, G | 1 |
| Rea, A | 1 |
| Pepe, S | 1 |
| Palmieri, G | 1 |
| Chirianni, A | 1 |
| De Stefano, A | 1 |
| Esposito, V | 1 |
| Montesarchio, V | 1 |
| Hedrick, EE | 1 |
| Mass, RD | 1 |
| Sarkar, S | 1 |
| Hass, HG | 1 |
| Horger, MS | 1 |
| Koppenhöfer, U | 1 |
| Trojan, J | 1 |
| Gregor, M | 1 |
| Klump, B | 1 |
| Scalamogna, R | 1 |
| Brugnatelli, S | 1 |
| Tinelli, C | 1 |
| Sagrada, P | 1 |
| Gattoni, E | 1 |
| Tronconi, MC | 1 |
| Riccardi, A | 1 |
| Luchena, G | 1 |
| Corazza, GR | 1 |
| Troppmann, M | 1 |
| Kullmann, A | 1 |
| Golder, S | 1 |
| Herold, T | 1 |
| Herfarth, H | 1 |
| Grossmann, J | 1 |
| Schlottmann, K | 1 |
| Kullmann, F | 1 |
| Casey, M | 1 |
| Press, M | 1 |
| Viens, P | 1 |
| Gorbounova, V | 1 |
| Raats, JI | 1 |
| Roychowdhury, D | 1 |
| Paoletti, P | 1 |
| Rubin, S | 1 |
| Siriwittayakorn, P | 1 |
| Somwangprasert, A | 1 |
| Monzo, M | 1 |
| Moreno, I | 1 |
| Navarro, A | 1 |
| Ibeas, R | 1 |
| Artells, R | 1 |
| Gel, B | 1 |
| Martinez, F | 1 |
| Moreno, J | 1 |
| Hernandez, R | 1 |
| Navarro-Vigo, M | 1 |
| Schmid, P | 1 |
| Kühnhardt, D | 1 |
| Kiewe, P | 1 |
| Lehenbauer-Dehm, S | 1 |
| Schippinger, W | 1 |
| Lange, W | 1 |
| Preiss, J | 1 |
| Niederle, N | 1 |
| Brossart, P | 1 |
| Freier, W | 1 |
| Kümmel, S | 1 |
| Van de Velde, H | 1 |
| Regierer, A | 1 |
| Possinger, K | 2 |
| Sohn, HJ | 1 |
| von Delius, S | 1 |
| Lersch, C | 1 |
| Mayr, M | 1 |
| Stock, K | 1 |
| Schulte-Frohlinde, E | 1 |
| Schmid, RM | 1 |
| Eckel, F | 1 |
| Milandri, C | 1 |
| Calzolari, F | 1 |
| Tison, C | 1 |
| Giampalma, E | 1 |
| Cecconetto, L | 1 |
| Golfieri, R | 1 |
| Fedeli, SL | 1 |
| Fedeli, A | 1 |
| Casadei, V | 1 |
| Ceccolini, M | 1 |
| Nakano, K | 1 |
| Nukui, A | 1 |
| Suzuki, K | 1 |
| Sugaya, Y | 1 |
| Yuzawa, M | 1 |
| Morita, T | 1 |
| Kimmick, GG | 1 |
| Bhalla, K | 1 |
| Robert, N | 1 |
| Berry, D | 1 |
| Lemke, S | 1 |
| Hudis, C | 1 |
| Winer, E | 1 |
| Giusti, RM | 1 |
| Shastri, K | 1 |
| Pilaro, AM | 1 |
| Fuchs, C | 1 |
| Cordoba-Rodriguez, R | 1 |
| Koti, K | 1 |
| Rothmann, M | 1 |
| Men, AY | 1 |
| Hughes, M | 1 |
| Keegan, P | 1 |
| Weiss, KD | 1 |
| Lim, JY | 1 |
| Cho, JY | 2 |
| Paik, YH | 1 |
| Lee, DK | 1 |
| Park, HJ | 1 |
| Yoon, DS | 1 |
| Ruzzo, A | 1 |
| Canestrari, E | 1 |
| Bisonni, R | 1 |
| Torresi, U | 1 |
| Floriani, I | 1 |
| Andreoni, F | 1 |
| Maltese, P | 1 |
| Rulli, E | 1 |
| Humar, B | 1 |
| Giustini, L | 1 |
| Magnani, M | 1 |
| Di Pietrantonio, D | 1 |
| Boulet, T | 1 |
| Honore, C | 1 |
| Bonnet, S | 1 |
| Goere, D | 1 |
| Kohneh-Shahri, N | 1 |
| Raynard, B | 1 |
| Viel, E | 1 |
| Demarchi, MF | 1 |
| Chaigneau, L | 1 |
| Nguyen, T | 1 |
| Legat, C | 1 |
| Stein, U | 1 |
| Thiery-Vuillemin, A | 1 |
| Limat, S | 1 |
| Pivot, X | 1 |
| Kundel, Y | 1 |
| Purim, O | 1 |
| Stemmer, SM | 1 |
| Tichler, T | 1 |
| Sulkes, J | 1 |
| Sulkes, A | 1 |
| Brenner, B | 1 |
| Kim, MM | 1 |
| Mansfield, PF | 1 |
| Das, P | 1 |
| Badgwell, BD | 1 |
| Phan, AT | 1 |
| Delclos, ME | 1 |
| Maru, D | 1 |
| Krishnan, S | 1 |
| Cho, DY | 1 |
| Park, JC | 1 |
| Bae, SB | 1 |
| Cho, IS | 1 |
| Han, CS | 1 |
| Yun, HJ | 1 |
| Kim, S | 1 |
| Koberle, D | 1 |
| Schonenberger, A | 1 |
| Mattmann, S | 1 |
| Rochlitz, C | 1 |
| Schuller, JC | 1 |
| Ribi, K | 1 |
| Cardellino, GG | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Russo, S | 1 |
| Perin, T | 1 |
| Veronesi, A | 1 |
| Saadati, H | 1 |
| Ribelles, N | 1 |
| López-Siles, J | 1 |
| Sánchez, A | 1 |
| González, E | 1 |
| Sánchez, MJ | 1 |
| Sánchez-Rovira, P | 1 |
| Márquez, A | 1 |
| Sevilla, I | 1 |
| Alba, E | 1 |
| Dickler, MN | 1 |
| Cobleigh, MA | 1 |
| Miller, KD | 1 |
| Klein, PM | 1 |
| Winer, EP | 2 |
| Herrmann, C | 1 |
| Abel, U | 1 |
| Stremmel, W | 2 |
| Jaeger, D | 1 |
| Herrmann, T | 1 |
| Simkens, L | 1 |
| Antonini, N | 1 |
| van Krieken, H | 1 |
| Punt, C | 1 |
| Desimone, P | 1 |
| Braich, T | 1 |
| Evars, JP | 1 |
| Hrushesky, WJ | 1 |
| Jolivet, J | 1 |
| Daliani, DD | 1 |
| Eisenberg, PD | 1 |
| Weems, J | 1 |
| Lord, R | 1 |
| Fueger, R | 1 |
| Logothetis, CJ | 1 |
| Benoit, G | 1 |
| Di Palma, M | 2 |
| Blanchet, P | 1 |
| Lecouturier, S | 1 |
| Yataghene, Y | 1 |
| Decroix, Y | 1 |
| Jardin, A | 1 |
| Hiddemann, W | 2 |
| Schüller, J | 2 |
| Weiss, J | 1 |
| Lohrmann, HP | 1 |
| Schmitz-Hübner, U | 1 |
| Bodenstein, H | 1 |
| Schöber, C | 1 |
| Wilke, H | 4 |
| Grem, J | 1 |
| Jodrell, DI | 1 |
| Oster, W | 1 |
| Canney, PA | 1 |
| Yosef, H | 1 |
| Kaye, SB | 1 |
| Hamuro, J | 1 |
| Kikuchi, T | 1 |
| Takatsuki, F | 1 |
| Suzuki, M | 1 |
| Glisson, BS | 1 |
| Tessitore, J | 1 |
| Huberman, M | 1 |
| Bruzzi, P | 1 |
| Del Mastro, L | 2 |
| Garrone, O | 1 |
| Bertelli, G | 1 |
| Guelfi, M | 1 |
| Pastorino, S | 1 |
| Rosso, R | 4 |
| Sertoli, MR | 1 |
| Sundfør, K | 1 |
| Tropé, CG | 1 |
| Högberg, T | 1 |
| Onsrud, M | 1 |
| Koern, J | 1 |
| Simonsen, E | 1 |
| Bertelsen, K | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Karaayvaz, M | 1 |
| Arat, AR | 1 |
| Kaern, J | 2 |
| Tropé, C | 2 |
| Sundfoer, K | 1 |
| Kristensen, GB | 1 |
| Cripps, MC | 1 |
| Andersen, JS | 1 |
| Portenoy, RK | 1 |
| Green, MR | 1 |
| Tarassoff, PG | 1 |
| Brown, TD | 2 |
| Casper, ES | 1 |
| Storniolo, AM | 1 |
| Roca, E | 1 |
| Pennella, E | 1 |
| Sardi, M | 1 |
| Carraro, S | 1 |
| Barugel, M | 1 |
| Milano, C | 1 |
| Fiorini, A | 1 |
| Giglio, R | 1 |
| Gonzalez, G | 1 |
| Kneitschel, R | 1 |
| Aman, E | 1 |
| Jarentchuk, A | 1 |
| Blajman, C | 2 |
| Nadal, J | 1 |
| Santarelli, MT | 1 |
| Navigante, A | 1 |
| Majello, E | 1 |
| Testa, A | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Skinazi, F | 1 |
| Zins, M | 1 |
| Menu, Y | 1 |
| Bernades, P | 1 |
| Guglielmi, A | 1 |
| Aschele, C | 1 |
| Grossi, F | 1 |
| Tixi, L | 1 |
| Klaassen, U | 2 |
| Seeber, S | 2 |
| Paradiso, A | 1 |
| Rabinovich, M | 1 |
| Vallejo, C | 1 |
| Machiavelli, M | 1 |
| Romero, A | 1 |
| Perez, J | 1 |
| Lacava, J | 1 |
| Cuevas, MA | 1 |
| Rodriquez, R | 1 |
| Leone, B | 1 |
| Sapia, MG | 1 |
| Simone, G | 1 |
| De Lena, M | 1 |
| Suc, E | 1 |
| Brunet, P | 1 |
| Becouarn, Y | 1 |
| Marty, M | 3 |
| Extra, JM | 1 |
| Ganem, G | 1 |
| Negrier, S | 1 |
| Merrouche, Y | 1 |
| Burki, F | 2 |
| Herait, P | 1 |
| Chao, D | 1 |
| Kornek, G | 1 |
| Marczell, A | 1 |
| Salem, G | 1 |
| Karner, J | 1 |
| Kovats, E | 1 |
| Burger, D | 1 |
| Greiner, R | 1 |
| Pidlich, J | 2 |
| Schneeweiss, B | 2 |
| Raderer, M | 5 |
| Rosen, H | 1 |
| Depisch, D | 4 |
| Kaba, SE | 1 |
| Kyritsis, AP | 2 |
| Hess, K | 1 |
| Yung, WK | 2 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Jaeckle, KA | 2 |
| Levin, VA | 2 |
| Ishii, H | 1 |
| Okada, S | 2 |
| Tokuuye, K | 2 |
| Nose, H | 1 |
| Okusaka, T | 2 |
| Yoshimori, M | 1 |
| Nagahama, H | 1 |
| Sumi, M | 1 |
| Kagami, Y | 1 |
| Sjövall, MP | 1 |
| Brain, E | 1 |
| Garrino, C | 1 |
| Carbonero, IG | 1 |
| Itzhaki, M | 1 |
| Goldschmidt, E | 1 |
| Regensberg, C | 1 |
| Pappo, E | 1 |
| Hagipantelli, R | 1 |
| Musset, M | 1 |
| Holroyde, C | 1 |
| Mintzer, D | 1 |
| Nuamah, I | 1 |
| Armstead, B | 1 |
| Douglass, HO | 1 |
| Chu, L | 1 |
| Sutton, LM | 1 |
| Peterson, BL | 1 |
| Havlin, KA | 1 |
| Blijham, GH | 1 |
| Nitti, D | 2 |
| Sahmoud, T | 3 |
| Curran, D | 2 |
| Couvreur, ML | 2 |
| Lise, M | 1 |
| Rauschecker, H | 2 |
| dos Santos, JG | 1 |
| Roelofsen, F | 1 |
| Paillot, B | 1 |
| Lacave, AJ | 1 |
| Blijham, G | 1 |
| Jacob, JH | 1 |
| De Besi, P | 1 |
| Gay, F | 1 |
| Rahman, ZU | 1 |
| Frye, DK | 1 |
| Smith, TL | 1 |
| Champlin, RE | 1 |
| Hortobagyi, GN | 1 |
| You, NC | 1 |
| Min, JS | 1 |
| Nemunaitis, J | 2 |
| Cox, J | 3 |
| Meyer, W | 1 |
| Courtney, A | 1 |
| Mues, G | 1 |
| Brambilla, C | 1 |
| Moliterni, A | 1 |
| Terenziani, M | 1 |
| Zambetti, M | 2 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Walsh, G | 1 |
| Ebbs, S | 1 |
| Baum, M | 1 |
| Sacks, N | 1 |
| McKinna, J | 1 |
| Käufer, C | 1 |
| Ohl, U | 1 |
| Klaasen, U | 1 |
| Westerhausen, M | 1 |
| Schott, G | 1 |
| Harstick, A | 1 |
| Bade, J | 1 |
| Horster, A | 1 |
| Schubert, U | 1 |
| Hecker, H | 1 |
| Weyhofen, R | 1 |
| Harstrick, A | 1 |
| Eberhardt, W | 1 |
| Müller, C | 1 |
| Korn, M | 1 |
| Hanske, M | 1 |
| Diergarten, K | 1 |
| Tourani, JM | 1 |
| Pfister, C | 1 |
| Berdah, JF | 1 |
| Benhammouda, A | 1 |
| Salze, P | 1 |
| Paule, B | 1 |
| Guillet, P | 1 |
| Chretien, Y | 1 |
| Brewer, Y | 1 |
| Untereiner, M | 1 |
| Malaurie, E | 1 |
| Tadrist, Z | 1 |
| Pavlovitch, JM | 1 |
| Hauteville, D | 1 |
| Mejean, A | 1 |
| Azagury, M | 1 |
| Mayeur, D | 1 |
| Lucas, V | 1 |
| Krakowski, I | 1 |
| Larregain-Fournier, D | 1 |
| Abourachid, H | 1 |
| Andrieu, JM | 1 |
| Chastang, C | 1 |
| Doci, R | 1 |
| De Waele, B | 1 |
| Nakajima, T | 1 |
| Apolone, G | 1 |
| Lasser, P | 1 |
| Cocconi, G | 1 |
| Kerr, D | 1 |
| Hietschold, SM | 1 |
| Hejna, M | 2 |
| Kornek, GV | 4 |
| Brodowicz, T | 1 |
| Fiebiger, WC | 1 |
| Branda, RF | 1 |
| Nigels, E | 1 |
| Lafayette, AR | 1 |
| Hacker, M | 1 |
| Koizumi, M | 1 |
| Matsumoto, S | 1 |
| Yamashita, T | 1 |
| Ogata, E | 1 |
| Valencak, J | 1 |
| Weinländer, G | 1 |
| Fiebiger, W | 2 |
| Miholic, J | 1 |
| Neuberg, D | 1 |
| Pisansky, TM | 1 |
| Ginsberg, RJ | 1 |
| Pajak, T | 1 |
| Salter, M | 1 |
| Jones, SE | 2 |
| LoRusso, PM | 1 |
| Kuter, I | 1 |
| Vogel, C | 1 |
| Osterwalder, B | 5 |
| Burger, HU | 3 |
| Brown, CS | 1 |
| Griffin, T | 2 |
| DeVore, RF | 1 |
| Rivkin, SE | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Mikhak, B | 1 |
| Zahurak, M | 1 |
| Abeloff, MD | 1 |
| Fetting, JH | 1 |
| Davidson, NE | 1 |
| Donehower, RC | 1 |
| Waterfield, W | 1 |
| Balbiani, L | 1 |
| Block, J | 1 |
| Coppola, F | 1 |
| Chacon, R | 1 |
| Fein, L | 1 |
| Bonicatto, S | 1 |
| Alvarez, A | 1 |
| Schmilovich, A | 1 |
| Delgado, FM | 1 |
| Rose, PG | 1 |
| Bundy, BN | 1 |
| Watkins, EB | 1 |
| Thigpen, JT | 1 |
| Deppe, G | 1 |
| Maiman, MA | 1 |
| Clarke-Pearson, DL | 1 |
| Insalaco, S | 1 |
| Madsen, EL | 1 |
| Overgaard, M | 1 |
| Rose, C | 1 |
| Dombernowsky, P | 1 |
| Mouridsen, HT | 1 |
| Warner, E | 1 |
| Jensen, JL | 1 |
| Cripps, C | 1 |
| Khoo, KE | 1 |
| Kerr, IA | 1 |
| Fields, AL | 1 |
| Hrincu, A | 1 |
| Villar-Grimalt, A | 1 |
| Candel, MT | 1 |
| Lizón, J | 1 |
| Sánchez, B | 1 |
| Frau, A | 1 |
| Gorostidi, B | 1 |
| Goedkoop, R | 1 |
| Rayson, D | 1 |
| Adjei, AA | 1 |
| Wold, LE | 1 |
| Ingle, JN | 1 |
| Miller, M | 1 |
| Marth, C | 1 |
| Sundfor, K | 1 |
| Espie, M | 1 |
| Cottu, PH | 1 |
| Cuvier, C | 1 |
| Lerebours, F | 1 |
| Popov, I | 1 |
| Radosavljević, D | 1 |
| Nikolić-Tomasević, Z | 1 |
| Lim, WT | 1 |
| Koo, WH | 1 |
| Au, E | 1 |
| Khoo, KS | 1 |
| Gmyrek, R | 1 |
| Beer, R | 1 |
| Elizeri, Y | 1 |
| Oster, MW | 1 |
| Silvers, DN | 1 |
| Schneiderman, P | 1 |
| Grossman, ME | 1 |
| Gilles-Amar, V | 1 |
| Krulik, M | 1 |
| Anderson, N | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Ottosson-Lönn, S | 1 |
| Ostenstad, B | 2 |
| Mjaaland, I | 1 |
| Palm-Sjövall, M | 1 |
| Wist, E | 2 |
| Müller, HH | 1 |
| Bezwoda, WR | 1 |
| Peters, WA | 1 |
| Liu, PY | 1 |
| Barrett, RJ | 1 |
| Stock, RJ | 1 |
| Monk, BJ | 1 |
| Berek, JS | 1 |
| Souhami, L | 1 |
| Grigsby, P | 1 |
| Gordon, W | 1 |
| List, M | 1 |
| Humerickhouse, R | 1 |
| Dolan, ME | 1 |
| Sulzen, L | 1 |
| Hsieh, YC | 1 |
| Papadakou, M | 1 |
| Xidakis, E | 1 |
| Boukis, H | 1 |
| Poulis, A | 1 |
| Panagos, G | 1 |
| Lefantzis, D | 1 |
| Paulino, AC | 1 |
| Latona, C | 1 |
| Adelstein, DJ | 1 |
| Rice, TW | 1 |
| Rybicki, LA | 1 |
| Larto, MA | 1 |
| Ciezki, J | 1 |
| Saxton, J | 1 |
| DeCamp, M | 1 |
| Vargo, JJ | 1 |
| Dumot, JA | 1 |
| Zuccaro, G | 1 |
| De Vreede, I | 1 |
| Steers, JL | 1 |
| Burch, PA | 2 |
| Rosen, CB | 1 |
| Gunderson, LL | 1 |
| Haddock, MG | 1 |
| Burgart, L | 1 |
| Gores, GJ | 1 |
| Papamichael, D | 1 |
| Silvestrini, R | 1 |
| Luisi, A | 1 |
| Cipriani, S | 1 |
| Daidone, MG | 1 |
| Colevas, AD | 1 |
| Adak, S | 1 |
| Amrein, PC | 1 |
| Barton, JJ | 1 |
| Costello, R | 1 |
| Homma, H | 1 |
| Mezawa, S | 1 |
| Takada, K | 1 |
| Kukitsu, T | 1 |
| Oku, T | 1 |
| Akiyama, T | 1 |
| Kusakabe, T | 1 |
| Miyanishi, K | 1 |
| Niitsu, Y | 1 |
| Mani, S | 1 |
| Hochster, H | 1 |
| Beck, T | 1 |
| Chevlen, EM | 1 |
| O'Rourke, MA | 1 |
| Weaver, CH | 1 |
| Bell, WN | 2 |
| White, R | 1 |
| McGuirt, C | 1 |
| Levin, J | 2 |
| Hohneker, J | 1 |
| Kucuk, O | 1 |
| Shevrin, DH | 1 |
| Bonomi, PD | 1 |
| Simmonds, PC | 1 |
| Moiseenko, VM | 2 |
| O'Reilly, SM | 1 |
| Dalbot, DC | 1 |
| Van Belle, S | 1 |
| Gordon, RJ | 1 |
| Parnis, FX | 1 |
| Olver, IN | 1 |
| Norman, J | 1 |
| Taylor, A | 1 |
| Russell, J | 1 |
| Patterson, K | 1 |
| Keefe, D | 1 |
| Marafioti, T | 1 |
| Block, M | 1 |
| Schroeder, G | 1 |
| Braich, TA | 1 |
| Michalak, JC | 1 |
| Hatfield, AK | 1 |
| Kuross, SA | 1 |
| Lamont, JP | 1 |
| Kuhn, JA | 1 |
| Landers, SA | 1 |
| McCarty, TM | 1 |
| Schäfer, U | 1 |
| Schüller, P | 1 |
| Micke, O | 1 |
| Willich, N | 1 |
| Curley, S | 2 |
| Vauthey, J | 1 |
| Sawaf, HB | 1 |
| Dubrow, R | 1 |
| Allen, P | 1 |
| Ellis, LM | 1 |
| Lenzi, R | 2 |
| Lynch, P | 1 |
| Rich, TA | 1 |
| Płuzańska, A | 1 |
| Mrsic-Krmpotic, Z | 1 |
| Berzins, J | 1 |
| Nagykalnai, T | 1 |
| Wigler, N | 1 |
| Renard, J | 1 |
| Munier, S | 1 |
| Weil, C | 1 |
| Hollis, D | 1 |
| Wakasugi, H | 1 |
| Saisho, H | 1 |
| Ishikawa, O | 1 |
| Matsuno, S | 1 |
| Sato, T | 1 |
| Lionetto, R | 1 |
| Carnino, F | 1 |
| Guarneri, D | 1 |
| Gallo, L | 1 |
| Contu, A | 1 |
| Pronzato, P | 1 |
| Vesentini, L | 1 |
| Bergaglio, M | 1 |
| Comis, S | 1 |
| Ansari, R | 1 |
| Batist, G | 1 |
| Kocha, W | 1 |
| Kuperminc, M | 1 |
| Maroun, J | 2 |
| Walde, D | 1 |
| Weaver, C | 1 |
| Harrison, E | 1 |
| Semenova, AI | 1 |
| Orlova, RV | 1 |
| Mueller, HH | 1 |
| Mattes, E | 1 |
| Gassel, HJ | 1 |
| Junginger, T | 1 |
| Saeger, HD | 1 |
| Schramm, H | 1 |
| Staib-Sebler, E | 1 |
| Vetter, G | 1 |
| Heinrich, S | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Broët, P | 1 |
| Romain, S | 1 |
| Daver, A | 1 |
| Ricolleau, G | 1 |
| Quillien, V | 1 |
| Rallet, A | 1 |
| Asselain, B | 1 |
| Martin, PM | 1 |
| Spyratos, F | 1 |
| Ancona, E | 1 |
| Ruol, A | 1 |
| Santi, S | 1 |
| Merigliano, S | 1 |
| Sileni, VC | 1 |
| Koussis, H | 1 |
| Zaninotto, G | 1 |
| Bonavina, L | 1 |
| Peracchia, A | 1 |
| Szatkowska, L | 1 |
| Mazurkiewicz, M | 1 |
| Brzozowska, A | 1 |
| Mini, E | 1 |
| Nobili, S | 1 |
| Dentico, P | 1 |
| Angelelli, B | 1 |
| Scicolone, S | 1 |
| Mazzei, T | 1 |
| Schuell, B | 1 |
| Ulrich-Pur, H | 2 |
| Penz, M | 1 |
| Lang, F | 2 |
| Lenauer, A | 2 |
| Omasa, M | 1 |
| Hirata, T | 1 |
| Shoji, T | 1 |
| Bando, T | 1 |
| Hasegawa, S | 1 |
| Inui, K | 1 |
| Bensmaïne, MA | 1 |
| Brienza, S | 1 |
| Bornstein, R | 1 |
| Yu, IR | 1 |
| Parker, RJ | 1 |
| McLaren, CE | 1 |
| Nguyen, KP | 1 |
| Li, KT | 1 |
| Fruehauf, JP | 1 |
| Hess, KR | 1 |
| Wong, ET | 1 |
| Prados, MD | 1 |
| Goulart, BH | 1 |
| Martins, RG | 1 |
| Lynch, TJ | 1 |
| Oshaughnessy, JA | 1 |
| Blum, J | 1 |
| Miles, D | 1 |
| Bell, D | 1 |
| Laws, S | 1 |
| Gedlicka, C | 1 |
| Webb, A | 1 |
| Waters, JS | 1 |
| Norman, A | 1 |
| Massey, A | 1 |
| Granberg, D | 1 |
| Eriksson, B | 1 |
| Wilander, E | 1 |
| Grimfjärd, P | 1 |
| Fjällskog, ML | 1 |
| Skogseid, B | 1 |
| McGavin, JK | 1 |
| Goa, KL | 1 |
| Pentheroudakis, G | 1 |
| Lim, KC | 1 |
| Dunlop, DJ | 1 |
| Soukop, M | 1 |
| Eatock, MM | 1 |
| George, CM | 1 |
| Rini, BI | 1 |
| Geoffroy, FJ | 1 |
| Kollipara, P | 1 |
| Blanke, CD | 2 |
| Shultz, J | 1 |
| Modiano, M | 1 |
| Isaacs, R | 1 |
| Kasimis, B | 1 |
| Schilsky, R | 1 |
| Fleagle, J | 1 |
| Kemeny, N | 1 |
| Carlin, D | 1 |
| Hammershaimb, L | 3 |
| Haller, D | 1 |
| Keizer, HJ | 1 |
| Douma, J | 1 |
| Skovsgaard, T | 1 |
| Muller, EW | 1 |
| Ten Napel, CH | 1 |
| Croles, JJ | 1 |
| Lochs, H | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Mansouri, H | 1 |
| Bougnoux, Ph | 1 |
| Tubiana-Mathieu, N | 1 |
| Lotz, V | 1 |
| West, WH | 1 |
| Wong, A | 2 |
| Colwell, B | 1 |
| Thirlwell, MP | 1 |
| White, RL | 1 |
| Yates, BB | 1 |
| McGuirt, PV | 1 |
| Nicholson, BP | 1 |
| Paul, DM | 1 |
| Hande, KR | 1 |
| Shyr, Y | 1 |
| Meshad, M | 1 |
| Cohen, A | 1 |
| Johnson, DH | 1 |
| Ballo, MT | 1 |
| Milas, L | 1 |
| Mason, K | 1 |
| Charnsangavej, C | 2 |
| Wong, AB | 1 |
| Phan, T | 1 |
| Nguyen, Q | 1 |
| Jakob, A | 1 |
| Knop, S | 1 |
| Schupp, M | 1 |
| Boyer, M | 1 |
| Burger, U | 1 |
| Garin, A | 1 |
| McKendric, J | 1 |
| Ferrario, E | 1 |
| Vitali, M | 1 |
| Beretta, E | 1 |
| Seregni, E | 1 |
| Bombardieri, E | 1 |
| Crucitta, E | 1 |
| De Lucia, L | 1 |
| Del Prete, S | 1 |
| Comella, G | 1 |
| Tynninen, O | 1 |
| von Boguslawski, K | 1 |
| Heikkilä, R | 1 |
| Saksela, E | 1 |
| Paavonen, T | 1 |
| Macdonald, KO | 1 |
| Yehuda, P | 1 |
| Shirota, Y | 1 |
| Ichikawa, W | 1 |
| Nihei, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours[NCT02591030] | Phase 2/Phase 3 | 191 participants (Actual) | Interventional | 2015-12-15 | Completed | ||
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER[NCT00719797] | Phase 3 | 509 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY REINTRODUCTION OF FOLFOXIRI PLUS BEVACIZUMAB AT PROGRESSION Versus FOLFOX PLUS BEVACIZUMAB FOLLOWED BY FOLFIRI PLUS BEVACIZUMAB AT PROGRESSION IN FIRST- AND SECOND-LINE TREATMENT OF UNRESECTABLE METASTATIC[NCT02339116] | Phase 3 | 654 participants (Anticipated) | Interventional | 2015-02-26 | Active, not recruiting | ||
| Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to UGT1A1 Genotyping Versus Regorafenib Monotherapy in Patients With Previously Treated Metastatic Colorectal Cancer: A Prospective, Randomized, Controlled Study[NCT03880877] | Phase 2 | 153 participants (Anticipated) | Interventional | 2019-02-26 | Recruiting | ||
| Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study[NCT03719924] | Phase 2 | 106 participants (Actual) | Interventional | 2019-03-07 | Active, not recruiting | ||
| Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer: a Prospective Phase II Study[NCT06148402] | Phase 2 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen[NCT02923921] | Phase 3 | 567 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
| Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1[NCT04455282] | 100 participants (Anticipated) | Observational | 2021-02-01 | Recruiting | |||
| A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)[NCT00828386] | Phase 3 | 83 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Low accrual) | ||
| A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Ca[NCT00513292] | Phase 3 | 280 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receivi[NCT01442649] | Phase 2 | 133 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer[NCT01068327] | Phase 1 | 46 participants (Actual) | Interventional | 2007-11-05 | Completed | ||
| A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284] | Phase 3 | 781 participants (Actual) | Interventional | 2012-05-30 | Completed | ||
| A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636] | Phase 2 | 160 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05[NCT00126256] | Phase 3 | 570 participants (Anticipated) | Interventional | 2002-02-28 | Completed | ||
| An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™)[NCT01588990] | Phase 4 | 128 participants (Actual) | Interventional | 2012-06-26 | Completed | ||
| A Multi-institutional, Randomized Controlled, Phase II Clinical Trial on Comparison of Efficacy and Safety of Nedaplatin Plus 5-Fu Combined With and Without Endostar® Continuous Intravenous Infusion in Refractory Nasopharyngeal Carcinoma[NCT02590133] | Phase 2 | 328 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study[NCT00006479] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Active, not recruiting | ||
| Simultaneous RESEction of Colorectal Cancer With Synchronous Liver MeTastases (RESECT): A Feasibility Study[NCT02954913] | 41 participants (Actual) | Interventional | 2017-02-14 | Completed | |||
| Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052] | Phase 3 | 240 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma[NCT05314400] | 300 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | |||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00625651] | Phase 1/Phase 2 | 202 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.[NCT03042000] | 1,200 participants (Anticipated) | Interventional | 2017-02-28 | Not yet recruiting | |||
| FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY[NCT00002523] | Phase 3 | 1,011 participants (Actual) | Interventional | 1993-04-30 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Complete Pathologic Response Rectal Cancers EYSAC.1 Study[NCT03351959] | 1,000 participants (Anticipated) | Observational | 2018-01-01 | Recruiting | |||
| Open-label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Canc[NCT00705016] | Phase 1/Phase 2 | 184 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes[NCT02115204] | Phase 3 | 2,011 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| A Phase Ib/II Trial of Capeox Regimen Combined With Sintilimab and Bevacizumab in First-line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT05640609] | Phase 1/Phase 2 | 57 participants (Anticipated) | Interventional | 2023-03-10 | Recruiting | ||
| A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer[NCT00548548] | Phase 3 | 774 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)[NCT00786058] | 0 participants | Expanded Access | Approved for marketing | ||||
| Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Advanced Pancreatic Cancer Patients Progressed After First-line Gemcitabine and S-1: A Randomized Controlled Study[NCT02558868] | Phase 2 | 80 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949] | Phase 1/Phase 2 | 39 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2021-07-01 | Enrolling by invitation | ||
| Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb in Metastatic reNal Cell Carcinoma[NCT04462445] | Phase 2 | 25 participants (Actual) | Interventional | 2015-06-25 | Completed | ||
| The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680] | 200 participants (Anticipated) | Observational | 2016-06-30 | Active, not recruiting | |||
| Comparison of High Tone Therapy and TENS Therapy in Chemotherapy-induced Polyneuropathy[NCT03978585] | 51 participants (Actual) | Interventional | 2019-09-03 | Completed | |||
| Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease[NCT00719199] | Phase 1 | 21 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Sponsor will discontinue further development of EMD 1201081) | ||
| Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial[NCT01145404] | Phase 2 | 76 participants (Anticipated) | Interventional | 2010-06-30 | Terminated (stopped due to Changes of SoC for third line therapy resulting in poor recruitment) | ||
| Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer[NCT02591667] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS[NCT01878422] | Phase 3 | 350 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.[NCT01490996] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'[NCT00577031] | Phase 4 | 205 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Managem[NCT02008656] | Phase 2 | 358 participants (Actual) | Interventional | 2013-11-30 | Active, not recruiting | ||
| Rectal Microbiome Variability Among Rectal Cancer Cohorts Including Complete Clinical Responders, Pathologic Responders, and Early Recurrence[NCT04223102] | 40 participants (Anticipated) | Interventional | 2020-02-18 | Active, not recruiting | |||
| A Prospective Multicenter Randomized Controlled Trial of the Clinical Efficacy of Neoadjuvant Therapy Based on Organoids Drug Sensitivity Versus Empirical Neoadjuvant Therapy in the Treatment of Advanced Rectal Cancer[NCT05352165] | 192 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial[NCT03038256] | Phase 2 | 244 participants (Anticipated) | Interventional | 2018-01-31 | Recruiting | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group[NCT03561142] | Phase 2 | 94 participants (Anticipated) | Interventional | 2018-06-15 | Recruiting | ||
| Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076] | Phase 3 | 1,256 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy[NCT04749108] | Phase 2/Phase 3 | 1,075 participants (Anticipated) | Interventional | 2021-11-26 | Recruiting | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maint[NCT00973609] | Phase 3 | 853 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial[NCT02717923] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Randomized Non-inferiority Trial of Radiotherapy Plus Nimotuzumab or Cisplatin in Patients With Favorable Response to Induction Chemotherapy for Low-risk Locoregionally Advanced-Staged Nasopharyngeal Carcinoma[NCT04456322] | Phase 3 | 326 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| A Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Sintilimab Plus Capecitabine Versus Capecitabine Alone as Adjuvant Therapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT05201859] | Phase 2 | 150 participants (Anticipated) | Interventional | 2022-03-29 | Recruiting | ||
| Randomized Phase II Trial of Concurrent Chemoradiotherapy With or Without Nimotuzumab for High Risk Nasopharyngeal Carcinoma After Induction Chemotherapy[NCT04223024] | Phase 2 | 246 participants (Actual) | Interventional | 2019-12-12 | Active, not recruiting | ||
| Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0[NCT01621217] | Phase 1 | 21 participants (Anticipated) | Interventional | 2012-06-30 | Completed | ||
| A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSC[NCT00774319] | Phase 2 | 70 participants (Anticipated) | Interventional | 2008-12-31 | Recruiting | ||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin[NCT03388190] | Phase 2 | 80 participants (Actual) | Interventional | 2018-05-29 | Active, not recruiting | ||
| Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer[NCT00381706] | Phase 2 | 245 participants (Actual) | Interventional | 2006-09-15 | Completed | ||
| Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan[NCT04223479] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2020-01-15 | Completed | ||
| An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With M[NCT01111604] | Phase 2 | 158 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905] | Phase 2 | 44 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Completed | ||
| A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck[NCT04107103] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)[NCT06163534] | 500 participants (Anticipated) | Observational [Patient Registry] | 2024-01-30 | Not yet recruiting | |||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies[NCT06061705] | 100 participants (Anticipated) | Interventional | 2023-12-30 | Not yet recruiting | |||
| 1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
| A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion [NCT03356223] | Phase 2 | 25 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer - a Two Step Study With a Retrospective Analyses Followed by a Translational Phase II Study[NCT04350021] | 40 participants (Anticipated) | Observational | 2019-03-01 | Recruiting | |||
| A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma[NCT00012389] | Phase 3 | 0 participants | Interventional | 2000-12-31 | Completed | ||
| Phase I / II Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in the Second-line Treatment of Advanced Gastric Cancer[NCT04286711] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Docetaxel and Irinotecan Combination as a Second Line Treatment of Metastatic Gastric Cancer; a Phase II Multicenter Study[NCT04770623] | Phase 2 | 24 participants (Actual) | Interventional | 2021-03-05 | Completed | ||
| A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma[NCT03116555] | Phase 2 | 37 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | ||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC).[NCT02249650] | Phase 1 | 21 participants (Actual) | Interventional | 2017-07-10 | Completed | ||
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel[NCT02175446] | Phase 2 | 61 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Role of Circulating Tumour DNA (ctDNA) Testing in Assessing for Alterations of Primary Anti-Epidermal Growth Factor Receptor (EGFR) Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients[NCT05051592] | 40 participants (Anticipated) | Observational | 2021-03-26 | Recruiting | |||
| Biomarker-Panel Enriched Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After Induction Treatment With Chemotherapy + Cetuximab in Metastatic Colorectal Cancer (mCRC)[NCT02978313] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Evaluation of Individual Peripheral Blood Circulating Tumor Cells Combined With Tumor Marker Detection of Efficacy of Chemotherapy in Patients With Advanced Colorectal Cancer: A Observational Clinical Trial[NCT02948985] | 100 participants (Anticipated) | Observational [Patient Registry] | 2017-01-31 | Not yet recruiting | |||
| Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer[NCT00154102] | Phase 3 | 1,221 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer[NCT03259009] | 73 participants (Anticipated) | Observational [Patient Registry] | 2017-10-01 | Not yet recruiting | |||
| Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer[NCT02416609] | 44 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809] | Phase 2 | 252 participants (Actual) | Interventional | 2003-02-01 | Completed | ||
| European Study Group For Pancreatic Cancer - Trial 3[NCT00058201] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2001-07-31 | Completed | ||
| Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma[NCT02749136] | Phase 2 | 44 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck[NCT00003888] | Phase 3 | 359 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer[NCT00193219] | Phase 2 | 36 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression[NCT00303758] | Phase 3 | 202 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer[NCT00192075] | Phase 2 | 84 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Phase III Multicenter Study of the Effects on Quality of Life of Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer[NCT00540800] | Phase 3 | 139 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer[NCT00508274] | Phase 3 | 52 participants (Actual) | Interventional | 2007-07-18 | Terminated (stopped due to Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.) | ||
| A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer[NCT00536809] | Phase 1 | 12 participants (Actual) | Interventional | 2007-09-26 | Completed | ||
| A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Me[NCT00182715] | Phase 3 | 2,421 participants (Anticipated) | Interventional | 2005-03-31 | Active, not recruiting | ||
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer[NCT03714490] | Phase 2 | 200 participants (Anticipated) | Interventional | 2018-10-23 | Recruiting | ||
| Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER[NCT02268006] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Randomized Phase II Trial Evaluating [Radiotherapy-Docetaxel-5 Fluorouracil] Association Versus [Radiotherapy-Docetaxel-Cisplatin] Association in Non Resecables First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112697] | Phase 2 | 71 participants (Actual) | Interventional | 2003-10-06 | Completed | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Wit[NCT00408408] | Phase 3 | 1,206 participants (Actual) | Interventional | 2006-11-30 | Active, not recruiting | ||
| Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753] | Phase 1 | 14 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study[NCT01433614] | Phase 3 | 304 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer[NCT01658033] | Phase 2 | 72 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers[NCT00797446] | 10 participants (Actual) | Observational | 2007-09-30 | Terminated (stopped due to Slow enrollment, feasibility issues) | |||
| Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692] | 200 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver[NCT00019786] | Phase 2 | 67 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma[NCT01833832] | Phase 2 | 11 participants (Actual) | Interventional | 2013-04-12 | Completed | ||
| Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT00557206] | Phase 2 | 35 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Funding was terminated) | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma[NCT00005649] | Phase 2 | 0 participants | Interventional | 1998-07-31 | Completed | ||
| A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER[NCT00002888] | Phase 3 | 0 participants | Interventional | 1997-03-31 | Completed | ||
| Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement[NCT00003902] | Phase 1/Phase 2 | 110 participants (Anticipated) | Interventional | 1999-03-31 | Completed | ||
| Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer[NCT02004769] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer[NCT00142038] | Phase 2 | 80 participants | Interventional | 2004-03-31 | Completed | ||
| Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Not enough inclusion) | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases[NCT01095523] | Phase 2 | 0 participants (Actual) | Interventional | 2010-01-14 | Withdrawn | ||
| CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer[NCT00004885] | Phase 3 | 430 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors[NCT04790708] | 250 participants (Anticipated) | Interventional | 2018-07-02 | Recruiting | |||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver[NCT00003834] | Phase 2 | 44 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction[NCT00054457] | Phase 2 | 46 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER[NCT00002716] | Phase 3 | 135 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer[NCT02119026] | Phase 2 | 120 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Randomized Clinical Trial: Comparison of the Efficacy of Topical 0.2% Loteprednol Etabonate and Topical 0.1% Dexamethasone in Impending Recurrent Pterygium[NCT04075227] | Phase 4 | 108 participants (Actual) | Interventional | 2015-10-16 | Completed | ||
| Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study[NCT02342392] | Phase 2/Phase 3 | 36 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma[NCT00139230] | Phase 2 | 30 participants | Interventional | 1997-01-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies[NCT02238509] | Phase 2 | 154 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer[NCT00078572] | Phase 3 | 408 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations[NCT01264081] | Phase 2 | 34 participants (Actual) | Interventional | 2011-05-20 | Terminated (stopped due to Protocol would not be able to reach stated accrual.) | ||
| Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer[NCT01309607] | Phase 2 | 34 participants (Anticipated) | Interventional | 2011-04-30 | Active, not recruiting | ||
| Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases[NCT01934894] | Phase 2 | 11 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Study was terminated due to lack of significant signal of efficacy) | ||
| Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer[NCT05553522] | Phase 1 | 40 participants (Anticipated) | Interventional | 2023-09-18 | Recruiting | ||
| Phase I Study of Irinotecan Followed by Capecitabine in Patients With Advanced Breast Carcinoma[NCT00083148] | Phase 1 | 12 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| The Effect and Safety on Unresectable CRLM From RFA in Combination With Second-line Chemotherapy and Bevacizumab Compared With the Combination of Second-line Chemotherapy and Bevacizumab: a Randomized and Controlled Clinical Trial[NCT03686254] | Phase 2/Phase 3 | 160 participants (Anticipated) | Interventional | 2018-07-16 | Recruiting | ||
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy[NCT01921673] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant[NCT00080301] | Phase 3 | 752 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Randomized Trial of Irinotecan, Leucovorin, 5-FU (ILF) Versus ILF Plus Cisplatin (PILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer[NCT00320294] | Phase 2 | 86 participants | Interventional | 2005-02-28 | Active, not recruiting | ||
| A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy[NCT00109265] | Phase 2 | 0 participants | Interventional | 2001-05-31 | Completed | ||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer[NCT01704690] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to The enrollment of the study is much slower than expected.) | ||
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473] | Phase 2 | 120 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| Study on Adaptive Radiotherapy and Multimodal Information of Cervical Cancer Assisted by Artificial Intelligence[NCT04022018] | 122 participants (Anticipated) | Interventional | 2019-12-18 | Recruiting | |||
| AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer[NCT00600210] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn (stopped due to low patient accrual) | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.[NCT03256916] | Phase 3 | 348 participants (Anticipated) | Interventional | 2018-01-16 | Recruiting | ||
| Phase II Trial To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix[NCT04789941] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)[NCT05660083] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | ||
| A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.[NCT01126138] | Phase 3 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| Prospective Registry Study of Neoadjuvant Therapy in Conjunction With Liver Transplantation for Cholangiocarcinoma[NCT00301379] | 59 participants (Actual) | Observational | 2005-08-12 | Terminated (stopped due to Low accrual) | |||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | ||
| RANDOMIZED STUDY OF PREOPERATIVE CHEMOTHERAPY VERSUS SURGERY ALONE IN ESOPHAGUS CANCER[NCT00002897] | Phase 3 | 240 participants (Anticipated) | Interventional | 1992-07-31 | Completed | ||
| Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic[NCT01045941] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to The study was never initiated) | |||
| The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167] | Phase 2 | 21 participants (Actual) | Interventional | 2007-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)
| Intervention | Months (Median) |
|---|---|
| Pegilodecakin + FOLFOX | 4.99 |
| FOLFOX | 5.17 |
Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date. (NCT02923921)
Timeframe: Randomization to date of death from any cause (Up To 30 Months)
| Intervention | Months (Median) |
|---|---|
| Pegilodecakin + FOLFOX | 5.78 |
| FOLFOX | 6.28 |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants who discontinued study treatment (for reasons other than progression) before entering concurrent phase were considered to have non-evaluable response. (NCT02923921)
Timeframe: Randomization to PD (Up To 30 Months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Pegilodecakin + FOLFOX | 4.6 |
| FOLFOX | 5.6 |
The 12-month survival rate is defined as the percentage of participants who have not died 12 months after the date of randomization. (NCT02923921)
Timeframe: From randomization to until the date of first documented date of death from any cause within 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pegilodecakin + FOLFOX | 14.7 |
| FOLFOX | 19.1 |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Up To 30 Months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Pegilodecakin + FOLFOX | 42.8 |
| FOLFOX | 36.6 |
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant did not have a complete baseline disease assessment, then PFS was censored at the enrollment date, regardless whether or not objectively determined PD or death had been observed for the participant. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)
| Intervention | Months (Median) |
|---|---|
| Pegilodecakin + FOLFOX | 2.14 |
| FOLFOX | 2.10 |
"Surgery was categorized as breast conserving surgery (Partial Mastectomy) or non-conserving surgery (Total Mastectomy or Modified Radical Mastectomy). Reported below is the percentage of patients receiving Partial Mastectomy. This was calculated by dividing the number of patients receiving Partial Mastectomy by the total number of patients undergoing surgery multiplied by 100 (to obtain the percentage)." (NCT00513292)
Timeframe: From time surgery to up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 37.7 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 39.1 |
Difference from pretreatment LVEF (%) at 24 weeks [median change from baseline Inter Quartile Range (IQR)]. (NCT00513292)
Timeframe: Baseline, at 24 week
| Intervention | percent (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | -3 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | -4 |
pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy (among those with Metastasis to movable ipsilateral axillary lymph node(s) (cN1-3) disease). (NCT00513292)
Timeframe: Up to 5 years
| Intervention | Percentage (95% confidence Interval) (Number) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 48.3 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 46.7 |
DFS defined as inoperable progressive disease, gross residual disease following definitive surgery, local, regional or distant recurrence, contralateral breast cancer, other second primary cancers, and death prior to recurrence or second primary cancer. DFS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. (NCT00513292)
Timeframe: From time to registration to time of event, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | NA |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | NA |
All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12. Difference from pretreatment LVEF (%) at 12 weeks [median change from baseline Inter Quartile Range (IQR)]. (NCT00513292)
Timeframe: At 12 week
| Intervention | percent (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 2 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | -3 |
OS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. (NCT00513292)
Timeframe: From time to registration to death, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | NA |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | NA |
Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates. (NCT00513292)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 56.5 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 54.2 |
The summary of asymptomatic decrease in LVEF. (NCT00513292)
Timeframe: Baseline, at 12 week
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| no decrease or decrease < 10%, still above LLN | decrease < 10%, below lower limit of normal (LLN) | decrease 10-15%, still above lower limit of normal | decrease 10-15%, below lower limit of normal (LLN) | decrease > 15%, still above lower limit of norm | decrease > 15%, below lower limit of normal | |
| FEC-75 Then Paclitaxel/Trastuzumab | 92.3 | 0.8 | 6.2 | 0 | 0.8 | 0 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 82.5 | 0 | 11.7 | 0 | 2.9 | 2.9 |
The summary of asymptomatic changed in LVEF. (NCT00513292)
Timeframe: Baseline, at 24 week
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| no decrease or decrease < 10%, still above LLN | decrease < 10%, below lower limit of normal (LLN) | decrease 10-15%, still above lower limit of normal | decrease 10-15%, below lower limit of normal (LLN) | decrease > 15%, still above lower limit of normal | decrease > 15%, below lower limit of normal (LLN) | |
| FEC-75 Then Paclitaxel/Trastuzumab | 83.3 | 0.8 | 7.9 | 2.4 | 1.6 | 4.0 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 73.1 | 3.1 | 15.4 | 0.8 | 6.9 | 0.8 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | mL/min (Mean) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 71.4 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 182 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue - Baseline | Fatigue - Change at Cycle 3 | Fatigue - Change at Cycle 5 | Fatigue - Change at Cycle 7 | Fatigue - Change at Cycle 9 | Fatigue - Change at Cycle 11 | Fatigue - Change at Cycle 13 | Fatigue - Change at Cycle 15 | Fatigue - Change at Cycle 17 | Fatigue - Change at Cycle 19 | Fatigue - Change at Cycle 21 | Fatigue - Change at Cycle 23 | Fatigue - Change at Cycle 25 | Fatigue - Change at Cycle 27 | Fatigue - Change at Cycle 29 | Fatigue - Change at Cycle 31 | Fatigue - Change at Cycle 33 | Fatigue - Change at Cycle 35 | Fatigue - Change at EOT | Nausea and Vomiting - Baseline | Nausea and Vomiting - Change at Cycle 3 | Nausea and Vomiting - Change at Cycle 5 | Nausea and Vomiting - Change at Cycle 7 | Nausea and Vomiting - Change at Cycle 9 | Nausea and Vomiting - Change at Cycle 11 | Nausea and Vomiting - Change at Cycle 13 | Nausea and Vomiting - Change at Cycle 15 | Nausea and Vomiting - Change at Cycle 17 | Nausea and Vomiting - Change at Cycle 19 | Nausea and Vomiting - Change at Cycle 21 | Nausea and Vomiting - Change at Cycle 23 | Nausea and Vomiting - Change at Cycle 25 | Nausea and Vomiting - Change at Cycle 27 | Nausea and Vomiting - Change at Cycle 29 | Nausea and Vomiting - Change at Cycle 31 | Nausea and Vomiting - Change at Cycle 33 | Nausea and Vomiting - Change at Cycle 35 | Nausea and Vomiting - Change at EOT | Pain - Baseline | Pain - Change at Cycle 3 | Pain - Change at Cycle 5 | Pain - Change at Cycle 7 | Pain - Change at Cycle 9 | Pain - Change at Cycle 11 | Pain - Change at Cycle 13 | Pain - Change at Cycle 15 | Pain - Change at Cycle 17 | Pain - Change at Cycle 19 | Pain - Change at Cycle 21 | Pain - Change at Cycle 23 | Pain - Change at Cycle 25 | Pain - Change at Cycle 27 | Pain - Change at Cycle 29 | Pain - Change at Cycle 31 | Pain - Change at Cycle 33 | Pain - Change at Cycle 35 | Pain - Change at EOT | Dyspnoea - Baseline | Dyspnoea - Change at Cycle 3 | Dyspnoea - Change at Cycle 5 | Dyspnoea - Change at Cycle 7 | Dyspnoea - Change at Cycle 9 | Dyspnoea - Change at Cycle 11 | Dyspnoea - Change at Cycle 13 | Dyspnoea - Change at Cycle 15 | Dyspnoea - Change at Cycle 17 | Dyspnoea - Change at Cycle 19 | Dyspnoea - Change at Cycle 21 | Dyspnoea - Change at Cycle 23 | Dyspnoea - Change at Cycle 25 | Dyspnoea - Change at Cycle 27 | Dyspnoea - Change at Cycle 29 | Dyspnoea - Change at Cycle 31 | Dyspnoea - Change at Cycle 33 | Dyspnoea - Change at Cycle 35 | Dyspnoea - Change at EOT | Insomnia - Baseline | Insomnia - Change at Cycle 3 | Insomnia - Change at Cycle 5 | Insomnia - Change at Cycle 7 | Insomnia - Change at Cycle 9 | Insomnia - Change at Cycle 11 | Insomnia - Change at Cycle 13 | Insomnia - Change at Cycle 15 | Insomnia - Change at Cycle 17 | Insomnia - Change at Cycle 19 | Insomnia - Change at Cycle 21 | Insomnia - Change at Cycle 23 | Insomnia - Change at Cycle 25 | Insomnia - Change at Cycle 27 | Insomnia - Change at Cycle 29 | Insomnia - Change at Cycle 31 | Insomnia - Change at Cycle 33 | Insomnia - Change at Cycle 35 | Insomnia - Change at EOT | Appetite loss - Baseline | Appetite loss - Change at Cycle 3 | Appetite loss - Change at Cycle 5 | Appetite loss - Change at Cycle 7 | Appetite loss - Change at Cycle 9 | Appetite loss - Change at Cycle 11 | Appetite loss - Change at Cycle 13 | Appetite loss - Change at Cycle 15 | Appetite loss - Change at Cycle 17 | Appetite loss - Change at Cycle 19 | Appetite loss - Change at Cycle 21 | Appetite loss - Change at Cycle 23 | Appetite loss - Change at Cycle 25 | Appetite loss - Change at Cycle 27 | Appetite loss - Change at Cycle 29 | Appetite loss - Change at Cycle 31 | Appetite loss - Change at Cycle 33 | Appetite loss - Change at Cycle 35 | Appetite loss - Change at EOT | Constipation - Baseline | Constipation - Change at Cycle 3 | Constipation - Change at Cycle 5 | Constipation - Change at Cycle 7 | Constipation - Change at Cycle 9 | Constipation - Change at Cycle 11 | Constipation - Change at Cycle 13 | Constipation - Change at Cycle 15 | Constipation - Change at Cycle 17 | Constipation - Change at Cycle 19 | Constipation - Change at Cycle 21 | Constipation - Change at Cycle 23 | Constipation - Change at Cycle 25 | Constipation - Change at Cycle 27 | Constipation - Change at Cycle 29 | Constipation - Change at Cycle 31 | Constipation - Change at Cycle 33 | Constipation - Change at Cycle 35 | Constipation - Change at EOT | Diarrhoea - Baseline | Diarrhoea - Change at Cycle 3 | Diarrhoea - Change at Cycle 5 | Diarrhoea - Change at Cycle 7 | Diarrhoea - Change at Cycle 9 | Diarrhoea - Change at Cycle 11 | Diarrhoea - Change at Cycle 13 | Diarrhoea - Change at Cycle 15 | Diarrhoea - Change at Cycle 17 | Diarrhoea - Change at Cycle 19 | Diarrhoea - Change at Cycle 21 | Diarrhoea - Change at Cycle 23 | Diarrhoea - Change at Cycle 25 | Diarrhoea - Change at Cycle 27 | Diarrhoea - Change at Cycle 29 | Diarrhoea - Change at Cycle 31 | Diarrhoea - Change at Cycle 33 | Diarrhoea - Change at Cycle 35 | Diarrhoea - Change at EOT | Financial difficulties - Baseline | Financial difficulties - Change at Cycle 3 | Financial difficulties - Change at Cycle 5 | Financial difficulties - Change at Cycle 7 | Financial difficulties - Change at Cycle 9 | Financial difficulties - Change at Cycle 11 | Financial difficulties - Change at Cycle 13 | Financial difficulties - Change at Cycle 15 | Financial difficulties - Change at Cycle 17 | Financial difficulties - Change at Cycle 19 | Financial difficulties - Change at Cycle 21 | Financial difficulties - Change at Cycle 23 | Financial difficulties - Change at Cycle 25 | Financial difficulties - Change at Cycle 27 | Financial difficulties - Change at Cycle 29 | Financial difficulties - Change at Cycle 31 | Financial difficulties - Change at Cycle 33 | Financial difficulties - Change at Cycle 35 | Financial difficulties - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 29.16 | 7.35 | 8.40 | 9.54 | 7.89 | 11.30 | 8.33 | 7.41 | 6.70 | 8.93 | 10.39 | 10.80 | 7.66 | 9.66 | 11.67 | 14.07 | 15.15 | 14.44 | 12.31 | 5.88 | 6.68 | 6.98 | 6.61 | 6.20 | 8.97 | 6.82 | 6.85 | 3.45 | 6.56 | 3.99 | 7.87 | 4.02 | 7.25 | 1.67 | 13.33 | 3.03 | 3.33 | 6.64 | 20.47 | 2.68 | 2.52 | 3.00 | 2.72 | 6.64 | 5.16 | 7.26 | 9.39 | 8.74 | 7.25 | 8.33 | 5.75 | 5.07 | 4.17 | 10.00 | 7.58 | 6.67 | 10.85 | 13.45 | 3.63 | 5.75 | 6.98 | 6.89 | 8.19 | 6.36 | 3.58 | 5.16 | 6.78 | 3.79 | 4.04 | 1.23 | 3.03 | -1.75 | 16.67 | 16.67 | 16.67 | 6.53 | 24.15 | 0.37 | -0.08 | -2.37 | -0.24 | 2.56 | 0.65 | -2.19 | -1.92 | 1.64 | 0.74 | -0.93 | -0.00 | -1.52 | -3.33 | -4.44 | -6.06 | -3.33 | 5.31 | 17.38 | 9.10 | 9.02 | 9.84 | 9.98 | 14.53 | 10.67 | 10.74 | 8.91 | 9.84 | 13.04 | 12.38 | 11.49 | 15.94 | 15.00 | 15.56 | 15.15 | 16.67 | 12.03 | 12.71 | 2.42 | 3.77 | 2.63 | 5.35 | 4.42 | 4.58 | 4.92 | 5.43 | 8.33 | 6.06 | 9.26 | 5.75 | 1.45 | 6.67 | 22.22 | 12.12 | 10.00 | 3.78 | 10.37 | 11.72 | 10.85 | 14.63 | 11.44 | 15.46 | 11.26 | 11.02 | 10.34 | 15.25 | 14.07 | 18.52 | 10.34 | 13.64 | 16.67 | 20.00 | 18.18 | 30.00 | 7.31 | 20.12 | -1.83 | -1.32 | -0.99 | -0.49 | 3.30 | 1.11 | -0.27 | 0.77 | 1.67 | 4.44 | 2.94 | -4.60 | -2.90 | 0.00 | -2.22 | -3.03 | 0.00 | 2.97 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 0.77 | -0.02 | -0.03 | -0.04 | -0.05 | -0.07 | -0.05 | -0.06 | -0.05 | -0.05 | -0.09 | -0.14 | -0.08 | -0.08 | -0.08 | -0.12 | 0.02 | -0.05 | -0.11 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72.81 | -1.85 | -2.15 | -2.20 | -2.74 | -3.10 | -2.36 | -1.05 | -1.91 | -3.06 | -2.13 | -5.77 | -7.28 | -4.94 | -8.80 | -6.69 | -7.90 | -8.88 | -6.67 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 68.61 | -3.34 | -4.70 | -3.63 | -3.97 | -5.85 | -2.26 | -3.05 | -1.18 | -2.36 | -5.56 | -6.86 | -8.05 | -10.14 | -8.33 | -9.44 | -11.36 | -5.83 | -8.82 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical - Baseline | Physical - Change at Cycle 3 | Physical - Change at Cycle 5 | Physical - Change at Cycle 7 | Physical - Change at Cycle 9 | Physical - Change at Cycle 11 | Physical - Change at Cycle 13 | Physical - Change at Cycle 15 | Physical - Change at Cycle 17 | Physical - Change at Cycle 19 | Physical - Change at Cycle 21 | Physical - Change at Cycle 23 | Physical - Change at Cycle 25 | Physical - Change at Cycle 27 | Physical - Change at Cycle 29 | Physical - Change at Cycle 31 | Physical - Change at Cycle 33 | Physical - Change at Cycle 35 | Physical - Change at EOT | Role - Baseline | Role - Change at Cycle 3 | Role - Change at Cycle 5 | Role - Change at Cycle 7 | Role - Change at Cycle 9 | Role - Change at Cycle 11 | Role - Change at Cycle 13 | Role - Change at Cycle 15 | Role - Change at Cycle 17 | Role - Change at Cycle 19 | Role - Change at Cycle 21 | Role - Change at Cycle 23 | Role - Change at Cycle 25 | Role - Change at Cycle 27 | Role - Change at Cycle 29 | Role - Change at Cycle 31 | Role - Change at Cycle 33 | Role - Change at Cycle 35 | Role - Change at EOT | Emotional - Baseline | Emotional - Change at Cycle 3 | Emotional - Change at Cycle 5 | Emotional - Change at Cycle 7 | Emotional - Change at Cycle 9 | Emotional - Change at Cycle 11 | Emotional - Change at Cycle 13 | Emotional - Change at Cycle 15 | Emotional - Change at Cycle 17 | Emotional - Change at Cycle 19 | Emotional - Change at Cycle 21 | Emotional - Change at Cycle 23 | Emotional - Change at Cycle 25 | Emotional - Change at Cycle 27 | Emotional - Change at Cycle 29 | Emotional - Change at Cycle 31 | Emotional - Change at Cycle 33 | Emotional - Change at Cycle 35 | Emotional - Change at EOT | Cognitive - Baseline | Cognitive - Change at Cycle 3 | Cognitive - Change at Cycle 5 | Cognitive - Change at Cycle 7 | Cognitive - Change at Cycle 9 | Cognitive - Change at Cycle 11 | Cognitive - Change at Cycle 13 | Cognitive - Change at Cycle 15 | Cognitive - Change at Cycle 17 | Cognitive - Change at Cycle 19 | Cognitive - Change at Cycle 21 | Cognitive - Change at Cycle 23 | Cognitive - Change at Cycle 25 | Cognitive - Change at Cycle 27 | Cognitive - Change at Cycle 29 | Cognitive - Change at Cycle 31 | Cognitive - Change at Cycle 33 | Cognitive - Change at Cycle 35 | Cognitive- Change at EOT | Social - Baseline | Social - Change at Cycle 3 | Social - Change at Cycle 5 | Social - Change at Cycle 7 | Social - Change at Cycle 9 | Social - Change at Cycle 11 | Social - Change at Cycle 13 | Social - Change at Cycle 15 | Social - Change at Cycle 17 | Social - Change at Cycle 19 | Social - Change at Cycle 21 | Social - Change at Cycle 23 | Social - Change at Cycle 25 | Social - Change at Cycle 27 | Social - Change at Cycle 29 | Social - Change at Cycle 31 | Social - Change at Cycle 33 | Social - Change at Cycle 35 | Social - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 81.79 | -3.73 | -3.95 | -4.62 | -4.36 | -6.99 | -4.99 | -3.54 | -5.10 | -5.68 | -5.70 | -7.87 | -5.75 | -6.59 | -7.67 | -9.33 | -5.45 | -10.00 | -11.16 | 79.91 | -6.26 | -5.66 | -6.68 | -6.55 | -8.76 | -7.36 | -7.18 | -9.58 | -9.84 | -9.78 | -10.65 | -10.92 | -10.14 | -10.83 | -14.44 | -15.15 | -15.00 | -12.11 | 78.96 | 1.14 | 0.74 | 1.58 | 1.69 | 0.08 | 0.93 | 2.51 | 2.91 | 1.39 | 0.06 | 1.75 | 4.98 | 1.57 | 2.64 | 1.30 | 0.25 | -0.00 | -2.87 | 86.90 | -1.77 | -1.87 | -1.99 | -2.18 | -4.27 | -2.83 | -2.28 | -3.45 | -5.00 | -5.56 | -5.71 | -6.90 | -5.80 | -6.67 | -5.56 | -10.61 | -11.67 | -4.98 | 80.57 | -2.05 | -2.86 | -4.78 | -4.56 | -7.09 | -5.56 | -6.18 | -5.56 | -5.28 | -5.56 | -7.62 | -4.60 | -2.17 | -5.00 | -7.78 | -1.52 | -1.67 | -9.01 |
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyponatremia: All Grades | Hyponatremia: Grades 3-4 | Hypernatremia: All Grades | Hypernatremia: Grades 3-4 | Hypocalcemia: All Grades | Hypocalcemia: Grades 3-4 | Hypercalcemia: All Grades | Hypercalcemia: Grades 3-4 | Hypokalemia: All Grades | Hypokalemia: Grades 3-4 | Hyperkalemia: All Grades | Hyperkalemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 181 | 32 | 75 | 1 | 213 | 5 | 52 | 2 | 121 | 16 | 166 | 10 |
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anaemia: All Grades | Anaemia: Grades 3-4 | Thrombocytopenia: All Grades | Thrombocytopenia: Grades 3-4 | Leukopenia: All Grades | Leukopenia: Grades 3-4 | Neutropenia: All Grades | Neutropenia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 535 | 14 | 293 | 13 | 532 | 72 | 450 | 227 |
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Chloride| Chloride>ULN | BUN | BUN>ULN | UREA | UREA>ULN | LDH | LDH>ULN | Total proteins | Total proteins>ULN | | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 135 | 217 | 41 | 83 | 60 | 250 | 79 | 423 | 162 | 77 |
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine: All Grades | Creatinine: Grades 3-4 | Hyperbilirubinemia: All Grades | Hyperbilirubinemia: Grades 3-4 | AST: All Grades | AST: Grades 3-4 | ALT: All Grades | ALT: Grades 3-4 | Alkaline phosphatase: All Grades | Alkaline phosphatase: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 161 | 2 | 130 | 9 | 342 | 12 | 270 | 10 | 465 | 23 |
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No delay and no dose modification | Any delay and/or dose modification | Delay only | Delay and Aflibercept modified | Delay and FOLFIRI modified | Delay and Aflibercept and Folfiri modified | Only Aflibercept modified | Only FOLFIRI modified | Both Aflibercept and FOLFIRI modified | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 119 | 660 | 163 | 39 | 308 | 97 | 5 | 43 | 5 |
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INR<1.5 | INR>=1.5 to <3 | INR>=3 to <5 | INR>=5 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 106 | 0 | 2 | 2 |
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Hypoglycemia: All Grades | Hypoglycemia: Grades 3-4 | Hyperglycemia: All Grades | Hyperglycemia: Grades 3-4 | Hypoalbuminemia: All Grades | Hypoalbuminemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 90 | 6 | 403 | 30 | 241 | 6 |
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Proteinuria with hematuria | Proteinuria with hypertension | Proteinuria with hematuria and hypertension | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72 | 4 | 3 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 286 | 123 | 54 | 5 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (All Grades) | Any TEAEs (Grades 3-4) | Any serious TEAE | Any serious related TEAE | Any TEAE leading to death | Any TEAE (permanent treatment discontinuation) | Any TEAE (premature treatment discontinuation) | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 769 | 609 | 272 | 159 | 47 | 208 | 104 |
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| UPCR<=1 | UPCR>=1 to <=2 | UPCR>=2 to <=3 | UPCR>3 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 265 | 51 | 24 | 27 |
Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 94 |
| B (Placebo + Gemcitabine or Capecitabine) | 147 |
Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.
| Intervention | percentage of participants (Number) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 19.8 |
| B (Placebo + Gemcitabine or Capecitabine) | 12.7 |
(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 407 |
| B (Placebo + Gemcitabine or Capecitabine) | 348 |
(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 103 |
| B (Placebo + Gemcitabine or Capecitabine) | 81 |
(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 111 |
| B (Placebo + Gemcitabine or Capecitabine) | 82 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between longitudinal NLR (longitudinal NLR ≤5 vs NLR >5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 2.2 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. PFS was defined as time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between longitudinal NLR (longitudinal NLR ≤5 vs N>5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.3 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. PFS was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (carcinoembryonic antigen [CEA]) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between NLR (NLR less than or equal to [≤] 5 vs greater than [>] 5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.4 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between NLR (NLR ≤ 5 vs > 5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
NLR was calculated from laboratory values as ratio of Neutrophils to Lymphocytes. NLR normalization was assessed by adding first post-baseline measurement of NLR to the primary model. This is equivalent to testing whether first change in NLR is significantly associated with outcome. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of ≥1 new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration.The association between NLR normalization (first NLR post-baseline ≤5 vs >5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 0.9 |
DDC was defined as PFS + PFS-B. In cases where a participant did not enter Phase B, then DDC was defined as PFS. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. PFS-B was time from start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate DDC. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.0 |
Overall Survival in Phase B was defined as the time from the start of treatment in Phase B to death due to any cause. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: From the start of Phase B treatment death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 14.9 |
OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 25.0 |
The results include percentage of participants who underwent potentially curative liver resection. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
PFS until first progression was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: Baseline up to first disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A | 9.2 |
PFS in Phase B (PFS-B) was defined as the time from the start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 6.7 |
Survival beyond first progression was defined as the time from the date of first disease progression to death due to any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate survival beyond first disease progression. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 12.6 |
TFS was defined as time from the start of initial treatment to documentation of first disease progression without entering Phase B, or second disease progression having entered Phase B. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate TFS. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.8 |
AQoL-8D provides a global utility score and consists of 8 separately scored dimensions including Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.736 | 0.773 | 0.813 | 0.878 | 0.808 | 0.809 | 0.825 | 0.910 | 0.819 | 0.856 | 0.730 | 0.960 | 0.965 | 0.958 | 0.967 | 0.942 | 0.927 | 0.931 | 0.866 | 0.887 | 0.940 | 0.919 | 0.937 | 0.950 | 0.708 | 0.788 | 0.791 | 0.989 | 0.981 | 0.875 |
AQoL-8D provides a global utility score and comprised of 35 questions from which 8 dimensions (Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses) are derived. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.747 | 0.760 | 0.767 | 0.796 | 0.800 | 0.831 | 0.818 | 0.851 | 0.822 | 0.827 | 0.839 | 0.856 | 0.831 | 0.815 | 0.871 | 0.869 | 0.859 | 0.880 | 0.915 | 0.864 | 0.806 | 0.811 | 0.709 | 0.739 | 0.718 | 0.792 | 0.696 | 0.620 | 0.800 | 0.810 | 0.874 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, end of treatment (EOT) (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.830 | 0.857 | 0.865 | 0.853 | 0.869 | 0.892 | 0.872 | 0.881 | 0.894 | 0.843 | 0.898 | 0.915 | 0.844 | 0.899 | 0.878 | 0.899 | 0.873 | 0.909 | 0.947 | 0.852 | 0.933 | 0.813 | 0.900 | 0.817 | 0.768 | 0.901 | 0.819 | 0.843 | 1.000 | 0.835 | 0.816 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.814 | 0.859 | 0.894 | 0.897 | 0.866 | 0.837 | 0.876 | 0.874 | 0.908 | 0.811 | 0.806 | 0.844 | 1.000 | 1.000 | 0.844 | 0.833 | 0.844 | 0.833 | 0.827 | 0.816 | 0.844 | 0.844 | 0.827 | 0.844 | 0.809 | 0.740 | 0.772 | 0.827 | 0.827 | 1.000 |
FACT-C is one part of the FACIT Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 103.47 | 108.71 | 108.19 | 114.89 | 110.60 | 111.28 | 114.78 | 120.39 | 108.08 | 110.50 | 109.33 | 125.00 | 119.00 | 117.00 | 126.00 | 123.00 | 127.00 | 126.00 | 127.00 | 126.00 | 123.00 | 124.00 | 126.00 | 130.00 | 101.67 | 98.72 | 102.50 | 126.33 | 125.00 | 124.67 |
FACT-C is one part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 103.84 | 103.33 | 106.34 | 109.66 | 109.39 | 111.30 | 111.40 | 113.51 | 113.92 | 115.11 | 114.00 | 115.99 | 113.54 | 112.36 | 119.48 | 116.38 | 113.69 | 112.94 | 117.55 | 115.86 | 106.00 | 112.00 | 105.00 | 103.94 | 102.89 | 104.00 | 105.50 | 109.00 | 119.00 | 103.61 | 115.00 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A and Phase B | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase B | 0 | 0 |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
The BOR rate is defined as the percentage of the participants having achieved confirmed complete response (CR) or partial response (PR) as the best overall response according to radiological assessments (based on RECIST Version 1.0). (NCT00705016)
Timeframe: Evaluations will be performed every 6 weeks until progression reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | percentage of participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 46.8 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 26.7 |
| Cetuximab+5-FU+Cisplatin | 35.5 |
The disease control rate is defined as the percentage of participants having achieved confirmed CR, PR or stable disease (SD) as best overall response according to radiological assessments (based on RECIST Version 1.0). (NCT00705016)
Timeframe: Evaluations will be performed every 6 weeks until progression reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | percentage of participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 85.5 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 73.3 |
| Cetuximab+5-FU+Cisplatin | 80.6 |
Duration of response is defined as the time from the first assessment of CR or PR until the date of the first occurrence of progressive disease (PD), or until the date of death. (NCT00705016)
Timeframe: Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.8 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.1 |
| Cetuximab+5-FU+Cisplatin | 6.4 |
The OS time is defined as the time from randomization to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. (NCT00705016)
Timeframe: Time from randomization to death, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 12.4 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 10.6 |
| Cetuximab+5-FU+Cisplatin | 11.6 |
The PFS is defined as the duration from randomization until radiological progression (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) or death due to any cause. Only deaths within 84 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. Investigator read is the assessment of all imaging by the treating physician at the local trial site. (NCT00705016)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 6.4 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 5.6 |
| Cetuximab+5-FU+Cisplatin | 5.7 |
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00705016)
Timeframe: Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 61 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 59 |
| Cetuximab+5-FU+Cisplatin | 61 |
TTF is defined as the time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 84 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. (NCT00705016)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.6 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.5 |
| Cetuximab+5-FU+Cisplatin | 4.3 |
Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization to the end of study, up to 26 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 7.1 |
| Placebo | 5.8 |
The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until death, up to 26 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 12.1 |
| Placebo | 10.1 |
Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression or death, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 6.7 |
| Placebo | 5.3 |
Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until 28-days after the last study treatment was administered, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 6.9 |
| Placebo | 5.4 |
Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression; assessed every 6 weeks for the first year and every 12 weeks thereafter, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 7.0 |
| Placebo | 5.6 |
Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s). (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.
| Intervention | participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Bevacizumab | 143 | 168 |
| Placebo | 111 | 186 |
The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. (NCT00548548)
Timeframe: From randomization until 3 months after last dose (up to 26 months)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any Adverse event | Serious AE | Grade 3/4/5 AE | Grade 5 AE | Deaths not due to Progression | |
| Bevacizumab | 380 | 134 | 293 | 18 | 31 |
| Placebo | 377 | 137 | 294 | 25 | 29 |
Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks. (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with Disease Control | Participants without Disease Control | |
| Bevacizumab | 300 | 87 |
| Placebo | 271 | 116 |
For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 8.52 |
For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 10.39 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 50.76 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 23.15 |
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than [<]10 millimeters [mm]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 58.79 |
CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 54.64 |
CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 49.24 |
Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 52.63 |
Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 82.74 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 9.70 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 50.25 |
Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 3.93 |
Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 6.69 |
"Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual EQ-5D-3 Level (3L) user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state)." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Last visit | Absolute change from baseline | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 80.24 | 74.94 | -5.30 |
The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable. (NCT00577031)
Timeframe: At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curative, no residual disease | Curative, residual disease | Curative, unknown | Curative, not applicable | Palliative, no residual disease | Palliative, residual disease | Palliative, unknown | Palliative, not applicable | Biopsy, residual disease | Biopsy, not applicable | Unknown, unknown | Unknown, not applicable | Other, residual disease | Other, not applicable | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 55.77 | 13.46 | 3.85 | 7.69 | 3.85 | 7.69 | 3.85 | 1.92 | 1.92 | 1.92 | 1.92 | 3.85 | 1.92 | 3.85 |
"The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.~The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Wild-type (n=18) | Gene mutation (n=15) | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 88.89 | 66.67 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
Overall survival (OS) was defined as the time from study entry to death of any cause. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 11.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 8.6 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 11.8 |
Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 7.1 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.9 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.8 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 61 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 45 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 54 |
Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity. The median TTF with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 5.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.3 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.7 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Squamous Cell Carcinoma (ECF + Cetuximab) | 67 |
| Arm B: Squamous Cell Carcinoma (IC + Cetuximab) | 13 |
| Arm C: Squamous Cell Carcinoma (FOLFOX + Cetuximab) | 60 |
DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to < 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.) (NCT01111604)
Timeframe: Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 35.6 |
| mFOLFOX-6 + Ramucirumab | NA |
| mFOLFOX-6 + Icrucumab | NA |
A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals. (NCT01111604)
Timeframe: 31 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFOX-6 + Ramucirumab | 0 |
Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive. (NCT01111604)
Timeframe: Baseline Until Death from Any Cause (Up to 163 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 53.6 |
| mFOLFOX-6 + Ramucirumab | 41.7 |
| mFOLFOX-6 + Icrucumab | 42.0 |
The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes [target or non-target] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression. (NCT01111604)
Timeframe: Baseline until Disease Progression (Up to 95 Weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX-6 | 14 |
| mFOLFOX-6 + Ramucirumab | 3.8 |
| mFOLFOX-6 + Icrucumab | 3.8 |
Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum. (NCT01111604)
Timeframe: Cycle 5, 1 Hour Post End of Infusion
| Intervention | microgram/milliliter (µg/mL) (Geometric Mean) |
|---|---|
| mFOLFOX-6 + Ramucirumab | NA |
| mFOLFOX-6 + Icrucumab | 201 |
Trough (prior to infusion, Ctrough) concentrations measured in serum. (NCT01111604)
Timeframe: Cycle 5, Prior to Infusion
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| mFOLFOX-6 + Ramucirumab | 53.6 |
| mFOLFOX-6 + Icrucumab | 146 |
PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit. (NCT01111604)
Timeframe: Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 18.4 |
| mFOLFOX-6 + Ramucirumab | 21.4 |
| mFOLFOX-6 + Icrucumab | 15.9 |
A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module. (NCT01111604)
Timeframe: Baseline up to 165 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Any TEAE | Any SAE | Any Grade ≥3 AE | Any AE leading to discontinuation (any drug) | |
| mFOLFOX-6 | 49 | 11 | 30 | 6 |
| mFOLFOX-6 + Icrucumab | 52 | 12 | 31 | 11 |
| mFOLFOX-6 + Ramucirumab | 52 | 18 | 37 | 18 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 46.9 |
| FOLFIRI Alone | 38.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 31.3 |
| FOLFIRI Alone | 36.1 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 57.3 |
| FOLFIRI Alone | 39.7 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 84.3 |
| FOLFIRI Alone | 85.5 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00154102)
Timeframe: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 9.6 |
| FOLFIRI Alone | 7.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 16.2 |
| FOLFIRI Alone | 16.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 23.5 |
| FOLFIRI Alone | 20.0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 19.9 |
| FOLFIRI Alone | 18.6 |
Participants with no residual tumor after on-study surgery for metastases (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
| Intervention | Participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 29 |
| FOLFIRI Alone | 10 |
"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 8.9 |
| FOLFIRI Alone | 8.0 |
"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 9.9 |
| FOLFIRI Alone | 8.4 |
"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 7.4 |
| FOLFIRI Alone | 7.7 |
Please refer to Adverse Events section for further details (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 599 |
| FOLFIRI Alone | 597 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| At baseline | At week 8 | At week 16 | At week 24 | At week 32 | At week 40 | |
| Cetuximab Plus FOLFIRI | 58.88 | 59.02 | 60.77 | 61.83 | 59.68 | 63.43 |
| FOLFIRI Alone | 60.33 | 61.83 | 63.29 | 64.06 | 65.07 | 64.02 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| At baseline | At week 8 | At week 16 | At week 24 | At week 32 | At week 40 | |
| Cetuximab Plus FOLFIRI | 75.21 | 74.14 | 73.72 | 76.31 | 74.04 | 76.58 |
| FOLFIRI Alone | 77.28 | 76.71 | 76.67 | 77.98 | 75.64 | 78.07 |
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 2 |
| Placebo | 8 |
Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 5 |
| Placebo | 26 |
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 41 |
| Placebo | 53 |
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 3 |
| Placebo | 10 |
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 16 |
| Placebo | 51 |
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 13 |
| Placebo | 17 |
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 7 |
| Placebo | 9 |
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 34 |
| Placebo | 37 |
Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Days (Median) |
|---|---|
| Pegfilgrastim (Neulasta) | 318 |
| Placebo | 322 |
Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 47 |
| Placebo | 49 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 31 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 55 |
Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 25.7 |
Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 9 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 12.7 |
| A + FOLFOX 4 | 7.9 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A + FOLFOX 4 - Avastin Subgroup | 5.2 |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. (NCT00192075)
Timeframe: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 20.6 |
| A + FOLFOX 4 | 19.7 |
Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 8.6 |
| A + FOLFOX 4 | 9.5 |
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG - Avastin Subgroup | 13.7 |
| A + FOLFOX 4 - Avastin Subgroup | 11.5 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 8.6 |
| A + FOLFOX 4 | 9.7 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG - Avastin Subgroup | 13.7 |
| A + FOLFOX 4 - Avastin Subgroup | 13.8 |
Percentage of participants who were alive at 12 months and 24 months. (NCT00192075)
Timeframe: randomization to the date of death from any cause (up to 24 months)
| Intervention | percentage of participants alive (Number) | |
|---|---|---|
| 12-Month Survival | 24-Month Survival | |
| A + FOLFOX 4 - Avastin Subgroup | 83.3 | 66.7 |
| A+FFG - Avastin Subgroup | 75.6 | 50.4 |
Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either >=1 Grade 4 or >=2 Grade 3 adverse events (NCT00192075)
Timeframe: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia (Grade 3) | Neutropenia (Grade 4) | Thrombocytopenia (Grade 3) | Thrombocytopenia (Grade 4) | Leukopenia (Grade 3) | Leukopenia (Grade 4) | Anemia (Grade 3) | Anemia (Grade 4) | Febrile neutropenia (Grade 3) | Febrile neutropenia (Grade 4) | Diarrhea (Grade 3) | Diarrhea (Grade 4) | Small intestinal obstruction (Grade 3) | Small intestinal obstruction (Grade 4) | Fatigue (Grade 3) | Fatigue (Grade 4) | Cerebral infarction (Grade 3) | Cerebral infarction (Grade 4) | Hyperglycemia (Grade 3) | Hyperglycemia (Grade 4) | Dehydration (Grade 3) | Dehydration (Grade 4) | Deep vein thrombosis (Grade 3) | Deep vein thrombosis (Grade 4) | Myocardial infarction (Grade 3) | Myocardial infarction (Grade 4) | Subdural hematoma (Grade 3) | Subdural hematoma (Grade 4) | Perirectal abscess (Grade 3) | Perirectal abscess (Grade 4) | Hypoxia (Grade 3) | Hypoxia (Grade 4) | |
| A + FOLFOX 4 - Avastin Subgroup | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| A+FFG - Avastin Subgrouup | 3 | 5 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (CR+PR) | Stable Disease (SD) | Disease Control Rate (CR+PR+SD) | Progressive Disease | Unknown | |
| A + FOLFOX 4 - Avastin Subgroup | 1 | 8 | 9 | 8 | 17 | 1 | 0 |
| A+FFG - Avastin Subgroup | 0 | 0 | 0 | 11 | 11 | 6 | 1 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (CR+PR) | Stable Disease (SD) | Disease Control Rate (CR+PR+SD) | Progressive Disease | Unknown | |
| A + FOLFOX 4 | 2 | 15 | 17 | 16 | 33 | 7 | 2 |
| A+FFG | 1 | 3 | 4 | 21 | 25 | 14 | 3 |
"CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A partial response requires a decrease of 30% or more, complete response requires all target lesions disappear, Progression requires an increase of at least 20%, and Stable disease falls in between these two. All responses have a repeat assessment to confirm the response." (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 57.7 |
Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 8.18 |
PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 6.34 |
Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment. (NCT00508274)
Timeframe: at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 53.55 |
Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 4.07 |
On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 4276 days (treatment duration ranged from 13 - 4246 days) for Lapatinib and 3384 days (treatment duration ranged form 8 - 3354 days) for Capecitabine. Total deaths was collected from study start to study end (LPLV). (NCT00508274)
Timeframe: up to 4276 days for Lapatinib/up to 3384 days for Capecitabine (on-treatment), approx. 12 years (all collected deaths)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Total Deaths | On-treatment Deaths | |
| Lapatinib + Capecitabine | 11 | 2 |
Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months
| Intervention | participants (Number) | |
|---|---|---|
| Participants with any site of relapse | Participants with CNS disease as first site of relapse | |
| Lapatinib + Capecitabine | 17 | 2 |
The overall response is defined as the number of participants whose tumor response was classified as a complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in the sum of the longest diameter of target lesions) per Response Evaluation Criteria in Solid Tumors. Response was measured for participants in Phase II only. To determine response, radiographic images were taken at baseline, 8 weeks, and every 8 weeks thereafter until the participant withdrew from the study. (NCT00536809)
Timeframe: Baseline to response (up to 135 days)
| Intervention | participants (Number) |
|---|---|
| Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2 | 2 |
The percentage of patients assessed by physical exam as Clinical Complete Response according to RECIST. (NCT00408408)
Timeframe: Three to four weeks after the last chemotherapy dose, on average at 6 or 13 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 52.3 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 64.6 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 51.3 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 59.1 |
| Arm 3A: Docetaxel + Gem Then AC | 52.6 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 60 |
Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST. (NCT00408408)
Timeframe: Assessed at cycle 5 of chemotherapy, on average at 15 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 30 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 43.3 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 29.8 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 34.5 |
| Arm 3A: Docetaxel + Gem Then AC | 37.9 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 42 |
Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST. (NCT00408408)
Timeframe: Assessed at cycle 5 of chemotherapy, on average at 15 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 77 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 87.6 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 73.7 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 84 |
| Arm 3A: Docetaxel + Gem Then AC | 82.6 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 88 |
The percentage of patients assessed by physical exam as Clinical Complete Response or Clinical Partial Response according to RECIST. (NCT00408408)
Timeframe: Three to four weeks after the last chemotherapy dose on average 6 or 13 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 79.9 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 87.7 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 75.4 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 90.7 |
| Arm 3A: Docetaxel + Gem Then AC | 83.3 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 80.5 |
Percentage of patients free from local recurrence following mastectomy, local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer after 5 years. (NCT00408408)
Timeframe: Measured through 5 years after study enrollment
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 73.4 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 72.2 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 68.5 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 77.1 |
| Arm 3A: Docetaxel + Gem Then AC | 72.9 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 74.8 |
Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen. (NCT00408408)
Timeframe: Time of surgery, on average 6 or 13 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 33.7 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 31.6 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 23.5 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 36.1 |
| Arm 3A: Docetaxel + Gem Then AC | 27.6 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 35.8 |
Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes. (NCT00408408)
Timeframe: Time of surgery, on average 6 or 13 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 27.3 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 24.4 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 18.7 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 27.4 |
| Arm 3A: Docetaxel + Gem Then AC | 22.9 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 30.3 |
Number of patients with Grade 4 or above surgery-related toxicities (NCT00408408)
Timeframe: 24 months after study entry
| Intervention | participants (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 1 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 1 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 0 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 1 |
| Arm 3A: Docetaxel + Gem Then AC | 0 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 1 |
The number of patients who experienced Grade 1 or above Adverse Events. Referring to the Adverse Events tables for specifics. (NCT00408408)
Timeframe: 24 months after study entry
| Intervention | participants (Number) |
|---|---|
| Arm 1A: Docetaxel Then AC | 180 |
| Arm 1B Docetaxel + Bev Then AC + Bev | 157 |
| Arm 2A: Docetaxel + Capecitabine Then AC | 172 |
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 185 |
| Arm 3A: Docetaxel + Gem Then AC | 158 |
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 185 |
Amount of time subject survives without intraperitoneal disease progression after treatment. Disease progression is defined as imageable tumor nodules or increasing ascites persistent on computed tomography (CT) scan as interpreted by the official interpretation of the imaging studies. (NCT01833832)
Timeframe: Amount of time subject survives without intraperitoneal disease progression after treatment, an average of 17 months
| Intervention | Months (Median) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 19 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01833832)
Timeframe: Date treatment consent signed to date off study, approximately 34 months and 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 8 |
Patients who died following the HIPEC procedure. The HIPEC is a surgical procedure in which two large bore catheters are inserted in the abdominal wall over the liver and pelvis. The physician closes the abdominal fascia and the catheters are connected to a perfusion circuit. The temperature of the catheters is carefully monitored while the physician ensures the perfusion is distributed properly by manually moving the abdomen. (NCT01833832)
Timeframe: Patients were assessed every 3 months up to an average of 17 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 0 |
Percentage of participants who are alive after treatment. (NCT01833832)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 66.7 |
QOL characteristics were collected using The Functional Assessment of Cancer Therapy-Colorectal Quality of Life (QOL) questionnaire version 4, a validated survey that interrogates physical, emotional, functional, and social well being in cancer related issues on a 5-point scale. Scores range from 0 to 108 points. Higher scores are consistent with a better outcome. (NCT01833832)
Timeframe: Prior to surgery, 6 weeks post surgery, and 3 months post surgery
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Prior to surgery | 6 weeks after surgery | 3 months after surgery | |
| Cytoreductive Surgery Followed by HIPEC | 82.6 | 76.4 | 80.2 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
"Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).~Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 244.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 315 |
The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). (NCT02119026)
Timeframe: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 373.00 |
| B: XELOX + BEV Followed by XELIRI + BEV | 370.00 |
The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. (NCT02119026)
Timeframe: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 241 |
| B: XELOX + BEV Followed by XELIRI + BEV | 280 |
The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | Participants (Count of Participants) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 32 |
| B: XELOX + BEV Followed by XELIRI + BEV | 36 |
Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. (NCT02119026)
Timeframe: date of death or date of last tumor assessment (28d safety f-u) in patients without death
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 593.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 643 |
"The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 129 |
| B: XELOX + BEV Followed by XELIRI + BEV | 155 |
Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 185.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 178.0 |
Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 4 | 21 | 26 | 2 |
| B: XELOX + BEV Followed by XELIRI + BEV | 1 | 23 | 30 | 0 |
Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | Not available (NA) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 7 | 11 | 6 | 0 | 8 |
| B: XELOX + BEV Followed by XELIRI + BEV | 8 | 13 | 2 | 0 | 1 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01264081)
Timeframe: Date treatment consent signed to date off study, approximately, 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Lapatinib | 3 |
The count of participants with a partial response and complete response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions. (NCT01264081)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Partial Response | Complete Response | Stable Disease | Progressive Disease | |
| Lapatinib | 0 | 0 | 2 | 0 |
The number of patients with Complete Response, Partial Response or Stable Disease extending beyond 6 months (CR+PR+SD ≥ 6 months), determined by RECIST v1.1. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion; SD=Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since the treatment started. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, and every 3 cycles thereafter until treatment discontinuation, projected 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib) | 2 |
| Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
The number of patients with Complete and Partial Response (CR+PR) of CNS lesions assessed per modified RECIST Criteria for Evaluation of Intracranial Disease. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, then every 9 weeks until treatment discontinuation, projected 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
| Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
The number of participants having Complete and Partial Responses (CR+PR) of extra-cranial lesions assessed per RECIST v1.1 Criteria. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks for 8 cycles, then every 9 weeks until treatment discontinuation, up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
| Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
The maximum tolerated dose (MTD) of cabazitaxel and lapatinib will be determined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. A listing of DLTs are reported in the subsequent Primary Outcome Measure. (NCT01934894)
Timeframe: weekly for 3 weeks
| Intervention | mg/m^2 of cabazitaxel + lapatinib (Number) |
|---|---|
| Cabazitaxel and Lapatinib | NA |
During the safety lead-in, a standard 3+3 dose escalation design is used to determine the maximum tolerated dose (MTD) of cabazitaxel with lapatinib. The MTD would be determined by the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) during 1 cycle (21 days) of therapy. If 2 of 6 patients within a dose level experiences a DLT, that dose level would be defined as exceeding the MTD and the previous dose level would be evaluated. DLTs are assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. (NCT01934894)
Timeframe: weekly for 3 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| febrile neutropenia | neutropenia | diarrhea | septic shock | |
| Dose Level 1 | 0 | 0 | 0 | 1 |
| Dose Level 2 | 1 | 1 | 2 | 0 |
"Computed for all patients with a best response of Partial or Complete per RECIST (a 4-item scale as described in previous outcome measure), calculated from the time when these criteria were first met until the first date of documented progression or death." (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | months (Median) |
|---|---|
| Ixabepilone + Capecitabine | 6.4 |
| Capecitabine | 5.6 |
"Participants with best response of Complete or Partial according to Response Evaluation Criteria in Solid Tumors (RECIST) a 4-item scale wherein complete response=disappearance of all target lesions and partial response=30% decrease in the sum of the longest diameter of target lesions" (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | percent (Mean) |
|---|---|
| Ixabepilone + Capecitabine | 34.7 |
| Capecitabine | 14.3 |
OS was defined as the time from randomization to death. Participants who did not die at the time of the analysis were censored at the latest follow-up date. Median OS with 95% CI was estimated using the Kaplan Meier product limit method. (NCT00080301)
Timeframe: from date of randomization until death
| Intervention | Months (Median) |
|---|---|
| Ixabepilone + Capecitabine | 12.9 |
| Capecitabine | 11.1 |
PFS defined as the time in months from randomization to date of progression. Patients who died without a reported prior progression were considered to have progressed on date of death; those who didn't progress or die were censored on date of last tumor assessment. Median PFS time with 95% CI estimated using the Kaplan Meier product limit method. (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | Months (Median) |
|---|---|
| Ixabepilone + Capecitabine | 5.85 |
| Capecitabine | 4.17 |
Time to response was summarized using descriptive statistics and was defined as the time from first dose of study treatment until measurement criteria were first met for Partial Response or Complete Response. (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | weeks (Median) |
|---|---|
| Ixabepilone + Capecitabine | 11.7 |
| Capecitabine | 12.0 |
Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms. (NCT00080301)
Timeframe: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment.
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 3 (n=282; n=273) | Week 6 (n=227; n=214) | Week 9 (n=194; n=184) | Week 12 (n=173; n=158) | Week 15 (n=148; n=145) | Week 18 (n=122; n=121) | Week 21 (n=116; n=101) | Week 24 (n=95; n=82) | |
| Capecitabine | 0.3 | 1.1 | 1.8 | 1.4 | 1.7 | 1.7 | 1.1 | 2.3 |
| Ixabepilone + Capecitabine | -0.4 | -0.2 | -0.6 | -1.3 | -0.7 | -1.0 | -0.7 | -0.8 |
Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0 (NCT00080301)
Timeframe: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Deaths on-study or within 30 days of last dose | Treatment-related Serious Adverse Events (SAEs) | Treatment-related Adverse Events (AEs) | Treatment-related AEs leading to Discontinuation | |
| Capecitabine | 40 | 31 | 330 | 25 |
| Ixabepilone + Capecitabine | 33 | 91 | 357 | 137 |
(NCT00375999)
Timeframe: One year
| Intervention | month (Median) |
|---|---|
| Treatment Group | 13.4 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
67 reviews available for fluorouracil and Disease Exacerbation
| Article | Year |
|---|---|
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Dru | 2019 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments of actinic cheilitis: A systematic review of the literature.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Cheilitis; Combined Modality Therapy; Dermabrasion; D | 2020 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Ca | 2020 |
Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature.
Topics: Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colonic Neoplasms; Disease Progression; Elec | 2020 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac | 2020 |
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
Topics: Antineoplastic Agents; Diclofenac; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; | 2021 |
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neo | 2021 |
5-Fluorouracil-induced exacerbation of rosacea.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Disease Progression; Fluorouracil; Humans; K | 2016 |
A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Disease | 2017 |
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Colorectal Neoplasms; Disea | 2018 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase | 2013 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neopl | 2003 |
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel | 2013 |
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy | 2013 |
Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2014 |
The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progress | 2014 |
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2015 |
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
JAAD Grand Rounds quiz: Red-brown hyperkeratotic papules in a 69-year-old man.
Topics: Aged; Biopsy, Needle; Disease Progression; Exanthema; Fluorouracil; Follow-Up Studies; Humans; Immun | 2015 |
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Ne | 2016 |
Cancer drug resistance: redox resetting renders a way.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP B | 2016 |
Current perspective on actinic keratosis: a review.
Topics: Adult; Age Factors; Aged; Cost of Illness; Dermatologic Agents; Disease Progression; Female; Fluorou | 2017 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Topics: Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Fluorouracil; | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Flu | 2010 |
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fluorouracil; Ge | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2010 |
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progress | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as | 2010 |
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2012 |
Thymidylate synthase: a critical target for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2002 |
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neo | 2002 |
Moving forward with capecitabine: a glimpse of the future.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2002 |
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK mult
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Costs and | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2003 |
[Colon cancer in pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cesarean Section; C | 2003 |
Current research directions for locally advanced cervix cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
[Palliative therapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
[Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitab | 2004 |
[Recent progress in chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2004 |
Combined-modality therapy of rectal cancer with irinotecan-based regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
Critical evaluation of current treatments in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2005 |
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamid | 2005 |
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2005 |
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II | 2006 |
Guidelines for management of Bowen's disease: 2006 update.
Topics: Adjuvants, Immunologic; Aminoquinolines; Bowen's Disease; Cautery; Cryotherapy; Curettage; Disease P | 2007 |
Clinical studies with epothilones for the treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progress | 2008 |
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Optimizing chemotherapy for patients with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 1999 |
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2000 |
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Databases, Bibliographic; Disease Progr | 2000 |
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2001 |
493 trials available for fluorouracil and Disease Exacerbation
| Article | Year |
|---|---|
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid | 2022 |
Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera | 2022 |
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tu | 2022 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinic | 2019 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress | 2020 |
Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2020 |
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2020 |
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2021 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Disea | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore | 2018 |
miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2018 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Di | 2019 |
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ch | 2019 |
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2019 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2019 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2018 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2019 |
All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Disease Progressio | 2019 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Reg | 2013 |
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea | 2014 |
Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2013 |
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease P | 2013 |
Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Di | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2014 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; | 2014 |
GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinogenesis; Carc | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2014 |
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast N | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; An | 2014 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; | 2014 |
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolite | 2015 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorecta | 2015 |
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2015 |
Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dise | 2015 |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; D | 2015 |
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetu | 2015 |
Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2016 |
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease Progression | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2016 |
Long-term update of the 24954 EORTC phase III trial on larynx preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam | 2016 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2017 |
Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dr | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2008 |
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2009 |
Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Rin | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disea | 2008 |
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2008 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2008 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas | 2009 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neopl | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2008 |
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Fema | 2009 |
The singapore 5-Fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Progression; Double | 2009 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2009 |
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2009 |
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compo | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
[Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deo | 2009 |
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2009 |
Optic disc and visual field changes after trabeculectomy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Combined Modality Therapy; Disease Progression; Dou | 2009 |
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diseas | 2009 |
Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Disease Progression | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2010 |
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease | 2010 |
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African Ame | 2009 |
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies | 2010 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2010 |
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Disease Progression; E | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; | 2009 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2009 |
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2010 |
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2010 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2010 |
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capecitabine; Colorectal Neop | 2011 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2010 |
Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2010 |
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dos | 2011 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; | 2010 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Ther | 2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; An | 2010 |
Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Progressio | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2010 |
[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamet | 2010 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Ne | 2010 |
Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2010 |
Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Female; Fl | 2010 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2011 |
Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2010 |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2010 |
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2011 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progres | 2010 |
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Pro | 2010 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2010 |
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacolog | 2010 |
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Disease Progression; Endocrine Gland Ne | 2011 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2010 |
Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2011 |
Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes.
Topics: Aged; Aged, 80 and over; Disease Progression; Drug Therapy, Combination; Female; Fibrinolytic Agents | 2011 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplas | 2012 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2011 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecit | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2011 |
Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2011 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2011 |
Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemother | 2011 |
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Disease Progress | 2011 |
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemothe | 2011 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2011 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2011 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Doce | 2012 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modal | 2012 |
Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxy | 2013 |
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Enzyme-Linked I | 2012 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2013 |
Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2013 |
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery-report of four cases.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arterial Occlusive Diseases; Catheterization | 2002 |
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2002 |
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progres | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progress | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disea | 2002 |
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2003 |
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 2003 |
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK mult
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Costs and | 2003 |
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2003 |
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2003 |
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Dru | 2003 |
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Pr | 2003 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat | 2003 |
European experience of docetaxel and cisplatin in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease | 2002 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2003 |
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 2003 |
A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2003 |
A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progre | 2003 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2003 |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2003 |
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2003 |
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cos | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Anti | 2003 |
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal | 2003 |
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2003 |
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progress | 2003 |
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2003 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2004 |
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dru | 2004 |
Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Disease Progression; D | 2004 |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar | 2004 |
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2004 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2004 |
Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2004 |
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2004 |
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2004 |
Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2004 |
Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progression; Fe | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deo | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2004 |
Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Confidence Intervals | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2004 |
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2004 |
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast | 2005 |
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2005 |
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2005 |
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2005 |
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fem | 2005 |
Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasm | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2005 |
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Dis | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survi | 2005 |
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2005 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M | 2006 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dis | 2006 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2006 |
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2006 |
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationsh | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Fe | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytid | 2006 |
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2006 |
Effect of trabeculectomy on lens opacities in an East Asian population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Cataract; Combined Modality Therapy; Disease Progre | 2006 |
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Datab | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2006 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2006 |
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D | 2006 |
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De | 2006 |
Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dat | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2007 |
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; | 2007 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2006 |
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2007 |
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Ce | 2007 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cispla | 2007 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined | 2007 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2008 |
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Camptothecin; Cyclin A; De | 2008 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; | 2007 |
A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; D | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2007 |
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemothera | 2007 |
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2008 |
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2007 |
Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Diseas | 2007 |
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetaboli | 2007 |
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; De | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disea | 2007 |
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2007 |
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Combined Chemo | 2008 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2008 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease P | 2007 |
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2008 |
The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus.
Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, S | 2007 |
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2007 |
Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2008 |
The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluo | 2007 |
Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Pro | 2007 |
An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; | 2007 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2007 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progre | 2008 |
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2007 |
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Pr | 2007 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Ne | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; | 2008 |
Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera | 2007 |
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplas | 2007 |
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyti | 2008 |
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2007 |
Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administratio | 2009 |
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 2007 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Disease Progression; Fluorouracil; Humans; Interferon-alpha; Male; Prospective | 1995 |
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neop | 1994 |
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dieth | 1996 |
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1996 |
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1996 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Pr | 1996 |
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1996 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1996 |
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplasti | 1996 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon | 1997 |
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Topics: Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dise | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 1997 |
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Antimetaboli | 1997 |
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Can
Topics: Adult; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neopla | 1997 |
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 1997 |
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1998 |
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Drug Admini | 1998 |
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progress | 1998 |
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Pr
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1998 |
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 1998 |
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1998 |
5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Colorectal Neopl | 1998 |
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabin | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabin | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabin | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabin | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1999 |
A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1999 |
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 1999 |
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease | 1999 |
The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal | 1999 |
[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 1999 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
c-erb-B2 expression and response to treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2000 |
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2000 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Com | 2000 |
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cell Division | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progr | 2000 |
A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ductal, Breast; Cathet | 2000 |
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2000 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2000 |
Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubi | 2000 |
Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; An | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Fluorouracil; | 2000 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2001 |
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2001 |
Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease Pr | 2001 |
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2001 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2001 |
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2001 |
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neopla | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progressio | 2001 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxy | 2002 |
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2002 |
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2002 |
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Female; F | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2002 |
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Moda | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Epiru | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free | 2002 |
439 other studies available for fluorouracil and Disease Exacerbation
| Article | Year |
|---|---|
Synthesis and evaluation of novel benzophenone-thiazole derivatives as potent VEGF-A inhibitors.
Topics: Animals; Benzophenones; Cell Line, Tumor; Chemistry Techniques, Synthetic; Disease Progression; Drug | 2014 |
Prevotella contributes to individual response of FOLFOX in colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Diseas | 2021 |
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Ch | 2021 |
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents | 2021 |
Plakophilin3 loss leads to increased adenoma formation and rectal prolapse in APC
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Disease Progression; | 2022 |
Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neop | 2022 |
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Fluo | 2022 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas | 2023 |
The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2023 |
Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Progression; Fluorouracil; Gene | 2023 |
Bio-mediated synthesis of 5-FU based nanoparticles employing orange fruit juice: a novel drug delivery system to treat skin fibrosarcoma in model animals.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calorimetry, Differential Scanning; Caspase 9; Citrus sin | 2019 |
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2020 |
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Evolution; Clinical Trials, Phase III as | 2020 |
The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Female; Fluo | 2020 |
ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2019 |
Increase of MAL-II Binding Alpha2,3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangi | 2019 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combin | 2020 |
Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Disease Progre | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2020 |
Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Biomarkers, Tumor; | 2020 |
Visual field progression 8 years after trabeculectomy in Asian eyes: results from The Singapore 5-Fluorouracil Study.
Topics: Adult; Aged; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Glaucoma, Open-Angle; Hum | 2020 |
Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Disease Models, A | 2020 |
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2020 |
Challenges in Reirradiation of Intrahepatic Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2020 |
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Topics: Acneiform Eruptions; Adenocarcinoma; Administration, Topical; Aloe; Antineoplastic Agents; Antineopl | 2021 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause o | 2021 |
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidin | 2021 |
Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease Progression; Drug Resista | 2021 |
Diethylhexyl phthalate (DEHP) regulates the proliferation and chemosensitivity of esophageal squamous cell carcinoma cells via regulation of PTEN.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diethylhexyl Phthalate; Dise | 2021 |
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Stud | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Ch | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidenc | 2021 |
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic | 2021 |
MTA3 regulates malignant progression of colorectal cancer through Wnt signaling pathway.
Topics: Adult; Aged; Apoptosis; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Cyclin | 2017 |
Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Disease Progression; Drug Carr | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycyt | 2017 |
Prognostic relevance of Src activation in stage II-III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
Topics: Animals; Biopsy; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cell Prolifer | 2017 |
Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2017 |
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febr | 2018 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemo | 2018 |
Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Co | 2018 |
Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Di | 2018 |
[Experience of Ramucirumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer in Our Hospital].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2017 |
Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil.
Topics: Adenoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Cycle; | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cap | 2018 |
Post-Transcriptional Control of Angiotensin II Type 1 Receptor Regulates Osteosarcoma Cell Death.
Topics: Aged; Animals; Apoptosis; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Disease Pr | 2018 |
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cont | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; | 2018 |
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Topics: Activin Receptors, Type II; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2018 |
Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell Movement; Cisplatin; Colon; Colonic Neoplas | 2018 |
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benef | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease | 2019 |
Chemotherapy-induced
Topics: Animals; Apoptosis; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Dr | 2018 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p.
Topics: Aged; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Diseas | 2019 |
ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Animals; Antimetabolites, Antineoplastic; Autophagy; B | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor | 2019 |
TGF-β1 protects colon tumor cells from apoptosis through XAF1 suppression.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival | 2019 |
Addressing the Challenges of Treating Actinic Keratosis
Topics: Dermatologic Agents; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Ac | 2019 |
Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fema | 2019 |
The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; | 2019 |
Acute Renal Transplant Failure Secondary to an Obstructing Ileal Conduit Adenocarcinoma: Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Disease Progress | 2019 |
Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia.
Topics: Animals; Bone Marrow; Bone Marrow Failure Disorders; CDX2 Transcription Factor; Cell Transformation, | 2019 |
Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report.
Topics: Abdominal Pain; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothe | 2020 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor | 2020 |
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progressio | 2019 |
Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy.
Topics: Antineoplastic Agents; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; | 2014 |
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2013 |
Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2013 |
[Combination therapy herceptin+xeloda].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2002 |
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-B | 2013 |
Neoadjuvant-intensified treatment for rectal cancer: time to change?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2013 |
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square D | 2013 |
The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Li | 2013 |
Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Disease Prog | 2013 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; D | 2013 |
53BP1 sensitizes breast cancer cells to 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Surv | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2014 |
Crohn's disease with worsening symptoms.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Mo | 2013 |
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Topics: Adult; Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cap | 2013 |
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L | 2014 |
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease P | 2013 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; | 2013 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2013 |
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease | 2013 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2014 |
Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; D | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycy | 2013 |
Intradural tumor recurrence after resection of extradural metastasis: a rare but potential complication of intraoperative durotomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; C | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Color | 2014 |
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytid | 2013 |
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas | 2014 |
Colon cancer, version 3.2014.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Co | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemo | 2014 |
The impact of inflammatory lipid mediators on colon cancer-initiating cells.
Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Dinoprostone; Disease Progression; Drug | 2015 |
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2014 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2015 |
LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Cell Line, Tumor; Cell Movement; Cell Prolif | 2014 |
Evaluation of the progression and treatment of experimental periodontitis in rats subjected to chemotherapy with 5-fluorouracil.
Topics: Alveolar Bone Loss; Animals; Dental Scaling; Disease Progression; Fluorouracil; Leukocytes; Male; Ne | 2015 |
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati | 2014 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2014 |
Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Chemoembolization, Therapeutic; Disea | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Semi-radical chemoradiotherapy for 53 esophageal squamous cell carcinomas with supraclavicular lymph node metastasis in a single institutional retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2014 |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2015 |
Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Is | 2015 |
Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte | 2015 |
MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplas | 2015 |
A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Ph | 2015 |
Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; DNA Repair; | 2015 |
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-delta; | 2015 |
Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; DNA Repair; Female; Fluorouracil; Genotype; | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2016 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2014 |
A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Cy | 2015 |
[Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progressi | 2015 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothec | 2016 |
5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method.
Topics: Aged; Base Sequence; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Dose-Response Relation | 2015 |
The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, | 2015 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 2016 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2015 |
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fem | 2016 |
Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferati | 2016 |
Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2015 |
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neo | 2015 |
[A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course].
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
[Treatment results for different categories of vaginal intraepithelial neoplasia with electrocoagulation, 5-fluorouracil and combined treatment].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squam | 2015 |
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal | 2016 |
Hepatic Arterial Infusion Chemotherapy for Life Threatening Patients due to Liver Metastases from Colorectal Cancer with Cetuximab.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal N | 2015 |
DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; | 2016 |
NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2016 |
High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Cycle Checkpoints; Cell Line | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Surv | 2016 |
NFκB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Drug Resi | 2016 |
Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Disease Progression; F | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C | 2016 |
Role of γ-glutamyl cyclotransferase as a therapeutic target for colorectal cancer based on the lentivirus-mediated system.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Fluorouracil; gamma-Glutamyl | 2016 |
Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Colon; Coloni | 2016 |
Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2016 |
RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carc | 2016 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro | 2016 |
Comparison of the expression and function of Lin28A and Lin28B in colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Prol | 2016 |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dise | 2017 |
[Efficacy of 5-FU hepatic arterial infusion with l-leucovorin for patients with unresectable colorectal liver metastasis].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hum | 2008 |
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2008 |
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms | 2009 |
[Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2008 |
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Prote | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluoroura | 2008 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2008 |
Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Chemoembolization, Therape | 2008 |
[Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolizati | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fem | 2008 |
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptoth | 2009 |
5-Fluorouracil treatment of problematic scars.
Topics: Adult; Antimetabolites; Cicatrix, Hypertrophic; Disease Progression; Female; Fluorouracil; Follow-Up | 2009 |
rNAPc2 inhibits colorectal cancer in mice through tissue factor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; C | 2009 |
Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2009 |
[5-FU based chemoradiotherapy for unresectable locally advanced pancreatic cancer].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Dose-Response Relations | 2009 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2009 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2008 |
Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2009 |
Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Colonic | 2010 |
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A case of hepatocellular carcinoma rapidly progressing after percutaneous radiofrequency ablation successfully treated with low-dose 5-FU and CDDP].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2009 |
Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Colorectal Neoplasms; D | 2009 |
Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2009 |
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progress | 2009 |
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as To | 2009 |
The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2009 |
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2009 |
Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
Topics: Adenoma, Villous; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 2009 |
Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Female; Fluorouracil; Humans; Lymphatic | 2009 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Che | 2010 |
Bilateral ocular hypertension with rapidly progressive optic neuropathy in a teen.
Topics: Adolescent; Antimetabolites; Disease Progression; Female; Fluorouracil; Fundus Oculi; Glaucoma, Open | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplast | 2010 |
Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.
Topics: Aged; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Fluo | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy | 2010 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2010 |
High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; F | 2010 |
[A case successfully treated with total pelvic exenteration after preoperative chemotherapy FOLFOX4 plus bevacizumab for unresectable sigmoid colon cancer with extramural progression].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; C | 2010 |
The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neo | 2010 |
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytid | 2010 |
[Chemotherapy of colonic cancer].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2010 |
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Fluorouracil; Head and Neck N | 2010 |
Trastuzumab beyond progression: a cost-utility analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F | 2010 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I | 2010 |
Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fluoroura | 2011 |
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma; Cell Migration Assays; Cell Transformation, Neopla | 2010 |
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2011 |
A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2010 |
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Mod | 2010 |
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
Topics: Adult; Antineoplastic Agents; Cell Differentiation; Cell Transformation, Neoplastic; Disease Progres | 2010 |
Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; D | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
[Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorou | 2010 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2010 |
[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Thymidylate synthase expression as a predictor of clinical response to 5-fluorouracil-based chemoradiotherapy in patients with maxillary sinus squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2011 |
Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Progression; Female; Fluoro | 2010 |
A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolida | 2011 |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl | 2011 |
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
Exacerbation of seborrheic dermatitis by topical fluorouracil.
Topics: Administration, Topical; Aged; Aged, 80 and over; Dermatitis, Seborrheic; Dermatologic Agents; Disea | 2011 |
Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas | 2012 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capeci | 2011 |
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Protocols; Dise | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro.
Topics: Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Calcium; Carcinoma, Hepatoce | 2011 |
Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2011 |
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomar | 2011 |
Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
Topics: Carcinoma, Hepatocellular; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Imm | 2011 |
Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chromosomes, Human, Pair 2; | 2012 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; | 2011 |
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidin | 2011 |
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2011 |
[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; | 2011 |
Ubc9 expression predicts chemoresistance in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2011 |
Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Topics: Abdominal Neoplasms; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin D1; Disease Progression; | 2012 |
miRNA signature associated with outcome of gastric cancer patients following chemotherapy.
Topics: Adult; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastric Muco | 2011 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progressi | 2011 |
[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2011 |
[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2012 |
Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Carcinoma, Signet | 2012 |
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; D | 2012 |
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2013 |
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
Topics: 3' Untranslated Regions; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; | 2013 |
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluo | 2013 |
[Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo.
Topics: Animals; Autophagy; Biomarkers, Tumor; Cell Cycle; Cell Nucleus; Cell Proliferation; Cell Transforma | 2012 |
Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colorectal Neopl | 2012 |
[Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and | 2013 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy | 2012 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
[The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
[A case of cutaneous mammary re-irradiation].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Ch | 2012 |
Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: Preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinom | 2013 |
Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disea | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2012 |
Chemotherapy with or without radiotherapy in patients with locoregionally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2002 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Chemoradiation for adenocarcinoma of the anus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq | 2003 |
Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Flu | 2003 |
Significance of thymidylate synthase activity in renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, T | 2003 |
Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Brain Neoplasms; Cell Line | 2003 |
Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer--preliminary results.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progress | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorourac | 2003 |
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2003 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2003 |
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2003 |
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Floxuridine; Fluorouraci | 2003 |
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Cluster Analysis; Disease Progression; Down-Re | 2004 |
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents | 2004 |
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Topics: Acyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bi | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2004 |
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Division; Colonic Neop | 2004 |
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2004 |
Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2004 |
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; | 2004 |
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Clinical Trials a | 2005 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
Topics: Colorectal Neoplasms; Disease Progression; Drug Screening Assays, Antitumor; Female; Fluorouracil; H | 2005 |
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Treatment of advanced malignant eccrine poroma with locoregional chemotherapy.
Topics: Acrospiroma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; F | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisp | 2005 |
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2005 |
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Surviv | 2005 |
Preoperative chemoradiation in rectal cancer: why we need a common language.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Progression; Dose F | 2005 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra | 2005 |
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronothera | 2005 |
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog | 2005 |
Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea | 2005 |
Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma; Case-Control Studies; Cisplat | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes.
Topics: Anthracyclines; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2005 |
Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorect | 2006 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy | 2006 |
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2006 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma.
Topics: 5'-Nucleotidase; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; CD3 Complex; Colorectal | 2006 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Tri | 2006 |
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Disease-Free Survi | 2007 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2006 |
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progress | 2007 |
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2007 |
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Ther | 2006 |
Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Topics: Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; C | 2006 |
Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; C | 2006 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St | 2006 |
Targeted therapy for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2006 |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2007 |
Disseminated intravascular coagulation at presentation of advanced gastric cancer.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Cisplatin; Disease Pro | 2006 |
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2007 |
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia | 2007 |
Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters.
Topics: Aged; Angiography; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Car | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 2007 |
Drug resistance to 5-FU linked to reactive oxygen species modulator 1.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Disease Progression; Drug Resistance, | 2007 |
Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 2007 |
Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Progression; Female; Fluorou | 2007 |
Exclusive chemoradiotherapy for patients with medically inoperable early-stage oesophageal cancer.
Topics: Cisplatin; Combined Modality Therapy; Disease Progression; Esophageal Neoplasms; Fluorouracil; Human | 2007 |
Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendo | 2007 |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydr | 2007 |
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progress | 2007 |
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemot | 2007 |
Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cohort Studi | 2007 |
Progression-free survival is a surrogate for survival in advanced colorectal cancer.
Topics: Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin | 2007 |
The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2007 |
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; D | 2008 |
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2007 |
Capecitabine for treatment of advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycyti | 2007 |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2008 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; | 2009 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2008 |
Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease P | 2008 |
Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2008 |
[Non-resectable metastases from colorectal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; F | 2008 |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carboxylesterase; Colorectal Neopla | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
[Treatment using concomitant radiochemotherapy of N+ M0 stage urothelial tumors of the bladder].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1995 |
Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Avian Sarcoma Viruses; Combined Modality Th | 1996 |
Primary chemotherapy of advanced head and neck cancer: where do we go from here?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P | 1996 |
A prospective evaluation of the treatment of primary or metastatic liver carcinoma with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1996 |
Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoemboliz | 1996 |
p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis.
Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Female; Fluoroura | 1996 |
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1997 |
Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1997 |
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Disease Progression; Female; Flu | 1996 |
Should patients with advanced colorectal cancer be treated with chemotherapy?
Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Di | 1997 |
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progress | 1997 |
Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Progression; Fem | 1998 |
Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 1998 |
Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Topics: Adult; Alkaline Phosphatase; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1999 |
Metaplastic breast cancer: prognosis and response to systemic therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1999 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, C | 1999 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carci | 1999 |
Guidelines for management of Bowen's disease. British Association of Dermatologists.
Topics: Antimetabolites; Bowen's Disease; Carcinoma, Squamous Cell; Cautery; Cryotherapy; Disease Progressio | 1999 |
Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 2000 |
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Cholangiocarcinoma; Disease Progression; Disease-Fre | 2000 |
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Cohort Studie | 2001 |
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hu | 2001 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2001 |
Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2001 |
Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
Topics: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2001 |
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Cancer, Regiona | 2001 |
Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Coh | 2001 |
Experience in treatment of metastatic pulmonary carcinoid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoi | 2001 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; | 2002 |
Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2002 |
Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2002 |